Timothy grass allergens and methods and uses for immune response modulation

ABSTRACT

The invention relates to Timothy Grass proteins and peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses of Timothy Grass proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease; and inducing immunological tolerance to the allergen in a subject.

RELATED APPLICATION INFORMATION

This application claims priority to application Ser. No. 61/596,156, filed Feb. 7, 2012, and application Ser. No. 61/734,886, filed Dec. 7, 2012, both of which applications are expressly incorporated herein by reference in their entirety.

GOVERNMENT SUPPORT

This invention received government support from the National Institutes Health contract NIH-NIAIDHHSN272200700048C. The government has certain rights in the invention.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 6, 2013, is named 051501-0420334_SL.txt and is 1,444,840 bytes in size.

FIELD OF THE INVENTION

The invention relates to Timothy Grass (TG) proteins and peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses of such proteins and peptides, including methods of modulating an immune response, protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease and inducing immunological tolerance to the allergen in a subject.

INTRODUCTION

Allergic diseases such as rhinitis and asthma pose a significant burden to both patients and society as a whole (1). Recent studies have estimated that up to 20% of the population in the US and Western Europe suffers from these diseases, (2, 3). Despite this high incidence, existing therapy is mostly symptomatic, and immunotherapy treatments are successful in only a fraction of patients and can be associated with significant safety concerns (4). Consequently, much effort in allergy research has been devoted to the development of safer and more effective immunological treatments.

T cells play an important role in the pathogenesis of allergic diseases. However, the proteins considered as potential immunogens of allergenic T cell responses have traditionally been limited to those that induce IgE responses. Allergic respiratory diseases are associated with high levels of IgE antibodies to certain allergenic proteins and elevated levels of eosinophils that infiltrate the target tissue (5). Production of Th2 cytokines (IL-4, IL-5 and IL-13; (6)) regulates these events as they are critical for the switch to IgE production by differentiating B cells and promote the influx of eosinophils and other inflammatory cells that contribute to airway pathology.

Despite the importance of Th2 cells and their associated cytokines in the pathogenesis of allergic respiratory disease, studies of antigens considered as triggers of T cell responses have so far been mostly limited to those known to bind IgE antibodies (7, 8) and induce IgE-mediated immediate hypersensitivity reactions (9). Timothy grass (TG) pollen is an inhaled allergen for which major IgE-reactive allergens have been shown to trigger Th2 responses. As disclosed herein, surprisingly Timothy Grass proteins have been discovered that are recognized by Th2 responses independent of IgE-reactivity, including IgG reactive proteins.

SUMMARY

Disclosed herein are novel Timothy Grass (TG) proteins and peptides, as well as methods and uses of such novel Timothy Grass proteins and peptides. Timothy Grass proteins and peptides described include antigens and allergens. Also disclosed herein are Timothy Grass proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses of such Timothy Grass proteins and peptides.

In accordance with the invention, there are provided proteins and peptides including, consisting of or consisting essentially of an amino acid sequence of a Timothy Grass protein or a subsequence, portion, homologue, variant or derivative thereof. In certain embodiments a Timothy Grass protein comprises, consists of or consists essentially of an amino acid sequence of a protein or peptide set out in Table 1 (SEQ ID NOS 1-620, respectively, in order of appearance), Table 2 (SEQ ID NOS 621-1442, respectively, in order of appearance) Table 4 (SEQ ID NOS 1443-2264, respectively, in order of appearance) or Table 6, or a subsequence, portion, homologue, variant or derivative thereof. In other embodiments a Timothy Grass protein or peptide does not consist of the sequence set forth in Table 1 as SEQ ID NOs:204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 282, 283, 284, 285, 286, 287, 289, 290, 291, 292, 293, 294, 295, 296, 489, 490 or 491; and/or does not consist of the sequence set forth in Table 4 as SEQ ID NOs:1517, 1542, 1598, 1679, 1761, 1849, 1850, 1851, 1935, 2040, 2116, 2133 or 2134.

In certain embodiments, a protein or peptide elicits, stimulates, induces, promotes, increases or enhances an anti-allergen immune response. In other certain embodiments, a protein or peptide decreases, reduces, inhibits, suppresses or disrupts an anti-allergen immune response. In particular aspects of the proteins and peptides described herein, an anti-allergen immune response is an anti-Timothy Grass allergen response. In further certain embodiments, a protein or peptide elicits, stimulates, induces, promotes, increases or enhances immunological tolerance (desensitizes) to an allergen, for example, a Timothy Grass allergen such as an amino acid sequence set forth Table 1 (SEQ ID NOS 1-620, respectively, in order of appearance), Table 2 (SEQ ID NOS 621-1442, respectively, in order of appearance), Table 4 (SEQ ID NOS 1443-2264, respectively, in order of appearance) or Table 6, or a subsequence, portion, homologue, variant or derivative thereof. In certain aspects, an anti-allergen response or immunological tolerance comprises a T cell response, for example a Th2 cell response (e.g., memory T cell response). In particular embodiments a protein or peptide is an IgG antigen.

In different embodiments, a protein or peptide includes, consists of or consists essentially of an amino acid sequence of a protein or peptide with open reading frame identification M.693, M.692, M.125, M.714, M.721, M.705, M.591, M.418, M.689, M.644, M.414, M.624, M.617, M.704, M.331, M.604, M.291, M.151, M.498, M.561, M.399, M.603, M.226, M.636, M.473, M.437, M.634, M.676, M.422, M.431, M.387, M.722, M.610, M.574, M.531, M.305, M.282, M.271, M.159, M.83, M.348, M.285, M.288, M.287, M.212, M.715, M.725, M.694, M.701, M.595, M.718, M.720, M.723, M.648, M.662, M.576, M.618, M.631, M.682, M.421, M.654, M.393, M.669, M.625, M.655, M.524, M.570, M.341, M.342, M.450, M.343, M.639, M.555, M.546, M.606, M.628, M.248, M.466, M.328, M.695, M.658, M.560, M.548, M.269, M.728, M.653, M.759, M.765, M.747, M.763, M.733, M.651, M.677, M.597, M.547, M.761, M.571, M.562, M.657, M.738, M.734, M.621, M.741, M.177, M.579, M.513, M.446, M.388, M.391, M.593, M.506, M.395, M.381, M.372, M.619, M.656, M.525, M.698, M.699, M.439, M.630, M.708, M.620, M.758, M.764, M.746, M.762, M.716, M.726, MN.66, M.717, M.727, M.719, M.724, M.577, M.8, M.235, M.678, M.675, M.641, M.499, M.583, M.649, M.6, M.29, M.34, M.183, M.101, M.149, M.164, M.129, M.45, M.116, M.165, M.146, M.69, M.123, M.107, M.3, M.113, M.204, M.174, M.178, M.191, M.580, M.587, M.594, M.539, M.569, M.588, M.615, M.578, M.352, M.514, M.419, M.443, M.540, M.640, M.642, M.646, M.627, M.626, M.645, M.652, M.650, M.559, M.622, M.565, M.567, M.581, M.609, M.182, M.134, M.283, M.297, M.367, M.84, M.189, M.586, M.496, M.255, M.471, M.575, M.163, M.314, M.194, M.294, M.472, M.369, M.104, M.206, M.24, M.469, M.420, M.444, M.697, M.687, M.713, M.638, M.673, M.700, M.702, M.707, M.710, M.683, M.670, M.643, M.663, M.664, M.666, M.748, M.731, M.735, M.750, M.752, M.756, M.754, M.608, M.740, M.39, M.303, M.389, M.390, M.284, M.201, M.28, M.364, M.344, M.74, M.180, M.317, M.298, M.192, M.77, M.92, M.144, M.9, M.296, M.187, M.172, M.72, M.38, M.239, M.289, M.240, M.214, M.365, M.614, M.598, M.632, M.633, M.616, M.690, M.607, M.672, M.545, M.671, M.272, M.301, M.202, M.492, M.647, M.457, M.686, M.495, M.486, M.729, M.760, M.668, M.599, M.417, M.635, M.584, M.592, M.709, M.489, M.392, M.347, M.458, M.464, M.415, M.520, M.410, M.467, M.494, M.374, M.118, M.346, M.318, M.519, M.600, M.254, M.438, M.479, M.523, M.380, M.480, M.371, M.482, M.261, M.108, M.260, M.556, M.461, M.400, M.474, M.490, M.491, M.401, M.470, M.409, M.435, M.553, M.537, M.402, M.481, M.483, M.554, M.538, M.234, M.237, M.264, M.563, M.566, M.532, M.557, M.573, M.549, M.550, M.551, M.558, M.463, M.684, M.739, M.637, M.517, M.712, M.732, M.711, M.730, M.736, M.737, M.247, M.13, M.57, M.61, M.47, M.43, M.32, M.518, M.267, M.73, M.270, M.150, M.366, M.679, M.680, M.230, M.530, M.667, M.505, M.488, M.445, M.436, M.508, M.688, M.613, M.487, M.552, M.572, M.336, M.534, M.213, M.384, M.220, M.147, M.127, M.145, M.33, M.110, M.173, M.50, M.249, M.18, M.5, M.25, M.394, M.329, M.330, M.345, M.323, M.316, M.130, M.131, M.203, M.227, M.128, M.70, M.292, M.526, M.585, M.681, M.685, M.596, M.660, M.674, M.703, M.504, M.515, M.521, M.493, M.497, M.509. M.533, M.484, M.302, M.478, M.222, M.691, M.510, M.119, M.535, M.543, M.528, M.529, M.373, M.590, M.361, M.432, M.477, M.408, M.568, M.589, M.462, M.516, M.522, M.412, M.4, M.256, M.56, M.55, M.64, M.22, M.148, M.205, M.332, M.171, ME.3566, ME.4276, ME.4056, ME.3805, ME.3720, ME.3916, ME.3855, ME.1412, ME.4234, ME.4088, ME.4115, ME.4210, ME.3897, ME.4229, ME.4231, ME.4280, ME.4281, ME.1571, ME.4190, ME.4230, ME.3882, MN.82, MN.124, MN.169, MN.185, MN.140, MN.201, MN.193, MN.183. MN.184, MN.173, MN.210, MN.206, MN.136, MN.94, MN.83, MN.14, MN.3, MN.46, MN.17, MN.20, MN.12, MN.35, MN.15, MN.38, MN.74, MN.41, MN.67, MN.27, MN.75, MN.47, MN.33, MN.86, MN.59, MN.8, MN.51, MN.62, MN.56, MN.30, MN.81, MN.91, MN.36, MN.71, MN.80, MN.76, MN.96, MN.106, MN.90, MN.57, MN.25, MN.108, MN.186, MN.58, MN.6, MN.77, MN.107, MN.203, MN.204, MN.211, MN.205, MN.68, MN.98, MN.93, MN.113, MN.123, MN.69, MN.178, MN.182, MN.4, MN.166, MN.167, MN.172, MN.168, MN.105, MN.39, MN.194, MN.195, MN.101, MN.116, MN.181, MN.97, MN.54, MN.156. MN.117, MN.163, MN.175, MN.102, MN.202, MN.157, MN.119, MN.114, MN.92, MN.88, MN.153, MN.95, MN.128, MN.122, MN.118, MN.99, MN.72, MN.214, MN.219, MN.220, MN.199, MN.224, MN.218, MN.215, MN.207, MN.223, MN.221, MN.222, MN.216, MN.162, MN.142, MN.158, MN.141, MN.53, MN.111, MN.112, MN.120, MN.130, MN.132, MN.127, MN.121, MN.139, MN.146, MN.64, MN.87, MN.89, MN.37 or MN.164, or subsequence, portion, homologue, variant or derivative thereof.

As disclosed herein, in certain embodiments proteins and peptides have a length in a range of about 5-10, 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 45-50, 50-60, 60-70, 70-80, 90-100, 100-125, 125-150, 150-175, 175-200, 200-250, 250-300, or more amino acid residues. In other embodiments, proteins and peptides have a length in a range of up to 25 amino acids in length, or from about 7 to 20; 8 to 30; 8 to 25; 8 to 20; 9 to 30; 9 to 25; 9 to 20; 10 to 30; 10 to 25; 10 to 30 amino acid residues.

Proteins and peptides include isolated and purified forms. Proteins and peptides also include those immobilized on a substrate, as well as amino acid sequences, subsequences, portions, homologues, variants, and derivatives immobilized on a substrate.

Proteins and peptides can be included in compositions, for example, a pharmaceutical composition. In particular embodiments, a pharmaceutical composition is suitable for specific or non-specific immunotherapy, or is a vaccine composition.

Isolated nucleic acid (including isolated nucleic acid) encoding a protein or peptide (TG protein or peptide), or a subsequence, portion, homologue, variant or derivative thereof are provided. In one embodiment, a nucleic acid encodes an amino acid sequence of a protein or peptide set forth in Table 1 (SEQ ID NOS 1-620, respectively, in order of appearance), Table 2 (SEQ ID NOS 621-1442, respectively, in order of appearance), Table 4 (SEQ ID NOS 1443-2264, respectively, in order of appearance) or Table 6, or a subsequence, portion, homologue, variant or derivative thereof.

Also provided are cells expressing a protein or peptide described herein. In various embodiments, a cell expresses a Timothy Grass protein that includes, consists of or consists essentially of an amino acid sequence of a protein or peptide set out in Table 1 (SEQ ID NOS 1-620, respectively, in order of appearance), Table 2 (SEQ ID NOS 621-1442, respectively, in order of appearance) Table 4 (SEQ ID NOS 1443-2264, respectively, in order of appearance) or Table 6, or a subsequence, portion, homologue, variant or derivative thereof. In certain aspects, a cell is a eukaryotic or prokaryotic cell and may be a mammalian, insect, fungal or bacterium cell.

Methods and uses and medicaments of proteins and peptides of the invention are included. In various embodiments, there are provided methods and uses of modulating an immune response against an allergen in a subject. In one embodiment, a method or use includes administering (delivering) an allergen to a subject an amount of the protein described herein sufficient to modulate the immune response against the allergen in the subject.

Such methods, uses and medicaments also include modulating immune activity of a cell against an allergen; and desensitizing, inducing, eliciting, increasing or improving in the cell immunological tolerance to an allergen. In particular embodiments, a method or use includes contacting a cell with an amount of the protein or peptide of any one of the above-mentioned embodiments, sufficient to modulate the immune activity of the cell against the allergen (e.g., against an allergen from which the peptide or protein derives), or administering to a subject an allergen from which the peptide or protein derives in order to desensitize, induce, elicit, increase or improve immunological tolerance to the allergen or to modulate an immune response against an allergen in a subject (e.g., an allergen from which the peptide or protein derives).

Invention proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof are suitable as a reagent for example, for specific immunotherapy. In particular embodiments, a protein or peptide suitable as a reagent includes, consists of or consists essentially of an amino acid sequence of a protein or peptide set forth in Table 1 (SEQ ID NOS 1-620, respectively, in order of appearance), Table 2 (SEQ ID NOS 621-1442, respectively, in order of appearance), Table 4 (SEQ ID NOS 1443-2264, respectively, in order of appearance) or Table 6, or a subsequence, portion, homologue, variant or derivative thereof.

Such methods, uses and medicaments further include reducing risk or providing a subject protection against an allergic reaction, allergic response, allergic disorder or allergic disease. In one embodiment, a method or use includes administering to the subject an amount of the protein or peptide sufficient to reduce risk or provide the subject with protection against the allergic reaction, allergic response, allergic disorder or allergic disease. Non-limiting examples of an allergic reaction or allergic response include allergic alveolitis, allergic bronchopulmonary aspergillosis, allergic conjunctivitis, allergic coryza, allergic dermatitis, allergic vasculitis, and allergic rhinitis.

Such methods, uses and medicaments additionally include treating an allergic reaction, allergic response, allergic disorder or allergic disease. In one embodiment, a method or use includes administering to the subject an amount of the protein or peptide, sufficient to treat the subject for the allergic response, allergic disorder or allergic disease.

In such methods, uses and medicaments, a peptide or protein can be derived from or based upon the allegen or can be derived from or based upon an allergen originating from the same organism as the allergen. More particularly, for example, a protein or peptide can be derived from or based upon an allergen causing the allergic reaction, allergic response, allergic disorder or allergic disease or said peptide derives from an allergen belonging to the same organism as the allergen causing said allergic reaction, allergic response, allergic disorder or allergic disease. Additionally, for example, a protein or peptide can be based upon or derived from an amino acid sequence set forth in Table 1 (SEQ ID NOS 1-620, respectively, in order of appearance), Table 2 (SEQ ID NOS 621-1442, respectively, in order of appearance), Table 4 (SEQ ID NOS 1443-2264, respectively, in order of appearance) or Table 6, or a subsequence, portion, homologue, variant or derivative thereof.

In various embodiments, a method or use desensitizes or induces, elicits, increases or improves immunological tolerance of a subject to an allergen in Table 1 (SEQ ID NOS 1-620, respectively, in order of appearance), Table 2 (SEQ ID NOS 621-1442, respectively, in order of appearance), Table 4 (SEQ ID NOS 1443-2264, respectively, in order of appearance) or Table 6. In various other embodiments, a method or use desensitizes or induces, elicits, increases or improves immunological tolerance of a subject to an amino acid sequence set forth in Table 1 (SEQ ID NOS 1-620, respectively, in order of appearance), Table 2 (SEQ ID NOS 621-1442, respectively, in order of appearance), Table 4 (SEQ ID NOS 1443-2264, respectively, in order of appearance) or Table 6, or a subsequence, portion, homologue, variant or derivative thereof.

As set forth herein a protein, peptide, method, use or medicament can include administration or delivery by any means, systemically, regionally or locally. In particular aspects, a protein or peptide is administered cutaneously, subcutaneously, epicutaneously, intracutaneously, intramuscularly, intravenously, orally, mucosally, by inhalation or nasally. As also set forth herein a protein, peptide, method, use or medicament can include repeatedly contacting a cell with, or administering to a subject, the protein or peptide, multiple times.

Proteins and peptides can be used in diagnostic and detection methods and uses. In one embodiment, detecting an allergic response, or diagnosing an allergy in a subject, a method or use includes contacting a cell from the subject (which may be an ex vivo or in vivo cell) with a protein or peptide as set forth herein; and determining if the protein or peptide modulates an immune response or activity from the contacted cell. If the protein or peptide modulates an immune response or activity from the contacted cell (which may be an ex vivo or in vivo cell) detects an allergic response or indicates that the subject has an allergic response or an allergy. In particular aspects, modulation of immune response or activity is determined by assaying for a hypersensitive reaction or response, such as a cutaneous immunological hypersensitive reaction.

Subjects in accordance with invention include mammals, such as humans. In particular embodiments, a subject has exhibited a symptom of, or suffers from, an allergic reaction, allergic response, allergic disorder or allergic disease. In more particular embodiments, a subject has had an allergic reaction or allergic response to a Timothy Grass allergen or another Grass of the order Poales. In additional particular embodiments, a subject has had an allergic reaction or allergic response to an allergen derived from or produced by Timothy Grass, such as an allergen or an amino acid sequence set forth in Table 1 (SEQ ID NOS 1-620, respectively, in order of appearance), Table 2 (SEQ ID NOS 621-1442, respectively, in order of appearance), Table 4 (SEQ ID NOS 1443-2264, respectively, in order of appearance) or Table 6, or a subsequence, portion, homologue, variant or derivative thereof. In further particular embodiments, a subject has had an allergic reaction or allergic response to an allergen derived from or produced by Timothy Grass selected from Phl p 1, Phl p 5, Phl p6 or a homologous allergen or antigen thereto.

DESCRIPTION OF DRAWINGS

FIG. 1 shows that known allergens do not account for the total T cell response against whole pollen extract. 35 pools (average 20 peptides/pool) of overlapping peptides spanning the ten major TG allergens along with whole TG extract were screened for recognition by PBMCs from allergic donors using IL-5 ELISPOT assays. The majority of donors who had an IL-5 T cell response to TG extract of ≧100 SFC per million input PBMCs showed a response pattern similar to that shown in panel A, with several pools eliciting strong IL-5 responses. However, some donors showed a response pattern as depicted in panel B, where a vigorous response was detected against extract but no response was detected against peptides from known allergens. In total, as shown in panel C, 33% of donors reacted to none of the peptide pools despite strong extract responses (n=21).

FIGS. 2A-2B show a 2D gel electrophoresis and immunoblot analysis of TG extract using pooled sera from allergic donors. TG pollen extract was run on a 2D gel and stained with Coomassie brilliant blue (A). A second gel run in parallel was blotted and probed with a serum pool from 8 TG-allergic donors to identify proteins reactive with human IgE and IgG. Anti IgE-red, anti IgG-green, dual reactivity-yellow (B).

FIGS. 3A-3B show that a majority of TG specific T cells target novel antigens. A) Bar chart indicating the IL-5 response rate of PBMCs from allergic and non-allergic donors to peptide pools from known and novel antigens. Open bars indicate response rates from allergic donors, solid bars indicate responses from normal donors (n=20 per donor group). B) Bar chart showing the total number of IL-5 producing T cells targeting novel antigens (light grey) vs. known allergens (dark grey) in normal and allergic patients.

FIG. 4 shows percentage recognition of novel Timothy grass antigens (NTGA) by TG allergic donors. Bar chart showing percentage of donors producing IL-5 in response to novel Timothy grass antigens (NTGA)-derived peptide stimulation. NTGAs are categorized according to antibody reactivity as indicated on the X-axis. The dashed line indicates the minimum threshold of ≧20% recognition to be considered an allergen.

FIG. 5 shows that memory T cells are the source of IL-5 T cell responses after in vitro expansion. IL-5 production in naïve and memory T cells in response to TG extract (TG), the dominant known (TG P20) and novel peptide pools (NTGA P19) were measured after 14 days of expansion following TG stimulation in vitro (n=6).

FIGS. 6A-6B show T cell responses against conventional and novel TG antigens can be detected directly ex vivo. A) FACS plot showing the Th2 T cell subset sorted based on expression of CXCR3 (Th1) and CCR4 (Th2). B) IL-5 production by Th2 cells from allergic donors in response to TG extract, the dominant known (TG P20) and novel (NTGA P19) peptide pools as measured ex vivo (n=8).

FIG. 7 shows production of IL-4, IL-5, IL-13 and all Th2 cytokines (IL-4, 5 and 13 combined) in response to TG extract, PHA, TG P20 and NTGA P19. TG stimulated cells were cultured in vitro with IL-2 for 14 days. Cells were re-stimulated with TG extract, the dominant known and novel TG peptide pools (TG P20 and NTGA P19) and PHA. Th2 cytokine production was measured by ELISPOT to determine the best read-out system.

FIGS. 8A-8B show deconvolution of positive peptide pools to identify T-cell reactive antigens and epitopes. IL-5 production from PBMC of allergic individuals in response to single peptides was measured. A) Number of recognition events (defined as one peptide recognized by at least one patient with a magnitude of ≧20 SFC) per antigen tested. B) Sum of the magnitudes of IL-5 responses against peptides from each positive antigen.

DETAILED DESCRIPTION

As disclosed herein, T cell responses against Timothy Grass (TG) allergen do not correlate with IgE levels and T cell responses in TG pollen allergic individuals. Furthermore, as also disclosed herein a third of the patients studied had no Th2 cell response against any of the known IgE reactive proteins despite having strong responses against whole TG extract. The invention relates to in part to the discovery that TG pollen extract contains novel T cell antigens in addition to the known IgE-inducing allergens.

Thus, in accordance with the invention, there are provided novel Timothy grass proteins and novel Timothy grass peptides, and subsequences, portions, homologues, variants and derivatives thereof. A Timothy grass protein or peptide as described herein may include any Timothy grass protein or peptide, or a subsequence, portion, homologue, variant or derivative thereof. In certain embodiments, a Timothy grass protein or peptide as described herein may include a novel Timothy grass protein or peptide, or a subsequence, portion, homologue, variant or derivative thereof.

In particular embodiments, a Timothy grass protein or peptide described herein includes, consists or consists essentially of a protein or peptide having an open reading frame amino acid sequence set out in Table 1 (SEQ ID NOS:1-620, respectively, in order of appearance), or a subsequence, portion, homologue, variant or derivative thereof (e.g, of all or a part of an amino acid sequence in Table 1 (SEQ ID NOS:1-620, respectively, in order of appearance). In other embodiments, a Timothy grass protein or peptide, includes, consists or consists essentially of an amino acid sequence of a protein or peptide set forth in Table 1 (SEQ ID NOS 1-620, respectively, in order of appearance), Table 2 (SEQ ID NOS 621-1442, respectively, in order of appearance), Table 4 (SEQ ID NOS 1443-2264, respectively, in order of appearance) or Table 6, or a subsequence, portion, homologue, variant or derivative thereof (e.g, of all or a part of an amino acid sequence in Table 1 (SEQ ID NOS 1-620, respectively, in order of appearance), Table 2 (SEQ ID NOS 621-1442, respectively, in order of appearance), Table 4 (SEQ ID NOS 1443-2264, respectively, in order of appearance) or Table 6. In certain embodiments, a Timothy grass protein, peptide, subsequence, portion, homologue, variant or derivative thereof, includes, consists of or consists essentially of an amino acid sequence of a protein or peptide with open reading frame identification M.693, M.692, M.125, M.714, M.721, M.705, M.591, M.418, M.689, M.644, M.414, M.624, M.617, M.704, M.331, M.604, M.291, M.151, M.498, M.561, M.399, M.603, M.226, M.636, M.473, M.437, M.634, M.676, M.422, M.431, M.387, M.722, M.610, M.574, M.531, M.305, M.282, M.271, M.159, M.83, M.348, M.285, M.288, M.287, M.212, M.715, M.725, M.694, M.701, M.595, M.718, M.720, M.723, M.648, M.662, M.576, M.618, M.631, M.682, M.421, M.654, M.393, M.669, M.625, M.655, M.524, M.570, M.341, M.342, M.450, M.343, M.639, M.555, M.546, M.606, M.628, M.248, M.466, M.328, M.695, M.658, M.560, M.548, M.269, M.728, M.653, M.759, M.765, M.747, M.763, M.733, M.651, M.677, M.597, M.547, M.761, M.571, M.562, M.657, M.738, M.734, M.621, M.741, M.177, M.579, M.513, M.446, M.388, M.391, M.593, M.506, M.395, M.381, M.372, M.619, M.656, M.525, M.698, M.699, M.439, M.630, M.708, M.620, M.758, M.764, M.746, M.762, M.716, M.726, MN.66, M.717, M.727, M.719, M.724, M.577, M.8, M.235, M.678, M.675, M.641, M.499, M.583, M.649, M.6, M.29, M.34, M.183, M.101, M.149, M.164, M.129, M.45, M.116, M.165, M.146, M.69, M.123, M.107, M.3, M.113, M.204, M.174, M.178, M.191, M.580, M.587, M.594, M.539, M.569, M.588, M.615, M.578, M.352, M.514, M.419, M.443, M.540, M.640, M.642, M.646, M.627, M.626, M.645, M.652, M.650, M.559, M.622, M.565, M.567, M.581, M.609, M.182, M.134, M.283, M.297, M.367, M.84, M.189, M.586, M.496, M.255, M.471, M.575, M.163, M.314, M.194, M.294, M.472, M.369, M.104, M.206, M.24, M.469, M.420, M.444, M.697, M.687, M.713, M.638, M.673, M.700, M.702, M.707, M.710, M.683, M.670, M.643, M.663, M.664, M.666, M.748, M.731, M.735, M.750, M.752, M.756, M.754, M.608, M.740, M.39, M.303, M.389, M.390, M.284, M.201, M.28, M.364, M.344, M.74, M.180, M.317, M.298, M.192, M.77, M.92, M.144, M.9, M.296, M.187, M.172, M.72, M.38, M.239, M.289, M.240, M.214, M.365, M.614, M.598, M.632, M.633, M.616, M.690, M.607, M.672, M.545, M.671, M.272, M.301, M.202, M.492, M.647, M.457, M.686, M.495, M.486, M.729, M.760, M.668, M.599, M.417, M.635, M.584, M.592, M.709, M.489, M.392, M.347, M.458, M.464, M.415, M.520, M.410, M.467, M.494, M.374, M.118, M.346, M.318, M.519, M.600, M.254, M.438, M.479, M.523, M.380, M.480, M.371, M.482, M.261, M.108, M.260, M.556, M.461, M.400, M.474, M.490, M.491, M.401, M.470, M.409, M.435, M.553, M.537, M.402, M.481, M.483, M.554, M.538, M.234, M.237, M.264, M.563, M.566, M.532, M.557, M.573, M.549, M.550, M.551, M.558, M.463, M.684, M.739, M.637, M.517, M.712, M.732, M.711, M.730, M.736, M.737, M.247, M.13, M.57, M.61, M.47, M.43, M.32, M.518, M.267, M.73, M.270, M.150, M.366, M.679, M.680, M.230, M.530, M.667, M.505, M.488, M.445, M.436, M.508, M.688, M.613, M.487, M.552, M.572, M.336, M.534, M.213, M.384, M.220, M.147, M.127, M.145, M.33, M.110, M.173, M.50, M.249, M.18, M.5, M.25, M.394, M.329, M.330, M.345, M.323, M.316, M.130, M.131, M.203, M.227, M.128, M.70, M.292, M.526, M.585, M.681, M.685, M.596, M.660, M.674, M.703, M.504, M.515, M.521, M.493, M.497, M.509. M.533, M.484, M.302, M.478, M.222, M.691, M.510, M.119, M.535, M.543, M.528, M.529, M.373, M.590, M.361, M.432, M.477, M.408, M.568, M.589, M.462, M.516, M.522, M.412, M.4, M.256, M.56, M.55, M.64, M.22, M.148, M.205, M.332, M.171, ME.3566, ME.4276, ME.4056, ME.3805, ME.3720, ME.3916, ME.3855, ME.1412, ME.4234, ME.4088, ME.4115, ME.4210, ME.3897, ME.4229, ME.4231, ME.4280, ME.4281, ME.1571, ME.4190, ME.4230, ME.3882, MN.82, MN.124, MN.169, MN.185, MN.140, MN.201, MN.193, MN.183. MN.184, MN.173, MN.210, MN.206, MN.136, MN.94, MN.83, MN.14, MN.3, MN.46, MN.17, MN.20, MN.12, MN.35, MN.15, MN.38, MN.74, MN.41, MN.67, MN.27, MN.75, MN.47, MN.33, MN.86, MN.59, MN.8, MN.51, MN.62, MN.56, MN.30, MN.81, MN.91, MN.36, MN.71, MN.80, MN.76, MN.96, MN.106, MN.90, MN.57, MN.25, MN.108, MN.186, MN.58, MN.6, MN.77, MN.107, MN.203, MN.204, MN.211, MN.205, MN.68, MN.98, MN.93, MN.113, MN.123, MN.69, MN.178, MN.182, MN.4, MN.166, MN.167, MN.172, MN.168, MN.105, MN.39, MN.194, MN.195, MN.101, MN.116, MN.181, MN.97, MN.54, MN.156. MN.117, MN.163, MN.175, MN.102, MN.202, MN.157, MN.119, MN.114, MN.92, MN.88, MN.153, MN.95, MN.128, MN.122, MN.118, MN.99, MN.72, MN.214, MN.219, MN.220, MN.199, MN.224, MN.218, MN.215, MN.207, MN.223, MN.221, MN.222, MN.216, MN.162, MN.142, MN.158, MN.141, MN.53, MN.111, MN.112, MN.120, MN.130, MN.132, MN.127, MN.121, MN.139, MN.146, MN.64, MN.87, MN.89, MN.37 or MN.164, or subsequence, portion, homologue, variant or derivative thereof. The foregoing and other TG proteins and peptides set forth herein may be used in the methods and uses, including methods and uses disclosed herein.

In particular embodiments, a protein or peptide includes, consists of or consists essentially of a Timothy Grass amino acid sequence set forth in Table 1 (SEQ ID NOS 1-620), or a subsequence, portion, homologue, variant or derivative thereof. Said homologues may have at least 65%, 70, 75, 80, 85, 90 or 95% homology or identity to the corresponding Timothy Grass amino acid sequence set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. Such subsequences may be 7 to 30 amino acids in length, and optionally further where at least 7 amino acids has at least 75%, or at least 80%, 85%, 90% identity or homology to at least 7 contiguous amino acids of the corresponding Timothy Grass amino acid sequence set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. Moreover, a subsequence may be 7 to 25 amino acids in length, such as 7 to 20; 8 to 30; 8 to 25; 8 to 20; 9 to 30; 9 to 25; 9 to 20; to 30; 10 to 25; 10 to 30 amino acids in length and wherein at least 8, such as at least 9, 10, 11, 12, 13, 14 or 15 amino acids of the subsequence has at least 75%, such as at least 80%, 85%, 90% identity or homology to at least 8, such as at least 9, 10, 11, 12, 13, 14 or 15 amino acids, respectively, contiguous amino acids of said corresponding Timothy Grass amino acid sequence set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. In various aspects, a protein or peptide does not consist of a sequence set forth in Table 1 as SEQ ID NOs:204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 282, 283, 284, 285, 286, 287, 289, 290, 291, 292, 293, 294, 295, 296, 489, 490 and/or 491.

In additional particular embodiments, a protein or peptide includes, consists of or consists essentially of an amino acid sequence set forth in Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264), Table 6 or a variant or derivative thereof. A variant may be a longer peptide, for example, of up to 30 amino acids in length and which includes a corresponding amino acid sequence as set forth in Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. A variant may also include a peptide of 7 to 30 amino acids in length and which includes a subsequence of at least 7 amino acids having at least 75% identity or homology, such as at least 80 or 85% identity or homology, to at least 7 contiguous amino acids of the corresponding amino acid sequence set forth in Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. A longer variant peptide may be up to 25 amino acids in length, such as up to 24, 23, 22, 21, 20, 19 or 19 amino acids in length. The variant may be a peptide of 7 to 25 amino acids in length, such as 7 to 20; 8 to 30; 8 to 25; 8 to 20; 9 to 30; 9 to 25; 9 to 20; 10 to 30; 10 to 25; 10 to 30 amino acids in length and wherein said subsequence is of at least 8, 9 or 10 amino acids having at least 75% (such as at least 80% or 85%) identity or homology to at least 8, 9 or 10 contiguous amino acids, respectively, of said corresponding amino acid sequence set forth in Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. In various aspects, a protein or peptide does not consist of sequences set forth in Table 4 as SEQ ID NOs:1517, 1542, 1598, 1679, 1761, 1849, 1850, 1851, 1935, 2040, 2116, 2133 and/or 2134.

As used herein, an “antigen” refers to a substance, including but not limited to a protein or peptide that elicits, induces, stimulates, promotes or enhances an immune response when administered to a subject. An immune response elicited by an antigen may include, but is not limited to, a B cell or a T cell response. An immune response can include a cellular response with a particular pattern of lymphokine/cytokine production (e.g., Th1, Th2), a humoral response (e.g., antibody production), or a combination thereof, to a particular antigen. For example, if a subject previously exposed to an allergen (i.e., is sensitized or is hypersensitive) comes into contact with the allergen again, allergic asthma may develop due to a Th2 response characterized by an increased production of type 2 cytokines (e.g., IL-4, IL-5, IL-9, and/or IL-13) secreted by CD4+ T lymphocytes.

As used herein an “epitope” refers to a region or part of an antigen that elicits an immune response when administered to a subject. In particular embodiments, an epitope may be comprised of a region or part of a Timothy grass protein or peptide (e.g, of all or a part of an amino acid sequence in Table 1 (SEQ ID NOS 1-620, respectively, in order of appearance), Table 2 (SEQ ID NOS 621-1442, respectively, in order of appearance), Table 4 (SEQ ID NOS 1443-2264, respectively, in order of appearance) or Table 6. In more particular embodiments, an epitope may be comprised of a region or part of a TG protein or peptide set forth in Table 1 (SEQ ID NOS 1-620, respectively, in order of appearance), Table 2 (SEQ ID NOS 621-1442, respectively, in order of appearance), Table 4 (SEQ ID NOS 1443-2264, respectively, in order of appearance) or Table 6. In particular aspects, an epitope is a T cell epitope, i.e., an epitope that elicits, stimulates, induces, promotes, increases or enhances a T cell activity, function or response.

An antigen, epitope, allergen, or composition thereof can modulate an undesired or abnormal inflammatory response. An antigen, epitope, allergen, or composition thereof as described herein may alter the Th2 response by, for example, shifting the immune response toward a Th1 phenotype that is less damaging. That is, an altered (or modulated) immune response can decrease, inhibit, suppress, or reduce sensitivity (desensitize) to an antigen, epitope, or allergen, or against inflammatory responses (e.g., allergy, asthma, rash, wheezing, coughing, eye irritation, etc.) caused by an antigen, epitope, or allergen (e.g., a TG protein or peptide set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6).

Accordingly, non-limiting examples of antigens, allergens are peptides and proteins having defined amino acid sequences and which comprise T cell epitopes, i.e., elicit, stimulate, induce, promote, increase or enhance a T cell response or activity. Antigens and allergens can be analyzed to determine whether they include at least one T cell epitope using any number of assays (e.g. T cell proliferation assays, lymphokine secretion assays, T cell non-responsiveness studies, etc.).

The term “allergen” refers to an antigen which elicits, induces, stimulates, or enhances an immune response by a cell or the immune system of an exposed animal (e.g., human). An antigen is an allergen when the specific immune response is the development of enhanced sensitivity or a hypersensitivity to the antigen, but the antigen itself is not typically innately harmful. An allergen is therefore a particular type of antigen that can cause development of enhanced or increased sensitivity or hypersensitivity in a subject. For example, an allergen can elicit production of IgE antibodies in predisposed subjects. However, as disclosed herein an allergen need not elicit production of IgE antibodies. Other examples of responses elicited by allergens include T cell responses or activity, such as production of a lymphokine, cytokine, or effector function on other cells. Responses caused by allergens are also described, for example, in Mol. Biol. of Allergy and Immunology, ed. R. Bush, Immunology and Allergy Clinics of North American Series (August 1996). Although the terms “allergen” and “antigen” have a different meaning, reference to “allergen” herein includes reference to “antigen” and reference to “antigen” herein includes reference to “allergen.”

Typically, allergens are organic substances, such as proteins, peptides, nucleotides, carbohydrates, lipids, fats, nucleic acid, and combinations or mixtures thereof. Allergen(s) as used herein include, but are not limited to a specific allergen protein, mixture of allergen proteins, an extract of an allergen, chemically or genetically manufactured allergen, or any combination thereof (e.g., a TG protein or peptide set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6).

In certain embodiments, proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof, described herein (e.g., a TG protein or peptide set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6) stimulate, induce, promote, increase or enhance an immune response. In particular embodiments, a protein or peptide is a T cell antigen, allergen or epitope. In additional particular embodiments, a protein or peptide, a subsequence, portion, homologue, variant or derivative thereof, elicit, stimulate, promote, induce or enhance a T cell response, which may include but is not limited to a Th2 cell response. In further particular embodiments, a TG protein or peptide, a subsequence, portion, homologue, variant or derivative thereof, modulates, inhibits, or reduces T cell response, which may include but is not limited to a Th2 cell response. In certain embodiments, a T cell response is an anti-allergen immune response, including but not limited to an anti-TG immune response.

As used herein, the term “immune response” includes T cell (cellular) mediated and/or B cell (humoral) mediated immune responses, or both cellular and humoral responses. Exemplary immune responses include T cell responses, e.g., lymphokine production, cytokine production and cellular cytotoxicity. T-cell responses include Th1 and/or Th2 responses. In addition, the term immune response includes responses that are indirectly effected by T cell activation, e.g., antibody production (humoral responses) and activation of cytokine responsive cells, e.g., eosinophils, macrophages. Immune cells involved in the immune response include lymphocytes, such as T cells (CD4+, CD8+, Th1 and Th2 cells, memory T cells) and B cells; antigen presenting cells (e.g., professional antigen presenting cells such as dendritic cells, macrophages, B lymphocytes, Langerhans cells, and non-professional antigen presenting cells such as keratinocytes, endothelial cells, astrocytes, fibroblasts, oligodendrocytes); natural killer (NK) cells; myeloid cells, such as macrophages, eosinophils, mast cells, basophils, and granulocytes.

As set forth herein, a particular immunoglobulin (Ig) isotype may be produced in response to an antigen (allergen). For example, an “IgG antigen” refers to an antigen that induces an IgG antibody response. Likewise, an “IgE antigen” refers to an antigen that induces an IgE antibody response; an “IgA antigen” refers to an antigen that induces an IgA antibody response, and so forth. In certain embodiments, such an immunoglobulin (Ig) isotype produced in response to an antigen may also elicit production of other isotypes. For example, an IgG antigen may induce an IgG antibody response in combination with one more of an IgE, IgA, IgM or IgD antibody response. Accordingly, in certain embodiments, an IgG antigen may induce an IgG antibody response without inducing an IgE, IgA, IgM or IgD antibody response.

The invention encompasses methods and uses for reducing, decreasing, preventing the development of sensitization or hypersensitization to an antigen(s) or allergen(s), such as a TG antigen or allergen. Accordingly, in other embodiments, a protein or peptide, subsequence, portion, homologue, variant or derivative thereof (e.g., a TG protein or peptide set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6), decreases, inhibits, suppresses or reduces a T cell response, which may include but is not limited to a Th2 cell response. In certain embodiments, the T cell response is an anti-allergen immune response, such as a memory T cell response.

In accordance with another aspect of the invention there are provided a TG protein or peptide, a subsequence, portion, homologue, variant or derivative thereof, wherein the protein or peptide elicits, stimulates, induces, promotes, increases or enhances an anti-allergen immune response. In another aspect, there are provided a TG protein or peptide, subsequence, portion, homologue, variant or derivative thereof, wherein the protein or peptide decreases, reduces, inhibits, suppresses or disrupts an anti-allergen immune response.

As will be understood by a person of skill in the art, a protein or a subsequence, portion, homologue, variant or derivative thereof as described herein (e.g., a TG protein or peptide set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6), may elicit, stimulate, induce, promote, increase or enhance certain elements of an anti-allergen immune response while decreasing, reducing, inhibiting, suppressing or reducing other elements of the anti-allergen response, either contemporaneously or sequentially. In one non-limiting example, a protein or a subsequence, portion, homologue, variant or derivative thereof (e.g., a TG protein or peptide set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6) may elicit, stimulate, induce, promote, increase or enhance proliferation of regulatory T cells while decreasing, reducing, inhibiting, suppressing or reducing production of proinflammatory lymphokines/cytokines.

An “anti-allergen,” “anti-protein,” or “anti-peptide immune response” refers to an immune response that is particular or specific for the protein or peptide, e.g., allergen. In such instances, the response is specifically triggered (elicited, stimulated, increased, induced, or promoted) by the protein or peptide, e.g., allergen (e.g., a TG protein or peptide). Although an “anti-allergen” immune response is specifically triggered by a given allergen, the immune response itself can be characterized by general features of immune responses, such as T cell (cellular) and/or B cell (humoral) immune responses, as set forth herein.

As disclosed herein, a TG protein, peptide, subsequence, portion, homologue, variant or derivative thereof, may elicit, stimulate, induce, promote, increase or enhance immunological tolerance to an antigen, including an allergen (e.g., a TG protein or peptide set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6). In certain embodiments, a TG protein, peptide, subsequence, portion, homologue, variant or derivative thereof, described herein may elicit, stimulate, induce, promote, increase or enhance immunological tolerance to an allergen. Thus in certain embodiments a protein, peptide, subsequence, portion, homologue, variant or derivative thereof, described herein may be effective in use or treatment (e.g., therapeutic) of an allergic reaction or allergic immune response, including but not limited to an allergic response following a secondary or subsequent exposure of a subject to an antigen or allergen. In particular embodiments, immunological tolerance elicited, stimulated, induced, promoted, increased or enhanced from use or administration of a TG protein, peptide, subsequence, portion, homologue, variant or derivative thereof, may involve modulation of T cell activity, including but not limited to CD4+ T cells, CD8+ T cells, Th1 cells, Th2 cells and regulatory T cells (Tregs), and memory T cells. For example, immunological tolerance elicited, stimulated, induced, promoted, increased or enhanced from use or administration of a TG protein, peptide, subsequence, portion, homologue, variant or derivative thereof (e.g., a TG protein or peptide set forth in Table 1 (SEQ ID NOS 1-620, respectively, in order of appearance), Table 2 (SEQ ID NOS 621-1442, respectively, in order of appearance), Table 4 (SEQ ID NOS 1443-2264, respectively, in order of appearance) or Table 6)-inflammatory lymphokines/cytokines produced by T cells. Thus, in accordance with certain aspects of the invention, there are provided TG proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof, that elicit, stimulate, induce, promote, increase or enhance immunological tolerance to an antigen or allergen (e.g., a TG protein or peptide).

Accordingly, methods and uses of inducing immunological tolerance in a subject to an allergen are provided. In one embodiment, a method or use reduces occurrence, frequency, severity, progression, or duration of physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated an allergic response to the allergen in the subject. Thus, in various embodiments, inducing immunological tolerance can protect a subject against or treat a subject for an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen.

As disclosed herein, surprisingly TG proteins and antigens that elicit Th2 immune responses are not a priori IgE reactive. Thus, there are provided methods and uses of providing specific immunotherapy to a subject, in which a subject is administered an amount of a protein or peptide that is an IgG, IgA, IgM or IgD antigen. In a particular embodiment, a method or use includes administering to the subject an amount of a protein or peptide that is an IgG antigen.

In certain embodiments of the invention methods and uses, the allergen is a TG protein or peptide. In more particular embodiments, the allergen is an amino acid sequence of a protein or peptide set forth in Table 1 (SEQ ID NOS 1-620, respectively, in order of appearance), Table 2 (SEQ ID NOS 621-1442, respectively, in order of appearance), Table 4 (SEQ ID NOS 1443-2264, respectively, in order of appearance) or Table 6, or a subsequence, portion, homologue, variant or derivative thereof. In other non-limiting embodiments, the allergen includes, consists of or consists essentially of an amino acid sequence set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6.

In other embodiments of invention methods and uses, the allergen is not a Timothy grass protein or peptide. Non-limiting examples of such allergens include proteins and peptides from grass, trees, dust mites, insects, pollen, including but not limited to alder, Alternaria rot fungus, American cockroach, American house dust mite, Ash, Aspergillus fumigatus, Bermuda grass, Birch, Canary grass, Cat, Cladosporium herbarum, Common cypress, Cypress, Date palm, Dog, English plantain, European house dust mite, Giant ragweed, Japanese cypress, Kentucky blue grass, Lolium perenne, Orchard grass, Penicillium chrysogenum, Prickly juniper, Russian thistle, Rye grass, Sweet vernal grass or White oak.

An allergic reaction refers to a local or general reaction in a subject following contact with a specific antigen (e.g., allergen) to which the subject had been previously exposed and had become sensitized. The immunologic interaction of antigen (e.g., allergen) with sensitized lymphocytes (T cells) and/or antibody can give rise to inflammation and tissue damage. An allergy is an undesirable immune response or reaction that can therefore produce damage to self-tissues and cells, usually through inflammatory reactions.

One non-limiting example of an allergy is asthma. Asthma, which can be extrinsic or allergic asthma (also referred to as reactive airway disease), is an inflammatory disease of the lungs characterized by a generally reversible airway obstruction. Non-limiting features of allergic asthma include elevated concentrations of serum IgE, pulmonary eosinophilia, airway hyper-responsiveness, excessive airway mucus production, and airway remodeling marked by peribronchiolar collagen deposition and increases in airway smooth muscle mass. Other exemplary allergic reactions or inflammatory conditions include allergic alveolitis, allergic bronchopulmonary aspergillosis, allergic dermatitis, eczema, allergic conjunctivitis, allergic coryza, allergic vasculitis, rhinosinusitis, and allergic rhinitis.

Hypersensitivity or hyper-responsiveness used in reference to an immune response means an abnormal response or condition in which an antigen or allergen elicits an exaggerated immune response. For example, allergic asthma can result from repeated exposure to airborne allergens that trigger detrimental immunological responses, such as persistent inflammation in the bronchial wall, which can in turn cause structural and functional changes in the respiratory system. After allergen contact by sensitized subjects (i.e., those subjects that have already been exposed to the allergen), the immune response is dependent on CD4+ T lymphocytes that are skewed to a T helper (Th) 2 phenotype. Th2 cytokines, for example, IL-4, IL-5, IL-9, and IL-13 are produced and are believed to contribute to asthma pathogenesis. For example, IL-4 drives the T helper response in favor of Th2, resulting in enhanced production of IgE; IL-5, which with granulocyte macrophage colony stimulating factor (GM-CSF) and IL-3, is important for the production of eosinophils; and IL-13, which is required for airway hyper-responsiveness and mucous metaplasia, which are downstream pathophysiological features that are closely linked with clinical asthma. All of these cytokines, together with TGF-beta have been implicated in airway remodeling. Increased numbers of airway eosinophils is also associated with disease severity, although the role of eosinophils in the pathology of asthma is not entirely understood, (see, e.g., Lee et al., Science 305:1773 (2004); Humbles et al., Science 305:1776 (2004)). The resulting structural and morphometric changes (remodeling) include subepithelial fibrosis, goblet cell hyperplasia and metaplasia, which result in functional consequences such as loss of distensibility of asthmatic airways, bronchial hyper-reactivity (even in the absence of the allergen), and an accelerated progressive decrease in forced expiratory volume at 1 second time intervals. Th2 cytokines may also prime and activate eosinophils to release proinflammatory agents, lipid mediators, and other cytokines thought to contribute to the observed tissue damage, remodeling, and hyper-responsiveness.

As used herein, the term “tolerance,” “anergy,” or “antigen (allergen)-specific tolerance” refers to a reduction, loss, inhibition, suppression or decrease, of T cells to T cell receptor-mediated stimulation by an allergen or antigen. The reduction can lead to educed or non-responsiveness (insensitivity) of T cells to an allergen or antigen. Such insensitivity is generally antigen-specific and persists after exposure to the antigenic peptide has ceased. For example, tolerance in T cells is characterized by lack of lymphokine/cytokine production, e.g., IL-2, IFN-γ, or TNF-β. T-cell anergy occurs when T cells are exposed to antigen or allergen and receive a first signal (a T cell receptor or CD-3 mediated signal) in the absence of a second signal (a costimulatory signal). Under these conditions, re-exposure of the cells to the same antigen or allergen (even if re-exposure occurs in the presence of a costimulatory molecule) results in failure to produce cytokines and subsequently failure of T cells to proliferate. Thus, a failure to produce lymphokines/cytokines prevents proliferation. Tolerized T cells can, however, proliferate if cultured with cytokines (e.g., IL-2). For example, T cell anergy can also be observed by the lack of IL-2 production by T lymphocytes as measured by ELISA or by a proliferation assay using an indicator cell line.

As used herein, the term “immunological tolerance” refers to a) a decreased or reduced level of a specific immunological response (thought to be mediated at least in part by antigen-specific effector T lymphocytes, B lymphocytes, antibody, a combination); b) a delay in the onset or progression of a specific immunological response; or c) a reduced risk of the onset or progression of a specific immunological response to an antigen or allergen. “Specific” immunological tolerance occurs when tolerance is preferentially invoked against certain antigens (allergens) in comparison with other antigens (allergens). Tolerance is an active antigen dependent process and differs from non-specific immunosuppression and immunodeficiency.

An increase, improvement, enhancement or induction of “tolerance” refers to a decrease, reduction, inhibition, suppression, or limiting or controlling or clearing of specific immunological reactivity to an antigen as compared to reactivity to the antigen in a previous exposure to the same antigen. Thus in certain embodiments, a method or use of inducing immunological tolerance in a subject to an allergen includes elimination of an allergic response of the subject to the allergen. Immunological tolerance in a subject to an allergen can also be reflected by reducing the occurrence, frequency, severity, progression, or duration of an allergic response of the subject to the antigen or allergen.

While desirably tolerance can refer to non-reactivity to an antigen or allergen, tolerance need not be complete non-reactivity and can only be partial, and in any event is reflected by a decrease, inhibition, suppression or reduction in specific immunological reactivity to an antigen or allergen as compared to reactivity to the antigen or allergen in a previous exposure to the same antigen or allergen (or epitope thereof). Thus, in another embodiment, a method or use of inducing immunological tolerance in a subject to an allergen includes stabilizing or maintaining the level of an allergic response in the subject to the allergen.

Induction of immune tolerance (also referred to as desensitization), and the relative amount of immune tolerance, can be measured by methods disclosed herein or known to the skilled artisan. For example, induction of immune tolerance can be measured by modulation of lymphokine and/or cytokine level in said animal. As such, modulation can be an increase of a cytokine level, for instance an increase of a cytokine level at least 1.5, 2, 3 times or more relative to before said induction. Alternatively, modulation can be a decrease of the level of a particular cytokine level, for instance a decrease of the cytokine level is at least 1.5, 2, 3 times or more relative to before said induction. The lymphokines/cytokines chosen to measure can be from any relevant lymphokines/cytokines, such as IL-2, IL-5, IL-4, IL-6, IL-10, IL-12, IL-13, TNF-α, IFN-γ, IFN-α, TGF-β, MCP-1, RANK-L and Flt3L.

As disclosed herein, peptides and proteins of the invention are useful in methods and uses, for example, of “specific” immunotherapy. The term “specific” immunotherapy refers to a therapy particular or specific for the protein or peptide, e.g., allergen. To achieve “specific immunotherapy” an antigen is administered to a subject in order to achieve immunological tolerance of the subject to an antigen, including for example, an allergen.

More particularly, specific immunotherapy may be conducted by administering an antigen derived from the antigen (e.g. allergen) against which immunological tolerance is sought. Alternatively, immunotherapy can be conducted by “non-specific” immunotherapy using a different antigen or protein than the antigen against which immunological tolerance is sought. For example as described in US patent application publication US2012/0100164A1, which relates to the treatment of a hypersensitivity immune response, such as allergic rhinitis or asthma, via bystander suppression by use of an antigen unrelated to the allergen triggering the hypersensitivity immune response in an individual to be treated provided that the antigen is obtainable from the source material, e.g. Grass pollen, comprising the “triggering” allergen (e.g. Phl p 1, 5 or 6).

Thus, in different embodiments, the TG antigen administered and antigen (e.g. allergen) against which immunological tolerance is sought may be the same or a different TG protein. In one embodiment, a method or use includes administering to a subject an amount of a TG protein or peptide, or subsequence, portion, homologue, variant or derivative thereof sufficient to elicit, stimulate, induce, promote, increase, enhance or augment immunological tolerance to an allergen in the subject. In one aspect, a TG antigen is administered to a subject during specific immunotherapy to treat the subject for an allergic reaction to the same TG antigen. In a different aspect, a TG antigen is administered to a subject during specific immunotherapy to treat the subject for an allergic reaction to a different TG antigen. In another embodiment, a method includes administering to a subject an amount of a nucleic acid encoding all or a portion (e.g., a T cell epitope) of a Timothy grass protein or peptide, or subsequence, portion, homologue, variant or derivative thereof sufficient to elicit, stimulate, induce, promote, increase, enhance or augment immunological tolerance to an allergen in the subject. In various embodiments, a method or use of specific immunotherapy reduces, inhibits, suppresses or decreases sensitivity or (hyper)sensitivity to the protein or peptide, e.g., allergen, or elicits, stimulates, increases, induces, promotes or improves tolerance of the protein or peptide, e.g., allergen. Typically a subject is administered a protein or peptide, e.g., allergen, for example, via a subcutaneous injection.

Methods and uses include multi-dose regimens. For example, a method or use can begin with small doses of allergen, and the doses are increased for repeated contact or administration.

A variant or derivative of an antigen (e.g., a TG protein or peptide set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6), including an allergen as described herein, or a subsequence or portion of an antigen or allergen, include molecules that are structurally similar and functionally similar (e.g, of all or a part of an amino acid sequence in Table 1 (SEQ ID NOS 1-620, respectively, in order of appearance), Table 2 (SEQ ID NOS 621-1442, respectively, in order of appearance), Table 4 (SEQ ID NOS 1443-2264, respectively, in order of appearance) or Table 6). A variant, derivative or subsequence of antigen or allergen is functionally similar to the antigen or allergen sequence if the variant, derivative or subsequence is capable of eliciting a detectable or measurable immune response, even if it is a reduced immune response compared to the nonvariant/non-derived or native sequence, which may be determined using methods, including animal models and in vitro assays, described herein and know to one of skill in the art. For example, an immune response may be determined by quantitative and/or qualitative determination of lymphokine/cytokine production (e.g., by T cells), antibody production (including class and/or isotype), cellular mobilization, migration or motility, and optionally in vivo, such as an animal model of antigen/allergen immune responsiveness. An immune response of variant, derivative or subsequence of antigen or allergen compared to the non-variant/non-derivatized/native full length antigen or allergen may be ascertained by analysis of a particular measure (such as lymphokine/cytokine production, immunoglobulin production, cell mobilization, migration, motility, etc.) and may be greater, less than or comparable, e.g., within 5%, 10%, 15%, or 20% or 25% of the immune response of non-variant/non-derivatized/native full length antigen or allergen. For example, levels of Th1 lymphokines/cytokines, such as IFN-γ IL-2, and TNF-β and Th2 cytokines, such as IL-4, IL-5, IL-9, IL-10, and IL-13, may be determined according to methods described herein or known to one of skill in the art.

As disclosed herein, proteins and peptides, or a subsequence, portion, homologue, variant or derivative thereof include those having all or at least partial sequence identity to one or more exemplary proteins and peptides, or a subsequence, portion, homologue, variant or derivative thereof (e.g., TG sequences set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442,), Table 4 (SEQ ID NOS 1443-2264) or Table 6). The term “identity” and “identical” and grammatical variations thereof, mean that two or more referenced entities are the same (e.g., peptides or polynucleotide molecules). Thus, where two proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof are identical, they have the same amino acid sequence. The identity can be over a defined area (region or domain) of the sequence. “Areas, regions or domains” of homology or identity mean that a portion of two or more referenced entities share homology or are the same.

Identity can be determined by comparing each position in aligned sequences. A degree of identity between amino acid sequences is a function of the number of identical or matching amino acids at positions shared by the sequences, i.e. over a specified region. Optimal alignment of sequences for comparisons of identity may be conducted using a variety of algorithms, as are known in the art, including the ClustalW program, available at http://clustalw.genome.ad.jp, the local homology algorithm of Smith and Waterman, 1981, Adv. Appl. Math 2: 482, the homology alignment algorithm of Needleman and Wunsch, 1970, J. Mol. Biol. 48:443, the search for similarity method of Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA 85: 2444, and the computerized implementations of these algorithms (such as GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, Madison, Wis., U.S.A.). Sequence identity may also be determined using the BLAST algorithm, described in Altschul et al., 1990, J. Mol. Biol. 215:403-10 (using the published default settings). Software for performing BLAST analysis may be available through the National Center for Biotechnology Information (through the internet at http://www.ncbi.nlm.nih.gov/). Such algorithms that calculate percent sequence identity (homology) generally account for sequence gaps and mismatches over the comparison region or area. For example, a BLAST (e.g., BLAST 2.0) search algorithm (see, e.g., Altschul et al., J. Mol. Biol. 215:403 (1990), publicly available through NCBI) has exemplary search parameters as follows: Mismatch-2; gap open 5; gap extension 2. For polypeptide sequence comparisons, a BLASTP algorithm is typically used in combination with a scoring matrix, such as PAM100, PAM 250, BLOSUM 62 or BLOSUM 50. FASTA (e.g., FASTA2 and FASTA3) and SSEARCH sequence comparison programs are also used to quantitate the extent of identity (Pearson et al., Proc. Natl. Acad. Sci. USA 85:2444 (1988); Pearson, Methods Mol Biol. 132:185 (2000); and Smith et al., J. Mol. Biol. 147:195 (1981)). Programs for quantitating protein structural similarity using Delaunay-based topological mapping have also been developed (Bostick et al., Biochem Biophys Res Commun. 304:320 (2003)).

As described herein, TG proteins and peptides include homologues of TG proteins and peptides (e.g., of allor a part of any amino acid sequence in any of Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. A polypeptide sequence or polynucleotide sequence is a “homologue” of, or is “homologous” to, another sequence if the two sequences have substantial identity over a specified region and a functional activity of the sequences is preserved or conserved, at least in part (as used herein, the term ‘homologous’ does not infer nor exclude evolutionary relatedness).

Examples of “homologues” of invention peptides and proteins include proteins or peptides of non-Timothy grass allergens, including for example other grass allergens such as grasses of the order Poales, that are homologous to a Timothy grass peptide or protein described herein. For example, in particular embodiments, proteins or peptides of the present invention may be proteins or peptides of grasses of the order of Poales, Panicum virgatum, Zea mays, Oryza sativa, Ricinus communis, Alnus glutinosa, Spinacia oleracea, Sorghum bicolor, Arabidopsis thaliana, Triticum aestivum, Capsella bursa-pastoris, Brassica napus, Mesembryanthemum crystallinum, Gossypium hirsutum, Brassica rapa subsp. chinensis, Solanum lycopersicum, Solanum tuberosum, Populus trichocarpa or Chara coralline.

Accordingly, in particular embodiments, methods and uses of the invention include homologues of peptides and proteins from non-Timothy grass allergens, including for example other grass antigens and allergens, such non-TG proteins and peptides considered to be homogoues as set forth herein. Thus, as a non-limiting example, peptide and protein homologues from non-Timothy grass antigens or allergens may be administered to modulate immune activity or immune response against a Timothy grass allergen or antigen or to treat an allergic reaction, allergic response, allergic disorder or allergic disease associated with a Timothy grass allergen or antigen. As another non-limiting example, peptide and protein homologues from non-Timothy grass antigens or allergens may be administered to modulate immune activity or immune response against a non-Timothy grass allergen or antigen or to treat an allergic reaction, allergic response, allergic disorder or allergic disease associated with a non-Timothy grass allergen or antigen.

Two polypeptide sequences or polynucleotide sequences are considered to be substantially identity if, when optimally aligned (with gaps permitted), they share at least about 40% sequence identity or greater (e.g. 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, etc. identify over a specific region), for example, over all or a part of any amino acid sequence in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6, or if the sequences share defined functional motifs (e.g., epitopes). The percent identity can extend over the entire sequence length or a portion of the sequence (e.g., over all or a part of any amino acid sequence in any of Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. In particular aspects, the length of the sequence sharing the percent identity is 2, 3, 4, 5 or more contiguous amino acids, e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, etc. contiguous amino acids (e.g., over all or a part of any amino acid sequence in any of Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. In additional particular aspects, the length of the sequence sharing the percent identity is 20 or more contiguous amino acids, e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, etc. contiguous amino acids (e.g., over all or a part of any amino acid sequence in any of Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. In further particular aspects, the length of the sequence sharing the percent identity is 35 or more contiguous amino acids, e.g., 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 45, 47, 48, 49, 50, etc., contiguous amino acids (e.g., over all or a part of any amino acid sequence in any of Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. In yet further particular aspects, the length of the sequence sharing the percent identity is 50 or more contiguous amino acids, e.g., 50-55, 55-60, 60-65, 65-70, 70-75, 75-80, 80-85, 85-90, 90-95, 95-100, etc. contiguous amino acids (e.g., over all or a part of any amino acid sequence in any of Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6.

An “unrelated” or “non-homologous” sequence shares less than 30% identity. More particularly, shares less than about 25% identity, with a protein, peptide or polynucleotide of the invention over a specified region of homology.

A variant or derivative of a protein or peptide refers to a modified or variant form of the protein or peptide, or subsequence, portion or homologue thereof (e.g., over all or a part of any amino acid sequence in any of Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6). Such modified forms, such as amino acid deletions, additions and substitutions, of the proteins and peptides can also be used in the invention uses, methods and compositions, including methods for modulating an immune response, eliciting, stimulating, inducing, promoting, increasing, or enhancing immunological tolerance and protecting and treating subjects against an allergic reaction or response, as set forth herein.

Thus, in accordance with the invention, modified, variant and derivative forms of proteins and peptides, subsequences, portions, and homologues thereof (e.g., of a TG protein or peptide set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6) are provided that have one or more functions or activities of unmodified, non-variant and non-derivatized forms of proteins and peptides. Such forms, referred to as “modifications”, “variants” or “derivatives” and grammatical variations thereof deviate from a reference sequence. For example, as described herein, a protein, peptide, subsequence, portion, or homologue thereof may comprise, consist or consist essentially of an amino acid sequence that is a modification, variant, or derivative of a TG protein or an amino acid sequence set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. Such modifications, variants, or derivatives may have greater or less activity or function than a reference protein or peptide, such as ability to elicit, stimulate, induce, promote, increase, enhance, activate, modulate, inhibit, decreases, suppress, or reduce an immune response (e.g. a T cell response) or elicit, stimulate, induce, promote, increase or enhance immunological tolerance (desensitize) to an antigen or allergen. Thus, proteins, peptides, or subsequences, portions or homologues thereof include sequences having substantially the same, greater or less relative activity or function as a reference antigen or allergen (e.g., any of the TG proteins or peptides set forth in any of Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6) for example, an ability to elicit, stimulate, induce, promote, increase, enhance, activate, modulate, inhibit, suppress, decrease or reduce an immune response (e.g. a T cell response) or elicit, stimulate, induce, promote, increase or enhance immunological tolerance to an antigen or allergen in vitro or in vivo.

A variant or derivative therefore includes deletions, including truncations and fragments; insertions and additions, including tagged polypeptides and fusion proteins; substitutions, for example conservative substitutions, site-directed mutants and allelic variants; and modifications, including peptoids having one or more non-amino acyl groups (q.v., sugar, lipid, etc.) covalently linked to the peptide and post-translational modifications.

Non-limiting examples of modifications include one or more amino acid substitutions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20-25, 25-30, 30-50, 50-100, or more residues), additions and insertions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20-25, 25-30, 30-50, 50-100, or more residues) and deletions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20-25, 25-30, 30-50, 50-100) of a reference protein, peptide, or subsequence or portion thereof (e.g., over all or a part of any amino acid sequence in any of Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6). In particular embodiments, a modified or variant sequence retains at least part of a function or an activity of unmodified sequence, and can have less than, comparable, or greater, but at least a part of, a function or activity of a reference sequence, for example, the ability elicit, stimulate, induce, promote, increase, enhance, activate, modulate, inhibit, suppress, decrease, or reduce an immune response (e.g. a T cell response) or elicit, stimulate, induce, promote, increase or enhance immunological tolerance to an allergen. Such immune responses include, for example, among others, induced, increased, enhanced, stimulated, activated, modulated, inhibited, suppressed, decreased or reduced expression, production or activity of a cytokine (e.g., IL-5), an antibody (e.g. increase production of IgG antibodies, decrease production of IgE) or an immune cell (e.g. CD4+ T cell, CD8+ T cell, Th1 cell, Th2 cell or regulatory T cell).

Variants and derivatives of proteins and peptides include naturally-occurring polymorphisms or allelic variants, strain variants, as well as synthetic proteins and peptides that contain a limited number of conservative amino acid substitutions of the amino acid sequence. A variety of criteria can be used to indicate whether amino acids at a particular position in a protein or peptide are similar. In making such changes, substitutions of like amino acid residues can be made on the basis of relative similarity of side-chain substituents, for example, their size, charge, hydrophobicity, hydrophilicity, and the like, and such substitutions may be assayed for their effect on the function of the peptide by routine testing.

Specific non-limiting examples of substitutions include conservative and non-conservative amino acid substitutions. A “conservative substitution” is the replacement of one amino acid by a biologically, chemically or structurally similar residue. Biologically similar means that the substitution does not destroy a biological activity. Structurally similar means that the amino acids have side chains with similar length, such as alanine, glycine and serine, or a similar size. Chemical similarity means that the residues have the same charge, or are both hydrophilic or hydrophobic. For example, a conservative amino acid substitution is one in which an amino acid residue is replaced with an amino acid residue having a similar side chain, which include amino acids with basic side chains (e.g., lysine, arginine, histidine); acidic side chains (e.g., aspartic acid, glutamic acid); uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, histidine); nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan); beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan). Particular examples include the substitution of one hydrophobic residue, such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acids, or glutamine for asparagine, serine for threonine, and the like. Proline, which is considered more difficult to classify, shares properties with amino acids that have aliphatic side chains (e.g., Leu, Val, Ile, and Ala). In certain circumstances, substitution of glutamine for glutamic acid or asparagine for aspartic acid may be considered a similar substitution in that glutamine and asparagine are amide derivatives of glutamic acid and aspartic acid, respectively. Conservative changes can also include the substitution of a chemically derivatized moiety for a non-derivatized residue, for example, by reaction of a functional side group of an amino acid. Variants and derivatives of proteins and peptides include forms having a limited number of one or more substituted residues.

An addition can be a covalent or non-covalent attachment of any type of molecule. Specific examples of additions include glycosylation, acetylation, phosphorylation, amidation, formylation, ubiquitination, and derivatization by protecting/blocking groups and any of numerous chemical modifications. Additional specific non-limiting examples of an addition are one or more additional amino acid residues. Accordingly, proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof, can be a part of or contained within a larger molecule, such as another protein or peptide sequence, such as a fusion or chimera with a different (distinct) sequence.

In particular embodiments, an addition is a fusion (chimeric) sequence, an amino acid sequence having one or more molecules not normally present in a reference native (wild type) sequence covalently attached to the sequence. The term “chimeric” and grammatical variations thereof, when used in reference to a sequence, means that the sequence contains one or more portions that are derived from, obtained or isolated from, or based upon other physical or chemical entities. For example, a chimera of two or more different proteins may have one part a protein, peptide, subsequence, portion, homologue or variant thereof, and a second part of the chimera may be from a different sequence, or unrelated protein sequence.

Another particular example of a sequence having an amino acid addition is one in which a second heterologous sequence, i.e., heterologous functional domain is attached (covalent or non-covalent binding) that confers a distinct or complementary function. Heterologous functional domains are not restricted to amino acid residues. Thus, a heterologous functional domain can consist of any of a variety of different types of small or large functional moieties. Such moieties include nucleic acid, peptide, carbohydrate, lipid or small organic compounds, such as a drug (e.g., an antiviral), a metal (gold, silver), and radioisotope. For example, a tag such as T7 or polyhistidine can be attached in order to facilitate purification or detection of a protein, peptide, etc. Accordingly, there are provided proteins, peptides, subsequences, portions and homologues thereof (e.g., a TG protein or peptide set forth in Table 1, Table 2, Table 4 or Table 6), and a heterologous domain, wherein the heterologous functional domain confers a distinct function on the protein, peptide, subsequence, portion or homologue thereof.

Linkers, such as amino acid or peptidomimetic sequences may be inserted between the sequence and the addition (e.g., heterologous functional domain) so that the two entities maintain, at least in part, a distinct function or activity. Linkers may have one or more properties that include a flexible conformation, an inability to form an ordered secondary structure or a hydrophobic or charged character, which could promote or interact with either domain Amino acids typically found in flexible protein regions include Gly, Asn and Ser. Other near neutral amino acids, such as Thr and Ala, may also be used in the linker sequence. The length of the linker sequence may vary without significantly affecting a function or activity of the fusion protein (see, e.g., U.S. Pat. No. 6,087,329). Linkers further include chemical moieties and conjugating agents, such as sulfo-succinimidyl derivatives (sulfo-SMCC, sulfo-SMPB), disuccinimidyl suberate (DSS), disuccinimidyl glutarate (DSG) and disuccinimidyl tartrate (DST).

Further non-limiting examples of additions are detectable labels. Thus, in another embodiment, the invention provides proteins, peptides, subsequences, portions and homologues thereof, that are detectably labeled. Specific examples of detectable labels include fluorophores, chromophores, radioactive isotopes (e.g., S³⁵, P³², I¹²⁵), electron-dense reagents, enzymes, ligands and receptors. Enzymes are typically detected by their activity. For example, horseradish peroxidase is usually detected by its ability to convert a substrate such as 3,3-′,5,5-′-tetramethylbenzidine (TMB) to a blue pigment, which can be quantified.

Another non-limiting example of an addition is an insertion of an amino acid within any protein, peptide, subsequence, portion or homologue thereof (e.g., any protein or sequence set forth herein, such as in any amino acid sequence of Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6). In particular embodiments, an insertion is of one or more amino acid residues inserted into the amino acid sequence of a protein or peptide, or subsequence, portion or homologue thereof, such as any TG protein or sequence set forth herein, such as in as in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6.

Modified and variant proteins, peptides, subsequences, portions or homologues thereof also include one or more D-amino acids substituted for L-amino acids (and mixtures thereof), structural and functional analogues, for example, peptidomimetics having synthetic or non-natural amino acids or amino acid analogues and derivatized forms. Modifications include cyclic structures such as an end-to-end amide bond between the amino and carboxy-terminus of the molecule or intra- or inter-molecular disulfide bond. Proteins, peptides, subsequences, portions and homologues thereof may be modified in vitro or in vivo, e.g., post-translationally modified to include, for example, sugar residues, phosphate groups, ubiquitin, fatty acids, lipids, etc.

Specific non-limiting examples of modified and variant proteins, peptides, subsequences, portions and homologues thereof include proteins or peptides comprising, consisting or consisting essentially of an amino acid sequence comprising at least one amino acid deletion from a full length TG protein or amino acid sequence set forth in any of Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. In particular embodiments, a protein, peptide, or subsequence, portion or homologue thereof is from about 2 to up to one amino acid less than the full length protein sequence. In additional particular embodiments, a protein subsequence or portion is from about 2 to 5, 5 to 10, 10 to 15, 15 to 20, 20 to 25, 25 to 50, 50 to 100 amino acids in length, provided that said subsequence or portion is at least one amino acid less in length than the full-length protein sequence.

The term “subsequence” or “portion” means a fragment or part of the full length molecule. A subsequence or portion therefore consists of one or more amino acids less than the full length protein or peptide. A subsequence or portion can have one or more amino acids less than the full length protein or peptide internally or terminal amino acid deletions from either amino or carboxy-termini. Subsequences and portions can vary in size. For example, a subsequence or portion of a protein or peptide can be as small as an epitope capable of binding an antibody (i.e., about five amino acids) up to a polypeptide that is one amino acid less than the entire length of a reference protein or peptide.

As used herein, subsequences and portions may also include or consist of one or more amino acid additions or deletions, wherein the subsequence or portion does not comprise the full length native/wild type protein or peptide sequence. Accordingly, total subsequence or portion lengths can be greater than the length of the full length native/wild type protein or peptide, for example, where a protein or peptide subsequence is fused or forms a chimera with another polypeptide.

The invention provides isolated and/or purified proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof. In particular embodiments, isolated and/or purified proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof, comprise, consist of or consist essentially of an amino acid sequence of a TG protein or peptide set forth in any of Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. In particular embodiments, the isolated and/or purified proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof include a T cell epitope (e.g., Th2 cell epitope).

The term “isolated,” when used as a modifier of a composition, means that the compositions are made by the hand of man or are separated, completely or at least in part, from their naturally occurring in vivo environment. Generally, isolated compositions are substantially free of one or more materials with which they normally associate with in nature, for example, one or more protein, nucleic acid, lipid, carbohydrate, cell membrane. The term “isolated” does not exclude alternative physical forms of the composition, such as fusions/chimeras, multimers/oligomers, modifications (e.g., phosphorylation, glycosylation, lipidation) or derivatized forms, or forms expressed in host cells produced by the hand of man.

An “isolated” composition (e.g., proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof, for example, of any TG protein or sequence set forth herein, such as in any of Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6) can also be “substantially pure” or “purified” when free of most or all of the materials with which it typically associates with in nature. Thus, an isolated protein, peptide, subsequence, portion, homologue, variant or derivative thereof, that also is substantially pure or purified does not include polypeptides or polynucleotides present among millions of other sequences, such as peptides of an peptide library or nucleic acids in a genomic or cDNA library, for example.

A “substantially pure” or “purified” composition can be combined with one or more other molecules. Thus, “substantially pure” or “purified” does not exclude combinations of compositions, such as combinations of proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof (e.g., multiple proteins, peptides, subsequences, etc.), and other antigens, agents, drugs or therapies.

Proteins and peptide (e.g., antigens and allergens) can be prepared recombinantly, chemically synthesized, isolated from a biological material or source, and optionally modified, or any combination thereof. A biological material or source would include an organism that produced or possessed any proteins or peptide (e.g., antigen or allergen) set forth herein (e.g., as listed in any of Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 3, Table 4 (SEQ ID NOS 1443-2264) or Table 6). A biological material or source may further refer to a preparation in which the morphological integrity or physical state has been altered, modified or disrupted, for example, by dissection, dissociation, solubilization, fractionation, homogenization, biochemical or chemical extraction, pulverization, lyophilization, sonication or any other means of manipulating or processing a biological source or material. Subsequences, variants, homologues and derivatives can be prepared, for example, by substituting, deleting or adding one or more amino acid residues in the amino acid sequence of a protein, peptide, subsequence, portion or homologue thereof, and screening for biological activity, for example eliciting an immune response. A skilled person will understand how to make such derivatives or variants, using standard molecular biology techniques and methods, described for example in Sambrook et al. (2001) Molecular Cloning: a Laboratory Manual, 3^(rd) ed., Cold Spring Harbour Laboratory Press).

The invention also provides protein or peptide (e.g., proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof, for example, of any TG protein or sequence set forth herein, such as in as in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6, immobilized on or attached to a substrate. The protein or peptide (e.g., proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof, for example, of any TG protein or sequence set forth herein, such as in as in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6 can optionally have a unique or distinct position or address on the substrate.

Substrates to which protein or peptide (e.g., proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof, for example, of any TG protein or sequence set forth herein, such as in as in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6, can be immobilized or attached include essentially any physical entity such as a two dimensional surface that is permeable, semi-permeable or impermeable, either rigid or pliable and capable of either storing, binding to or having attached thereto or impregnated.

Substrates include dry solid medium (e.g., cellulose, polyester, nylon, or mixtures thereof etc.), such as glass, silica, plastic, polyethylene, polystyrene, polypropylene, polyacetate, polycarbonate, polyamide, polyester, polyurethane, or polyvinylchloride. Substrates include structures having sections, compartments, wells, containers, vessels or tubes, separated from each other to avoid or prevent cross-contamination or mixing with each other or with other reagents. Multi-well plates, which typically contain 6, 12, 26, 48, 96, to 1000 wells, are one particular non-limiting example of such a structure.

Substrates also include supports used for two- or three-dimensional arrays of sequences. The sequences are typically attached to the surface of the substrate (e.g., via a covalent bond) at defined positions (locations or addresses). Substrates can include a number of sequences, for example, 1, 2, 3, 4, 5, 5 to 10, 10 to 15, 15 to 20, 20 to 25, 25 to 30, 30 to 35, 35 to 40, 40 to 45, 45 to 50, 50 to 75, 75 to 100, 100 to 150, 150 to 200, 200 to 250, 250 to 300, up to all proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof, such as in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. Such substrates, also referred to as “arrays,” can have any protein density; the greater the density the greater the number of sequences that can be screened on a given chip. Substrates that include a two- or three-dimensional array of sequences, and individual protein sequences therein, may be coded in accordance with the invention.

The invention also provides nucleic acids encoding proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof, for example, of amino acid sequences set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. Such nucleic acid sequences encode a sequence at least 40% or more (e.g., 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%) identical to an exemplary protein, peptide, subsequence, portion, homologue, variant or derivative thereof, for example, of any amino acid sequence set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. In an additional embodiment, a nucleic acid encodes a sequence having a modification, such as one or more amino acid additions (insertions), deletions or substitutions of protein, peptide, subsequence, portion, homologue, variant or derivative thereof, for example, of an amino acid sequence set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6.

The terms “nucleic acid,” “polynucleotide” and “polynucleoside” and the like refer to at least two or more ribo- or deoxy-ribonucleic acid base pairs (nucleotides/nucleosides) that are linked through a phosphoester bond or equivalent. Nucleic acids include polynucleotides and polynucleosides. Nucleic acids include single, double or triplex, circular or linear, molecules. Exemplary nucleic acids include but are not limited to: RNA, DNA, cDNA, genomic nucleic acid, naturally occurring and non-naturally occurring nucleic acid, e.g., synthetic nucleic acid.

Nucleic acids can be of various lengths. Nucleic acid lengths typically range from about 20 bases to 20 Kilobases (Kb), or any numerical value or range within or encompassing such lengths, 10 bases to 10 Kb, 1 to 5 Kb or less, 1000 to about 500 bases or less in length. Nucleic acids can also be shorter, for example, 100 to about 500 bases, or from about 12 to 24, 24 to 45, 45 to 90, 90 to 250, or about 250 to 500 bases in length, or any numerical value or range or value within or encompassing such lengths. In particular aspects, a nucleic acid sequence has a length from about 10-20, 20-30, 30-50, 50-100, 100-150, 150-200, 200-250, 250-300, 300-400, 400-500, 500-1000, 1000-2000 bases, or any numerical value or range within or encompassing such lengths. Shorter nucleic acids are commonly referred to as “oligonucleotides” or “probes” of single- or double-stranded DNA. However, there is no upper limit to the length of such oligonucleotides.

Nucleic acid sequences further include nucleotide and nucleoside substitutions, additions and deletions, as well as derivatized forms and fusion/chimeric sequences (e.g., encoding recombinant polypeptide). For example, due to the degeneracy of the genetic code, nucleic acids include sequences and subsequences degenerate with respect to nucleic acids that encode proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof, (e.g., substitutions, additions, insertions and deletions), for example, of amino acid sequences set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6.

Nucleic acids can be produced using various standard cloning and chemical synthesis techniques. Techniques include, but are not limited to nucleic acid amplification, e.g., polymerase chain reaction (PCR), with genomic DNA or cDNA targets using primers (e.g., a degenerate primer mixture) capable of annealing to the encoding sequence. Nucleic acids can also be produced by chemical synthesis (e.g., solid phase phosphoramidite synthesis) or transcription from a gene. The sequences produced can then be translated in vitro, or cloned into a plasmid and propagated and then expressed in a cell (e.g., a host cell such as eukaryote or mammalian cell, yeast or bacteria, in an animal or in a plant).

Nucleic acid may be inserted into a nucleic acid construct in which expression of the nucleic acid is influenced or regulated by an “expression control element.” An “expression control element” refers to a nucleic acid sequence element that regulates or influences expression of a nucleic acid sequence to which it is operatively linked. Expression control elements include, as appropriate, promoters, enhancers, transcription terminators, gene silencers, a start codon (e.g., ATG) in front of a protein-encoding gene, etc.

An expression control element operatively linked to a nucleic acid sequence controls transcription and, as appropriate, translation of the nucleic acid sequence. Expression control elements include elements that activate transcription constitutively, that are inducible (i.e., require an external signal for activation), or derepressible (i.e., require a signal to turn transcription off; when the signal is no longer present, transcription is activated or “derepressed”), or specific for cell-types or tissues (i.e., tissue-specific control elements).

Nucleic acid can also be inserted into a plasmid for propagation into a host cell and for subsequent genetic manipulation. A plasmid is a nucleic acid that can be propagated in a host cell, plasmids may optionally contain expression control elements in order to drive expression of the nucleic acid encoding proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof in the host cell. A vector is used herein synonymously with a plasmid and may also include an expression control element for expression in a host cell (e.g., expression vector). Plasmids and vectors generally contain at least an origin of replication for propagation in a cell and a promoter. Plasmids and vectors are therefore useful for genetic manipulation and expression of proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof, for example, of amino acid sequences set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. Accordingly, vectors that include nucleic acids encoding or complementary to proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof, for example, of amino acid sequences set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6, are provided.

In accordance with the invention, there are provided particles (e.g., viral particles) and transformed host cells that express and/or are transformed with a nucleic acid that encodes and/or express proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof, for example, of amino acid sequences set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. Particles and transformed host cells include but are not limited to virions, and prokaryotic and eukaryotic cells such as bacteria, fungi (yeast), plant, insect, and animal (e.g., mammalian, including primate and human, CHO cells and hybridomas) cells. For example, bacteria transformed with recombinant bacteriophage nucleic acid, plasmid nucleic acid or cosmid nucleic acid expression vectors; yeast transformed with recombinant yeast expression vectors; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid); insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus); and animal cell systems infected with recombinant virus expression vectors (e.g., retroviruses, adenovirus, vaccinia virus), or transformed animal cell systems engineered for stable expression. The cells may be a primary cell isolate, cell culture (e.g., passaged, established or immortalized cell line), or part of a plurality of cells, or a tissue or organ ex vivo or in a subject (in vivo).

The term “transformed” or “transfected” when used in reference to a cell (e.g., a host cell) or organism, means a genetic change in a cell following incorporation of an exogenous molecule, for example, a protein or nucleic acid (e.g., a transgene) into the cell. Thus, a “transfected” or “transformed” cell is a cell into which, or a progeny thereof in which an exogenous molecule has been introduced by the hand of man, for example, by recombinant DNA techniques.

The nucleic acid or protein can be stably or transiently transfected or transformed (expressed) in the host cell and progeny thereof. The cell(s) can be propagated and the introduced protein expressed, or nucleic acid transcribed. A progeny of a transfected or transformed cell may not be identical to the parent cell, since there may be mutations that occur during replication.

Expression of proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof and nucleic acid in particles or introduction into target cells (e.g., host cells) can also be carried out by methods known in the art. Non-limiting examples include osmotic shock (e.g., calcium phosphate), electroporation, microinjection, cell fusion, etc. Introduction of nucleic acid and polypeptide in vitro, ex vivo and in vivo can also be accomplished using other techniques. For example, a polymeric substance, such as polyesters, polyamine acids, hydrogel, polyvinyl pyrrolidone, ethylene-vinylacetate, methylcellulose, carboxymethylcellulose, protamine sulfate, or lactide/glycolide copolymers, polylactide/glycolide copolymers, or ethylenevinylacetate copolymers. A nucleic acid can be entrapped in microcapsules prepared by coacervation techniques or by interfacial polymerization, for example, by the use of hydroxymethylcellulose or gelatin-microcapsules, or poly (methylmethacrolate) microcapsules, respectively, or in a colloid system. Colloidal dispersion systems include macromolecule complexes, nano-capsules, microspheres, beads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and liposomes.

Liposomes for introducing various compositions into cells are known in the art and include, for example, phosphatidylcholine, phosphatidylserine, lipofectin and DOTAP (e.g., U.S. Pat. Nos. 4,844,904, 5,000,959, 4,863,740, and 4,975,282; and GIBCO-BRL, Gaithersburg, Md.). piperazine based amphilic cationic lipids useful for gene therapy also are known (see, e.g., U.S. Pat. No. 5,861,397). Cationic lipid systems also are known (see, e.g., U.S. Pat. No. 5,459,127). Polymeric substances, microcapsules and colloidal dispersion systems such as liposomes are collectively referred to herein as “vesicles.” Accordingly, viral and non-viral vector means delivery into cells are included.

TG proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof, for example, of TG amino acid sequences set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6, are provided, can be employed in various methods and uses. Such methods and uses include, for example, administration in vitro and in vivo of one or more proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof, such as the TG amino acid sequences set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6, or subsequences, portions, homologues, variants or derivatives thereof. The methods and uses provided include methods and uses of modulating an immune response, including, among others, methods and uses of protecting and treating subjects against a disorder, disease; and methods and uses of providing specific immunotherapy; and methods and uses of diagnosis.

In particular embodiments, methods and uses include administration or delivery of a protein, peptide, subsequence, portion, homologue, variants or derivative thereof described herein (e.g., of any TG amino acid sequences set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6) to modulate an immune response in a subject, including, for example, modulating an immune response to an allergen or antigen.

As used herein, the term “modulate,” means an alteration or effect on the term modified. For example, the term modulate can be used in various contexts to refer to an alteration or effect of an activity, a function, or expression of a polypeptide, gene or signaling pathway, or a physiological condition or response of an organism. In certain embodiments, modulating involves decreasing, reducing, inhibiting, suppressing or disrupting an immune response of a subject to an antigen or allergen. In other embodiments, modulating involves eliciting, stimulating, inducing, promoting, increasing or enhancing an immune response of a subject to an antigen or allergen. Thus, where the term “modulate” is used to modify the term “immune response against an allergen in a subject” this means that the immune response in the subject to the allergen is altered or affected (e.g., decreased, reduced, inhibited, suppressed, limited, controlled, prevented, elicited, promoted, stimulated, increased, induced, enhanced, etc.).

Methods and uses of modulating an immune response against an antigen or allergen as described herein may be used to provide a subject with protection against an allergic response or reaction to the allergen, or allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with the allergen. Accordingly, in other embodiments, methods and uses include administering a protein, peptide, subsequence, portion, homologue, variant or derivative thereof described herein (e.g., of any TG amino acid sequences set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6) to protect or treat a subject against an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen. In still other embodiments, methods and uses include administering or delivering a protein, peptide, subsequence, portion, homologue, variant or derivative thereof described herein (e.g., of any TG amino acid sequences set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6) to elicit, stimulate, induce, promote, increase or enhance immunological tolerance of a subject to an antigen or allergen.

In various embodiments, there are provided methods and uses of providing a subject with protection against an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen. In various aspects, a method or use includes administering to the subject an amount of a protein, peptide, subsequence, portion, homologue, variant or derivative thereof described herein (e.g., of any TG amino acid sequences set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6) sufficient to provide the subject with protection against the allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with the allergen.

Methods and uses of the invention include providing a subject with protection against an antigen or allergen, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with the exposure to the antigen or allergen, for example, vaccinating the subject to protect against an allergic response to the allergen, for example with any TG amino acid sequences set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. In certain embodiments, methods and uses include protecting the subject against an allergic response or reaction by inducing tolerance of the subject (desensitizing) to the allergen.

As used herein, the terms “protection,” “protect” and grammatical variations thereof, when used in reference to an allergic response or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with the exposure to allergen, means preventing an allergic response, reaction, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with the exposure to the allergen, or reducing or decreasing susceptibility to an allergic response, reaction, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with the exposure to the allergen.

An allergic response includes but is not limited to an allergic reaction, hypersensitivity, an inflammatory response or inflammation. In certain embodiments allergic response may involve one or more of cell infiltration, production of antibodies, production of cytokines, lymphokines, chemokines, interferons and interleukins, cell growth and maturation factors (e.g., differentiation factors), cell proliferation, cell differentiation, cell accumulation or migration (chemotaxis) and cell, tissue or organ damage or remodeling. In particular aspects, an allergic response may include Allergic rhinitis; Onchocercal dermatitis; Atopic dermatitis; allergic conjunctivitis; Drug reactions; Nodules, eosinophilia, rheumatism, dermatitis, rashes, hives, and swelling (NERDS); esophageal and a gastrointestinal allergy.

Allergic responses can occur systemically, or locally in any region, organ, tissue, or cell. In particular aspects, an allergic response occurs in the skin, the upper respiratory tract, the lower respiratory tract, pancreas, thymus, kidney, liver, spleen, muscle, nervous system, skeletal joints, eye, mucosal tissue, gut or bowel.

Methods and uses herein include treating a subject for an allergic response, allergic disorder or allergic disease, as well as one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen. Such methods and uses include administering to a subject an amount of a protein, peptide, subsequence, portion, homologue, variant or derivative thereof described herein (e.g., any TG amino acid sequences set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6) sufficient to treat the subject for the allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with the allergen.

As will be understood by a person skilled in the art, treating an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen may include decreasing, reducing, inhibiting, suppressing, limiting, controlling or clearing an allergic response, an allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with the allergen. Thus in certain embodiments, a method or use of treating a subject for a an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen comprises elimination of the allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with the allergen from a subject. In other embodiments, a method or use of treating a subject for an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen includes reducing occurrence, frequency, severity, progression, or duration of the allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with the allergen in the subject. In yet another embodiment, a method or use of treating a subject for an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen, includes stabilizing the allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with the allergen in a subject by preventing an increase in the occurrence, frequency, severity, progression, or duration of the allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with contact of the subject with an allergen.

Methods and uses of the invention include treating or administering a subject previously exposed to an antigen or allergen. Thus, in certain embodiments, methods and uses are for treating or protecting a subject from an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with secondary or subsequent exposure to an antigen or allergen.

Physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an antigen/allergen treatable in accordance with the invention methods and uses include but are not limited to asthma, allergic asthma, bronchiolitis and pleuritis, Allergic rhinitis; Onchocercal dermatitis; Atopic dermatitis; allergic conjunctivitis; Drug reactions; Nodules, eosinophilia, rheumatism, dermatitis, rashes, hives, and swelling (NERDS); esophageal and a gastrointestinal allergy, Airway Obstruction, Apnea, Asbestosis, Atelectasis, Berylliosis, Bronchiectasis, Bronchiolitis, Bronchiolitis Obliterans Organizing Pneumonia, Bronchitis, Bronchopulmonary Dysplasia, Empyema, Pleural Empyema, Pleural Epiglottitis, Hemoptysis, Hypertension, Kartagener Syndrome, Meconium Aspiration, Pleural Effusion, Pleurisy, Pneumonia, Pneumothorax, Respiratory Distress Syndrome, Respiratory Hypersensitivity, Rhinoscleroma, Scimitar Syndrome, Severe Acute Respiratory Syndrome, Silicosis, Tracheal Stenosis, eosinophilic pleural effusions, Histiocytosis; chronic eosinophilic pneumonia; hypersensitivity pneumonitis; Allergic bronchopulmonary aspergillosis; Sarcoidosis; Idiopathic pulmonary fibrosis; pulmonary edema; pulmonary embolism; pulmonary emphysema; Pulmonary Hyperventilation; Pulmonary Alveolar Proteinosis; Chronic Obstructive Pulmonary Disease (COPD); Interstitial Lung Disease; and Topical eosinophilia.

Timothy grass proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof, described herein may elicit, stimulate, induce, promote, increase or enhance immunological tolerance to an antigen, including an allergen. Methods and uses of the invention therefore further include inducing immunological tolerance of a subject to an antigen or allergen. Thus, for example, Timothy grass proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof, described herein can be effective in treatment (e.g., therapeutic) of an allergic immune response, including but not limited to an allergic immune response following a secondary or subsequent exposure of a subject to an antigen. In one embodiment, a method or use includes administering to the subject an amount of a protein, peptide, subsequence, portion, homologue, variant or derivative thereof described herein (e.g., any TG amino acid sequences set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6) sufficient to induce tolerance in the subject to the antigen or allergen. In particular aspects, the immunological tolerance elicited, stimulated, induced, promoted, increased or enhanced may involve modulation of T cell activity, including but not limited to CD4+ T cells, CD8+ T cells, Th1 cells, Th2 cells and regulatory T cells. For example, immunological tolerance elicited, stimulated, induced, promoted, increased or enhanced from administration of the Timothy grass proteins or peptides, or subsequence, portion, homologue, variant or derivative thereof, may involve modulation of the production or activity of pro-inflammatory or anti-inflammatory cytokines produced by T cells.

In additional embodiments, a method or use of inducing immunological tolerance in a subject to an allergen includes a reduction in occurrence, frequency, severity, progression, or duration of physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated an allergic response to the allergen in the subject. Thus, in certain embodiments, inducing immunological tolerance can protect a subject against or treat a subject for an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an antigen or allergen.

Methods and uses of inducing immunological tolerance described herein may include eliciting, stimulating, inducing, promoting, increasing or enhancing an immune response. In certain embodiments, inducing immunological tolerance may include eliciting, stimulating, inducing, promoting, increasing or enhancing an immune response that decreases, reduces, inhibits, suppresses, limits, controls or clears an allergic response. For example, in certain embodiments inducing immunological tolerance may include eliciting, stimulating, inducing, promoting, increasing or enhancing proliferation or activity of regulatory T cells. In other embodiments, inducing immunological tolerance may include eliciting, stimulating, inducing, promoting, increasing or enhancing an immune response that promotes an allergic response. As will be understood by a person of skill in the art, a method or use that elicits, stimulates, induces, promotes, increases or enhances an immune response that promotes an allergic response may still induce immunological tolerance by also eliciting, stimulating, inducing, promoting, increasing or enhancing an immune response that decreases, reduces, inhibits, suppresses, limits, controls or clears an allergic response. In particular embodiments, inducing immunological tolerance includes eliciting, stimulating, inducing, promoting, increasing or enhancing an immune responses that decreases, reduces, inhibits, suppresses, limits, controls or clears an allergic response that is stronger than the immune response that promotes an allergic response. In other embodiments, inducing immunological tolerance includes eliciting, stimulating, inducing, promoting, increasing or enhancing more immune responses that decrease, reduce, inhibit, suppress, limit, controls or clear an allergic response than immune responses that promote an allergic response.

Methods and uses of the invention include treating a subject via specific immunotherapy. In one embodiment, a method or use includes administering to the subject an amount of a protein, peptide, subsequence, portion, homologue, variant or derivative thereof described herein (e.g., any TG amino acid sequences set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. In one aspect, an antigen (allergen) administered to a subject during specific immunotherapy to treat the subject is the same antigen (allergen) to which the subject has been sensitized or is hypersensitive (e.g., allergic). In another non-limiting aspect, an antigen (allergen) administered to a subject to treat the subject is a different antigen (allergen) to which the subject has been sensitized or is hypersensitive (e.g., allergic). Thus in different embodiments, the antigen administered and antigen (e.g., allergen) against which immunological tolerance is sought may be the same protein (antigen, allergen), may be proteins (antigens, allergens) of the same organism or may be proteins (antigens, allergens) of different organisms.

In accordance with the invention, methods and uses include therapeutic (following antigen/allergen exposure) and prophylactic (prior to antigen/allergen exposure) uses and methods. For example, therapeutic and prophylactic methods and uses of treating a subject for an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen, include but are not limited to treatment of a subject having or at risk of having an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen; treating a subject with an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen; and methods and uses of protecting a subject from an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an antigen/allergen (e.g., provide the subject with protection against an allergic reaction to an allergen), to decrease or reduce the probability of an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen, in a subject and to decrease or reduce susceptibility of a subject to an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen, to inhibit or prevent an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen, in a subject. Accordingly, methods and uses can treat an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen, or provide a subject with protection from an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen (e.g., prophylactic protection).

As described herein, proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof include T cell epitopes, such as Th2 cell epitopes. Accordingly, methods and uses of the invention include administering an amount of a protein, peptide, subsequence, portion, homologue, variant or derivative thereof (e.g., a T cell epitope) to a subject sufficient to provide the subject with protection against an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen. In another embodiment, a method includes administering an amount of a protein, peptide, subsequence, portion, homologue, variant or derivative thereof (e.g., a T cell epitope, such as a Th2 cell epitope) to a subject sufficient to treat, vaccinate or immunize the subject against an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen.

In accordance with the invention, methods and uses of modulating anti-allergen activity of T cells, including but not limited to CD8⁺ T cells, CD4⁺ T cells, Th1 cells or Th2 cells, in a subject are provided. In one embodiment, a method or use includes administering to a subject an amount of a protein, peptide, subsequence, portion, homologue, variant or derivative thereof, such as a T cell epitope, sufficient to modulate Th2 cell activity in the subject.

In all methods and uses of the invention, any appropriate protein, peptide, subsequence, portion, homologue, variant or derivative thereof can be used or administered. In particular non-limiting examples, the protein, peptide, subsequence, portion, homologue, variant or derivative thereof comprises, consists of or consists essentially of a TG amino acid sequence of a protein or peptide set forth in in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6, or a subsequence, portion, homologue, variant or derivative thereof.

In certain embodiments, two or more proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof, may be administered to a subject. In particular embodiments, a protein, peptide, subsequence, portion, homologue, variant or derivative thereof consists of or consists essentially of an amino acid sequence of a TG protein or peptide set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6, or subsequence, portion, homologue, variant or derivative thereof, and is administered with one or more other proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof. Two or more proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof may be administered as a combination composition, or administered separately, such as concurrently or in series or sequentially. Different proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof, may be administered to a subject in the same amount, volume or concentration, or different amounts, volumes or concentrations. Thus, in certain embodiments, the subject may be administered the same amount of two or more different proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof; and in other embodiments, the subject may be administered one protein, peptide, subsequence, portion, homologue, variant or derivative thereof in an amount, volume or concentration greater than one or more other protein, peptide, subsequence, portion, homologue, variant or derivative thereof administered to the subject.

Methods and uses of the invention include a favorable response or an improvement in one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an antigen/allergen. In particular embodiments, a favorable response or improvement includes but is not limited to reduce, decrease, suppress, limit, control or inhibit an allergic response including reducing, decreasing, suppressing, limiting, controlling or inhibiting immune cell proliferation, function or activity, or eliciting, stimulating, inducing, promoting, increasing or enhancing immune cell proliferation or activity (e.g. regulatory T cells); or reduce, decrease, suppress, limit, control or inhibit the amount of allergen. In additional particular embodiments, an amount of a protein, peptide, subsequence, portion, homologue, variant or derivative thereof is sufficient to elicit, stimulate, induce, promote, increase or enhance or augment immunological tolerance to an allergen; or decrease, reduce, inhibit, suppress, prevent, control, or limit an allergic reaction or response. In further particular embodiments, an amount of a protein, peptide, subsequence, portion, homologue, variant or derivative thereof is sufficient to protect a subject from an allergic response or reduce, decrease, limit, control or inhibit susceptibility to an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen.

Methods and uses of the invention therefore include any therapeutic or beneficial effect. In various methods embodiments, an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen is reduced, decreased, inhibited, limited, delayed or prevented. Physiological conditions, disorders, illnesses and diseases associated with an antigen/allergen include but are not limited to asthma, allergic asthma, bronchiolitis and pleuritis, Allergic rhinitis; Onchocercal dermatitis; Atopic dermatitis; allergic conjunctivitis; Drug reactions; Nodules, eosinophilia, rheumatism, dermatitis, rashes, hives, and swelling (NERDS); esophageal and a gastrointestinal allergy, Airway Obstruction, Apnea, Asbestosis, Atelectasis, Berylliosis, Bronchiectasis, Bronchiolitis, Bronchiolitis Obliterans Organizing Pneumonia, Bronchitis, Bronchopulmonary Dysplasia, Empyema, Pleural Empyema, Pleural Epiglottitis, Hemoptysis, Hypertension, Kartagener Syndrome, Meconium Aspiration, Pleural Effusion, Pleurisy, Pneumonia, Pneumothorax, Respiratory Distress Syndrome, Respiratory Hypersensitivity, Rhinoscleroma, Scimitar Syndrome, Severe Acute Respiratory Syndrome, Silicosis, Tracheal Stenosis, eosinophilic pleural effusions, Histiocytosis; chronic eosinophilic pneumonia; hypersensitivity pneumonitis; Allergic bronchopulmonary aspergillosis; Sarcoidosis; Idiopathic pulmonary fibrosis; pulmonary edema; pulmonary embolism; pulmonary emphysema; Pulmonary Hyperventilation; Pulmonary Alveolar Proteinosis; Chronic Obstructive Pulmonary Disease (COPD); Interstitial Lung Disease; and Topical eosinophilia. Symptoms and complications associated with an allergen include but are not limited to cell infiltration, production of antibodies, production of cytokines, lymphokines, chemokines, interferons and interleukins, cell growth and maturation factors (e.g., differentiation factors), cell proliferation, cell differentiation, cell accumulation or migration and cell, tissue or organ damage or remodelling, allergic rhinitis; Onchocercal dermatitis; Atopic dermatitis; allergic conjunctivitis; Drug reactions; Nodules, eosinophilia, rheumatism, dermatitis, rashes, hives, and swelling (NERDS); esophageal and a gastrointestinal allergy. Additional symptoms of antigen/allergen exposure are known to one of skill in the art and treatment thereof in accordance with the invention is provided.

Methods and uses of the invention moreover include reducing, decreasing, inhibiting, delaying or preventing onset, progression, frequency, duration, severity, probability or susceptibility of one or more adverse symptoms, disorders, illnesses, diseases or complications caused by or associated with an antigen/allergen. In further various particular embodiments, methods and uses include improving, accelerating, facilitating, enhancing, augmenting, or hastening recovery of a subject from an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an antigen/allergen. In yet additional various embodiments, methods and uses include stabilizing an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an antigen/allergen.

A therapeutic or beneficial effect is therefore any objective or subjective measurable or detectable improvement or benefit provided to a particular subject. A therapeutic or beneficial effect can but need not be complete ablation of all or any allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen. Thus, a satisfactory clinical endpoint is achieved when there is an incremental improvement or a partial reduction in an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen, or an inhibition, decrease, reduction, suppression, prevention, limit or control of worsening or progression of an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen, over a short or long duration (hours, days, weeks, months, etc.).

A therapeutic or beneficial effect also includes reducing or eliminating the need, dosage frequency or amount of a second therapeutic protocol or active such as another drug or other agent (e.g., anti-inflammatory) used for treating a subject having or at risk of having an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen. For example, reducing an amount of an adjunct therapy, such as a reduction or decrease of a treatment for an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen, or a specific immunotherapy, vaccination or immunization protocol is considered a beneficial effect. In addition, reducing or decreasing an amount of protein, peptide, subsequence, portion, homologue, variant or derivative thereof, used for specific immunotherapy, vaccination or immunization of a subject to provide protection to the subject is considered a beneficial effect.

As disclosed herein, invention proteins, peptides, subsequences, etc., can be used in methods of providing specific immunotherapy to a subject, such as a subject with or at risk of an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen. In one embodiment, a method or use includes administering to a subject an amount of a protein, peptide, subsequence, portion, homologue, variant or derivative thereof sufficient to elicit, stimulate, induce, promote, increase, enhance or augment immunological tolerance in the subject to an antigen/allergen. In another embodiment, a method includes administering to a subject an amount of a nucleic acid encoding all or a portion (e.g., a T cell epitope) of a protein, peptide, subsequence, portion, homologue, variant or derivative thereof sufficient to elicit, stimulate, induce, promote, increase, enhance or augment immunological tolerance of the subject to an allergen.

When an antigen(s) or allergen(s) is administered to induce tolerance, an amount or dose of the antigen or allergen to be administered, and the period of time required to achieve a desired outcome or result (e.g., to desensitize or develop tolerance to the antigen or allergen) can be determined by one skilled in the art. The antigen or allergen may be administered to the patient through any route known in the art, including, but not limited to oral, inhalation, sublingual, epicutaneous, intranasal, and/or parenteral routes (intravenous, intramuscular, subcutaneously, and intraperitoneal).

Methods and uses of the invention include administration of a protein, peptide, subsequence, portion, homologue, variant or derivative thereof to a subject prior to contact by or exposure to an allergen; administration prior to, substantially contemporaneously with or after a subject has been contacted by or exposed to an allergen; and administration prior to, substantially contemporaneously with or after an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen. A subject contacted by or exposed to an allergen may have contact or exposure over a period of 1-5, 5-10, 10-20, 20-30, 30-50, 50-100 hours, days, months, or years.

Invention compositions (e.g., proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof, including T cell epitopes, for example, of an amino acid sequence of a TG protein or peptide set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6), methods and uses can be combined with any compound, agent, drug, treatment or other therapeutic regimen or protocol having a desired therapeutic, beneficial, additive, synergistic or complementary activity or effect. Exemplary combination compositions and treatments include multiple proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof such as T cell epitopes as described herein (e.g., of an amino acid sequence of a TG protein or peptide set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6), and second actives, such as anti-allergen compounds, agents, drugs, treatments and therapies, including but not limited to anti-histamines, anti-inflammatories, decongestants and corticosteroids as well as agents that assist, promote, stimulate or enhance efficacy. Such anti-allergen drugs, agents, treatments and therapies can be administered or performed prior to, substantially contemporaneously with or following any method or use described herein, for example, a therapeutic use or method of treating a subject for an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen, or a method or use of providing specific immunotherapy to a subject.

Accordingly, methods and uses include combinations of TG proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof and second actives, and administering as a combination with a second active, or administered separately, such as concurrently or in series or sequentially (prior to or following) to administering a second active to a subject. The invention therefore provides combinations of one or more proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof, in combination with a second active, including but not limited to any compound, agent, drug, therapeutic regimen, treatment protocol, process, remedy or composition, such as anti-histamine, anti-inflammatory, decongestant and corticosteroid, or immune tolerance stimulating, enhancing or augmenting protocol, or specific immunotherapy protocol set forth herein or known in the art. The compound, agent, drug, therapeutic regimen, treatment protocol, process, remedy or composition can be administered or performed prior to, substantially contemporaneously with or following administration of one or more proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof, or a nucleic acid encoding all or a portion (e.g., a T cell epitope) of a protein, peptide, subsequence, portion, homologue, variant or derivative thereof, to a subject. Specific non-limiting examples of combination embodiments therefore include the foregoing or other compound, agent, drug, therapeutic regimen, treatment protocol, process, remedy or composition.

An exemplary combination is a TG protein, peptide, subsequence, portion, homologue, variant or derivative thereof, and a different protein, peptide, or subsequence, portion, homologue, variant or derivative thereof, of an amino acid sequence of a TG protein or peptide set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6. Another exemplary combination is a protein, peptide, subsequence, portion, homologue, variant or derivative thereof, and an immunological tolerance inducing molecule.

In invention methods and uses in which there is a desired outcome or effect, such as a therapeutic or prophylactic method or use that provides a benefit from treatment, protection, inducing immunological tolerance, vaccination or specific immunotherapy, a TG protein, peptide, subsequence, portion, homologue, variant or derivative thereof can be administered in a sufficient or effective amount. As used herein, a “sufficient amount” or “effective amount” or an “amount sufficient” or an “amount effective” refers to an amount that provides, in single (e.g., primary) or multiple (e.g., booster) doses, alone or in combination with one or more other compounds, treatments, therapeutic regimens or agents (e.g., a drug), a long term or a short term detectable or measurable improvement in a given subject or any objective or subjective benefit to a given subject of any degree or for any time period or duration (e.g., for minutes, hours, days, months, years, or cured).

An amount sufficient or an amount effective can but need not be provided in a single administration and can but need not be achieved by a particular protein, peptide, subsequence, portion, homologue, variant or derivative thereof, alone, optionally in a combination composition or method or use that includes a second active. In addition, an amount sufficient or an amount effective need not be sufficient or effective if given in single or multiple doses without a second or additional administration or dosage, since additional doses, amounts or duration above and beyond such doses, or additional antigens, compounds, drugs, agents, treatment or therapeutic regimens may be included in order to provide a given subject with a detectable or measurable improvement or benefit to the subject. For example, to increase, enhance, improve or optimize specific immunotherapy, after an initial or primary administration of one or more proteins, peptides, subsequences, portions, homologues, variants or derivative thereof, the subject can be administered one or more additional “boosters” of one or more proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof. Such subsequent “booster” administrations can be of the same or a different type, formulation, dose, concentration, route, etc.

An amount sufficient or an amount effective need not be therapeutically or prophylactically effective in each and every subject treated, nor a majority of subjects treated in a given group or population. An amount sufficient or an amount effective means sufficiency or effectiveness in a particular subject, not a group of subjects or the general population. As is typical for such methods, different subjects will exhibit varied responses to a method of the invention, such as immunization, vaccination, specific immunotherapy and therapeutic treatments.

The term “subject” includes but is not limited to a subject at risk of allergen contact or exposure as well as a subject that has been contacted by or exposed to an allergen. A subject also includes those having or at risk of having or developing an immune response to an antigen or an allergen. Such subjects include mammalian animals (mammals), such as a non-human primate (apes, gibbons, gorillas, chimpanzees, orangutans, macaques), a domestic animal (dogs and cats), a farm animal (poultry such as chickens and ducks, horses, cows, goats, sheep, pigs), experimental animal (mouse, rat, rabbit, guinea pig) and humans. Subjects include animal disease models, for example, mouse and other animal models of allergic response known in the art.

Accordingly, subjects appropriate for treatment include those having or at risk of exposure to an antigen or allergen, also referred to as subjects in need of treatment. Subjects in need of treatment therefore include subjects that have been exposed to or contacted with an antigen or allergen, or that have an ongoing contact or exposure or have developed one or more adverse symptoms caused by or associated with an antigen or allergen, regardless of the type, timing or degree of onset, progression, severity, frequency, duration of the symptoms.

Target subjects and subjects in need of treatment also include those at risk of allergen exposure or contact or at risk of having exposure or contact to an allergen. Accordingly, subjects include those at increased or elevated (high) risk of an allergic reaction; has, or has previously had or is at risk of developing hypersensitivity to an allergen; and those that have or have previously had or is at risk of developing asthma.

More particular target subjects include subjects allergic to particular Timothy Grass antigens and/or allergens. In particular embodiments, a subject is allergic to a Timothy grass pollen allergen, such as a Phl p 1, Phl p 5, and/or Phl p 6 allergen, or is allergic to a homologous allergen, such as a Group 1, Group 5 and/or Group 6 Grass Pollen allergen, e.g. Grass Pollen from Grass of the order Poales.

Invention compositions, methods and uses are therefore applicable to treating a subject who is at risk of allergen exposure or contact but has not yet been exposed to or contacted with the allergen. Prophylactic uses and methods are therefore included. Target subjects for prophylaxis may be at increased risk (probability or susceptibility) of allergen exposure or contact as set forth herein. Such subjects are considered in need of treatment due to being at risk.

Subjects for prophylaxis need not be at increased risk but may be from the general population in which it is desired to protect a subject against an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen or to provide specific immunotherapy, for example. Such a subject that is desired to be protected against an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen or to be provided specific immunotherapy can be administered a protein, peptide, subsequence, portion, homologue, variant or derivative thereof. In another non-limiting example, a subject that is not specifically at risk of exposure to or contact by an allergen, but nevertheless desires protection against an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen, can be administered a protein, peptide, subsequence, portion, homologue, variant or derivative thereof. Such subjects are also considered in need of treatment.

“Prophylaxis” and grammatical variations thereof mean a method or use in which contact, administration or in vivo delivery to a subject is prior to contact with or exposure to an allergen. In certain situations it may not be known that a subject has been contacted with or exposed to an allergen, but administration or in vivo delivery to a subject can be performed prior to manifestation of an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen. For example, a subject can be provided protection against an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen or provided specific immunotherapy with a protein, peptide, subsequence, portion, homologue, variant or derivative thereof. In such case, a method or use can eliminate, prevent, inhibit, suppress, limit, decrease or reduce the probability of or susceptibility towards an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an antigen/allergen.

“Prophylaxis” can also refer to a method or use in which contact, administration or in vivo delivery to a subject is prior to a secondary or subsequent exposure to an antigen/allergen. In such a situation, a subject may have had a prior contact or exposure to an allergen. In such subjects, an acute allergic reaction may but need not be resolved. Such a subject typically may have developed anti-allergen antibodies due to the prior exposure. Immunization or vaccination, by administration or in vivo delivery to such a subject, can be performed prior to a secondary or subsequent allergen exposure. Such a method or use can eliminate, prevent, inhibit, suppress, limit, decrease or reduce the probability of or susceptibility towards a secondary or subsequent allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen. In certain embodiments, such a method or use includes providing specific immunotherapy to the subject to eliminate, prevent, inhibit, suppress, limit, decrease or reduce the probability of or susceptibility towards a secondary or subsequent allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an antigen/allergen.

Treatment of an allergic reaction or response can be at any time during the reaction or response. A protein, peptide, subsequence, portion, homologue, variant or derivative thereof, can be administered as a combination (e.g., with a second active), or separately concurrently or in sequence (sequentially) in accordance with the methods and uses described herein as a single or multiple dose e.g., one or more times hourly, daily, weekly, monthly or annually or between about 1 to 10 weeks, or for as long as appropriate, for example, to achieve a reduction in the onset, progression, severity, frequency, duration of one or more symptoms or complications associated with or caused by an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an antigen/allergen.

Accordingly, methods and uses of the invention can be practiced one or more times (e.g., 1-10, 1-5 or 1-3 times) an hour, day, week, month, or year. The skilled artisan will know when it is appropriate to delay or discontinue administration. A non-limiting dosage schedule is 1-7 times per week, for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20 or more weeks.

Doses can be based upon current existing protocols, empirically determined, using animal disease models or optionally in human clinical trials. Initial study doses can be based upon animal studies, e.g. a mouse, and the amount of protein, peptide, subsequence, portion, homologue, variant or derivative thereof, administered that is determined to be effective. Exemplary non-limiting amounts (doses) are in a range of about 0.1 mg/kg to about 100 mg/kg, and any numerical value or range or value within such ranges. Greater or lesser amounts (doses) can be administered, for example, 0.01-500 mg/kg, and any numerical value or range or value within such ranges. The dose can be adjusted according to the mass of a subject, and will generally be in a range from about 1-10 ug/kg, 10-25 ug/kg, 25-50 ug/kg, 50-100 ug/kg, 100-500 ug/kg, 500-1,000 ug/kg, 1-5 mg/kg, 5-10 mg/kg, 10-20 mg/kg, 20-50 mg/kg, 50-100 mg/kg, 100-250 mg/kg, 250-500 mg/kg, or more, two, three, four, or more times per hour, day, week, month or annually. A typical range will be from about 0.3 mg/kg to about 50 mg/kg, 0-25 mg/kg, or 1.0-10 mg/kg, or any numerical value or range or value within such ranges.

Doses can vary and depend upon whether the treatment is prophylactic or therapeutic, whether a subject has been previously exposed to the antigen/allergen, the onset, progression, severity, frequency, duration, probability of or susceptibility of the symptom, condition, pathology or complication, or vaccination or specific immunotherapy to which treatment is directed, the clinical endpoint desired, previous or simultaneous treatments, the general health, age, gender, race or immunological competency of the subject and other factors that will be appreciated by the skilled artisan. The skilled artisan will appreciate the factors that may influence the dosage and timing required to provide an amount sufficient for providing a therapeutic or prophylactic benefit.

Typically, for treatment, a protein, peptide, subsequence, portion, homologue, variant or derivative thereof, will be administered as soon as practical, typically within 1-2, 2-4, 4-12, 12-24 or 24-72 hours after a subject is exposed to or contacted with an allergen, or within 1-2, 2-4, 4-12, 12-24 or 24-48 hours after onset or development of one or more of an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an antigen/allergen.

For prophylactic treatment in connection with vaccination or specific immunotherapy, proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof, can be administered for a duration of 0-4 weeks, e.g., 2-3 weeks, prior to exposure to or contact by an allergen or at least within 1-2, 2-4, 4-12, 12-24, 24-48 or 48-72 hours prior to exposure to or contact by an allergen. For an acute allergic reaction, proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof may be administered at any appropriate time.

The dose amount, number, frequency or duration may be proportionally increased or reduced, as indicated by the status of the subject. For example, whether the subject has an allergic response, whether the subject has been exposed to or contacted by an allergen or is merely at risk of allergen contact or exposure, whether the subject is a candidate for or will be vaccinated or provided specific immunotherapy. The dose amount, number, frequency or duration may be proportionally increased or reduced, as indicated by any adverse side effects, complications or other risk factors of the treatment or therapy.

In methods and uses of the invention, the route, dose, number and frequency of administrations, treatments, vaccinations and specific immunotherapy, and timing/intervals between treatment, vaccination and specific immunotherapy, and allergen exposure can be modified. Although rapid induction of immune responses or immunological tolerance is desired for developing protective emergency vaccines against an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen, in certain embodiments, a desirable treatment will elicit robust, long-lasting protection against an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen. Thus, in certain embodiments, invention compositions, methods and uses provide long-lasting protection against an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen. Specific immunotherapy strategies can provide long-lived protection against an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen depending on the level of induced immunological tolerance or a T cell response or activity.

TG proteins or peptides, or subsequences, portions, homologues, variants or derivatives thereof can be provided in compositions, and in turn such compositions can be used in accordance with the invention methods and uses. Such compositions, methods and uses include pharmaceutical compositions and formulations. In certain embodiments, a pharmaceutical composition includes one or more TG proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof described herein (e.g., an amino acid sequence of a TG protein or peptide set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6). In particular, aspects, such compositions and formulations may be a vaccine, including but not limited to a vaccine to protect against an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen.

As used herein the term “pharmaceutically acceptable” and “physiologically acceptable” mean a biologically acceptable formulation, gaseous, liquid or solid, or mixture thereof, which is suitable for one or more routes of administration, in vivo delivery or contact. Such formulations include solvents (aqueous or non-aqueous), solutions (aqueous or non-aqueous), emulsions (e.g., oil-in-water or water-in-oil), suspensions, syrups, elixirs, dispersion and suspension media, coatings, isotonic and absorption promoting or delaying agents, compatible with pharmaceutical administration or in vivo contact or delivery. Aqueous and non-aqueous solvents, solutions and suspensions may include suspending agents and thickening agents. Such pharmaceutically acceptable carriers include tablets (coated or uncoated), capsules (hard or soft), microbeads, powder, granules and crystals. Supplementary active compounds (e.g., preservatives, antibacterial, antiviral and antifungal agents) can also be incorporated into the compositions.

To increase an immune response, immunological tolerance or protection against an allergic response, allergic disorder or allergic disease, or one or more physiological conditions, disorders, illnesses, diseases, symptoms or complications caused by or associated with an allergen, proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof, can be coupled to another protein such as ovalbumin or keyhole limpet hemocyanin (KLH), thyroglobulin or a toxin such as tetanus or cholera toxin. Proteins, peptides, subsequences, portions, homologues, variants or derivatives thereof can also be mixed with adjuvants.

Adjuvants include, for example: oil (mineral or organic) emulsion adjuvants such as Freund's complete (CFA) and incomplete adjuvant (IFA) (WO 95/17210; WO 98/56414; WO 99/12565; WO 99/11241; and U.S. Pat. No. 5,422,109); metal and metallic salts, such as aluminum and aluminum salts, such as aluminum phosphate or aluminum hydroxide, alum (hydrated potassium aluminum sulfate); bacterially derived compounds, such as Monophosphoryl lipid A and derivatives thereof (e.g., 3 De-O-acylated monophosphoryl lipid A, aka 3D-MPL or d3-MPL, to indicate that position 3 of the reducing end glucosamine is de-O-acylated, 3D-MPL consisting of the tri and tetra acyl congeners), and enterobacterial lipopolysaccharides (LPS); plant derived saponins and derivatives thereof, for example Quil A (isolated from the Quilaja Saponaria Molina tree, see, e.g., “Saponin adjuvants”, Archiv. für die gesamte Virusforschung, Vol. 44, Springer Verlag, Berlin, p 243-254; U.S. Pat. No. 5,057,540), and fragments of Quil A which retain adjuvant activity without associated toxicity, for example QS7 and QS21 (also known as QA7 and QA21), as described in WO96/33739, for example; surfactants such as, soya lecithin and oleic acid; sorbitan esters such as sorbitan trioleate; and polyvinylpyrrolidone; oligonucleotides such as CpG (WO 96/02555, and WO 98/16247), polyriboA and polyriboU; block copolymers; and immunostimulatory cytokines such as GM-CSF and IL-1, and Muramyl tripeptide (MTP). Additional examples of adjuvants are described, for example, in “Vaccine Design—the subunit and adjuvant approach” (Edited by Powell, M. F. and Newman, M. J.; 1995, Pharmaceutical Biotechnology (Plenum Press, New York and London, ISBN 0-306-44867-X) entitled “Compendium of vaccine adjuvants and excipients” by Powell, M. F. and Newman M.

Cosolvents may be added to a protein, peptide, subsequence, portion, homologue, variant or derivative thereof, composition or formulation. Non-limiting examples of cosolvents contain hydroxyl groups or other polar groups, for example, alcohols, such as isopropyl alcohol; glycols, such as propylene glycol, polyethyleneglycol, polypropylene glycol, glycol ether; glycerol; polyoxyethylene alcohols and polyoxyethylene fatty acid esters. Non-limiting examples of cosolvents contain hydroxyl groups or other polar groups, for example, alcohols, such as isopropyl alcohol; glycols, such as propylene glycol, polyethyleneglycol, polypropylene glycol, glycol ether; glycerol; polyoxyethylene alcohols and polyoxyethylene fatty acid esters.

Supplementary compounds (e.g., preservatives, antioxidants, antimicrobial agents including biocides and biostats such as antibacterial, antiviral and antifungal agents) can also be incorporated into the compositions. Pharmaceutical compositions may therefore include preservatives, anti-oxidants and antimicrobial agents.

Preservatives can be used to inhibit microbial growth or increase stability of ingredients thereby prolonging the shelf life of the pharmaceutical formulation. Suitable preservatives are known in the art and include, for example, EDTA, EGTA, benzalkonium chloride or benzoic acid or benzoates, such as sodium benzoate. Antioxidants include, for example, ascorbic acid, vitamin A, vitamin E, tocopherols, and similar vitamins or provitamins.

An antimicrobial agent or compound directly or indirectly inhibits, reduces, delays, halts, eliminates, arrests, suppresses or prevents contamination by or growth, infectivity, replication, proliferation, reproduction, of a pathogenic or non-pathogenic microbial organism. Classes of antimicrobials include antibacterial, antiviral, antifungal and antiparasitics. Antimicrobials include agents and compounds that kill or destroy (-cidal) or inhibit (-static) contamination by or growth, infectivity, replication, proliferation, reproduction of the microbial organism.

Exemplary antibacterials (antibiotics) include penicillins (e.g., penicillin G, ampicillin, methicillin, oxacillin, and amoxicillin), cephalosporins (e.g., cefadroxil, ceforanid, cefotaxime, and ceftriaxone), tetracyclines (e.g., doxycycline, chlortetracycline, minocycline, and tetracycline), aminoglycosides (e.g., amikacin, gentamycin, kanamycin, neomycin, streptomycin, netilmicin, paromomycin and tobramycin), macrolides (e.g., azithromycin, clarithromycin, and erythromycin), fluoroquinolones (e.g., ciprofloxacin, lomefloxacin, and norfloxacin), and other antibiotics including chloramphenicol, clindamycin, cycloserine, isoniazid, rifampin, vancomycin, aztreonam, clavulanic acid, imipenem, polymyxin, bacitracin, amphotericin and nystatin.

Particular non-limiting classes of anti-virals include reverse transcriptase inhibitors; protease inhibitors; thymidine kinase inhibitors; sugar or glycoprotein synthesis inhibitors; structural protein synthesis inhibitors; nucleoside analogues; and viral maturation inhibitors. Specific non-limiting examples of anti-virals include nevirapine, delavirdine, efavirenz, saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, zidovudine (AZT), stavudine (d4T), larnivudine (3TC), didanosine (DDI), zalcitabine (ddC), abacavir, acyclovir, penciclovir, ribavirin, valacyclovir, ganciclovir, 1,-D-ribofuranosyl-1,2,4-triazole-3 carboxamide, 9->2-hydroxy-ethoxy methylguanine, adamantanamine, 5-iodo-2′-deoxyuridine, trifluorothymidine, interferon and adenine arabinoside.

Pharmaceutical formulations and delivery systems appropriate for the compositions, methods and uses of the invention are known in the art (see, e.g., Remington: The Science and Practice of Pharmacy (2003) 20^(th) ed., Mack Publishing Co., Easton, Pa.; Remington's Pharmaceutical Sciences (1990) 18^(th) ed., Mack Publishing Co., Easton, Pa.; The Merck Index (1996) 12^(th) ed., Merck Publishing Group, Whitehouse, N.J.; Pharmaceutical Principles of Solid Dosage Forms (1993), Technonic Publishing Co., Inc., Lancaster, Pa.; Ansel ad Soklosa, Pharmaceutical Calculations (2001) 11^(th) ed., Lippincott Williams & Wilkins, Baltimore, Md.; and Poznansky et al., Drug Delivery Systems (1980), R. L. Juliano, ed., Oxford, N.Y., pp. 253-315).

Pharmaceutical compositions can be formulated to be compatible with a particular route of administration. Thus, pharmaceutical compositions include carriers, diluents, or excipients suitable for administration by various routes. Exemplary routes of administration for contact or in vivo delivery which a composition can optionally be formulated include inhalation, respiration, intranasal, intubation, intrapulmonary instillation, oral, buccal, intrapulmonary, intradermal, topical, dermal, parenteral, sublingual, subcutaneous, intravascular, intrathecal, intraarticular, intracavity, transdermal, iontophoretic, intraocular, opthalmic, optical, intravenous (i.v.), intramuscular, intraglandular, intraorgan, or intralymphatic.

Formulations suitable for parenteral administration include aqueous and non-aqueous solutions, suspensions or emulsions of the active compound, which preparations are typically sterile and can be isotonic with the blood of the intended recipient. Non-limiting illustrative examples include water, saline, dextrose, fructose, ethanol, animal, vegetable or synthetic oils.

Methods and uses of the invention may be practiced by any mode of administration or delivery, or by any route, systemic, regional and local administration or delivery. Exemplary administration and delivery routes include intravenous (i.v.), intraperitoneal (i.p.), intrarterial, intramuscular, parenteral, subcutaneous, intra-pleural, topical, dermal, intradermal, transdermal, transmucosal, intra-cranial, intra-spinal, rectal, oral (alimentary), mucosal, inhalation, respiration, intranasal, intubation, intrapulmonary, intrapulmonary instillation, buccal, sublingual, intravascular, intrathecal, intracavity, iontophoretic, intraocular, ophthalmic, optical, intraglandular, intraorgan, or intralymphatic.

For oral administration, a composition can take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (for example, pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (for example, lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (for example, magnesium stearate, talc or silica); disintegrants (for example, potato starch or sodium starch glycolate); or wetting agents (for example, sodium lauryl sulphate). The tablets can be coated by methods known in the art. Liquid preparations for oral administration can take the form of, for example, solutions, syrups or suspensions, or they can be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (for example, sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (for example, lecithin or acacia); non-aqueous vehicles (for example, almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (for example, methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations can also contain buffer salts, flavoring, coloring, and sweetening agents as appropriate.

For administration by inhalation, a composition can be delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

Invention TG proteins and peptides, e.g., a protein or peptide set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6), subsequences, portions, homologues, variants or derivatives thereof optionally along with any adjunct agent, compound, drug, composition, whether active or inactive, etc., can be packaged in unit dosage form (capsules, tablets, troches, cachets, lozenges) for ease of administration and uniformity of dosage. A “unit dosage form” as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active ingredient optionally in association with a pharmaceutical carrier (excipient, diluent, vehicle or filling agent) which, when administered in one or more doses, is calculated to produce a desired effect (e.g., prophylactic or therapeutic effect). Unit dosage forms also include, for example, ampules and vials, which may include a composition in a freeze-dried or lyophilized state; a sterile liquid carrier, for example, can be added prior to administration or delivery in vivo. Unit dosage forms additionally include, for example, ampules and vials with liquid compositions disposed therein. Individual unit dosage forms can be included in multi-dose kits or containers. Pharmaceutical formulations can be packaged in single or multiple unit dosage form for ease of administration and uniformity of dosage.

The invention also provides methods of diagnosing and detecting an allergic response or allergy in a subject. The methods can be performed in solution, in solid phase, in silica, in vitro, in a cell, and in vivo. In one embodiment, a method includes contacting a cell (e.g., T cell) from the subject with a TG protein, peptide, subsequence, portion, homologue, variant or derivative thereof, as described herein (e.g., of an amino acid sequence of a TG protein or peptide set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6); and determining if the protein or peptide modulates an immune response or activity of the contacted cell (e.g., T cell). A determination that the TG protein or peptide modulates an immune response or immune activity of the contacted cell indicates that the subject has an allergic response or an allergy, in particular, an allergy to the protein, peptide, subsequence, portion, homologue, variant or derivative thereof (e.g., of an amino acid sequence of a TG protein or peptide set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6). In a particular aspect, the immune activity determined is Th2 cell reactivity. In another particular aspect, immune response or activity is determined by assaying for a cutaneous immunological hypersensitive reaction.

The terms “determining,” “assaying” and “measuring” and grammatical variations thereof are used interchangeably herein and refer to either qualitative or quantitative determinations, or both qualitative and quantitative determinations, that involve manipulation or processing. When the terms are used in reference to measurement or detection, any means of assessing the relative amount, including the various methods set forth herein and known in the art, performed by the hand of man, is contemplated.

The invention provides kits including TG protein, peptide, subsequence, portion, homologue, variant or derivative thereof (e.g., of an amino acid sequence of a TG protein or peptide set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6), combination compositions and pharmaceutical formulations thereof, packaged into suitable packaging material. Kits can be used in various in vitro, ex vivo and in vivo methods and uses, for example a treatment method or use as disclosed herein.

A kit typically includes a label or packaging insert including a description of the components or instructions for use in vitro, in vivo, or ex vivo, of the components therein. A kit can contain a collection of such components, e.g., a TG protein, peptide, subsequence, portion, homologue, variant or derivative thereof (e.g., of an amino acid sequence of a TG protein or peptide set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6), alone, or in combination with another therapeutically useful composition (e.g., an immune modulatory drug).

The term “packaging material” refers to a physical structure housing the components of the kit. The packaging material can maintain the components sterilely, and can be made of material commonly used for such purposes (e.g., paper, corrugated fiber, glass, plastic, foil, ampules, vials, tubes, etc.).

Kits of the invention can include labels or inserts. Labels or inserts include “printed matter,” e.g., paper or cardboard, or separate or affixed to a component, a kit or packing material (e.g., a box), or attached to an ampule, tube or vial containing a kit component. Labels or inserts can additionally include a computer readable medium, such as a disk (e.g., hard disk), optical disk such as CD- or DVD-ROM/RAM, DVD, MP3, magnetic tape, or an electrical storage media such as RAM and ROM or hybrids of these such as magnetic/optical storage media, FLASH media or memory type cards.

Labels or inserts can include identifying information of one or more components therein, dose amounts, clinical pharmacology of the active ingredient(s) including mechanism of action, pharmacokinetics and pharmacodynamics. Labels or inserts can include information identifying manufacturer information, lot numbers, manufacturer location and date.

Labels or inserts can include information on a condition, disorder, disease or symptom for which a kit component may be used. Labels or inserts can include instructions for the clinician or for a subject for using one or more of the kit components in a method, use, treatment protocol or therapeutic regimen. Instructions can include dosage amounts, frequency or duration, and instructions for practicing any of the methods and uses, treatment protocols or therapeutic regimes set forth herein. Exemplary instructions include, instructions for modulating an immune response or activity of a cell against an allergen; modulating an immune response against an allergen in a subject; desensitizing, or inducing, eliciting, increasing or improving immunological tolerance to a protein or peptide allergen; reducing risk or providing a subject protection against an allergic reaction, allergic response, allergic disorder or allergic disease; treating an allergic reaction, allergic response, allergic disorder or allergic disease; or detecting an allergic response or diagnosing an allergy in a subject.

Labels or inserts can include information on any benefit that a component may provide, such as a prophylactic or therapeutic benefit. Labels or inserts can include information on potential adverse side effects, such as warnings to the subject or clinician regarding situations where it would not be appropriate to use a particular composition. Adverse side effects could also occur when the subject has, will be or is currently taking one or more other medications that may be incompatible with the composition, or the subject has, will be or is currently undergoing another treatment protocol or therapeutic regimen which would be incompatible with the composition and, therefore, instructions could include information regarding such incompatibilities.

Invention kits can additionally include other components. Each component of the kit can be enclosed within an individual container and all of the various containers can be within a single package. Invention kits can be designed for cold storage. Invention kits can further be designed to contain to the protein, peptide, subsequence, portion, homologue, variant or derivative thereof (e.g., of an amino acid sequence of a TG protein or peptide set forth in Table 1 (SEQ ID NOS 1-620), Table 2 (SEQ ID NOS 621-1442), Table 4 (SEQ ID NOS 1443-2264) or Table 6), or combination compositions or pharmaceutical compositions.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described herein.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the invention is not entitled to antedate such publication by virtue of prior invention.

As used in this specification and the appended claims, the use of an indefinite article or the singular forms “a,” “an” and “the” include plural reference unless the context clearly dictates otherwise. In addition, it should be understood that the individual peptides, proteins, antigens, allergens (referred to collectively as compositions), or groups of compositions, modeled or derived from the various components or combinations of the compositions, and substituents described herein, are disclosed by the application to the same extent as if each composition or group of compositions was set forth individually. Thus, selection of particular peptides, proteins, antigens, allergens, etc. is clearly within the scope of the invention.

As used in this specification and the appended claims, the terms “comprise”, “comprising”, “comprises” and other forms of these terms are intended in the non-limiting inclusive sense, that is, to include particular recited elements or components without excluding any other element or component. Unless defined otherwise all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. As used herein, “about” means + or −5%. The use of the alternative (e.g., “or”) should be understood to mean one, both, or any combination thereof of the alternatives, i.e., “or” can also refer to “and.”

As used in this specification and the appended claims, any concentration range, percentage range, ratio range or other integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated. For example, although numerical values are often presented in a range format throughout this document, a range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the use of a range expressly includes all possible subranges, all individual numerical values within that range, and all numerical values or numerical ranges including integers within such ranges and fractions of the values or the integers within ranges unless the context clearly indicates otherwise. This construction applies regardless of the breadth of the range and in all contexts throughout this patent document. Thus, to illustrate, reference to a range of 90-100% includes 91-99%, 92-98%, 93-95%, 91-98%, 91-97%, 91-96%, 91-95%, 91-94%, 91-93%, and so forth. Reference to a range of 90-100%, includes 91%, 92%, 93%, 94%, 95%, 95%, 97%, etc., as well as 91.1%, 91.2%, 91.3%, 91.4%, 91.5%, etc., 92.1%, 92.2%, 92.3%, 92.4%, 92.5%, etc., and so forth. Reference to a range of 5-10, 10-20, 20-30, 30-40, 40-50, 50-75, 75-100, 100-150, and 150-175, includes ranges such as 5-20, 5-30, 5-40, 5-50, 5-75, 5-100, 5-150, 5-171, and 10-30, 10-40, 10-50, 10-75, 10-100, 10-150, 10-175, and 20-40, 20-50, 20-75, 20-100, 20-150, 20-175, and so forth. Further, for example, reference to a series of ranges of 2-72 hours, 2-48 hours, 4-24 hours, 4-18 hours and 6-12 hours, includes ranges of 2-6 hours, 2, 12 hours, 2-18 hours, 2-24 hours, etc., and 4-27 hours, 4-48 hours, 4-6 hours, etc.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims. The invention is further exemplified by way of the following non-limited examples.

EXAMPLES Example 1

This example includes a description of materials and methods.

Donor Population.

Each donor was recruited following Institutional Review Board approval (Federal Wide Assurance number 00000032) and informed consent and assigned a study identification number. Donors were tested for allergen reactivity by skin prick tests to extracts from 32 common allergens. TG allergic donors were identified as having a skin reaction with a wheal of ≧5 mm in diameter to TG and a clinical history consistent with seasonal grass pollen allergy. Donors that had received specific immunotherapy were excluded. Non-allergic donors were identified as having negative skin prick tests to all allergens and no clinical history of allergy.

Identification of Novel TG Pollen Proteins.

Novel TG pollen proteins were identified as follows:

Assembly of TG Pollen Transcriptome.

Novel Timothy grass (TG) pollen proteins that are potential T cell antigens were identified by a combination of 2D gel/immunoblot analysis and cDNA sequence analysis of soluble pollen extract. Total RNA of TG pollen was isolated as previously described (Allergon AB, Ängelholm, Sweden) (31). In brief, 1 mg ground pollen was homogenized in 20 ml 4.2 M guanidine hiocyanate, 50 mM of BES pH 7.2, 4 mM EDTA followed by centrifugation at 15000 g for 15 min. Total RNA was prepared from the supernatant using the TRIzol LS Reagent (Invitrogen, Carlsbad, Calif., USA) according to the manufacturer's instructions. The RNA was then analyzed by high-throughput sequencing on an Illumina Genome Analyzer. First, double stranded cDNA was constructed from total RNA using the Illumina TotalPrep RNA Amplification kit (Ambion). The cDNA was then converted into fragments of approximately 200 bp using NEBNext® dsDNA Fragmentase™ (New England Biolabs). The ends were repaired, dA tails were added to the fragmented DNA using NEBNext® DNA Sample Preparation kit, and adaptors were added. Sequencing was performed on an Illumina Genome Analyzer IIx (GAIIx). Briefly, adaptor ligated cDNA was loaded into an Illumina flow cell. DNA was then bridge-amplified within the flowcell to generate millions of DNA clusters, using specific reagents and enzymes (Illumina Paired-End Cluster Generation Kit). The flow cell was then loaded onto the GAIIx equipped with a paired-end module, and 72 sequencing cycles were performed to generate sequence in both directions using Illumina Sequencing Kit v4. Replicate samples were run in 7 of the 8 lanes on the flow cell, producing over 280 million raw sequence reads of 72 bp in length. Reads went through several preprocessing steps using the FastX toolkit (33) before they were assembled into contigs: 1) the 3′ terminal base was removed; 2) low-complexity reads were removed; 3) portions of reads downstream of a low quality score were removed; 4) portions of reads corresponding to adapter sequencers were removed. The remaining reads were assembled into contigs using Velvet version 1.0.15 (32). Due to the excessive memory requirements inherent to de novo sequence assembly, the reads for each lane were considered separately and were each run with five different values for the word size parameter (k=21, 23, 25, 27, 29). The present inventors and others (33) have observed that different sets of contigs are obtained for each value for k. The contigs were further merged with Oases version 0.18.1 (D. R. Zerbino, European Bioinformatics Institute) into 1,764,158 putative transcripts. After redundancy reduction, 1,016,285 transcripts remained (including isoforms and other variants) with an average length of 245 bp and a maximum length of 6,884 bp.

2D DIGE (Difference Gel Electrophoresis) Analysis.

The complete 2D DIGE analysis was performed by Applied Biomics (Hayward, Calif., US). Briefly, TG extract was run on two 2D gels (3-10 pH range, 12% SDS-acrylamide gel), one was Coomassie blue stained, the other was blotted onto a nitrocellulose membrane. The membrane was then incubated with 5% dried milk in PBS/0.05% Tween to block non-specific binding and subsequently probed with a serum pool from 8 TG-allergic individuals at a dilution of 1:250. IgE and IgG binding was detected using goat anti-human IgE and rabbit anti-human IgG (Sigma-Aldrich, St. Louis, Mo.) and visualized using Cy2-conjugated donkey anti-goat IgG and Cy5-conjugated donkey anti-mouse IgG antibodies (Biotium, Hayward, Calif.).

Pollen Protein Identification by Mass Spectrometry.

Mass spectral protein identification was performed by Applied Biomics (Hayward, Calif., US). Briefly, spots of interest were selected from the 2D blot and the corresponding spots were identified on the stained SDS gel and cut out, washed several times to remove staining dye and other inhibitory chemicals. The spots were then dried to absorb maximum digestion buffer. Dried 2D gel spots were rehydrated in digestion buffer containing trypsin. Proteins were digested in-gel at 37° C. and then extracted from the gel with TFA extraction buffer. Subsequently the peptides were desalted using C-18 Zip-tips (Millipore) and mixed with CHCA matrix (alpha-cyano-4-hydroxycinnamic acid) and spotted into wells of a MALDI plate. Mass spectra of the peptides in each sample were obtained using an Applied Biosystems Proteomics Analyzer. The spectra were compared to the amino acid sequences encoded by putative ORFs from the de novo assembled TG pollen transcripts. All ORFs encoding for 15 amino acid residues or longer that had a >95% confidence hit as evaluated by the Mascot software package (Matrix science) were considered hits (Table 1). The amino acid sequences encoded by these ORFs were clustered using a custom script at a sequence similarity threshold of 90% to group together highly similar protein sequences. These sequences are encoded by different transcripts from the current assembly, which could arise from splice variants, allelic variation between cells of TG pollen, and from gene families with multiple members. Amino acid sequences that form one cluster are assigned one putative protein ID (Table 1).

Assembly of a Peptide Set Predicted to Promiscuously Bind HLA Class II Molecules.

For each 15-mer peptide encoded in the ORFs in Table 2, the binding affinity to a panel of 25 HLA class II molecules was predicted (Table 3) using a consensus prediction approach (21, 22). Peptides with predicted binding scores in the top 20% for a given allele were considered potential binders. Peptides predicted to bind 13 or more HLA molecules at this threshold were considered promiscuous binders, and selected for synthesis (after eliminating peptides overlapping by more than 9 contiguous residues). If less than 5 peptides from a given protein met this threshold, the top 5 peptides were chosen, and up to 4 peptides in proteins where length was prohibitive. In total, this resulted in the selection of 822 peptides from a total of 21,506 distinct 15-mers encoded in 620 ORFs (Table 2). As a control, a set of 105 peptides was derived from the known TG allergens using the same prediction approach. The selected peptides were purchased from A and A (San Diego, Calif.) as crude material on a small (1 mg) scale. Peptides that tested positive and were included in the dominant epitope pools were purchased as purified material (>95% pure) on a 5-10 mg scale.

PBMC Isolation and In Vitro Expansion of TG Extract-Specific T Cells.

PBMCs were isolated by density gradient centrifugation from one unit of blood (˜450 ml) and cryo-preserved as described previously (12). For in vitro expansions, PBMCs were thawed and cultured in RPMI 1640 (Ω Scientific, Tarzana, Calif.) supplemented with 5% human AB serum (Cellgro, Herndon, Va.) at a density of 2×106 cells/ml in 24-well plates (BD Biosciences, San Jose, Calif.) and stimulated with TG pollen extract (50 μg/ml) (Greer, Lenoir, N.C.). Cells were kept at 37° C., 5% CO2 and additional IL-2 and IL-7 (10 U/ml, eBioscience, San Diego, Calif.) was added every 3 d after initial antigenic stimulation. On day 14, cells were harvested and screened for reactivity against TG-specific peptide pools (16-25 peptides/pool, averaging 20 peptides/pool). On day 17, peptides from positive pools were tested individually to identify the reactive epitopes.

ELISPOT Assays.

The production of IL-5 from cultured PBMCs in response to antigen stimulation was measured by ELISPOT as described previously (12). Briefly, 1×105 cells/well were incubated with peptide, peptide pool or TG extract (10 μg/ml, 5 μg/ml and 50 μg/ml, respectively). After 24 h, cells were removed and plates were incubated with 2 μg/ml biotinylated anti-human IL-5 Ab (Mabtech) at 37° C. After 2 h, plates were washed and avidin-peroxidase-complex was added (Vector Laboratories, Burlingame, Calif.) for 1 h at RT. Peroxidase-conjugated spots were developed with 3-amino-9-ethylcarvazole solution (Sigma-Aldrich, St. Louis, Mo.). Criteria for peptide pool positivity were 100 SFCs/106 PBMCs, p≦0.05, and a stimulation index (SI)≧2. Criteria for individual peptides were the same except a minimum of 20 SFCs was counted as positive.

FACS Sorting of T Cell Subpopulations.

PBMCs were thawed, washed and counted. CD4+ T cells were isolated using a CD4+ T cell isolation Kit II (Miltenyi Biotec, Auburn, Calif.) according to manufacturer's instructions and subsequently stained with antibodies to sort desired T cell subpopulations. Memory and naïve T cell populations were sorted from CD4+ cells stained with CD45RA-FITC and CCR7-BL421. The naïve population was sorted as CD45RA+CCR7+ and the memory population was sorted as CD45RA− CCR7−/+. CD45RA+ CCR7− cells were not collected. Subsequently these subpopulations were put into culture with irradiated PBMC and stimulated with TG pollen extract and cultured for 14 days with IL-2 and IL-7 added every 3 days. IL-5 production in response to stimuli was assessed by ELISPOT. For Th1 and Th2 subpopulations, cells were sorted from CD4+ cells stained with CCR4−PECy7, CCR6−PE and CXCR3−APC. Th2 cells were sorted as CCR4+CCR6−CXCR3− T cells and Th1 cells were sorted as CCR4—CCR6+CXCR3+ T cells. Sorted cells were plated into ELISPOT plates with stimulus and CD4 depleted, irradiated PBMC as APC. IL-5 production was assessed after 24 h incubation.

Example 2

This example includes a description of studies showing that a significant fraction of TG reactive T cells in allergic donors do not target the major IgE reactive allergens.

In a previous study (12), the T cell epitopes in the ten known major IgE reactive allergens present in TG pollen were determined. Using 15-mer peptides overlapping by 10 residues that spanned the entire protein sequence of each of these allergens, 20 dominant epitopic regions accounting for the majority of T cell responses were identified. However, despite this comprehensive panel of peptides and the sensitivity of the T cell assays used, this study did not identify any IL-5 producing T cells responding to these ten allergens in 33% of the allergic donors tested despite strong responses (≧100 Spot Forming Cells (SFC)) to the whole TG extract (FIG. 1). These data suggested that a significant portion of the T cell response to TG was directed against antigens other than the known major IgE reactive allergens.

Example 3

This example includes a description of studies showing identification of novel TG pollen proteins through a combined transcriptomics and proteomics analysis.

As few proteins apart from IgE reactive allergens have been identified in TG (or any other allergenic grasses), the identification of all proteins with significant expression in TG pollen were pursued so that a more comprehensive analysis of T cell responses to TG could be performed. mRNA of TG pollen was isolated and analyzed by high-throughput sequencing on an Illumina Genome Analyzer. A total of 1,016,285 unique, putative transcripts (including allelic variants and isoforms) were identified. Of the ten known TG allergen proteins considered in the previous study (Phl p 1, 2, 3, 4, 5, 6, 7, 11, 12 and 13), all but one (Phl p 6) were identified in the transcriptome analysis with large fragments or entire sequences matching at >90% identity. Interestingly, one transcript matched the published Phl p 6 sequence with very high significance (Blast E-value of 4E-16) but much lower sequence identity (61%). This demonstrated that the transcripts identified from TG pollen mRNA recovered the vast majority of known allergens, but the approach herein also identified putative new variants of known allergens.

Next, a proteomics approach was utilized to determine which of the newly identified transcripts encoded proteins detectable in TG pollen. For this purpose, TG pollen extract was separated by 2D gel electrophoresis and either stained with Coomassie blue or immuno-blotted using a pool of sera from 8 TG allergic donors (FIG. 2) to detect proteins reactive with IgE and/or IgG antibodies. Spots were cut out from unstained gels, trypsin digested, and analyzed by peptide fingerprint mass mapping (using MS data) and peptide fragmentation mapping (using MS/MS data) to obtain amino acid sequences. Of 131 spots picked from the 2D gels, 119 could be assigned with high confidence to one or more open reading frames (ORFs) from the transcript sequences. After clustering ORFs with >90% sequence identity, it was found that the 119 identifiable spots corresponded to 89 non-redundant protein sequences including 6 of the known TG allergens. This left 83 distinct protein sequences corresponding to previously unidentified proteins identified by spots on the gel. To these was added another 10 proteins not identified in any spots cut out of the gel, but rather in a mass spec analysis of the whole TG extract. In total, this resulted in a set of 93 novel proteins from TG pollen that was further analyzed for T cell reactivity (Table 1).

To determine if any of the proteins identified were derived from contaminants (such as bacteria) possibly present in the TG pollen extract, the amino acid sequences were ran through NCBI BLAST. Two proteins (#27 and #38) had high homology to previously identified TG proteins that are not considered allergens. Of the remaining proteins, #76, had highly homologous (BLAST E value <10-10) matches in the rice genome (the closest to TG of all fully sequenced genomes available). Of the remaining proteins, none had similarly high homology to any publicly available sequence. Overall, based on similarity to known protein sequences, it was unlikely that the sets of protein sequences contained non-plant contaminants, indicating that the sequences were from bona fide TG proteins.

Example 4

This example includes a description of studies showing that T cells respond vigorously to epitopes from novel TG pollen proteins.

The 93 novel protein sequences were scanned for peptides predicted to bind to multiple HLA class II molecules. For each protein, all overlapping 15-mer peptides were analyzed and their binding affinity predicted to a panel of 25 HLA DR, DP and DQ molecules (Table 3) using a consensus approach of multiple machine learning methods (21,22). Non-overlapping peptides that were predicted to promiscuously bind multiple HLA class II molecules were selected from each protein. In total, this resulted in the selection of 822 peptides from a total of 21,506 distinct 15-mers (Table 2).

The 822 peptides were assembled into 42 pools of about 20 peptides each, which were analyzed for recognition by PBMCs from 20 TG allergic and 20 normal donors (Table 4). IL-5 ELISPOT assays were used to measure T cell reactivity because Th2 responses are important in allergy pathogenesis. In the studies herein, IL-5 is a more sensitive read-out in ELISPOT assays compared to other Th2 cytokines, namely IL-4 and IL-13 (FIG. 7) (15). In addition to peptide pools from novel allergens, 5 peptide pools from the ten known TG allergens assembled using the same prediction strategy were analyzed. Of the novel peptide pools 13/42 pools stimulated IL-5 production in PBMCs in over 20% of allergic donors. For the known allergen pools, 4/5 pools were recognized by over 20% of allergic donors. In contrast, none of the peptide pools elicited an IL-5 response in more than 10% of the non-allergic donors (FIG. 3 a).

When comparing the combined magnitude of responses directed against the known allergens vs. the Novel Timothy Grass Antigens (NTGA), it was evident that a very significant fraction of the T cell response to TG targeted the novel antigens. In fact, 61% of responding T cells (2,101 SFC, FIG. 3 b) recognized novel peptides while the response directed against the control panel of peptides from major known allergens only accounted for 39% of the T cell responses (1,345 SFC, FIG. 3 b). In the non-allergic population, the IL-5 responses were much weaker. However, the difference in response magnitude between the known allergens and novel antigens was even more pronounced, with 88.4% of the response targeting the novel antigens (574 SFC) and 11.6% targeting the known allergens (75 SFC). Overall, these data showed that a majority of Th2 cell responses against TG extract were directed against antigens other than the known IgE-reactive allergens.

Example 5

This example includes a description of studies showing identification of T cell reactive antigens and correlation with antibody reactivity.

Next, the positive peptide pools were deconvoluted to determine which individual peptides elicited the responses. IL-5 production was detected in at least one allergic donor for peptides from 54 of the 93 proteins analyzed with a total magnitude of 23,860 SFC (FIG. 8). To exclude spurious responses, T cell antigens for this study are defined as those proteins recognized in 20% or more of allergic donors, which is an established response threshold to define allergenic proteins when using skin test reactivity testing (23,24). Based on this cutoff, a total of thirteen novel T cell antigens were identified. Four of these T cell antigens were proteins targeted by both IgE and IgG, one protein was targeted by IgE only, five proteins were targeted by IgG only, and three proteins were not targeted by antibodies of either Ig class (FIG. 4). This means that eight of the novel T cell antigens were not targeted by IgE compared to five that were. The same holds true when comparing responses on the peptide level, or when considering the total number of responding T cells (Table 5). Overall, these data indicated that a sizeable fraction of the response against NTGAs is directed at proteins not recognized by IgE.

Example 6

This example includes a description of studies showing that IL-5 responses to novel antigens are made by memory T cells that can be detected directly ex vivo.

The data presented above indicated that almost two thirds (61%) of IL-5 producing T cell responses directed against pollen proteins were directed against the novel antigens, and that a majority of those responses targeted antigens not recognized by IgE. These responses were presumably the result of in vivo priming of T cells in the allergic patients, following pollen exposure. To exclude the possibility that these T cell response may be due to in vitro priming of T cells cultured with TG extract, it was examined whether the responding T cells were associated with either a memory or naïve phenotype. For this purpose two peptide pools were assembled: The TG P20 pool comprising the 20 most dominant peptides from known TG allergens identified in a previous study (12), accounting for about 90% of IL-5 responses detected against conventional IgE-reactive TG allergens in the study population; and an NTGA P19 pool comprising 19 of the most dominant peptides selected from IgE-unreactive Novel TG Antigens. These 19 peptides account for about 40% of the total IL-5 response against all novel antigens tested in our study population.

PBMC from 6 allergic donors were sorted into memory (CD45RA−) and naïve (CD45RA+CCR7+) T cell subsets. Subsequently, cells from both subpopulations were stimulated in vitro with TG pollen extract, and tested after expansion for IL-5 production (FIG. 5). Responses to each stimulus were significantly higher in the memory population compared to the naïve population. In response to TG extract stimulation, the median SFC detected was 80 and 1,108 in the naïve and memory populations, respectively. The TG P20 elicited no response in the naïve population and a median of 350 SFC in the memory population. Stimulation with NTGA P19 resulted in a median of 12 SFC in the naïve and 540 in the memory subset. As expected, high amounts of IL-5 were detected in the naïve and memory population in response to PHA, indicating that the cells were viable and responsive to T cell stimulation. Thus, overall far fewer antigen-specific IL-5 producing cells were found in the naïve T cell subset compared to the memory subset (p=0.0002), signifying that the T cell responses to both the TG P20 and NTGA P19 peptide pools were derived from memory T cells. Of note, the two pools of peptides cover different fractions of the total response against the sets of antigens from which they were derived. The dominant known peptide pool (TG P20) is made up of the 20 most dominant peptides, which account for >90% of the total IL5 response detected against all known peptides. In contrast the dominant novel peptide pool (NTGA P19) only accounts for 40% of the total IL5 response directed against all novel peptides screened. Thus a direct quantitative comparison of the response against them is not possible.

To further substantiate that the reactivity against the novel antigens was reflective of in vivo exposure, and not from primary responses induced in vitro, it was examined if responses against novel antigens could be detected directly ex vivo without any in vitro culture expansion. Since the frequency of antigen-specific precursor cells is very low, PBMCs from eight donors were presorted to obtain enriched Th1 or Th2 subpopulations, and cells were assessed for IL-5 production in response to TG extract and the dominant known and novel peptide pools in ELISPOT assays. As expected, IL-5 production for the Th1 subpopulation was not detectable for any of the stimuli except PHA. In contrast, as shown in FIG. 6, the Th2 subpopulation (CCR4+, CXCR3−) showed significant responses to each allergen stimulus compared to media alone (extract: p=0.01, TG20: p=0.03, NTGA19: p=0.01, Wilcoxon signed rank tests).

Example 7

This example includes a description of methods of determining in vivo efficacy of proteins and peptides of the invention, in particular, for treatment of allergy.

Peptides of the invention are evaluated for efficacy in treatment of allergy in a mouse model. In brief, six groups of BALB/cJ or HLA-transgenic mice are sensitized with repeat dosing of 1.5 micrograms of whole Timothy Grass (TG) allergen intranasally (in 25 uL) for 5×2 days over 2 weeks. This serves as a model system for investigation of allergic asthma caused by whole TG allergen.

The sensitized mice are left for one week before treatment with peptides of the invention. The treatment comprises intranasal delivery of TG peptides followed 30 minutes later by intranasal delivery of TG peptides daily for 5 days. Approximately 4 weeks later the mice are challenged with whole TG allergen for 2 days (2×15 ug/25 uL intranasally) and outcomes are measured 48 hours later. 5 doses of TG peptides are evaluated (10, 1, 0.1, 0.01 & 0.001 ug per peptide). Appropriate control experiments are conducted.

The outcomes measured are bronchial airway resistance following methacholine lung challenge (cm H20/mL/s), a measure of respiratory function, and a quantitation of inflammatory cells in the bronchoalveolar lavage (BAL) fluid.

For measurement of airway resistance, 48 hours after intranasal challenge over 2 days (2×15 ug) with Timothy Grass whole allergen, total respiratory system resistance (Rrs) is measured in response to intranasal saline and increasing doses of intravenous methacholine (MCh) using the Flexivent rodent ventilator. Using the resulting Rrs-MCh dose-response curves, indices of airway reactivity (Slope Rrs) and maximal degree of bronchoconstriction at 25 MCh mg/mL (Max Rrs @ 25 mg/mL) are measured. Values are means+/−SE.

For quantitation of inflammatory cells, bronchoalveolar lavage fluid (BALF) is assessed for total and differential inflammatory cell counts. Sections of lung tissue are stained with hematoxylin and eosin (H&E) and morphometrically quantified using a custom computerized analysis system (Northern Eclipse).

Example 8

This example includes a description of a clinical trial protocol of proteins and peptides of the invention for treatment of allergy.

Peptides of the invention are analyzed in a randomized, placebo-controlled, blind clinical trial for efficacy in reducing allergic symptoms. The study design of the clinical trial is in accordance with good clinical practice guidelines.

Baseline skin responses to Timothy Grass allergen for all subjects are established using a Baseline Challenge between 6 and 8 days prior to study medication administration. Two intradermal injections of 0.010 HEP (histamine equivalent prick) units of commercially available standard Timothy Grass allergen is administered, separated by a 30 minute time interval, into the volar surface of the left and right forearms respectively. Subjects are assessed to ensure that they experience a Late-Phase Skin Response (LPSR) to whole Timothy Grass allergen. The magnitude of the baseline reaction is recorded as follows: Eight hours after each injection the outline of any late-phase response is drawn onto the skin with a ballpoint pen. The longest and orthogonal diameters are measured and recorded for each response, and the area of the response in each arm is calculated. The average area of response in both arms of each subject is then calculated to provide the baseline reaction. Subjects who produced a suitable baseline reaction are assigned to dosing groups, randomized and entered into the Treatment Phase.

The Treatment Phase consists of a period of 21 days for each subject. During this period one group of subjects receives a single intradermal injection of either peptides of the invention (0.03, 0.3, 3, 12 nmol of each peptide per dose) or diluent placebo at Treatment Phase Visit 1 on day one. A cohort of 8 subjects receives treatment at each dose level (6 receives the peptides of the invention and 2 placebo). The first cohort of the intradermal group receives 0.03 nmol of each peptide in the mixture and each subsequent cohort in the group receives the next higher dose level.

Intradermal injections are made into the flexor surface of the left forearm. The total volume of the injection is 60 μL for all injections. After treatment, subjects have their skin response to whole allergen retested at Treatment Phase Visit 2 on day 21 (±3 days). Skin responses to Timothy Grass allergen are assessed by measurement of the late-phase responses 8 hours following intradermal administration of 0.010 HEP (histamine equivalent prick) units of commercially available standard Timothy Grass allergen as described above. The average area of response for both arms of each subject is then calculated as described above.

This average LPSR area after treatment is then compared to the baseline LPSR area for each subject. The overall change in LPSR area for all eight patients in each cohort is then evaluated.

Example 9

This example includes a discussion of results.

As dissolved herein, a third of TG allergic donors did not recognize any peptides derived from the 10 known IgE reactive TG allergens. This was puzzling as T cells from the same donors gave strong responses against the whole TG extract in the same sensitive ELISPOT assays. As a first explanation, the possibility that post-translational modifications might be essential for the recognition of some epitopes was considered. Such modifications would not be present in the peptides synthesized for our screening. However, a pilot study of peptides with hydroxylated prolines, which are thought to be prominent in some TG allergens (25), did not show any T cell reactivity at all. While this does not exclude that other post-translational modifications are present in T cell epitopes of TG, another hypothesis was anlayzed, namely that T cells target conventional peptides from antigens other than the 10 known IgE reactive allergens. Analysis of T cells as disclosed herein led to the identification of 93 novel TG proteins, out of which 54 elicited Th2 responses. The recognition of these novel T cell antigens provides an explanation for the originally observed gap in reactivity between known allergens and whole TG extract.

Immunological characterization of the novel TG proteins revealed that a majority were both antibody and T cell reactive. Of prime interest, it was demonstrated that T cell responses against peptides derived from these novel antigens were potent inducers of IL-5 responses in PBMCs from TG allergic patients. The T cell population that produced IL-5 against these novel antigens originated from the memory Th2 cell subset and could be detected by direct ex vivo analysis. This demonstrated the relevance of these novel T cell antigens as targets of in vivo allergic responses. Interestingly, in contrast to the findings in allergic individuals, non-allergic donors had no or very weak IL-5 responses to both the known TG allergens and the novel antigens. Without being limited to any particular theory, this may also be true for other types of T cell responses, or non-allergic individuals may show an increased magnitude of ‘tolerogenic’ responses against novel TG antigens such as IL-10 producing Tregs.

Remarkably, strong IL-5 production was seen not only in response to IgE-reactive antigens but also to several antigens that were not targeted by IgE. This suggested that Th2 responses to an antigen were not necessarily linked to IgE reacitivity. The idea of unlinked T cell help, meaning that T cells display a different antigen specificity than the B cells they affect, has been discussed in previous studies (18,20) and is also of great relevance to the immune response directed against the NTGAs. The natural structure of a pollen particle (or micro sized particles released upon hydration) provides physical linkage of various proteins, which are recognized by the immune system. Therefore, without being limited to any particular theory, the way in which pollen proteins are presented to B and T cells may allow for unlinked T cell help since the T cell-specific epitope derived from one antigen can be present on the same physical pollen particle as a second antigen recognized by B cells. As a result, the Th2 cell immune response directed against NTGAs may provide help for the allergic response directed against the major known IgE-reactive allergens present on the same pollen particle as the NTGAs.

The issue of whether T cell recognition is always necessarily linked to antibody recognition has broader significance in terms of the classic notion of linked recognition of an antigen by both helper T cells and antigen specific B cells. According to this notion, specific B cells internalize and process the antigen, leading to the presentation of antigen fragments bound by surface MHC class II molecules that can be recognized by specific T cells. This guarantees that the T cells deliver help to B cells specific for the same antigen (linked help). While in some instances it has been shown that T cells can only or preferentially provide help to B cells specific for the same protein (17,18) in other systems this was not the case (19, 20). It was found that two proteins that are present on the same particle could function together and T cells specific for one protein could provide help for B cells specific for the second protein (20). Therefore, it may be possible that as long as the antigen recognized by T cells is in some physical association with the target of B cell recognition (as in the case of a small virus, or a pollen particle), the integrity of the “antigenic bridge” is preserved.

Though the direct mechanisms by which such an immune-modulation may occur are unknown at this point, without being limited to any particular theory, there are several potential mechanism by which unlinked T cell help could potentially lead to the improvement of allergic symptoms. First, the data herein indicate that the majority of IL-5 responses are directed against NTGAs. Therefore down-regulating these responses should be of significant benefit in terms of reducing Th2-induced pathogenic effects. Secondly, induction of NTGA-specific Tregs or Th1 cells may help in the regulation, through by-stander mechanisms (26), of Th2 responses directed against known TG allergens present in the same pollen particle. Thirdly, the regulation of NTGA-specific Th2 responses may also result in downstream regulation of IgE and induction of blocking IgG antibody responses to known TG allergens, a hallmark of SIT treatment (27,28). Finally, induction of NTGA-specific Th1 or Treg cells may lead to NTGA-specific IgG production, which may interfere with IgE-induced mediator release and other immediate-type reactions by mechanisms such as steric hindrance, competition for antigen binding and inhibitory signaling through FcγRIIB (29,30). Overall, the data herein demonstrates that the novel antigens described herein are promising targets for a T cell focused specific immunotherapy, which could be safe for administration to higher risk patients such as asthmatics. As a result, therapies that specifically target T cell reactivity may provide a more efficacious and safer way to treat allergic patients, especially those suffering from severe asthma to whom current SIT regimens pose a significant risk of deleterious reactions.

This study is the first comprehensive transcriptomic- and proteomic-analysis of an inhaled allergen. 93 novel TG proteins were identified for which expression in the pollen itself was established, expanding the previously known set of such proteins by about an order of magnitude. The fact that 24 novel TG proteins targeted by IgE that do not overlap with the known IgE-reactive allergens were identified demonstrates this approach is a powerful tool for allergen discovery.

Example 10

This example includes a description of methods of determining in vivo efficacy of proteins and peptides of the invention, in particular, for treatment of allergy caused by an allergen unrelated to a protein disclosed herein, such as treatment of allergy by bystander suppression. A more complete description of such methods may be found in US patent application publication US2012/0100164A1 (e.g., examples 3, 4, 5 and 6).

Proteins/Peptides of the invention are evaluated for efficacy in prevention sensitization to Timothy Grass Pollen in a mouse model. In brief, naïve BALB/cJ or HLA-transgenic mice are treated daily by sublingual immunotherapy (SLIT) with about 10 μg of a protein or peptide of the invention for 2 weeks. Subsequently, the mice were immunized (made sensitized) by three weekly i.p. injections of either a mix of 10 μg of a protein or peptide of the invention and about 10 μg Timothy Grass Pollen extract or 10 μg of a protein or peptide of the invention alone, both adsorbed to aluminium hydroxide.

Subsequently, the mice are challenged intra-nasally (IN) with about 10 μg of Timothy Grass Pollen extract for four days so as to induce clinically relevant readouts of a Th2-driven immune response. The mice are sacrificed one day after the last challenge and blood, bronchoalveolar fluid (BAL), spleen and cervical lymph nodes are collected for analysis. This serves as a model system for investigation of preventing allergic rhinitis by bystander suppression of an allergic response caused by Timothy Grass allergens.

Clinically relevant readouts, such as airway hyper-reactivity and the fraction of eosinophils, are obtained on the last day of IN challenge. Airway hyper-reactivity is tested by using a whole body pletysmograph. Airflow obstruction was induced by challenging the mice with increasing concentrations of aerosolized metacholine. Pulmonary airflow obstruction was measured by enhanced pause (penh) in a period of 6 minutes after administration of metacholine. Differential counting of BAL fluid is performed by centrifuging BAL fluid and remove the supernatant. The remaining pellet was re-suspended in PBS and the fraction of eosinophils was determined by an automated cell counter (Sysmex).

T-cell proliferation assay is conducted by teasing spleen cells into single cell suspension and wash three times in medium. Cells are counted and adjusted to 1.67×10⁶ cells/mL. 3×10⁵ cells are added to each well of a 96 well flat-bottomed culture plate and the cells are stimulated by 0, 5, 25 and 125 μg/mL of a protein/peptide of the invention. The cells were cultured for 6 days at 37° C. and 5% CO2. Proliferation was measured by adding 0.5 μCi of 3H-thymidine to each well for the last 18 hours of the culture period, followed by harvesting the cells and counting the incorporated radiolabel.

Down-regulation of T-cell response via bystander suppression is observed in groups of mice treated sublingually by a protein/peptide of the invention and where mice are co-sensitized with the protein/peptide of the invention and Timothy grass extract.

Example 11

This example includes a description of methods of determining in vivo efficacy of proteins and peptides of the invention, in particular, for treatment of allergy caused by an allergen unrelated to a protein disclosed herein, such as treatment of allergy by bystander suppression. A more complete description of the methods may be found in US patent application publication US2012/0100164A1 (e.g., examples 3, 4, 5 and 6).

Proteins/Peptides of the invention are evaluated for efficacy in treating allergy caused by Timothy Grass Pollen in a mouse model. In brief, naïve BALB/cJ or HLA-transgenic mice are sensitized by three weekly i.p. injections of about 10 μg Timothy Grass Pollen extract adsorbed to aluminium hydroxide. Subsequently, the mice are treated by sublingual immunotherapy (SLIT) with 100 to 250 μg of a protein/peptide of the invention for 4 weeks, followed by 2 weeks of intranasal challenge with 10 μg Timothy Grass Pollen extract together with about 10 μg of a protein/peptide of the invention or 10 μg Timothy Grass Pollen alone.

In both sets of studies, the mice were sacrificed one day after the last challenge and blood, bronchoalveolar fluid (BAL), spleen and cervical lymph nodes were collected for analysis.

Evaluating Clinically Relevant Readouts:

Clinically relevant readouts, such as sneezes, airway hyper-reactivity and presence of eosinophils, are obtained on the last day of IN challenge.

Sneezing:

The mice are observed in an 8 min-period after intranasal administration of Timothy Grass Pollen Extract and the numbers of sneezes are counted during this period.

Airway Hyper-Reactivity:

Using a whole body pletysmograph, airflow obstruction is induced by increasing concentrations of aerosolized metacholine. Pulmonary airflow obstruction is measured by enhanced pause (penh) in a period of 6 minutes after administration of metacholine.

Differential Counting of BAL Fluid:

The BAL fluid is centrifuged and the supernatant is removed. The pellet was re-suspended in PBS and the fraction of eosinophils is determined by an automated cell counter (Sysmex).

Down-regulation of clinically relevant readouts (such as no of eosinophils in BAL) via bystander suppression are observed in groups of mice treated sublingually by a protein/peptide of the invention and where the mice are intranasally challenged to both the protein/peptide of the invention and Timothy grass extract.

TABLE 1 Panel of open reading frames corresponding to protein clusters identified by transcriptomic analysis of Timothy Grass (TG) pollen. Protein id ORF_id ORF_sequence (SEQ ID NOS: 1-620) 1 M.693 ........................................................................SDYLGKGVLKAVDNVNDII GPALIGKDPTEQTELDNFMVHQLDGTKNEYGWCKQKLGANAILAVSLAVCKAGALVKKIPLYQHIANLAGNKQLVLPVPAFNVINGGSHAG NKLAMQEFMILPIGASSFKEAMKMGVEVYHNLKSVIKKKYGQDATNVGDEGGFAPNIQENKEGLELLKTAIEKAGYTGKVVIGMDVAASEF YGEKDQTYDLNFKEENNDGSQKISGDSLKNVYKSFVSEYPIVSIEDPFDQDDWVHYAKMTEEIGEQVQIVGDDLLVINPTRVAKATAEKSC NALLLKVNQIGSVTESIEAVKMSKRAGWGVMTSHRSGETEDTFIADLAVGLSTGQIKTGAPCRSERLAKYNQLLRIEEELGAAAVYAGLKF RAPVEPY 1 M.692 ....................................................................DYLGKGVLKAVDNVNSII GPALIGKDPTEQTELDNFMVHQLDGTKNEYGWCKQKLGANAILAVSLAVCKAGALVKKIPLYQHIANLAGNKQLVLPVPAFNVINGGSHAG NKLAMQEFMILPIGASSFKEAMKMGVEVYHNLKSVIKKKYGQDATNVGDEGGFAPNIQENKEGLELLKTAIEKAGYTGKVVIGMDVAASEF YGEKDQTYDLNFKEENNDGSQKISGDSLKNVYKSFVSEYPIVSIEDPFDQDDWVHYAKMTEEIGEQVQIVGDDLLVINPTRVAKATAEKSC NALLLKVNQIGSVTESIEAVKMSKRAGWGVMTSHRSGETEDTFIADLAVGLSTGQIKTGAPCRSERLAKYNQLLRIEEELGAAAVYAGLKF RAPVEPY 1 M.125 .................................GNPTVEVDVCCSDGTFARAAVPSGASTGVYCALELRDGGSDYLGKGVLKGNRANVELF KIAVLLA 1 M.714 ...........PPPPAMAATIQSVKARQIFDSRGNPTVEVDVCCSDGIFARAAVPSGASTGVYEALELRDGGSDYLGKGVLKAVDNVNSII GPALIGKDPTEQTELDNFMVHQLDGTKNEWGWCKQKLGANAILAVSLAVCKAGALVKKIPLYQHIANLAGNKQLVLPVPAFNVINGGSHAG NKLAMQEFMTLPTGASSFKEAMKMGVEVYHNLKSVTKKKYGQDATNVGDEGGFAPNTQENKEGLELLKTAIEKAGYTGKVVIGMDVAASEF YGEKDQTYDLNFKEENNDGSQKISGDSLKNVYKSFVSEYPIVSIEDPFDQDDWVHYAKMTEEIGEQVQIVGDDLLVTNPTRVAKAIAEKSC NALLLKVNQIGSVTESIEAVKMSKRAGWGGMTSHRSGETEDTFIADLAVGLSTGQIKTGAPCRSERLAKYNQLLRIEEELGAAAVYAGLKF RA 1 M.721 .................................GNPTVEVDVCCSDGTFARAAVPSGASTGVIEALEIRDGGSDYLGKGVLKAVDNVNSII GPALLGKDPTEQTELDNFMVHQLDGTKNEWGWCKQKLGANAILAVSLAVCKAGALVKKIPLYQHIANLAGNKQLVLPVPAFNVINGGSHAG NKLAMQEFMTLPTGASSFKEAMKMGVEVYHNLKSVTKKKYGQDATNVGDEGGFAPNTQENKEGLELLKTAIEKAGYTGKVVIGMDVAASEF YGEKDQTYDLNFKEENNDGSQKISGDSLKNVYKSFVSEYPIVSIEDPFDQDDWVHYAKMTEEIGEQVQIVGDDLLVTNPTRVAKAIAEKSC NALLLKVNQIGSVTESIEAVKMSKRAGWGGMTSHRSGETEDTFIADLAVGLSTGQIKTGAPCRSERLAKYNQLLRIEEELGAAAVYAGLKF RAPVEPY 1 M.705 .........................................................................DYLGKGVLKAVDNVNSII GPALLGKDPTEQTELDNFMVHQLDGTKNEWGWCKQKLGANATLAVSLAVCKAGALVKKIPLYQHIANLAGNKQLVLPVPAFNVINGGSHAG NKLAMQEFMILPTGASSFKEAMKMGVEVYHNLKSVIKKKYGQDATNVGDEGGFAPNTQENKEGLELLKTAIEKAGYTGKVVIGMDVAASEF YGEKDQTYDLNFKEENNDGSQKISGDSLKNVYKSFVSEYPIVSIEDPFDQDDWVHYAKMTEEIGEQVQIVGDDLLVTNPTRVAKAIAEKSC NALLLKVNQIGSVTESIEAVKMSKRAGWGGMTSHRSGETEDTFIADLAVGLSTGQIKTGAPCRSERLAKYNQLLRIEEELGAAAVYAGLKF RAPVEPY 1 M.591 ........................................................................................... .................................................................ANLAGNKQLVLPVPAFNVINGGSHAG NKLAMQEFMTLPTGASSFKEAMKMGVEVYHNLKSVTKKKYGQDATNVGDEGGFAPNTQENKEGLELLKTAIEKAGYTGKVVIGMDVAASEF YGEKDQTYDLNFKEENNDGSQKISGDSLKNVYKSFVSEYPIVSIEDPFDQDDWVHYAKMTEEIGEQVQIVGDDLLVTNPTRVAKAIAEKSC NALLLKVNQIGSVTESIEAVKMSKRAGWGGMTSHRSGETEDTFIADLAVGLSTGQIKTGAPCRSERLAKYNQLLRIEEELGAAAVYAGLKF RA 1 M.418 .LRFPKASRSIPPPPAMAATIQSVKARQIFDSRGNPIVEVDVCCSDGTFARAAVPSGASTGVYEALELRDGGSDYLGKGVLKAVDNVNSII GPALLGKDPTEQTELDNFMVHQLDGTKNEWGWCKQKLGANATLAVSLAVCKAGALVKKIPLYQHIANLAGNKQL 1 M.689 .......RSIPPPPPAMAATIQSVKARQIFDSRGNPTVEVDVCCSDGIFARAAVPSGASTGVYEALELRDGGSDYLGKGVLKAVDNVNSII GPALLGKDPTEQTELDNFMVHQLDGTKNEWGWCKQKLGANAILAVSLAVCKAGALVKKIPLYQHIANLAGNKQLVLPVPAFNVINGGSHAG NKLAMQEFMTLPTGASSFKEAMKMGVEVYHNLKSVTKKKYGQDATNVGDEGGFAPNTQENKEGLELLKTAIEKAGYTGKVVIGMDVAASEF YGEKDQTYDLNFKEENNDGSQKISGDSLKNVYKSFVSEYPIVSIEDPFDQDDWVHYAKMTEEIGEQVQIVGDDLLVTNPTRVAKAIAEKSC NALLLKVNQIGSVTESIEAVKMSKRAGWGGMTSHRSGETEDTFI 1 M.644 ........................................................................SDYLGKGVLKAVDNVNSII GPALIGKDPTEQTELDNFMVHQLDGTKNEWGWCKQKLGANAILAVSLAVCKAGALVKKIPLYQHIANLAGNKQLVLPVPAFNVINGGSHAG NKLAMQEFMTLPTGASSFKEAMKMGVEVYHNLKSVTKKKYGQDATNVGDEGGFAPNTQENKEGLELLKTAIEKAGYTGKVVIGMDVAASEF YGEKDQTYDLNFKEENNDGSQKISGDSLKNVYKSFVSEYPIVSIEDPFDQDDWVHYAKMTEEIGEQVQIVGDDLLVTNPTRVAKAIAEKSC NALLLKVNQIGSVTESIEAVKMSKRAGWGGMTSHRSGETEDTFIADLAVGLSTGQIKTGA 1 M.414 .....ASRSIPPPPAMAATIQSVKAIRQIFDSRGNPIVEVDVCCSDGTFARAAVPSGASTGVYEALELRDGGSDYLGKGVLKAVDNVNSII GPALIGKDPTEQTELDNFMVHQLDGTKNEWGWCKQKLGANATLAVSLAVCKAGALVKKIPLYQHIANLAGNKQL 1 M.624 .................................GNPTVEVDVCCSDGIFARAAVPSGASTGVYEALELRDGGSDYLGKGVLKAVDNVNSII GPALIGKDPTEQTELDNFMVHQLDGTKNEWGWCKQKLGANAILAVSLAVCKAGALVKKIPLYQHIANLAGNKQLVLPVPAFNVINGGSHAG NKLAMQEFMTLPTGASSFKEAMKMGVEVYHNLKSVTKKKYGQDATNVGDEGGFAPNTQENKEGLELLKTAIEKAGYTGKVVIGMDVAASEF YGEKDQTYDLNFKEENNDGSQKISGDSLKNVYKSFVSEYPIVSIEDPFDQDDWVHYAKMTEEIGEQVQIVGDDLLVTNPTRVAKAIAEKSC NALLL 1 M.617 ....................................TVEVDVCCSDGIFARAAVPSGASTGVYEALELRDGGSDYLGKGVLKAVDNVNSII GPALIGKDPTEQTELDNFMVHQLDGTKNEWGWCKQKLGANAILAVSLAVCKAGALVKKIPLYQHIANLAGNKQLVLPVPAFNVINGGSHAG NKLAMQEFMTLPTGASSFKEAMKMGVEVYHNLKSVTKKKYGQDATNVGDEGGFAPNTQENKEGLELLKTAIEKAGYTGKVVIGMDVAASEF YGEKDQTYDLNFKEENNDGSQKISGDSLKNVYKSFVSEYPIVSIEDPFDQDDWVHYAKMTEEIGEQVQIVGDDLLVTNPTRVAKAIAEKSC NALLL 1 M.704 ....................................TVEVDVCCSDGIFARAAVPSGASTGVYEALELRDGGSDYLGKGVLKAVDNVNSII GPALIGKDPTEQTELDNFMVHQLDGTKNEWGWCKQKLGANAILAVSLAVCKAGALVKKIPLYQHIANLAGNKQLVLPVPAFNVINGGSHAG NKLAMQEFMTLPTGASSFKEAMKMGVEVYHNLKSVTKKKYGQDATNVGDEGGFAPNTQENKEGLELLKTAIEKAGYTGKVVIGMDVAASEF YGEKDQTYDLNFKEENNDGSQKISGDSLKNVYKSFVSEYPIVSIEDPFDQDDWVHYAKMTEEIGEQVQIVGDDLLVTNPTRVAKAIAEKSC NALLLKVNQIGSVTESIEAVKMSKRAGWGGMTSHRSGETEDTFIADLAVGLSTGQIKTGAPCRSERLAKYNQLLRIEEELGAAAVYAGL 1 M.331 .................................GNVTVEVDVCCSDGIFARAAVPSGASTGVYEALELRDGGSDYLGKGVLKAVDNVNSII GPALIGKDPTEQTELDNFMVHQLDGTKNEWGWCKQKVFFNTSADADAGAVAR 1 M.604 ........................................................................................... ........................................AILAVSLAVCKAGALVKKIPLYQHIANLAGNKQLVLPVPAFNVINGGSHAG NKLAMQEFMTLPTGASSFKEAMKMGVEVYHNLKSVTKKKYGQDATNVGDEGGFAPNTQENKEGLELLKTAIEKAGYTGKVVIGMDVAASEF YGEKDQTYDLNFKEENNDGSQKISGDSLKNVYKSFVSEYPIVSIEDPFDQDDWVHYAKMTEEIGEQVQIVGDDLLVTNPTRVAKAIAEKSC NALLLKVNQIGSVTESIEAVKMSKRAGWGGMTSHRSGETEDTFIADLAVGLSTGQIKTGAPCRSERLAKYNQLLRIEEELGAAAVYAGLKF 1 M.291 .................................GNPTVEVDVCCSDGIFARAAVPSGASTGVYEALELRDGGSDYLGKGVLKAVDNVNSII GPALIGKDPTEQTELDNFMVHQLDGTKNEWGWCKQKLGAN 1 M.151 ......IDPSSSSSPAMAATIQSVKARQIFDSRGNPTVEVDVCCSDGTFARAAVPSGASTGVYEALELRDGGS 1 M.498 ......IDPSSSSSPAMAATIQSVKARQIFDSRGNPTVEVDVCCSDGTFARAAVPSGASTGVYEALELRDGGSDYLGKGVLKAVDNVNSII GPALIGKDPIEQTELQNEMVHQLQGTKNEVGWCKQKLGANAILAVSLAVCKAGALVENIPLYQHIANLAGNKQLVLPVPAFNVINGGSHAG NKLAMQEEMILPIGASSFKEAMKMGVEVYRNLKKSVIKRKYGQQATNV 1 M.561 ........................................................................................... ............................................VSLAVCKAGALVKKIPLYQHIANLAGNKQLVLPVPAFNVINGGSHAG NKLAMQEFMILPTGASSFKEAMKMGVEVYHNLKSVIKKKYGQDATNVGDEGGFAPNIQENKEGLELLKTAIEKAGYTGKVVIGMDVAASEF YGEKDQTYDLNFKEENNDGSQKISGDSLKNVYKSFVSEYPIVSIEDPFDQDDWVHYAKMTEEIGEQVQIVGDDLLVTNPTRVAKAIAEKSC NALLLKVNQIGSVTESIEAVKMSKRAGWGVMTSHRSGETEDTFIA 1 M.399 ALRFPKASRSIPPPPAMAATIQSVKARQIFDSRQNPTVEVDVCCEDGTFARAAVPSGASIGVYEALELRDGGSDYLGKGVLKAVDNVNSII GFALIGKDPIEQIELDNFMVHQLDGIRNEWGWCKQKLGANAILAVSLAICKAGASVKKIPLYQ 1 M.603 ........................................................................................... ............................................VSLAVCKAGALVKKIPLYQHIANLAGNKQLVLPVPAFNVINGGSHAG NKLAMQEFMILPTGASSFKEAMKMGVEVYHNLKSVIKKKYGQDATNVGDEGGFAPNIQENKEGLELLKTAIEKAGYTGKVVIGMDVAASEF YGEKDQTYDLNFKEENNDGSQKISGDSLKNVYKSFVSEYPIVSIEDPFDQDDWVHYAKMTEEIGEQVQIVGDDLLVTNPTRVAKAIAEKSC NALLLKVNQIGSVTESIEAVKMSKRAGWGVMTSHRSGETEDTFIADLAVGLSTGQIKTGAPCRSERLAKYNQLLRIEEELGAAAVYAGLKF RA 1 M.226 ALRFPKASRSIPPPPAMAATIQSVKARQIFDSRGNPIVEVDVCCSDGTFARAAVPSGASTGVYFALELRDGGSDYLGK 2 M.636 ........................................................................................... ........................................................................................... .................................................................YGFPIVQRFLEGASSIDNHFRIASFE KNIPVLLGLLSVWNVSFLGYPARAILPYSQALEKLAPHIQQLSMESNGKGVSIDGVPLPYEAGEIDFGEPGTNGQHSFYQLIHQGRVIPCD FIGVIKSQQPVYLKGETVSNHDELMSNFFAQPDALAYGKNPEQLRSENVSENLIPHKTFKGNRPSLSFLLSSLSAYEIGQLLAIYEHRIAV QGFIWGINSFDQWGVELGKSLASQVRKQLHASRMEGKPVEGFNPSSASLLARYLAVEPSTPYDIIVLPKV 2 M.473 ................................................ENRSVLRVALRAPRDAVINSDGVNVVPEVWSVKDKIKQFSEIF RSGSWVGATGKPLINVVSVGIGGSFLGPLFVHTALQTDPEAAESAKGRQLRFLANVDPVDVARSIKDLDPETTLVVVVSKTFTTAETMLNA RIIKEWIVSSLGPQAVSKHMIAVSTNLKLVKEFGIDPNNAFAFWDWVGGRYSVCSAVGVLPLSLQYGFP 2 M.437 ...............................................................................VKDKIKQFSEIF RSGSWVGATGKPLINVVSVGIGGSFLGPLFVHTALQTDPEAAESAKGRQLRFLANVDPVDVARSIKDLDPETTLVVVVSKTFTTAETMLNA RIIKEWIVSSLGPQAVSKHMIAVSTNLKLVKEFGIDPNNAFAFWDWVGGRYSVCSAVGVLPLSLQYGFP 2 M.634 ........................KLAEAAKLKEKIEKMFNGEKINSTENRSVLHVALRAPRDAVINSDGVNVVPEVWSVKDKIKQFSEIF RSGSWVGATGKPLTNVVSVGIGGSFLGPLFVHTALQTDPEAAESAKGRQLRFLANVDPVDVARSIKDLDPEITLVVVVSKTFTTAETMLNA RTIKEWIVSSLGPQAVSKHMIAVSTNLKLVKEFGIDPNNAFAFWDWVGGRYSVCSAVGVLPLSLQYGFPIVQRFLEGASSIDNHFRTASFE KNIPVLLGLLSVWNVSFLGYPARAILPYSQALEKLAPHIQQLSMESNGKGVSIDGVPLPYEAGEIDFGEPGTNGQHSFYQLIHQGRVIPCD FYDANK 2 M.676 ........................KLAEAAKLKEKIEKMFNGEKINSTENRSVLHVALRAPRDAVINSDGVNVVPEVWSVKDKIKQFSEIF RSGSWVGATGKPLTNVVSVGIGGSFLGPLFVHTALQTDPEAAESAKGRQLRFLANVDPVDVARSIKDLDPEITLVVVVSKTFTTAETMLNA RTIKEWIVSSLGPQAVSKHMIAVSTNLKLVKEFGIDPNNAFAFWDWVGGRYSVCSAVGVLPLSLQYGFPIVQRFLEGASSIDNHFRTASFE KNIPVLLGLLSVWNVSFLGYPARAILPYSQALEKLAPHIQQLSMESNGKGVSIDGVPLPYEAGEIDFGEPGTNGQHSFYQLIHQGRVIPCD FIGVIKSQQPVYLKGETVSNHDELMSNFFAQPDALAYGKIPEQ 2 M.422 ........................................NGEKINSTENRSVLHVALRAPRDAVINSDGVNVVPEVWSVKDKIKQFSETF RSGSWVGATGKPLTNVVSVGIGGSFLGPLFVHTALQTDPEAAESAKGRQLRFLANVDPVDVARSIKDLDPETTLVVVVSKTFTTAETMLNA RTIKEWIVSSLGPQAVSKHMIAV 2 M.431 ........................................NGEKINSTENRSVLHVALRAPRDAVINSDGVNVVPEVWSVKDKIKQFSETF RSGSWVGATGKPLTNVVSVGIGGSFLGPLFVHTALQTDPEAAESAKGRQLRFLANVDPVDVARSIKDLDPETTLVVVVSKTFTTAETMLNA RTIKEWIVSSLGPQAVSKHMIAVST 2 M.387 .............................................................RDAVINSDGVNVVPEVWSVKDKIKQFSETF RSGSWVGATGKPLTNVVSVGIGGSFLGPLFVHTALQTDPEAAESAKGRQLRFLANVDPVDVARSIKDLDPETTLVVVVSKTFTTAETMLNA RTIKEWIVSSLGPQAVSKHMIAVST 2 M.722 ...................................................................................IKQFSEIF RSGSWVGATGKPLTNVVSVGIGGSFLGPLFVHTALQTDPEAAESAKGRQLRFLANVDPVDVARSIKDLDPEITLVVVVSKTFTTAETMLNA RTIKEWIVSSLGPQAVSKHMIAVSTNLKLVKEFGIDPNNAFAFWDWVGGRYSVCSAVGVLPLSLQYGFPIVQRFLEGASSIDNHFRTASFE KNIPVLLGLLSVWNVSFLGYPARAILPYSQALEKLAPHIQQLSMESNGKGVSIDGVPLPYEAGEIDFGEPGTNGQHSFYQLIHQGRVIPCD FIGVIKSQQPVYLKGETVSNHDELMSNFFAQPDALASRKTPAPLRSENVSENLIPHKTFKGNRPSLSFLLSSLSAYEIGQLLAIYEHRIAV QGFIWGINSFDQWGVELGKSLASQVRKQLHASRMEGKPVEGFNPSSASLLARYLAVEPSTPYDTTVLPKV 2 M.610 ...................................................................................IKQFSEIF RSGSWVGATGKPLTNVVSVGIGGSFLGPLFVHTALQTDPEAAESAKGRQLRFLANVDPVDVARSIKDLDPEITLVVVVSKTFTTAETMLNA RTIKEWIVSSLGPQAVSKHMIAVSTNLKLVKEFGIDPNNAFAFWDWVGGRYSVCSAVGVLPLSLQYGFPIVQRFLEGASSIDNHFRTASFE KNIPVLLGLLSVWNVSFLGYPARAILPYSQALEKLAPHIQQLSMESNGKGVSIDGVPLPYEAGEIDFGEPGTNGQHSFYQLIHQGRVIPCD FIGVIKSQQPVYLKGETVSNHDELMSNFFAQPDALAYGKIPEHSR 2 M.574 AEFEGVFLDFARQQATTETVDKLFKLAEAAKLKEKIEKMFNGEKINSIENRSVLHVALRAPRDAVINSDGVNVVPEVWSVKDKIKQFSEIF RSGSWVGATGKPLINVVSVGIGGSFLGPLFVHTALQTDPEAAESAKGRQLRFLANVDPVDVARSIKDLDPETTLVVVVSKTFTTAETMLNA RIIKEWIVSSLGPQAVSKHMIAVSTNLKLVKEFGIDPNNAFAFWDWVGGRYSVCSAVGVLPLSLQYGFPIVQRFLEGASSIDNHFRTASFE KNIPVLLGLLSV 2 M.531 ........................................................................................... .......................................EAAESAKGRQLRFLANVDPVDVARSIKDLDPETTLVVVVSKTFTTAETMLNA RIIKEWIVSSLGPQAVSKHMIAVSTNLKLVKEFGIDPNNAFAFWDWVGGRYSVCSAVGVLPLSLQYGFPIVQRFLEGASSIDNHFRTASFE KNIPVLLGLLSVWNVSFLGYPARAILPYSQALEKLAPHIQQLSMESNGKGVSIDGVPLPYEAGEIDFGEPGTNQQHEFYQLINQGRVIPCD FIGVIFSQQPVYLK 3 M.305 .....ILLVFAETAEPEVKVVDLTILSPDRPDLVLPIPFVADEKGYAFALKDGSTYSFRFSFIVSNNIVSGLKYTNTVWKTGVRVENQKMM LG 3 M.282 LLGQVDTEQLGETAEPEVKVVDLTILSPDRPDLVLPIPFVADEKGYAFALKDGSTYSFRFSFIVSNNIVSGLKYTNTVWKTGVRVENQKMM LG 3 M.271 ...........ETAEPEVKVVDLTILSPDRPDLVLPIPFVADEKGYAFALKDGSTYSFRFSFIVSNNIVSGLKYTNTVWKTGVRVENQKMM LGTFSPQPEP 3 M.159 ....................................................................................VENQKMM LGTFSPQPEPYIYVGEEESTTPAGIFARGSYSAKLKFVDDDGKVYLEMSYYFEIRKDWPIGQ 3 M.83 ........................................................................................... ...........IYVGEEESTTPAGIFARGSYSAKLKFVDDDGKVYLEMSYYFEIRKDWPIGQ 3 M.348 .......................................................YSFRFSFIVSNNIVSGLKYTNTVWKTGVRVENQKMM LGTFSPQPEPYIYVGEEESTTPAGIFARGSYSAKLKFVDDDGKVYLEMSYYFEIRKDWPIGQ 3 M.285 .......................................................YSFRFSFIVSNNIVSGLKYTNTVWKTGVRVENQKMM LGTFSPQPEPYIYVGEEESTTPAGIFARGSYSAKLKFVDDDGKVYLEMSYYFEIRKDWP 3 M.288 ...........HTAEPHVKVVDLTTISPDRPDLVLPIPFVADERGYAEALKDGSTYSFRFSFIVSNNIVSGLEYTNIVNKTGVRVENQKMM LGTFSPQPEPYIYVGEE 3 M.287 ..............................................................................WKTGVRVENQKMM LGTFSPQPEPYIYVGEEESTTPAGIFARGSYSAKLKFVDDDGKVYLEMSYYFEIRKDWPTGQ 3 M.232 .......EQLGHTAEPHVKVVDLTTISPDRPDLVLPIPFVADERGYAEALKDGSTYSFRFSFIVSNNIVSGLEYTNIVNKTGVR 4 M.715 .....MKTIFDFESIKKLLASPKFSFCFDGLHGVAGAYAKRMFVDELGASESSLLNCVPKEDFGGGHPDPNLTYAKELVERMGLGKSSSNV EPPEFGAAADGDADRNMVLGKRFFVTPSDSVAIIAANAVQSIPYFASGLKGVARSMPTSAALDVVAKNLNLKFFEVPTGWKFFGNLMDAGM CSVCGEESFGTGSDHIREKDGIWAVLAWLSIIAYKNKDNLGGDKLVSVEDIVLQHWATYGRHYYTRYDYENVDAEAAKELMANLVKMQSAL SDNVKLIKEIQPDVAEVVSSADEFEYKDPVDGSVSHQGIRYLFGDGSRLVFRLSGTGSVGATIRIYIEQYEKDSSKTGRESSDALSPLVDV ALKLSKIKEYIGRSAPTVIT 4 M.725 .....MKTIFESIKKLLASPKFSFCFDPGKGVAGAYAKRMFVDELGASESELINCVDPKEDFGGGHPNDFNLIYAKELVERMGIGKSSSNV EPPEFGAAADGDADRNMVLGKRFFVTPSDSVAIIAANAVQSIPYFASGLKGVARSMPTSAALDVVAKNLNLKFFEVPTGWKFFGNLMDAGM CSVGGEEEFGTGSDIHERLGIWLAVLAWLETIAYKNKDNLGGDKLVSVEDIVLOHWATYGRHVYYTRYDYENVDAEAAFELMANLKMGSAL SDVNKLTKEIQPDVAEVVSADNEFZYKDFVDGEVSKHQGIQYLFGDTGSRLSGTGSVATIRIYVIEQYEKDESKPSTGRESSDALSFLVDV ALKLSNIKEYTGRSAPIVIS 4 M.694 PSPFNSRTIFDFESIKKLLASPKFSFCFDGLHGVAGAYAKRMFVDELGASESSLLNCVPKEDFYGGGHPDNLTYAKELVERMGLGKSSSNV EPPEFGAAADGDADRNMVLGKRFFVTPSDSVAIIAANAVQSIPYFASGLKGVARSMPTSAALDVVAKNLNLKFFEVPTGWKFFGNLMDAGM CSVCGEESFGTGSDHIREKDGIWAVLAWLSIIAYKNKDNLGGDKLVSVEDIVLQHWATYGRHYYTRYDYENVDAEAAKELMANLVKMQSAL SDVNKLIKEIQPDVAEVVSADEFEYKDPVDGSVSKHQGIRYLFGDGSRLVFRLSGTGSVGATIRIYIEQYEKDSSKTGRESSDALSPLVDV ALKLSKIKEYTGRSAPTVIT 4 M.701 PSPFNSRTIFDFESIKKLLASPKFSFCFDGLHGVAGAYAKRMFVDELGASESYSLLNCVPKEDFGGGHPDNLTYAKELVERMGLGKSSSNV EPPEFGAAADGDADRNMVLGKRFFVTPSDSVAIIAANAVQSIPYFASGLKGVARSMPTSAALDVVAKNLNLKFFEVPTGWKFFGNLMDAGM CSVCGEESFGTGSDHIREKDGIWAVLAWLSIIAYKNKDNLGGDKLVSVEDIVLQHWATYGRHYYTRYDYENVDAEAAKELMANLVKMQSAL SDVNKLIKEIQPDVAEVVSADEFEYKDPVDGSVSKHQGIRYLFGDGSRLVFRLSGTGSVGATIRIYIEQYEKDSSKTGRESSDALSPLVDV ALKLSKIKEYTGRSAPTVIT 4 M.595 ...KLMKTIFDFESIKKLLASNPKFSFCFDGLHGVAGAYAKRMFVDELGASESSLLNCVPKEDFGGGHPDNLTYAKELVERMGLGKSSSNV EPPEFGAAADGDADRNMVLGKRFFVTPSDSVAIIAANAVQSIPYFASGLKGVARSMPTSAALDVVAKNLNLKFFEVPTGWKFFGNLMDAGM CSVCGEESFGTGSDHIREKDGIWAVLAWLSIIAYKNKDNLGGKLVSVEDIVLQHWATYGHRHYYTRYDYENVDAEAAKELMANLVKMQSAL SDVNKLIKEIQPDVAEVVSADEFEYKDPVDGSVS 4 M.718 ...KLMKTIFDFESIKKLLASPKFSFCFDGLHGVAGAYAKRMFVDELGASESSLLNCVPKEDFGGGHPYDNLTYAKELVERMGLGKSSSNV EPPEFGAAADGDADRNMVLGKRFFVTPSDSVAIIAANAVQSIPYFASGLKGVARSMPTSAALDVVAKNLNLKFFEVPTGWKFFGNLMDAGM CSVCGEESFGTGSDHIREKDGIWAVLAWLSIIAYKNKDNLGGKLVSVEDIVLQHWATYGRHYYHTRYDYENVDAEAAKELMANLVKMQSAL SDNKLIKEIQPDVAEVVSADEFEYKDPVDGSVSKHQGIRYLFGDGSRLVFRLSGTGSVGATIRIYTEQYTEKDSSKTGRESSDALSPLVDV ALNLSKIKEYTGRSAPTVIT 4 M.720 ...KLMKTIFDFESIKKLLASPKFSFCFDGLHGVAGAYAKRMFVDELGASESSLLNCVPKHEDFGGGHPDNLTYAKELVERMGLGKSSSNV EPPEFGAAADGDADRNMVLGKRFFVTPSDSVAIIAANAVQSIPYFASGLKGVARSMPTSAALDVVAKNLNLKFFEVPTGWKFFGNLMDAGM CSVCGEESFGTGSDHIREKDGIWAVLAWLSIIAYKNKDNLGGKLVSVEDIVLQHWAHTYGRHYYTRYDYENVDAEAAKELMANLVKMQSAL SDNKLIKEIQPDVAEVVSADEFEYKDPVDGSVSKHQGIRYLFGDGSRLVFRLSGTGSVGATIRIYTLEQYEKDSSKTGRESSDALSPLVDV ALNLSKIKEYTGRSAPTVIT 4 M.723 ......KTIFDFESIKKLLASPKFSFCFDGLHGVAGAYAKRMFVDELGASESSLLNCVPKHEDFGGGHPDNLTYAKELVERMGLGKSSSNV EPPEFGAAADGDADRNMVLGKRFFVTPSDSVAIIAANAVQSIPYFASGLKGVARSMPTSAALDVVAKNLNLKFFEVPTGWKFFGNLMDAGM CSVCGEESFGTGSDHIREKDGIWAVLAWLSIIAYKNKDNLGGKLVSVEDIVLQHWATYGLRHYYTRYDYENVDAEAAKELMANLVKMQSAL SDNKLIKEIQPDVAEVVSADEFEYKDPVDGSVSKHQGIRYLFGDGSRLVFRLSGTGSVGATIRIYTHEQYEKDSSKTGRESSDALSPLVDV ALNLSKIKEYTGRSAPTVIT 4 M.648 ...KLMKTIFDFESIKKLLASPKFSFCFDGLHGVAGAYAKRMFVDELGASESSLLNCVPKEDMFGGGHPDNLTYAKELVERMGLGKSSSNV EPPEFGAAADGDADRNMVLGKRFFVTPSDSVAIIAANAVQSIPYFASGLKGVARSMPTSAALDVVAKNLNLKFFEVPTGWKFFGNLMDAGM CSVCGEESFGTGSDHIREKDGIWAVLAWLSIIAYKNKDNLGGKLVSVEDIVLQHFWATYGRHYYTRYDYENVDAEAAKELMANLVKMQSAL SDNKLIKEIQPDVAEVVSKADEFEYKDPVDGSVSKHQGIRYLFGDGSRLLVFRLSGTGSVGAFTIRIYTEQYEKLDSSKTGRESSDALSPL 4 M.662 ....NSRTIFDFESINKLLASPKFSFCFDGLHGVAGAYAKRMFVDELGASESSLLNCVPKLEDFGGGHPDPNLIAKELVERMGLGKSSSNV EPPEFGAAADGDADRNMVLGKRFFVTPSDSVAIIAANAVQSIPYFASGLKGVARSMPTSAALDVVAKNLNLKFFEVPTGWKFFGNLMDAGM CSVCGEESFGTGSDHIREKDGIWAVLAWLSIIAYKNKDNLGGKLVSVEDIVLQHWATYGRHYFYTRYDYENVDAEAAKELMANLVKMQSAL SDNKLIKEIQPDVAEVVSADEFEYKDPVDKGSVSKHQGIRYLFGDGSRLVFRLSGTGSVGATIRIYTEQYEKDSSKTGRESSDALSPLVDV ALNLSKIKEYTG 4 M.576 ........................................................................................... ..............................................................................GWKFFGNLMDAGM CSVCGEESFGTGSDHIREKDGIWAVLAWLSIIAYKNKDNLGGKLVSVEDIVLQHWATYGRHYLYTRYDYENVDAEAAKELMANLVKMQSAL SDNKLIKEIQPDVAEVVSADEFEYKDPVDGSHVSKHQGIRYLFGDGSRLVFRLSGTGSVGATIRIYTEQYEKDSSKTGRESSDALSPLVDV ALNLSKIKEYTGRSAPTVIT 5 M.618 .............................DEYLAAVAKARRKLRGLIAEKNCAPLMLRIAWSHAGTFDVATKIGGPFGTMRCPAELAHGAN AGLDIAVRLLEPIKEQVPILSYADFYQLAGVVAVEITGGPEVPFHPGRQDKTEPPPEGRLPDATLGSDHLRQVFTAQMGLSDQDIVALSGG HTLGRCHKERSGFEGAWTANPLIFDNSYFTELLTGEKEGLLQLPTDKTLLTDPAFRPLVDKYAADEDAFFADYAEAHLKLSELGFGEATEG CC 5 M.631 .................GAMAAKCYPTVSDEYLAAVAKARRKLRGLIAEKNCAPLMLRIAWSHAGTFDVATKIGGPFGTMRCPAELAHGAN AGLDIAVRLLEPIKEQVPILSYADFYQLAGVVAVEITGGPEVPFHPGRQDKTEPPPEGRLPDATLGSDHLRQVFTAQMGLSDQDIVALSGG HTLGRCHKERSGFEGAWTANPLIFDNSYFTELLTGEKEGLLQLPTDKTLLTDPAFRPLVDKYAADEDAFFADYAEAHLKLSELGFGEATEG CC 5 M.682 ......................KCYPTVSDEYLAAVAKARRKLRGLIAEKNCAPLMLRIAWSHAGTFDVATKIGGPFGTMRCPAELAHGAN AGLDIAVRLLEPIKEQVPILSYADFYQLAGVVAVEITGGPEVPFHPGRQDKTEPPPEGRLPDATLGSDHLRQVFTAQMGLSDQDIVALSGG HTLGRCHKERSGFEGAWTANPLIFDNSYFTELLTGEKEGLLQLPTDKTLLTDPAFRPLVDKYAADEDAFFADYAEAHLKLSELGFGEATEG CC 5 M.421 ......................KCYPTVSDEYLAAVAKARRKLRGLIAEKNCAPLMLRIAWSHAGTFDVATKIGGPFGTMRCPAELAHGAN AGLDIAVRLLEPIKEQVPILSYADFYQLAGVVAVEITGGPEVPFHPGRQDKTEPPPEGRLPDATLGSDHLRQVFTAQMGLSDQDIVALSGG HTLG 5 M.654 .....................AKCYPTVSDEYLAAVAKARRKLRGLIAEKNCAPLMLRIAWSHAGTFDVATKIGGPFGTMRCPAELAHGAN AGLDIAVRLLEPIKEQVPILSYADFYQLAGVVAVEITGGPEVPFHPGRQDKTEPPPEGRLPDATLGSDHLRQVFTAQMGLSDQDIVALSGG HTLGRCHKERSGFEGAWTANPLIFDNSYFTELLTGEKEGLLQLPTDKTLLTDPAFRPLVDKYAADEDAFFADYAEAHLKLSELGFGEATEG CC 5 M.393 ...................................VAKARRKLRGLIAEKNCAPLMLRIAWSHAGTFDVATKIGGPFGTMRCPAELAHGAN AGLDIAVRLLEPIKEQVPILSYADFYQLAGVVAVEITGGPEVPFHPGRQDKTEPPPEGRLPDATLGSDHLRQVFTAQMGLSDQDIVAL 5 M.669 ...................................VAKARRKLRGLIAEKNCAPLMLRIAWSHAGTFDVATKIGGPFGTMRCPAELAHGAN AGLDIAVRLLEPIKEQVPILSYADFYQLAGVVAVEITGGPEVPFHPGRQDKTEPPPEGRLPDATLGSDHLRQVFTAQMGLSDQDIVALSGG HTLGRCHKERSGFEGAWTANPLIFDNSYFTELLTGEKEGLLQLPTDKTLLTDPAFRPLVDKYAADEDAFFADYAEAHLKLSELGFGEATEG CC 5 M.625 ...........AFPHPIGAMAAKCYPTVSDEYLAAVAKARRKLRGLIAEKNCAPLMLRIAWSHAGTFDVATKIGGPFGTMRCPAELAHGAN AGLDIAVRLLEPIKEQVPILSYADFYQLAGVVAVEITGGPEVPFHPGRQDKTEPPPEGRLPDATLGSDHLRQVFTAQMGLSDQDIVALSGG HTLGRCHKERSGFEGAWTANPLIFDNSYFTELLTGEKEGLLQLPTDKTLLTDPAFRPLVDKYAADEDAFFADYAEAHLKLSELGFGEATEG CC 5 M.65S HPDPQPHSSPTPAFPHPIGAMAAKCYPTVSDEYLAAVAKARRKLRGLIAEKNCAPLMLRIWSHAGTFDVATKIGGPFGTMRCPAELAHGAN AGLDIAVRLLEPIKEQVPILSYADFYQLAGVVAVEITGGPEVPFHPGRQDKTEPPPEGRLPDATLGSDHLRQVFTAQMGLSDQDIVALSGG HTLGRCHKERSGFEGAWTANPLIFDNSYFTELLTGEKEGLLQLPTDKTLLTDPAFRPLVDKYAADEDAFFADYAEAHLKLSELGFGEATEG CC 5 M.524 ........................................................................................... .....................................GGPEVPFHPGRQDKTEPPPEGRLPDATLGSDHLRQVFTAQMGLSDQDIVALSGG HTLGRCHKERSGFEGAWTANPLIFDNSYFTELLTGEKEGLLQLPTDKTLLTDPAFRPLVDKYAADEDAFFADYAEAHLKLSELGFGEATEG CC 6 M.570 ....................................AGLPQISDNEKSGFISLVSRYLSGEEEHTEWPKIHTPTDEVVVPYDTIDAPPEDL EATKALLDKLAVLNLNGGLGTTMGCTGPKSVIEVRNGFTFLDLIVLQIESLNKKYGSNVPLLLMNSFNTHEDTIKIVEKYANSSIDIHTFN QSQYPRVVADEFLPWPEKGKTDRDGWYPPGRGDIFPSLMNSGKLDLLLSQGKEYVEIANSDNLGAIVDMRILNRLIHRQNEYCMEVTPKTL ADVKGSTLISYEGRVQLLEIAQVPDAHVDEFKSIEKFKIFNTNN 6 M.341 ........................................................................................... ........................................................................................... ........................................................................................... .................................................................EVDGVKVLQLETAAGAAIFF DHAIGINVPRSRFLPVKATSDLQLVQSDLYTLVDGFVTRNSARTDPSNPSIELGPEFKKVGCFLGRFKSIPSIVELDSLKVSGDVWFGSGI VLK 6 M.342 ........................................................................................... ........................................................................................... ........................................................................................... .....................................................................EVDGVKVLQLETAAGAAIRFF DHAIGINVPRSRFLPVKATSDLQLVQSDLYTLVDGFVTRNSARTDPSNPSIELGPEFKKVGSFLGRFKSIPSIVELDSLKVSGDVWFGSGI VLN 6 M.450 ........................................................................................... ........................................................................................... .......................................................FIANSDNLGAIVDMKILNHLTHKQNEYCMEVTPKTL ADVKGGTLISYEGRVQLLEIAQVPDAHVDEFKSIEKFKIFNTNNLWVNLKAIKRLVEADALKMEIIPNPKEVDGVKVLQLETAAGAAIRFF DHAIGINVPRSRFLPVKATSDLQLVQSDLYTLVDGFVTRNSARTDPSNPSIELGPEFKK 6 M.343 ........................................................................................... ........................................................................................... ........................................................................................... ......................................................................EVDGVKVLQLETAAGAAIRFF DHAIGINVPRSRFLPVKATSDLQLVQSDLYTLVDGFVTRNSARTDPSNPSIELGPEFKKVGSFLGRFKSIPSIVELDSLKVSGDVWFGSGI VLK 6 M.639 TLLFPHTQISLPSVRTRKHLAATMADEKLAKLREAVAGLPQISDNEKSGFISLVSRYLSGDEEHIEWPKIHTPIDEVVVPYDTIDAPPEDL EATKALLNKLAVLKLNGGLGTTMGCTGPKSVIEVRNGFTFLDLIVLQIESLNKKYGSNVPLLLMNSFNTHEDTLKIVEKYANSSIDIHTFN QSQYPRVVADEFLPWPSKGKTDKDGWYPPGRGDIFPSLMNSGKLDLLLSQGKEYVFIANSDNLGAIVDMKILNHLIHKQNEYCMEVTPKTL ADVKGGTLISYEGRVQLLEIAQVPDAHVDEFKSIEKFKIFNTNNLWVNLKAIKRLVEADALKMEIIPNPKEVDTVNFF 6 M.555 ................................................................................YDSVDAPPEDL EATKALLNKLAVLKLNGGLGTTMGCTGPKSVIEVRNGFTFLDLIVLQIESLNKKYGSNVPLLLMNSFNTHEDTLKIVEKYANSSIDIHTFN QSQYPRVVADEFLPWPSKGKTDKDGWYPPGRGDIFPSLMNSGKLDLLLSQGKEYVFIANSDNLGAIVDMKILNHLIHKQNEYCMEVTPKTL ADVKGGTLISYEGRVQLLEIAQVPDAHVDEFKSIEKFKIFNTNNLWVNLKAIKRLVEADALKMEIIPNPKEVDTVNFF 6 M.546 ........................................................................................EDL EATKALLDKLAVLKLNGGLGTTMGCTGPKSVIEVRNGFTFLDLIVLQIESLNKKYGSNVPLLLMNSFNTHEDTLKIVEKYANSSIDIHTFN QSQYPRVVADEFLPWPSKGKTDKDGWYPPGRGDIFPSLMNSGKLDLLLSQGKEYVFIANSDNLGAIVDMKILNHLIHKQNEYCMEVTPKTL ADVKGGTLISYEGRVQLLEIAQVPDAHVDEFKSIEKFKIFNTNNLWVNLKAIKRLVEADALKMEIIPNPKEVDTVNFFRV 7 M.606 ...................................................................................GKLRLVFE GKDETVDLEVFNFTGAGGVALAMYNTDESIQGFAEASMAIAYEKKWPLYLSTKNTILKKYDGRFKDIFQAVYEADWNSKYEAAGIWYEHRL IDDMVAYALKSEGGYVWACKNYDGDVQSDFLAQGFGSLGLMTSVLMCPDGKNIEAEAAHGTVTRHFRVHQKGGETSTNSIASIFAWTRGLA HRAKLDDNARLLDFTQKLEDACVGTVESGKMTKDLALLVHGSSKVTRGDYLNTEEFIDAVAAELQSRLAAN 7 M.628 ..........................................................................ATDAVLKGPGKLRLVFE GKDETVDLEVFNFTGAGGVALAMYNTDESIQGFAEASMAIAYEKKWPLYLSTKNTILKKYDGRFKDIFQAVYEADWNSKYEAAGIWYEHRL IDDMVAYALKSEGGYVWACKNYDGDVQSDFLAQGFGSLGLMTSVLMCPDGKNIEAEAAHGTVTRHFRVHQKGGETSTNSIASIFAWTRGLA HRAKLDDNARLLDFTQKLEDACVGTVESGKMTKDLALLVHGSSKVTRGDYLNTEEFIDAVAAELQSRLAAN 7 M.248 ........................................................................................... .........................................................YPLFCRFNDIFQAVYEADWNSKYEAAGIWYEBRL IDDMVAYALKSEGGYVWACKNYDGDVQSDFLAQGFGSLGLMTSVLMCPD 7 M.466 ........................................................................................... ........................................................................................... ....................................................IEAEAAHGTVTRHFRVHQKGGETSTNSIASIFAWTRGLA HRAKLDDNARLLDFIQKLEDACVGTVESGKMTNDLALLVHGSSKVTRGDYLNTEEFIDAVAAELQSRLAAN 7 M.328 ........................................................................................... ........................................................................................... ...........................................................................STNSIASIFAWTRGLA HRAKLDDNARLLDFTQKLEDACVGTVESGKMTKDLALLVHGSSKVTRGDYLNTEEFIDAVAAELQSRLAAN 7 M.695 .............................PFSLCLLPSGTVFREPIICKNVPKLVPGWTKPICIGRHAFGDQYRATDAVLKGPGKLRLVFE GKDETVDLEVFNFTGAGGVALAMYNIDESIQGFAEASMAIAYEKKWPLYLSTKNTILKKYDGRFKDIFQAVYEADWKSKYEAAGIWYEHRL IDDMVAYALKSEGGYVWACKNYDGDVQSDFLAQGFGSLGLMTSVLMCPDGKTIEAEAAHGTVTRHFRVHQKGGETSTNSIASIFAWTRGLA HRAKLDDNARLLDFTQKLEDACVGTVESGKMTKDLALLVHGSSKVTRGDYLNTEEFIDAVAAELQSRLAAN 7 M.658 YNVAIKCATIIPDEDRVKEYNLKQMWEZPNGIIRNIINGTVFREFIICKNVPKLVPGWTKPICIGEAAFGDQYEATGAVLKGFGKLELVFE GKDETVDLEVFNFTGAGGVALAMYNTDESIQGFAEASMAIAYEKKWPLYLSTKNTILKKYDGRFKDIFQAVYEADWKSKYEAAGIWYEHRL IDDMVAYALKSEGGYVWACKNYDGDVQSDFLAQGFGSLGLMTSVLMCPDGKIIEAEAAHGIVTRHFRVHQKGGETSTNSIASIFAWTRGLA HRAKLDDNARLLDFTQKLEDACVGTVESGKMTKDLALLVHGSSKVTRGDYLNTEEFIDAVAAELQSRLAAN 7 M.560 ........................................................................................... ..DETVDLEVFNFTGAGGVALAMYNTDESIQGFAEASMAIAYEKKWPLYLSTKNTILKKYDGRFKDIFQAVYEADWKSKYEAAGIWYEHRL IDDMVAYALKSEGGYVWACKNYDGDVQSDFLAQGFGSLGLMTSVLMCPDGKIIEAEAAHGIVTRHFRVHQKGGETSTNSIASIFAWTRGLA HRAKLDDNARLLDFTQKLEDACVGTVESGKMTKDLALLVHGSSKVTRGDYLNTEEFIDAVAAELQSRLAAN 7 M.548 ........................................................................................... ..DETVDLEVFNFTGAGGVALAMYNTDESIQGFAEASMAIAYEKKWPLYLSTKNTILKKYDGRFKDIFQAVYEADWKSKYEAAGIWYEHRL IDDMVAYALKSEGGYVWACKNYDGDVQSDFLAQGFGSLGLMTSVLMCPDGKIIEAEAAHGIVTRHFRVHQKGGETSTNSIASIFAWTRGLA HRAKLDDNARLLDFTQKLEDACVGTVESGKMTKDLALLVHGSSKVTRGDYLNTEEFIDAVAAELQSRLAAN 7 M.269 ........................................................................................... ........................................................................................... ...........................................................................STNSIASIFAWTRGLA HRAKLDDNARLLDFTQKLEDACVGTVESGKMTKDLALLVHGSSKVTRGDYLNTEEFIDAVAAELQSRLAANCV 8 M.728 ........................................................................................... ........................................ILVIFDGNFNTAGMLVVQSGCWTWLKGGATSFAAGKGELFFETNVTAELMV DSMSLQPFSFEEWKSHRHESIAKERKKKVKITVHGSDGKVLPDAELSLERVAKGFPLGNAMTKEILDIPEYEKWFTSRFTVATMENEMKWY STEYDQNQELYEIPDKMLALAEKYNISVRGHNVFWDDQSKQMDWVSKLSAPQLKKAMEKRMKNVVSRYAGKLIHWDVLNENLHYSFFEDKL GKDASAEVFKEVAKLDDKPILFMNEYNTIEEPNDAAPLPTKYLAKLKQIQSYPGNSKLKYGIGLESHFDTPNIPYVRGSLDTLAQAKVPIW LIEIDVKKGPKQVEYLEEVMREGFAHPGVKGIVLWGAWHAKECYVMCLTDKNFKNLPVGDVVDKLITEWKAVPEDAKTDDKGVFEAELFHS ETNVTVKHHKSLKEPLMHIVDLDSKSEATIRAKK 8 M.653 ........................................................................................... ..............................................GNFNTAGMLVVQSGCWTWLKGGATSFAAGKGELFFETNVTAELMV DSMSLQPFSFEEWKSHRHESIAKERKKKVKITVHGSDGKVLPDAELSLERVAKGFPLGNAMTKEILDIPEYEKWFTSRFTVATMENEMKWY STEYDQNQELYEIPDKMLALAEKYNISVRGHNVFWDDQSKQMDWVSKLSAPQLKKAMEKRMKNVVSRYAGKLIHWDVLNENLHYSFFEDKL GKDASAEVFKEVAKLDDKPILFMNEYNTIEEPNDAAPLPTKYLAKLKQIQSYPGNSKLKYGIGLESHFDTPNIPYVRGSLDTLAQAKVPIW LIEIDVKKGPKQVEYLEEVMREGFAHPGVKGIVLWGAWHAKECYVM 8 M.759 .....................................................YSANIECEEZPPKPLYGGGILTGREAPAPVSACCKKLLM AKSKSAPAKGSTLKVELERDIHYTLSANLQLSKSTGDVKAILVTPDGNFNTAGMLVVQSGCNTMLKGGAISFAAGEGLFFETNVIAELVD SMSLQPFSFEEWKSSHRHESIAKERKKEVKITVBGSDGRKVLPDAELSERVANGEFLGNAMTKEILDIPEYEKWFTSRITVATMENEMKWYS TEYDQNQELYEIPDKMLALAEKYNISVRGHNVFWDDQSKQMDWVSKLSAPQLKKAMEKRMKNVVSRYAGKLIHMDVLNENLHYSFFEDKLG KDASAEVFKEVAKLDDKPILFMNEYNIIEEPNDAAPLPIRYLAKLKQIQSYPGNSKLKYGIGLESHFDIPNIPYVRGSLDTLAQAKVPIWL TEIDVKKGPNQVEYLEEVMREHFAHPGVKGIVLWGAWHAKECYVMCLTDKNFKNLPVGDVVDRLITITWKAVPEDAKIDDKGVEAELFHGE YNVIVKHKSLKEPLMIVDLDSKSEATIRAKK 8 M.765 ...HTTIVASGIENMKIFTRTWVLLLVVLLFEGCLAKSTKDERSDKSATYDYSANIECEPPKPLYGGGILTGAPAPVSAGGKKLLM AKSKSAPAKGSTLKVELERDIHYTLSANLQLSKSTGDVKAILVTPDGNFNTAGMLVVQSGCNTMLKGGAISFAAGEGLFFETNVIAELVD SMSLQPFSFEEWKSSHRHESIAKERKKEVKITVBGSDGRKVLPDAELSERVANGEFLGNAMTKEILDIPEYEKWFTSRITVATMENEMKWYS TEYDQNQELYEIPDKMLALAEKYNISVRGHNVFWDDQSKQMDWVSKLSAPQLKKAMEKRMKNVVSRYAGKLIHMDVLNENLHYSFFEDKLG KDASAEVFKEVAKLDDKPILFMNEYNIIEEPNDAAPLPIRYLAKLKQIQSYPGNSKLKYGIGLESHFDIPNIPYVRGSLDTLAQAKVPIWL TEIDVKKGPNQVEYLEEVMREHFAHPGVKGIVLWGAWHAKECYVMCLTDKNFKNLPVGDVVDRLITITWKAVPEDAKIDDKGVEAELFHGE YNVIVKHKSLKEPLMIVDLDSKSEATIRAKK 8 M.747 ........................................................................................... .....................................................................................LMV DEMALQPFSFEEWKSHRRESIAKERKEKVRTIVHGBDGKVLFDAELSLERVAKGTPLGNAMIKEILDIPEYEKNFISRFIVATMENEMKWY STEYLQMQELYEIPDKMLALAEKYSISVRGHMVFWDDQSSQMAVSKLSARQLKKAMERMKNVVSRTAGELIHWDVLMENLHTSFFEDKL GNDAZAEVERRVAKLDDKPILFMNEYNTIEEPNDAAPLPTKILAKLKQIQSYPGNERLEYGTGLESHFDTPNIPTVRGSLDTLAQAKVPIN LIEIDVKKGPPQVEYLEZVMREGFAINPGVTGIVLMGANHAKECYVMCLIDKNFNNLPVGDVVDKLITEWKAVPEDAKIDDKGVEAELFHG ETNVTVKHHKSLKEPLMHIVDLDEKSEATIRAKR 8 M.763 ALTHTTIVASGIENMKIPIRTWVLLLVVLLFEGCLAKSYKSERSDKSATYDYSANIECEKEPPKPLYGGGILTGAEAPAPVSAGGKKLLM AKSKSAPAKGSTLKVELEKDTHYTLSAWLQLSKSTGDVKAILVTPDGNFNTAGMLVVQSGCWTMLKGGATSFAAGKGLELFETNVIAELMV DSMSLQPESFEEWKSSHRHESIAKERKKKVRITVHGSDGKVLPDAELSLERVAKGEPLGNAMTKEILDIPEYEKWFISRFIVATMENEMKWY STEYDQNQELYEIPDKMLALAEKYNISVRGHNVFWDDQSKQMDWVSKLSAPQLKKAMEKRMKNVVSRYAGKLIHWDVLNENLHYSFFEDKL GKDASAEVFKEVAKLDDKPILFMNEYNTIEEPNDAAPLPIKYLAKLKQIQSYPGNSKLKYGIGLESHFDTPNIPYVRGSLDTLAQAKVPIW LTEIDVKKGPKQVEYLEEVMREGFAHPGVKGIVLWGAWHAKECYVMCLTDKNFKNLPVGDVVDKLIIEWKAVPEDALIDDNGVFEAELFHG EYNVIVKHKSLKEPLMHTVDLDSKSEATIRAKK 8 M.733 ........................................................................................... ..SKSAPAKGSILKVELERDTHYTLSANLCLLSKSTGDVKAILVTPDGNFNTAGMLVVQEGCNTMLKCCATSFAAGKGELFETNVIAELMV DSMALQPFSFERWLSHREEKKKEVTKIIVHGSDGKVLPDAELSLERVAKGTPLGNAMTREILDIPEYEKNFISRFIVATMENEMKWY STEYDQMQELYEIPDKMLALAEKYSISVRGHMVFWDDQSSQMAVSKLSARQLKKAMERMKNVVSRYAGKLIHWDVLNENLHYSFEEDML GKDASAEVFKEVAKLDDKPILFMNEYNTIEEPNDAAPLPIKYLAKLKQIQSYPGNSKLKYGIGLESHFDTPNIPYVRGSLDTLAQAKVPIW LTEIDVKKGPKQVEYLEEVMREGFAHPGVKGIVLWGAWHAKECYVMCLTDKNFKNLPVGDVVDKLIIEWKAVPEDALIDDNGVFEAELFHG EYNVIVKHKSLKEPLMHTVDLDSKSEATIRAKK 9 M.651 ........................................................................................... ........................................................................................... ........................................................................................... .....VSADKTAKVWDIMEDASGKVNRILVCIGGVDDMLVGCWQNDHLVIVSLGGTFNVFSASNPDKEPVSFAGHLKTVSSLIYFPQS NPRIMLSTSYDGVIIRWIQGVGYGGRLIRKNNTQIKCFVAAEEELITSGYDNMVFRIPLNGDQCGDAEEVDVGCQPNALNIAVQQPEFALI TIDSAIVLLHKSIVISIIRVEYTIISSAVSPLGTEAIVGAQDGKLRIYSISGDILTEEAVLERHRGAITSIHYSPDVSMFASADANREAAVA WDRATREIKLKNMLFHTARINCLAWSPDSRLVATGSIDICAITYDVDKPASSRITIKGAHLGGVHGLTFADNDILVTAGEDACVRVNKLVVP 9 M.677 ........................................................................................... ........................................................................................... ........................................................................................... ..VLTVSADKTAKYWDIMEDASGKVNRTLNVCTGIGGVDDMLVGCLWQNDHLVTVELGGTFNVFSASNPDKEPVSFAGHLKTVSALTYFPQS NPRIMLSTSYDGVIIRWIQGVGYGGRLIRKNNTQIKCFVAAEEELITSGYDNMVFRIPLNGDQCGDAEEVDVGCQPNALNIAVQQPEFALI TIDSAIVLLHKSIVISIIRVEYTIISSAVSPLGTEAIVGAQDGKLRIYSISGDILTEEAVLERHRGAITSIHYSPDVSMFASADANREAAVA WDRATREIKLKNMLFHTARINCLAWSPDSRLVATGSIDICAITYDVDKPASSRITIKGAHLGGVHGLTFADNDILVTAGEDACVRVNKLVV PQ 9 M.597 ........................................................................................... ........................................................................................... ........................................................................................... ...LTVSADKTAKYWDIMEDASGKVNRTLNVCTGIGGVDDMLVGCLWQNDHLVTVELGGIFNVFSASNPDKEPVSFAGHLKTVSSLTYFPQS NPRIMLSTSYDGVIIRWIQGVGYGGRLIRKNNTQIKCFVAAEEELITSGYDNMVFRIPLNGDQCGDAEEVDVGCQPNALNIAVQQPEFALI TIDSAIVLLHKSIVISTIRVEYTITSSAVSPDGTEAIVGAQDGKLRIYSISGDILTEEAVLERHRGAITSIHYSPDVSMFASADANREAAVA WDRATREIKLKNMLFHTARINCLAWSPDSRLVATGSIDICAI 9 M.547 ................PGGRRERRRPCMNQLQETYTACSPATERGERGILLGGGDAKIDIIVTCAGRIFTFRRLDAPLLANTYIEAYPTIVA RISPNGEWVASADVSGVRVNGRHGDRALKAEFEPISGRVDDLRWSPDGLRIVVSGDGKGKSIVRAEMDSGSIVGDTDGHSKRVLSCDFR PTRSFRIVICGEDYLASTYEGPPTKFRHSIRDNAWNCINTSPLGZKFFITYGSDKKGLTYDCKTGDETCELSSEDSSICSTYANNADS KQVLIVSAD 9 M.761 ............TLPDQSEEGERRRPKMAQLQEIYACSPATERGRGILLGGDAKIDIIVYCAGRTFFFRRLDAPLDAWTYTEHAYPITVA RISPNGEWVASADVSGVRVNGRHGDRALKAEFEPISGRVDDLRWSPDGLRIVVSGDGKGKSIVRAFMDSGSIVGDTDGHSKRVLSCDFR PIRSFRIVICGEDFLANYYEGPPTKFRHSIRDNAVNCIRYSPDGSKFITSSDKKGLTYDCKTGDETCELSSEDSHTGSTYAVSWSADS KQVLIVSADKTAKVWDIMEDASGKVNRILVCIGIGGVDDMLVGCLWQNDHLVTVSLGGIFNVFSASNPDKEPVSFAGHLKTVSSLTYFPQS NPRIMLSTSYDGVIIRWIQGVGYGGRLIRKKNNTQIKCFVAAEEELITSGYDNMVFRIPLNGDQCGDAESVDVGGQONALNIVQQPEFALI TTDSAIVLLHKSIVISTIRVEYTITSSAVSPDGTEAIVGAQDGKLRIYSISGDILTEEAVLERHRGAITSIHYSPDVSMFASADANREAAVA WDRATREIKLKNMLFHTARINCLAWSPDSRLVATGSIDICAIIYDVDKPASSRIIIKGILGGVHGLTFADNDILVTAGEDACVRVM 9 M.571 GITTLHSPIRGPILPDQSEEGERRRPQMNQLQETYACSPATERGRGILLGGDAKIDTIVYCAGRVFFRELDAPLDANTYIEIAYPTTVA RISPNGEWVASADVSGCVRVWGNNGDRALFAEFRPTSGRVDDLAMSPDGLEIYYSDGNGKSLVRAPMDSGSIVGLFDGHIKRVLSCDFE PTRSFRIVICGFDYLASTYEGPPTKFRHSIRDNAWNCINTSPLGZKFFITYGSDKKGLTYDCKTGDETCELSSEDSSICSTYAVSNSADS KQVLTVSAD 9 M.582 GITTLHSPIRGPILPDQSEEGERRRPQMNQLQETYACSPATERGRGILLGGDAKIDTIVYCAGRVFFRELDAPLDANTYIEIAYPTTVA RISPNGEWVASADVSGCVRVWGNNGDRALFAEFRPTSGRVDDLAMSPDGLEIYYSDGNGKSLVRAPMDSGSIVGLFDGHIKRVLSCDFR PTRSFRIVICGFDYLASTYEGPPTKFRHSIRDNAWNCINTSPLGZKFFITYGSDKKGLTYDCKTGDETCELSSEDSSICSTYAVSNSADS KQ 9 M.657 ........................................................................................... ........................................................................................... .....................................................................................SWSADS KQVLTVSADKTAKVWDIMEDASGKVNRILVCIGIGGVDDMLVGCLWQNDHLVTVSLGGIFNVFSASNPDKEPVSFAGHLKTVSSLTYFPQS NPRIMLSTSYDGVIIRWIQGVGYGGRLIRKKNNTQIKCFVAAEEELITSGYDNMVFRIPLNGDQCGDAESVDVGGQONALNIVQQPEFALI TTDSAIVLLHKSIVISTIRVEYTITSSAVSPDGTEAIVGAQDGKLRIYSISGDILTEEAVLERHRGAITSIHYSPDVSMFASADANREAAVA WDRATREIKLKNMLFHTARINCLAWSPDSRLVATGSIDICAIIYDVDKPASSRIIIKGILGGVHGLTFADNDILVTAGEDACVRVW 9 M.738 ........................................................................................... ..................................SSAPWAAVVIQKFILSCSFIFGIQSYAKFSEMCRWDSGDIVGDFDGHSKRVLSCDFK PIRSFRIVICGEDFLANYYEGPPTKFRHSIRDNAVNCIRYSPDGSKFITSSDKKGLTYDCKTGDETCELSSEDSHTGSTYAVSWSADS KQVLIVSADKTAKVWDIMEDASGKVNRILVCIGIGGVDDMLVGCLWQNDHLVTVSLGGIFNVFSASNPDKEPVSFAGHLKTVSSLTYFPQS NPRIMLSTSYDGVIIRWIQGVGYGGRLIRKNNTQIKCFVAAEEELITSGYDNMVFRIPLNGDQCGDAESVDVGGQONALNIVQQPEFALI TTDSAIVLLHKSIVISTIRVEYTITSSAVSPDGTEAIVGAQDGKLRIYSISGDILTEEAVLERHRGAITSIHYSPDVSMFASADANREAAVA WDRATREIKLKNMLFHTARINCLAWSPDSRLVATGSIDICAIIYDVDKPASSRITIKGILGGVHGLTFADNDILVTAGEDACVRVWKLVVP 9 M.734 ........................................................................................... .................................GSSAPWAAVVIQKFILSCSFIFGIQSYAKFSEMCRWDSGDIVGDFDGHSKRVLSCDFK PIRSFRIVICGEDFLANYYEGPPTKFRHSIRDNAVNCIRYSPDGSKFITSSDKKGLTYDCKTGDETCELSSEDSHTGSTYAVSWSADS KQVLIVSADKTAKVWDIMEDASGKVNRILVCIGIGGVDDMLVGCLWQNDHLVTVSLGGIFNVFSASNPDKEPVSFAGHLKTVSSLTYFPQS NPRIMLSTSYDGVIIRWIQGVGYGGRLIRKNNTQIKCFVAAEEELITSGYDNMVFRIPLNGDQCGDAESVDVGGQONALNIVQQPEFALI TTDSAIVLLHKSIVISTIRVEYTITSSAVSPDGTEAIVGAQDGKLRIYSISGDILTEEAVLERHRGAITSIHYSPDVSMFASADANREAAVA WDRATREIKLKNMLFHTARINCLAWSPDSRLVATGSIDICAIIYDVDKPASSRITIKGILGGVHGLTFADNDILVTAGEDACVRVW 9 M.621 ........................................................................................... ........................................................................................... ........................................................................................... ..............................CTGUGGVDDMLVGCLWQNDHLVTVSLGGTFNVFSASNPDKEPVSFAGHLKTVSSLTYFPQS NPRTMLSYSYDGVTIRWIQGVGYGGRLIRKNNTQIKCFVAAEEELITSGYDNMVFRIPLNGDQCGDAESVDVGGQPNALNIAVQQPEFALI TTDSAIVLLRKSTVISTTKVEYITSSAVSPDGTEAIVGAQCGKLRIYSISGOTLIEEAVLERNRGAITSIHYSPDVSMFASACANREAVA MDRATREIKLKNMLFHTARINCLAMSPDSRLVAIGSIDICAIVYDVDKPASSRITIKGAHLGGVHGLTFADNDILVIAGEDACVRVWKLVV P 9 M.741 ........................................................................................... ........................................................................................... ................CVRVWGRNGURALEFTPISGKVDDLRWSPGGLRVVSGDGKGKSLVKAPMMDSGETVGDFDGHISKRVLSCDFK PTRFFRIVTCGEDFLANYYEGAPPKFHSIRDHENFVNCIRYSPDGSRTITTVSSDKRGLIYDGFTGDKIGELSEDSHTGSIYAVSNEADS NPRIMLSTSYDGVTIRWIQGVGYGGRLIRKNNTQIKCFVAAEEELITSGYDNMVFRIPLNGDQCGDAESVDVGGQPNALNIAVQQPEFALI MDRATREIKLKNMLFHTARINCLAMSPDSRLVAIGSIDICAIVYDVDKPASSRITIKGAHLGGVHGLTFADNDILVIAGEDACVRVWKLVV P 10 M.177 GATIVVSGDGRYFSKDAVQITTKMAAANGVRRVWVGQDSLLSTPAVSAIIRERIAADGSKATGAFILTASH 11 M.579 ......................RDQVGLLVKGASEMGASRIKLRDGRDVLDSSVGPVETLENDLADLREKCVDAQVASGGGRMYT MDKYENDWDVVKRGWDAQVLDEAPYKSALEAVKILRAEPKANDQTLPAFVIVDKSGKSVGPIVDQDAVVTFNFRADRMVMLAKALFFAD FDEEDRVRVPKIKYAGMLQYDGELKLPMFTLVSPPLTERISGEYLVKNGVRTFACELVRFGHVITTWMGNMLAKLPFAD ITFNEQPKMKALEIREKIRGAILSGKFGQVRINLPN 11 M.513 .ESFAEGTLHLIGLLSDGGVHSRLDQVQLLVKGASERGAKRIRLHILIDGRDVLDGSSVGFVETLENDLAGLPEKGVDAQVASGGGRMYVI MDRYENDWDVVKRGWDAQVLGEAPYKKFKSALEAVKTLRAEPKANDQYLPAPVIVDESGKSVGPIVDGDAVVTFNFRADRMVMLAKALEFAD FDKFDRVRVPKIKYAGMLQYDGELKLPNKFLVSPPLIERISGEYLVKNGVR 11 M.446 ..................................................RDVLDGSSVGTVETLENDIAQLREKGVDAQVASGGGKMYVI MDRYENDWDVVKRGWDAQVLGEAPYKKFKSALEAVKTLRAEPKANDQYLPAPVIVDESGKSVGPIVDGDAVVTFNFRADRMVMLAKALEFAD FDKFDRVRVPKIKYAGMLQYDGELKLPNKFLVSPPLIERISGEYLVKNGVRI 11 M.388 ........................................................................................... ..................................................................DAVVIFNFRADRMVMLAKALEFAD FDKFDRVRVPKIKYAGMLQYDGELKLPNKFLVSPPLIERISGEYLVKNGVRIFACSEIVKFGHVIFFWNGNRSGYFDEIKEEYIEIPSDSG ITFNEQPKMKALEIAEKTRDAILSGKFDQVRINLP 11 M.391 ........................................................................................... ..................................................................DAVVIFNFRADRMVMLAKALEFAD FDKFDRVRVPKIKYAGMLQYDGELKLPNKFLVSPPLIERISGEYLVKNGVRIFACSEIVKFGHVIFFWNGNRSGYFDEIKEEYIEIPSDSG ITFNEQPKMKALEIAEKTRDAILSGKFDQVRINLPN 11 M.593 .......ESENVKEFSTINLFLVSLYFQLLVKGASERGAKRIRLHILIDGRDVLDGSSVGFVEILENDLAQLREKGVDAQVASGGRMYVI MDRYENDMDVVKRGWDAQVLGEAPYKFKSALEAVKTLRAEPKANDQYLPAFVIVDESGKSVGPIVDGDAVVTPNFRADRMVMLAKALEPAD FDKFDRVRVPKIKYAGMLQYDGELKLPMKFLVSPPLIERISGEYLVKNGVRTFACSETVKFGHVIFFWNGNRSGYFDETKEEYIEIPSDSG ITFNEQPKMKALEIAEKIRDAILSGKFDQVRINLPN 11 M.506 ................................................................................VISGGGRMYVI MDRYENDMDVVKRGWDAQVLGEAPYKFKSALEAVKTLRAEPKANDQYLPAFVIVDESGKSVGPIVDGDAVVTPNFRADRMVMLAKALEPAD FDKFDRVRVPKIKYAGMLQYDGELKLPMKFLVSPPLIERISGEYLVKNGVRTFACSETVKFGHVIFFWNGNRSGYFDETKEEYIEIPSDSG ITFNEQPKMKALEIAEKIRDAILSGKFDQVRINLPN 11 M.395 .....................................................................................GRMYVT MDRYENDWDVVKRGWDAQVLGEAPYKFKSALEAVKILRASPKANDQYLPAFVIVDESGKSVGPIVDGDAVYIFNFRADRMVMLAKALEFAD FDMFDRVRVPKIKYAGMIQYDGELKLPNKFLVSPPLIERISGEYVKNGVRTFAC 11 M.381 ........................................................................................... ....................................................................DAVVTFNFKADHVNMLAKALFAC FDKFDRVRVPKISTRAGGMLQGELMLPGKELTVSPPLIERISGEYENGVRIFACSETVRIGHYIEFMNGNRSGYTCEINECTIEIPSDSG ITFNEQPRMKALEIAEKISDRILSGK 11 M.372 KESFAEGILNLIGLLSDGGVHSRLDQVQLLVNGASERGASRIRLHILTDGRDVLDGSSVGIVEILENDLAQLREMGVDAQVARSGGGRMYVI MDHYENDWDVVKNGNDAQVLGEAPYKFKSPLEAVEILRAEP 12 M.615 CSSDYKLLCSSFPYITYHQGNNGNLSRLACPLNQKNK 12 M.656 CSSDYKLLCSSFPYITYHQGNNGNLSRLACPLNQKNKKKS 12 M.525 CSSDYKLLCSSFPYITYHQGNNGNLSRLACPLNQKNKKKS 13 M.698 ....AMDEEYDVTVLGTGLKECILSGLLSVDGLKVLRMDSNDIYGGESISLNLTKIWKRFKGSEATPDHLGVSKEYNVDMVPKFMMANGAL VRVLIRTSVIKYLNFKAVDGSFVYSNGKIHEVPAIDVEALKSNKNGKFEJROARKFFIYVQQYEEDPKSHEGLDLHKVITREVISKYGLE DDIVDFIGHALALHADDNYLDEPAIDIVKFMKLYAESLARFQGGSPYIYPLYGLGELPQAFARLSAVTGGIYMLNKPECKVEPDESGKAFG VISEGETAKCKKVVCDPSYLPDEVIKVGRVARAICIMKHPIPDIKDSHSVQIILPKKQLKRKSDMYVTCCSYAHNVAPKGKFIAFVSTEAE IDKPEIELKPGIDLLGPVEEIFFDIYDRYEPANAPEEDNCTVINSYDATTH 13 M.699 ....AMDEEYDVTVLGTGLKECILSGLLSVDGLKVLRMDSNDIYGGESISLNLTKIWKRFKGSEATPDHLGVSKEYNVDMVPKFMMANGAL VRVLIRTSVIKYLNFKAVDGSFVYSNGKIHEVPAIDVEALKSNKNGKFEJROARKFFIYVQQYEEDPKSHEGLDLHKVITREVISKYGLE DDIVDFIGHALALHADDNYLDEPAIDIVKFMKLYAESLARFQGGSPYIYPLYGLGELPQAFARLSAVTGGIYMLNKPECKVEPDESGKAFG VISEGETAKCKKVVCDPSYLPDEVIKVGRVARAICIMKHPIPDIKDSHSVQIILPKKQLKRKSDMYVTCCSYAHNVAPKGKFIAFVSTEAE TDKPEIELKPGIDLLGPVEEIFFDIYDRYEPANAPEEDNCTVINSYDATTH 13 M.439 ........................................................................................... ...............................................................................TTREVISKYGLE DDIVDFIGHALALHRDDNYLDEPAIDIVKRMLYAESLASFQGGSPYIYPLYGLGELPQAFARLSAVYGGTYMLNKPECKVEFDESGKAFG VTSEGETAKCKEVVCDPSYLPDKVIKVGKVARATCTMKRPIPDTKDSRSVQITLPKKQLKRKSDMYVTCCSY 13 M.630 ....AMDEEYDVTVLGTGLKECILSGLLSVDGLKVLRMDSNDIYGGESISLNLTKIWKRFKGSEATPDHLGVSKEYNVDMVPKFMMANGAL VRVLIRTSVIKYLNFKAVDGSFVYSNGKIHEVPAIDVEALKSNKNGKFEJROARKFFIYVQQYEEDPKSHEGLDLHKVITREVISKYGLE DDIVDFIGHALALHADDNYLDEPAIDIVKFMKLYAESLARFQGGSPYIYPLYGLGELPQAFARLSAVTGGIYMLNKPECKVEPDESGKAFG VISEGETAKCKKVVCDPSYLPDEVIKVGRVARAICIMKHPIPDIKDSHSVQIILPKKQLKRKSDMYVTCCSYA 13 M.708 ..........................LLSVDGLKVLHMDRNDYYGGESISLNTKIWKSRFKGSEATPDHLGVSKLYNVDMVTFFMMANGAL VRVLIRTSVIKYLNFKAVDGSFVYSNGKIHEVPAIDVEALKSNKNGKFEJROARKFFIYVQQYEEDPKSHEGLDLHKVITREVISKYGLE DDIVDFIGHALALHADDNYLDEPAIDIVKFMKLYAESLARFQGGSPYIYPLYGLGELPQAFARLSAVTGGIYMLNKPECKVEPDESGKAFG VISEGETAKCKKVVCDPSYLPDEVIKVGRVARAICIMKHPIPDIKDSHSVQIILPKKQLKRKSDMYVTCCSYAHNVAPKGKFIAFVSTEAE TDKPEIELKPGIDLLGPVEEIFFDIYDRYEPANAPEEDNCTVINSYDATTHFETTVKDVLALYSKIIGKELDLSVDLNAASAGESEAA 13 M.620 .....MDEEYDVTVLGTGLKECILSGLLSVDGLKVLRMDSNDIYGGESISLNLTKIWKRFKGSEATPDHLGVSKEYNVDMVPKFMMANGAL VRVLIRTSVIKYLNFKAVDGSFVYSNGKIHEVPAIDVEALKSNKNGKFEJROARKFFIYVQQYEEDPKSHEGLDLHKVITREVISKYGLE DDIVDFIGHALALHADDNYLDEPAIDIVKFMKLYAESLARFQGGSPYIYPLYGLGELPQAFARLSAVTGGIYMLNKPECKVEPDESGKAFG VISEGETAKCKKVVCDPSYLPDEVIKVGRVARAICIMKHPIPDIKDSHSVQIILPKKQ 14 M.758 LIGYLLNVVAIRRPPPVRCFSLRAW 14 M.764 LIGYLLNVVAIRRPPPVRCFSLRAW 14 M.746 LIGYLLNVVAIRRPPPVRCFSLRAW 14 M.762 LIGYLLNVVAIRRPPPVRCFSLRAW 15 M.716 PRVNFFKRYNLICVFW 15 M.726 PRVNFFKRYNLICVFWSKKKFRAW 16 MN.66 RSDEKLLSVFPEGVVYGAGIGPGYYGTNSFRIPSKEEIACDEALFPKTRPPPKPPRTLQKQIDSLCPGFCLKDVIPETYRIEER 17 M.717 NYCIRLSPFCCLYCILCCNYSMRLVTVM 17 M.727 NYCIRLSPFCCLYCILCCNYSMRLVTVM 17 M.719 NYCIRLSPFCCLYCILCCNYSMRLVTVM 17 M.724 NYCIRLSPFCCLYCILCCNYSMRLVTVM 17 M.577 NYCIRLSPFCCLYCILCCNYSMRLVTVM 18 M.8 NIPATWGAMEKLYDAGKARAIGVSWLASKKLGDLLAVARIPPA 19 M.235 DVNHATVKTSSGEKPVRELVQDDEWLNGPFIATVQQRGAAIIKARKLSSALSAASSACDHIRDWVLGTPEGTFVSMGVYSD 20 M.678 LKTEESRPSPKPNRIERRKREEHAPPPGQHIAMAASSRRASQLLGSAASRFLHSRGYAAAAAAPSPAVFVDKSTRVICQGITGKNGTFHTE QAIEYGTNMVGGVTPKKGGTEHLGLPVFNSVAEAKAETKANASVIYVPPPFAAAAIMEALEAELDLVVCITEGIPQHDMVKVKAALNRQSK TRLIGPNCPGIIKPGECKIGIMPGYIHKPGRIGIVSRSGTLTYEAVFQTTAVGLGQSTCVGMGGDPFNGTNFVDCLEKFVADPQTEGIVLI GEIGGTAEEDAAAFIQASKTDKPVVAFIAGLTAPPGRRMGHAGAIVSGGKGTAQDKIKALREAGVTVVESPAKIGSTMFEIFKQRGMVE 20 M.675 .....SRPSPKPNRIERRKREEHAPPPGQHIAMAASSRRASQLLGSAASRFLHSRGYAAAAAAPSPAVFVDKSTRVICQGITGKNGTFHTE QAIEYGTNMVGGVTPKKGGTEHLGLPVFNSVAEAKAETKANASVIYVPPPFAAAAIMEALEAELDLVVCITEGIPQHDMVKVKAALNRQSK TRLIGPNCPGIIKPGECKIGIMPGYIHKPGRIGIVSRSGTLTYEAVFQTTAVGLGQSTCVGMGGDPFNGTNFVDCLEKFVADPQTEGIVLI GEIGGTAEEDAAAFIQASKTDKPVVAFIAGLTAPPGRRMGHAGAIVSGGKGTAQDKIKALREAGVTVVESPAKIGSTMFEIFKQRGMVE 20 M.641 ............................................................AAAPSPAVFVDKSTRVICQGITGKNGTFHTE QAIEYGTNMVGGVTPKKGGTEHLGLPVFNSVAEAKAETKANASVIYVPPPFAAAAIMEALEAELDLVVCITEGIPQHDMVKVKAALNRQSK TRLIGPNCPGIIKPGECKIGIMPGYIHKPGRIGIVSRSGTLTYEAVFQTTAVGLGQSTCVGMGGDPFNGTNFVDCLEKFVADPQTEGIVLI GEIGGTAEEDAAAFIQASKTDKPVVAFIAGLTAPPGRRMGHAGAIVSGGKGTAQDKIKALREAGVTVVESPAKIGSTMFEIFKQRGMVE 20 M.499 ........................................................................................... ........................................................................................... .....................MPGYIHKPGRIGIVSRSGTLTYEAVFQTTAVGLGQSTCVGMGGDPFNGTNFVDCLEKFVADPQTEGIVLI GEIGGTAEEDAAAFIQASKTDKPVVAFIAGLTAPPGRRMGHAGAIVSGGKGTAQDKIKALREAGVTVVESPAKIGSTMFEIFKQRGMVE 20 M.583 ........................................................................................... .......QQVGGVTPKKGGTEHLGLPVFNSVAEAKAETKANASVIYVPPPFAAAAIMEALEAELDLVVCITEGIPQHDMVKVKAALNRQSK TRLIGPNCPGIIKPGECKIGIMPGYIHKPGRIGIVSRSGTLTYEAVFQTTAVGLGQSTCVGMGGDPFNGTNFVDCLEKFVADPQTEGIVLI GEIGGTAEEDAAAFIQASKTDKPVVAFIAGLTAPPGRRMGHAGAIVSGGKGTAQDKIKALREAGVTVVESPAKIGSTMFEIFKQRGMVE 20 M.649 ........................................................................................... EVLTSKRQQVGGVTPKKGGTEHLGLPVFNSVAEAKAETKANASVIYVPPPFAAAAIMEALEAELDLVVCITEGIPQHDMVKVKAALNRQSK TRLIGPNCPGIIKPGECKIGIMPGYIHKPGRIGIVSRSGTLTYEAVFQTTAVGLGQSTCVGMGGDPFNGTNFVDCLEKFVADPQTEGIVLI GEIGGTAEEDAAAFIQASKTDKPVVAFIAGLTAPPGRRMGHAGAIVSGGKGTAQDKIKALREAGVTVVESPAKIGSTMFEIFKQRGMVE 21 M.6 ........................................................................................... ............LRVQSDQAVFYQCYFDGYQDTLYTHAQRQFFRDCTVIGTIDFI 21 M.29 DGSGDFKIIKEALAKVPPKSASMYVMYIKEGTYKEYVIVPRIVINLVMIGDG 21 M.34 ........................................................................................... ..........VALRVQSDQAVFYQCYFDGYQDTLYTHAQRQFFRDCTVIGTIDFIFWITIWEL 21 M.183 ....................................................................................MKDIRVE NTAGADNHQAVALRVQSDQAVFYQCYFDGYQDTLYTHAQRQFFRDCTVTGTIDFIFGNSQVVIQN 21 M.101 ....................................................................................MKDIRVE NTAGADNHQAVALRVQSDQAVFYQCYFDGYQDTLYTHAQRQFFRDCTVTGTIDFIF 21 M.149 ................LAKVPPKSASMYVMYIKEGTYKEYVTVPRTVTNLVMIGDGAAKTIITGNKNFKMNLISMVAVS 21 M.164 .................LAKVPPKSASMYVMYIKEGTYKEYVTVPRTVTNLVMIGDGAAKTIITGNKNFKMNLI 21 M.129 ................LAKVPPKSASMYVMYIKEGTYKEYVTVPRTVTNLVMIGDGAAKTIITGNKNFKMNLI 21 M.45 .......................................................................DTATMEAIGNGFEMKDIRVE NTAGADNHQAVALRVQSDQAVFYQCYFDGAVTEEL 21 M.116 .................LAKVPPKSASMYVMYIKEGTYKEYVTVPRTVTNLVMIGDGAAKTIITGNKNFKMNLIIKD 21 M.165 .....................................................................TKDTATMEAIGNGFFMKDIRVE NTAGADNHQAVALRVQSDQAVFYQCYFDGYQDTLYTHAQRQFFRDCTV 21 M.146 .......................................................................DTATMEAIGNGFFMKDIRVE NTAGADNHQAVALRVQSDQAVFYQCYFDGYQDTLYTHAQRQFFRDCTV 21 M.69 ............................................................................EAIGNGFFMKDIRVE NTAGADNHQAVALRVQSDQAVFYQCYFDGYQDTLYTLMSFMKNP 21 M.123 .............AKVPPKSASMYVMYIKEGTYKEYVTVPRTVTNLVMIGDGAAKTIITGNKNFKMNLISKVAVSLV 21 M.107 ..............AKVPPKSASMYVMYIKEGTYKEYVTVPRTVTNLVMIGDGAAKTIITGNKNFKMNLTIKDTATM 21 M.3 ..................KSASMYVMYIKEGTYKEYVTVPRTVTNLVMIGDGATKTIIT 21 M.113 ...............VPPKSASMYVMYIKEGTYKEYVTVPRTVTNLVMIGDGAAKTIITGNKNFKMNL 21 M.204 .......................................................................DTATMEAIGNGFEMKDIRVE NTAGADNHQAVALRVQSDQAVFYQCYFDGYQDTLYTHAQRQFFRDCTVTGTIDEI 21 M.174 ...................SASMYVMYIKEGTYKEYVTVPRTVTNLVMIGDGAAKTIITGNKNFKMNLTTKDTATMEAIGNGFFMKDIRV 21 M.178 ..GSGDFKTIKEALAKVPPKSASMYVMYIKEGTYKEYVTVPRTVTNLVMIGDGAAKTIILKFLLPVMIVLAAP 21 M.191 .GSGDFKTIKEALAKVPPKSASMYVMYIKEGTYKEYVTVPRTVTNLVMIGDGAAKTIITGNKNFKMNLTTKDTA 22 M.580 .......................................PALVPMALPNQGTVDYPSFKLVIVGDGGTGKTTFVKRHLTGEFEKKYEPTIG VEVHPLDFTTNCGKIRFYCWDTAGQEKFGGLRDGYYIHGQCAIIMFDVTSRLTYKNVPTWHRDLCRVCENIPIVLCGNKVDVKNRQVKAKQ VTFHRKKNLQYYEISAKSNYNFEKPFLYLARKLAGDANIHFVEAVALKPPEVTFDLAMQQQHEAELAAAAAQPLPDDDDDLVE 22 M587 ...........................PAPPPTQHLPSPPALVPMALPNQGTVDYPSFKLVIVGDGGTGKTTFVKRHLTGEFEKKYEPTIG VEVHPLDFTTNCGKIRFYCWDTAGQEKFGGLRDGYYIHGQCAIIMFDVTSRLTYKNVPTWHRDLCRVCENIPIVLCGNKVDVKNRQVKAKQ VTFHRKKNLQYYEISAKSNYNFEKPFLYLARKLAGDANIHFVEAVALKPPEVTFDLAMQQQHEAELAAAAAQPLPDDDDDLVE 22 M.594 ...................VLLLRRTPPRSSSYPTVASPPALVPMALPNQGTVDYPSFKLVIVGDGGTGKITFVKEHLTGEFEKKYEPTIG VEVHPLDFTTNCGKIRFYCWDTAGQEKFGGLRDGYYIHGQCAIIMFDVTSRLTYKNVPTWHRDLCRVCENIPIVLCGNKVDVKNRQVKAKQ VTFHRKKNLQYYEISAKSNYNFEKPFLYLARKLAGDANIHFVEAVALKPPEVTFDLAMQQQHEAELAAAAAQPLPDDDDDLVE 22 M.539 ............................APPPTQQQPSPPALVPMALPNQGTVDYPSFKLVIVGDGGTGKITFVKRHLTGEFEKKYEPTIG VEVHPLDFTTNCGKIRFYCWDTAGQEKFGGLRDGYYIHGQCAIIMFDVTSRLTYKNVPTWHRDLCRVCENIPIVLCGNKVDVKNRQVKAKQ VTFHRKKNLQYYEISAKSNYNFEKPFLYLARKLAGDANIHFVEAVALKPPEVTFDLAMQQQHEAELAAAAAQPLPDDDDDLVE 22 M.569 ...................................MPSPPALVPMALPNQGTVDYPSFKLVIVGDGGTGKITFVKRHLTGEFEKKYEPTIG VEVHPLDFTTNCGKIRFYCWDTAGQEKFGGLRDGYYIHGQCAIIMFDVTSRLTYKNVPTWHRDLCRVCENIPIVLCGNKVDVKNRQVKAKQ VTFHRKKNLQYYEISAKSNYNFEKPFLYLARKLAGDANIHFVEAVALKPPEVTFDLAMQQQHEAELAAAAAQPLPDDDDDLVE 22 M.588 ..........................PPAPPPTQQQPSPPALVPMALPNQGTVDYPSFKLVIVGDGGTGKTTFVKRHLTGEFEKKYEPTIG VEVHPLDFTTNCGKIRFYCWDTAGQEKFGGLRDGYYIHGQCAIIMFDVTSRLTYKNVPTWHRDLCRVCENIPIVLCGNKVDVKNRQVKAKQ VTFHRKKNLQYYEISAKSNYNFEKPFLYLARKLAGDANIHFVEAVALKPPEVTFDLAMQQQHEAELAAAAAQPLPDDDDDLVE 22 M.615 APISASTGSPNSDSNIRVLLLRRTSPESAPPPTQQLPSPPALVPMALPNQGTVDYPSFKLVIVGDGGTGKTTFVKRHLTGEFEKKYEPTIG VEVHPLDFTTNCGKIRFYCWDTAGQEKFGGLRDGYYIHGQCAIIMFDVTSRLTYKNVPTWHRDLCRVCENIPIVLCGNKVDVKNRQVKAKQ VTFHRKKNLQYYEISAKSNYNFEKPFLYLARKLAGDANIHFVEAVALKPPEVTFDLAMQQQHEAELAAAAAQPLPDDDDDLVE 22 M.578 ....................................PSPPALVPMALPNQGTVDYPSFKLVIVGDGGTGKITFVKRHLTGEFEKKYEPTIG VEVHPLDFTTNCGKIRFYCWDTAGQEKFGGLRDGYYIHGQCAIIMFDVTSRLTYKNVPTWHRDLCRVCENIPIVLCGNKVDVKNRQVKAKQ VTFHRKKNLQYYEISAKSNYNFEKPFLYLARKLAGDANIHFVEAVALKPPEVTFDLAMQQQHEAELAAAAAQPLPDDDDDLVE 22 M.352 ................................................NQGTVDYPSFKLVIVGDGGTGKITFVKRHLTGEFEKKYEPTIG VEVHPLDFTTNCGKIRFYCWDTAGQEKFGGLRDGYYIHGQCAIIMFDVTSRLTYKNVPTWHRDLCRVCENIPIVLCG 22 M.514 ................................................NQGTVDYPSFKLVIVGDGGTGKITFVKRHLTGEFEKKYEPTIG VEVHPLDFTTNCGKIRFYCWDTAGQEKFGGLRDGYYIHGQCAIIMFDVTSRLTYKNVPTWHRDLCRVCENIPIVLCGNKVDVKNRQVKAKQ VTFHRKKNLQYYEISAKSNYNFEKPFLYLARKLAGDANIHFVEAVALKPPEVTFDLAMQQQHEAELAAAAAQPLPDDDDDLVE 23 M.419 RTSSWGSGASLKIDRRELVTTRIYGFL 23 M.443 RTSSWGSGASLKIDRRELVTTRIYGFL 24 M.540 ..........LVQRSREZDLHAAVAMATKREVGTLGEADLKGKKVELEADLNVPLDDAQKITDDTRIRASIPIIRFLLEKGARVILAS HLGRPKGVTPKFSLKPLVPRLSELLGVEVVMANDCIGEEVEKLAAALPEGGVLLLENVRFYKEEEKNDPEFAKKLASVADLYVNDAFGTAH RAHASIEGVIKELRPSVAGELMQKELDYLVGAVANPKKRPIAAIVGGSKVSSKIGVIESLLAKVDILILGGGMIFT 24 M.640 ............SRSPPIRSRFLHAAVAMAIKRAVGILGEADLKGKKVFLRADLNVPLDDAQKIIDDTRIRASIPTIKFLLEKGAKVILAS HLGRPKGVTPKFSLKPLVPRLSELLGVEVVMANDCIGEEVEKLAAALPEGGVLLLENVRFYKEEEKNDPEFAKKLASVADLYVNDAFGTAH RAHASTEGVTKFLRPSVAGFLMQKELDYLVGAVANPKKPFAAIVGGSKVSSKIGVIESLLAKVDILILGGGMIFTFYKAQGKAVGNSLVEE DKLELAISLIETAKAKGVSLLLPTDVVVADKFAPDAESKIVPADAIPDGWMGLDVGPDSIKTFSEALDTTKTVIWNGPMGVFEFEKFAAG 24 M.642 ............SRSPPIRSRFLHAAVAMAIKRAVGILGEADLKGKKVFLRADLNVPLDDAQKIIDDTRIRASIPTIKFLLEKGAKVILAS HLGRPKGVTPKFSLKPLVPRLSELLGVEVVMANDCIGEEVEKLAAALPEGGVLLLENVRFYKEEEKNDPEFAKKLASVADLYVNDAFGTAH RAHASTEGVTKFLRPSVAGFLMQKELDYLVGAVANPKKPFAAIVGGSKVSSKIGVIESLLAKVDILILGGGMIFTFYKAQGKAVGNSLVEE DKLELAISLIETAKAKGVSLLLPTDVVVADKFAPDAESKIVPADAIPDGWMGLDVGPDSIKTFSEALDTTKTVIWNGPMGVFEFEKFAAGI 24 M.646 ...........RPDRRFDLGFLHAAVAMATKRSVGTLGEADLKGKKVFLRADLNVPLDDAQKITDDTRIRASIPTIKFLLEKGAKVILAS HLGHPKGVTPKFSLKPLVPRLSELLGVEVVMANDCIGEEVEKLAAALPEGGVLLLENVRFYKEEEKNDPEFAKKLASVADLYVNDAFGTAH RAHASTEGVIKFLRPSVAGFLMQKELDYLVGAVANPKKPFAAIVGGSKVSSKIGVIESLLAKVDILILGGGMIFTFYKAQGKAVGNSLVEE DKLELATSLIETAKAKGVSLLLPTDVVVADKFAPDAESKIVSADAIPDGWMGLDVGPDSIKTFSEALDTTKTVIWNGPMGVFEFEKFAAGI D 24 M.627 ......................LHAAVAMATKRSVGILGEADLKGKKVFLRADLNVPLDDAQKIIDDTRIRASIPTIKFLLEKGAKVILAS HLGRPKGVTPKFSLKPLVPRLSELLGVEVVMANDCIGEEVEKLAAALPEGGVLLLENVRFYKEEEKNDPEFAKKLASVADLYVNDAFGTAH RAHASTEGVTKFLRPSVAGFLMQKELDYLVGAVANPKKPTAAIVGGSKVSSKIGVIESLLAKVDILILGGGMIFTFYKAQGKAVGNSLVEE DKLELATSLIETAKAKGVSLLLPTDVVVADKFAPDAESKTVPADAIPDGWMGLDVGPDSIKTFSEALDTTKTVIWNGPMGVFEFEKFAAGI 24 M.626 ............................AMATKRSVGTLGEADLKGKKVFLRADLNVPLDDAQKIIDDTRIRASIPTIKFLLEKGAKVILAS HLGRPKGVTPKFSLKPLVPRLSELLGVEVVMANDCIGEEVEKLAAALPEGGVLLLENVRFYKEEEKNDPEFAKKLASVADLYVNDAFGTAH RAHASTEGVTKFLRPSVAGFLMQKELDYLVGAVANPKKPFAAIVGGSKVSSKIGVIESLLAKVDILILGGGMIFTFYKAQGKAVGNSLVEE DKLELATSLIETAKAKGVSLLLPTDVVVADKFAPDAESKTVSADAIPDGWMGLDVGPDSIKTFSEALDTTKTVIWNGPMGVFEFEKFAAGT D 24 M.645 ..SLSLSLSLSRPDRRRFDLRFLHAAVAMATKRSVGILGEADLKGKKVFLRADLNVPLDDAQKITDDTRIRASIPTIKFLLEKGAKVILAS HLGRPKGVTPKFSLKPLVPRLSELLGVEVVMANDCIGEEVEKLAAALPEGGVLLLENVRFYKEEEKNDPEFAKKLASVADLYVNDAFGTAH RAHASTEGVTKFLRPSVAGFLMQKELDYLVGAVANPKKPTAAIVGGSKVSSKIGVIESLLAKVDILILGGGMIFTFYEAQGEAVGESLVEE DKLELATSLIETAKAKGVSLLLPTDVVVADKFAPDAESKTVPADAIPDGWMGLDVGPDSIKTFSEALDTTKTVIWNGPMGVFE 24 M.652 .........LPRPDRRRFDPGFSTQQAAMATKRSVGTLGEADLKGKKVFLRADLNVPLDDAQKITDDTRIRASIPTIKFLLEKGAKVILAS HLGRPKGVTPKFSLKPLVPRLSELLGVEVVMANDCIGEEVEKLAAALPEGGVLLLENVRFYKEEEKNDPEFAKKLASVADLYVNDAFGTAH RAHASTEGVTKFLRPSVAGFLMQKELDYLVGAVANPKKPTAAIVGGSKVSSKIGVIESLLAKVDILILGGGMIFTFYKAQGKAVGKSLVEE DKLELATSLIETAKAKGVSLLLPTDVVVADKFAPDAESKTVSADAIPEGWMGLDVGPDSIKTFSEALDTTKTVIWNGPMGVFEFEKFAA 24 M.650 .........LPRPDRRRFDPGFSTQQAAMATKRSVGTLGEADLKGKKVFLRADLNVPLDDAQKITDDTRIRASIPTILFLLEKGAKVILAS HLGRPKGVTPKFSLKPLVPRLSELLGVEVVMANDCIGEEVEKLAAALPEGGVLLLENVRFYKEEEKNDPEFAKKLASVADLYVNDAFGTAH RAHASTEGVTKFLRPSVAGFLMQKELDYLVGAVANPKKPTAAIVGGSKVSSKIGVIESLLAKVDILILGGGMIFTFYKAQGKAVGKSLVEE DKLELATSLIETAKAKGVSLLLPTDVVVADKFAPDAESKTVSADAIPEGWMGLDVGPDSIKTFSEALDTTKTVIWNGPMGVFEFEKFAA 24 M.559 ........................................................................................... FQGRPKGVTPKFSLKPLVPRLSELLGVEVVMANDCIGEEVEKLAAALPEGGVLLLENVRFYKEEEKNDPEFAKKLASVADLYVNDAFGTAH RAHASTEGVTKFLRPSVAGFLMQKELDYLVGAVANPKKPFAAIVGGSKVSSKIGVIESLLAKVDILILGGGMIFTFYKAQGKAVGKSLVEE DKLELATSLIETAKAKGVSLLLPTDVVVADKFAPDAESKTVSADAIPDGWMGLDVGPDSIKTFSEALDTTKTVIWNGPMGVFEFEKFAAGT 24 M.622 ...........................AMAIKRSVGTLGEADLKGKKVFLRADLNVPLDDAQKITDDTRIRASIPTILFLLEKGAKVILAS HLGRPKGVTPKFSLKPLVPRLSELLGVEVVMANDCIGEEVEKLAAALPEGGVLLLENVRFYKEEEKNDPEFAKKLASVADLYVNDAFGTAH RAHASTEGVTKFLRPSVAGFLMQKELDYLVGAVANPKKPTAAIVGGSEVSEKIGVIESLLAKVDILILGGGMIFTFYKAQGKAVGKSLVEE DKLELAISLIETAKAKGVSLLLPTDVVVADKFAPDAESKTVSADAIPEGWMGLDVGPDSIKTFSEALDITKTVIWNGPMGVFEFEKFAAG 24 M.565 ......................................................................................VILAS HLGRPKGVTPKFSLKPLVPRLSELLGVEVVMANDCIGEEVEKLAAALPEGGVLLLENVRFYKEEEKNDPEFAKKLASVADLYVNDAFGTAH RAHASTEGVTKFLRPSVAGFLMQKELDYLVGAVANPKKPTAAIVGGSKVSSKIGVIESLLAKVDILILGGGMIFTFYKAQGKAVGKSLVEE DKLELATSLIETAKAKGVSLLLPTDVVVADKFAPDAESKTVSADAIPEGWMGLDVGPDSIKTFSEALDTTKTVIWNGPMGVFEFEKFAAGT 24 M.567 ......................................................................................VILAS HLGRPKGVTPKFSLKPLVPRLSELLGVEVVMANDCIGEEVEKLAAALPEGGVLLLENVRFYKEEEKNDPEFAKKLASVADLYVNDAFGTAH RAHASTEGVTKFLRPSVAGFLMQKELDYLVGAVANPKKPTAAIVGGSKVSSKIGVIESLLAKVDILILGGGMIFTFYKAQGKAVGKSLVEE DKLELATSLIETAKAKGVSLLLPTDVVVADKFAPDAESKTVSADAIPDSWMGLDVGPDSIKTFSEALDITKTVIWNGPMGVFEFEKFAAGT D 24 M.581 .........................................................LDDAQKITDDTRIRASIPTIKFLLEKGAKVILAS HLGRPKGVTPKFSLKPLVPRLSELLGVEVVMANDCIGEEVEKLAAALPEGGVLLLENVRFYKEEEKNDPEFAKKLASVADLYVNDAFGTAH RAHASTEGVIKFLRPSVAGFLMQKELDYLVGAVANPKKPFAAIVGGSKVSEKIGVIESLLAKVDILILGGGMIFTFYKAQGKAVGKSLVEE DKLELAISLIETAKAKGVSLLLPTDVVVADKFAPDAESKTVSADAIPDGWMGLDVGPDSIKTFSEALDTTKT 25 M.609 KSAPALRILRSFPSHS 26 M.182 ........................................................................................... ........................................................................................... ....................................................VAAIKEESEGNLKGILGYVDEDLVSTDFQGDSRSSIFDA KAGIALNDNFVKLVSWYDNEWGYSIRVVD 26 M.134 ..................IMEKYDIVRGQNHHHDVKVKDAKILLFGEEEVFGCRNPEEIPNGAAGADYVVESIGVFIDKDKA 26 M.283 ........................................................................................... ........................................................................................... ....................................................AATYEQIKAAIKEESEGNLKGILGYVDEDLVSTDFQGDSRSSIFDA KAGIALNDNFVKLVSWYDNEWGYSIRVVDLIRHIHATK 26 M.297 ........................................................................................... ........................................................................................... ....................................................VAAIKEESEGNLKGILGYVDEDLVSTDFQGDSRSSIFDA KAGIALNDNFVKLVSWYDNEWGYSIRVVDLIRHIHATK 26 M.367 ........................................................................................... ...................................................................ATQKTVDGPSSKDWRGGRAASFNI IPSSTGAAKAVGKVLPVLNGKLTGMAFRVPTVDVSVVDLTVRLEKAAIYEQIKEESEGNLKGILGYVDEDLVSTDFQGDSRSSIFDA KAGNALNDNFVKLV 26 M.84 .................IMEKYDIVHGQNHHHDVKVKDAKILLFGEKEVFGCRNPEEIPWGAAGADYVVESIGV 26 M.189 ........................................................................................... ........................................................................................... ...............................................EESEGNLKGILGYVDEDLVSTDFQGDSRSSIFDA KAGIALNDNFVKLVSWYDNEWGYSIRVVDLIRHIHATK 26 M.586 ......VNDPFITTDYMTYMFKYDTVHGQWKHHDVKVKDAKTLLFGEKEVAVFGCRNPEEIPWGAAGADYVVESTGVFTDKDKAAAHIKGG AKKVIISAPSKDAPMFVCGVNEKEYTSDITIVSNASCTTNCLAPLAKVINDRFGIVEGLMITVHAMTATQKTVDGPSSKDWRGGRAASFNI IPSSTGAAKAVGKVLPVLNGKLTGMAFRVPTVDVSVVDLTVHLEKAATYEQIKAAIREESEGNLKGILGYVDEDLVSTDFQGDSESSIFDA KAGIALNDNEVNLVSWYDNEWGY 26 M.496 DVELVAVNDPFITTDYMTYMFKYDTVHGQWKHHDVKVKDAKTLLFGEKEVAVFGCRNPEEIPWGAAGADYVVESTGVFTDKDKAAAHIKGG AKKVIISAPSKDAPMFVCGVNEKEYTSDITIVSNASCTTNCLAPLAKVINDRFGIVEGLMITVHAMTATQKTVDGPSSKDWRGGRAASFNI IPSSTGAAKAVGKVLPVLNGKLTGMAFRVPTVDVSVVDLT 26 M.255 DVELVAVNDPFITTDYMTYMFKYDTVHGQWKHHDVKVKDAKTLLFGEKEVAVFGCRNPEEIPWGAAGADYVVESTGVFTDKDKA 26 M.471 DVELVAVNDPFITTDYMTYMFKYDTVHGQWKHHDVKVKDAKTLLFGEKEVAVFGCRNPEEIPWGAAGADYVVESTGVFTDKDKAAAHIKGG AKKVIISAPSKDAPMFVCGVNEKEYTSDITIVSNASCTTNCLAPLAKVINDRFGIVEGLMITVHAMTATQKTVDGPSSKDWRGGRAASFNI IPSSTGAAKAVGKVLPVLNG 26 M.575 DVELVAVNDPFITTDYMTYMFKYDTVHGQWKHHDVKVKDAKTLLFGEKEVAVFGCRNPEEIPWGAAGADYVVESTGVFTDKDKAAAHIKGG AKKVIISAPSKDAPMFVCGVNEKEYTSDITIVSNASCTTNCLAPLAKVINDRFGIVEGLMITVHAMTATQKTVDGPSSKDWRGGRAASFNI IPSSTGAAKAVGKVLPVLNGKLTGMAFRVPTVDVSVVDLTVHLEKAATYEQIKAAIREESEGNLKGILGYVDEDLVSTDFQGDSESSIFDA KAGIALNDNEVNL 27 M.163 ........................................................................................... ........................................................................................... ..........................................................PGSDAKKVAPEVTAEYTVRILQRTVPPAVPAIV FLSGGQSEEEATVNLNAMYKLQTKKPWFLSFSFGRA 27 M.314 ........................................................................................... ........................................................................................... ........................................................VTPGSDAKKVAPEVTAEYTVRILQRTVPPAVPAIV FLSGGQSEEEATVNLNAMNKLQTKKPWFLSFSFGRALQQSTLKAWSGKEENVEKAQKAFLVRCKANSEATL 27 M.194 ........................................................................................... ........................................................................................... ....................................................KPNMVTPGSDAKKVAPEVTAEYTVRILQRTVPPAVPAIV FLSGGQSEEEATVNLNAMNKLQTKKPWFLSFSFGR 27 M.294 ........................................................................................... ........................................................................................... ...................................................LKPNMVTPGSDAKKVAPEVTAEYTVRILQRTVPPAVPAIV FLSGGQSEEEATVNLNAMNKLQTKKPWFLSFSFGRALQQSTLKAWSGKEENVEKAQKA 27 M.472 ........................................................................................... .........................................................................SQLSIDQNAQGLARYAII CQENGLVPIVEPEILVDGPHDIERCAYVIEVVLAACYKALNDQHVLLEGSLLKPNMVTPGSDAKKVAPEVTAEYTVRILQRTVPPAVPAIV FLSGGQSEEEATVNLNAMNKLQTKKPWFLSFSFGRALQQSTLKAWSGKEENVEKAQKAFLVRCKANSEATLGTYKGDATLGEGASESLHVK DY 27 M.369 ........................................................................................... ........................................................................................... ........................................................VTPGSDAKKVAPEVTAEYTVRILQRTVPPAVPAIV FLSGGQSEEEATVNLNAMNKLQTKKPWFLSFSFGRALQQSTLKAWSGKEENVEKAQKAFLVRCKANSEATLGTYKGDATLGEGASESLHVK DYKY 27 M.104 ........................................................................................... ..................................KETTTQGHDDLGKRCAKYYEAGARFAKWRAVLKIGPNEPSQLSIDQNAQGLARYAML GFRREP 27 M.206 ........................................................................................... .........................................................RFAKWRAVLKIGPNEPSQLSIDQNACGLARYAII CQENGLVPIVEPEILVDGPHDIERCAYVTEVVLAACYKALND 27 M.24 ........................................................................................... ........................................................................................... ................................................GSLLKPNMVTPGSDAKKVAPEVIAEYTVRILQRTVPPAVPAIV FLSGQS 27 M.469 PFANPPQTSTMSAYCGKYKDELIKNAAYIGTFGKGILAADESTGTIGNREASINVENVEDNRRALRELLFTTPGALGHISGVILFEEILVQ ESKAGKPFVDILKENNVLPGIKVDNGTVELAGTDKEITTQGHDDLGKRCAKYYEAGARFAFWNAVLKIGPNEPSQLSIGQNAQGLARYAII CQENGLVFIVEPEILVDGP 28 M.420 VIPPAPHLKRWNRVVDTNLESPNDIVPEGAPFTGSGYRIAPYSSILLKATS 28 M.444 VIPPAPHLKRWNRVVDTNLESPNDIVPEGAPFTGSGYRIAPYSSILLKATS 29 M.697 ...................................GGVAAGYAAREFAKQGVQPGELAIISKESVAPYERPALSKGYLFPQNAARLPGFHT CVGSGGEKLLPEWYTEKGIELILSTEIVKADLASKTLTSAAGATFTYETLLIATGSSTIKLTDFGVQGAEANNILYLRDINDADKLVAAMQ AKKDGKAVVVGGGYIGLELSAALKLNNFDVTMVYPEPWCMPRLFTAGIAHFYEGYYASKGINIVKGTVASGFDADANGDVAVVKLKDGRVL DANIVIVGVGGRPLTGLFKGQVDEEKGGLKTDTFFETSVAGVYAIGDVASFPMKLYNEPRRVEHVDHARKSAEQAVKAIKAKESGETVAEY DYLPYFYSRSFDIAWQFYGDNVGESVLFGDNDPAAAKAKFGIYWVKDGKVVGVFLEGGSADENQAIAKVARAQPPA 29 M.687 ...................................GGVAAGYAAREFAKQGVQPGELAIISKESVAPYERPALSKGYLFPQNAARLPGFHT CVGSGGEKLLPEWYTEKGIELILSTEIVKADLASKTLTSAAGATFTYETLLIATGSSTIKLTDFGVQGAEANNILYLRDINDADKLVAAMQ AKKDGKAVVVGGGYIGLELSAALKLNNFDVTMVYPEPWCMPRLFTAGIAHFYEGYYASKGINIVKGTVASGFDADANGDVAVVKLKDGRVL DANIVIVGVGGRPLTGLFKGQVDEEKGGLKTDTFFETSVAGVYAIGDVASFPMKLYNEPRRVEHVDHARKSAEQAVKAIKAKESGETVAEY DYLPYFYSRSFDIAWQFYGDNVGESVLFGDNDPAAAKAKFGIYWVKDGKVVGVFLEGGSADENQAIAKV 29 M.713 ......LPRSFIHPSTDRSLAEMASEKHFKYVILGGGVAAGYAAREFAKQGVQPGELAIISKESVAPYERPALSKGYLFPQNAARLPGFHT CVGSGGEKLLPEWYTEKGIELILSTEIVKADLASKTLTSAAGATFTYETLLIATGSSTIKLTDFGVQGAEANNILYLRDINDADKLVAAMQ AKKDGKAVVVGGGYIGLELSAALKLNNFDVTMVYPEPWCMPRLFTAGIAHFYEGYYASKGINIVKGTVASGFDADANGDVAVVKLKDGRVL DANIVIVGVGGRPLTGLFKGQVDEEKGGLKTDTFFETSVAGVYAIGDVASFPMKLYNEPRRVEHVDHARKSAEQAVKAIKAKESGETVAEY DYLPYFYSRSFDIAWQFYGDNVGESVLFGDNDPAAAKAKFGIYWVKDGKVVGVFLEGGSADENQAIAKVARAQPPASDLEALGKE 29 M.638 ...................................RRPRRGYAAREFAKQGVQPGELAIISKESVAPYERPALSKGYLFPQNAARLPGFHT CVGSGGEKLLPEWYTEKGIELILSTEIVKADLASKTLTSAAGATFTYETLLIATGSSTIKLTDFGVQGAEANNILYLRDINDADKLVAAMQ AKKDGKAVVVGGGYIGLELSAALKLNNFDVTMVYPEPWCMPRLFTAGIAHFYEGYYASKGINIVKGTVASGFDADANGDVAVVKLKDGRVL DANIVIVGVGGRPLTGLFKGQVDEEKGGLKTDTFFETSVAGVYAIGDVASFPMKLYNEPRRVEHVDHARKSAEQAVKAIKAKESGETVAEY DYLPYFYSRSFDIAWQFYGDNV 29 M.673 ........................................................LAIISKESVAPYERPALSKGYLFPQNAARLPGFHT CVGSGGEKLLPEWYTEKGIELILSTEIVKADLASKTLTSAAGATFTYETLLIATGSSTIKLTDFGVQGAEANNILYLRDINDADKLVAAMQ AKKDGKAVVVGGGYIGLELSAALKLNNFDVTMVYPEPWCMPRLFTAGIAHFYEGYYASKGINIVKGTVASGFDADANGDVAVVKLKDGRVL DANIVIVGVGGRPLTGLFKGQVDEEKGGLKTDTFFETSVAGVYAIGDVASFPMKLYNEPRRVEHVDHARKSAEQAVKAIKAKESGETVAEY DYLPYFYSRSFDIAWQFYGDNVGESVLFGDNDPAAAKAKFGIYWVKDGKVVGVFLEGGSADENQAIAKVAR 29 M.700 .....................................KQRASAAREFAKQGVQPGELAIISKESVAPYERPALSKGYLFPQNAARLPGFHT CVGSGGEKLLPEWYTEKGIELILSTEIVKADLASKTLTSAAGATFTYETLLIATGSSTIKLTDFGVQGAEANNILYLRDINDADKLVAAMQ AKKDGKAVVVGGGYIGLELSAALKLNNFDVTMVYPEPWCMPRLFTAGIAHFYEGYYASKGINIVKGTVASGFDADANGDVAVVKLKDGRVL DANIVIVGVGGRPLTGLFKGQVDEEKGGLKTDTFFETSVAGVYAIGDVASFPMKLYNEPRRVEHVDHARKSAEQAVKAIKAKESGETVAEY DYLPYFYSRSFDIAWQFYGDNVGESVLFGDNDPAAAKAKFGIYWVKDGKVVGVFLEGGSADENQAIAKVARAQPPASDLEALGKE 29 M.702 ...........IHPSIDRWLAEMASEKHFKYVILGGGVAAGYAAREFAKQGVQPGELAIISKESVAPYERPALSKGYLFPQNAARLPGFHT CVGSGGEKLLPEWYTEKGIELILSTEIVKADLASKTLTSAAGATFTYETLLIATGSSTIKLTDFGVQGAEANNILYLRDINDADKLVAAMQ AKKDGKAVVVGGGYIGLELSAALKLNNFDVTMVYPEPWCMPRLFTAGIAHFYEGYYASKGINIVKGTVASGFDADANGDVAVVKLKDGRVL DANIVIVGVGGRPLTGLFKGQVDEEKGGLKTDTFFETSVAGVYAIGDVASFPMKLYNEPRRVEHVDHARKSAEQAVKAIKAKESGETVAEY DYLPYFYSRSFDIAWQFYGDNVGESVLFGDNDPAAAKAKFGIYWVKDGKVVGVFLEGGSADEN 29 M.707 .EFRFFLAHSSIHPETDRELAEMASEKHFKRYVILGGGVAAGYAAREFAKQGVQPGELAIIEKESVAPYERPALEKGYLFPQMAARLFGHT CVCSGGEKLLPEWYTEKGIELILSTEIVKADLAEKTLTSAAGATFTYETLLIATGSSTIKLTDZGVQGAEANNILYLRDINDADKLVAAMQ AKNDGKAVVVGGGYIGLELSAAENLNNFDVIMVYPEPWCMPRLFIACIAHIYEGYYASKINIVKGIVASGFDDADANGDVAVVKLKDGRVL DANIVIVGVGGRPLTGLFKGQVDEEKGGLKTDTFFETSVAGVYAIGDVASFPMKLYNEPRRVEHVDHARKSAEQAVKAIRAKESGETVAEY DYLPYFYSESFDTAWQFYGDNVGESVLFGDNDPAAKAKFGTYWVKDGKVVGVFLZGGSADEN 29 M.710 SSFRFFLAHSSIHPSTDSLAEMASEKHFKYVILGGGVAAGYAAREFAKQGVQPGELAIISKESVAPYERPALSKGYLFPQNAARLPGFHT CVGSGGEKLLPEWYTEKGIELILSTEIVKADLASKTLTSAAGATFTYETLLIATGSSTTKLTDFGVQGAEANNILYLRDINDADKLVAAMQ AKKDGKAVVVGGGYIGLELSAALKLNNFDVTMVYPEPWCMPRLFTAGIAHFYEGYYASKGINIVKGTVASGFDADANGDVAVVKLKDGRVL DANIVIVGVGGRPLTGLFKGQVDEEKGGLKTDTFFETSVAGVYAIGDVASFPMKLYNEPRRVEHVDHARKSAEQAVKAIRAKESGETVAEY DYLPYFYSRSFDIAWQFYGDNVGESVLFGDNDPAAAKAKFGTYWVKDGKVVGVFLEGGSADENQAIAKV 29 M.683 ..........................................AARFFAKQGVQPGELAITSKESVAPYERPALSKGYLFPQNAARLFGFHT CVGSGGEKLLPEWYTEKGIELILSTEIVKADLASKTLTSAAGATFTYETLLIATGSSTTKLTDFGVQGAEANNILYLRDINDADKLVAAMQ AKKDGKAVVVGGGYIGLELSAALKLNNFDVTMVYPEPWCMPRLFTAGIAHFYEGYYASKGINIVKGTVASGFDADANGDVAVVKLKDGRVL DANIVIVGVGGRPLTGLFKGQVDEEKGGLKTDTFFETSVAGVYAIGDVASFPMKLYNEPRRVEHVDHARKSAEQAVKAIRAKESGETVAEY DYLPYFYSRSFDIAWQFYGDNVGESVLFGDNDPAAAKAKFGTYWVKDGKVVGVFLEGGSADENQAIAKV 30 M.670 ....MAGGGVEDVYGEDRATEEQFVTPWSFSVASGHSLLRDPRHNKGLAFSEAERDAHYLRGLLPPAIVSQEHQEKKIMHNLRQYTVPLQR YIAMMDLQERNERLFYKLLIDNVEELLPVVYTPVVGEACQKYGSIYRRPQGLYTSLKDKGKVLEVLKNWPERSIQVIVVTDGERILGLGDL GCQGMGIPVGKLSLYTALGGVRPSACLPITIDVGTNNQTLLDDEYYIGLKQRRATGEEYHELLQEFMNAVKQNYGEKVLVQFEDFANHNAF DLLAKYSKSHLVFNDDIQGTASVVLAGLLAALKVIGGGLADQTYLFLGAGEAFTFIAELIALEMSKHTDLPLDDCRKKIWLV 30 M.643 ..REMAGGGVEDVYGEDRATEEQFVTPWSFSVASGHSLLRDPRHNKGLAFSEAERDAHYLRGLLPPAIVSQEHQEKKTMHNLRQYTVPLQR YIAMMDLQERNERLFYKLLIDNVEELLPVVYTPVVGEACQKYGSIYRRPQGLYTSLKDKGKVLEVLKNWPERSIQVIVVTDGERILGLGDL GCQGMGIPVGKLSLYTALGGVRPSACLPITIDVGTNNQTLLDDEYYIGLKQRRATGEEYHELLQEFMNAVKQNYGEKVLVQFEDFANHNAF DLLAKYSKSHLVFNDDIQGTASVVLAGLLAALKVIGGGLADQTYLFLGAGEAFTFIAELIALEMSKHTDLPLDDCRKKIWLV 30 M.663 ....MAGGGVEDVYGEDRATEEQFVTPWSFSVASGHSLLRDPRHNKGLAFSEAERDAHYLRGLLPPAIVSQEHQEKKIMHNLRQYTVPLQR YIAMMDLQERNERLFYKLLIDNVEELLPVVYTPVVGEACQKYGSIYRRPQGLYTSLKDKGKVLEVLKNWPERSIQVIVVTDGERILGLGDL GCQGMGIPVGKLSLYTALGGVRPSACLPITIDVGTNNQTLLDDEYYIGLKQRRATGEEYHELLQEFMNAVKQNYGEKVLVQFEDFANHNAF DLLAKYSKSHLVFNDDIQGTASVVLAGLLAALKVIGGGLADQTYLFLGAGEAGTGIAELIALEMSKHTDLPLDDCRKKIWLV 30 M.664 ....MAGGGVEDVYGEDRATEEQFVTPWSFSVASGHSLLRDPRHNKGLAFSEAERDAHYLRGLLPPAIVSQEHQEKKIMHNLRQYTVPLQR YIAMMDLQERNERLFYKLLIDNVEELLPVVYTPVVGEACQKYGSIYRRPQGLYTSLKDKGKVLEVLKNWPERSIQVIVVTDGERILGLGDL GCQGMGIPVGKLSLYTALGGVRPSACLPITIDVGTNNQTLLDDEYYIGLKQRRATGEEYHELLQEFMNAVKQNYGEKVLVQFEDFANHNAF DLLAKYSKSHLVFNDDIQGTASVVLAGLLAALKVIGGGLADQTYLFLGAGEAGTGIAELIALEMSKHTDLPLDDCRKKIWLV 30 M.666 ....MAGGGVEDVYGEDRATEEQFVTPWSFSVASGHSLLRDPRHNKGLAFSEAERDAHYLRGLLPPAIVSQEHQEKKIMHNLRQYTVPLQR YIAMMDLQERNERLFYKLLIDNVEELLPVVYTPVVGEACQKYGSIYRRPQGLYTSLKDKGKVLEVLKNWPERSIQVIVVTDGERILGLGDL GCQGMGIPVGKLSLYTALGGVRPSACLPITIDVGTNNQTLLDDEYYIGLKQRRATGEEYHELLQEFMNAVKQNYGEKVLVQFEDFANHNAF DLLAKYSKSHLVFNDDIQGTASVVLAGLLAALKVIGGGLADQTYLFLGAGEAGTGIAELIALEMSKHTDLPLDDCRKKIWLV 30 M.748 ..REMAGGGVEDVYGEDRATEEQFVTPWSFSVASGHSLLRDPRHNKGLAFSEAERDAHYLRGLLPPAIVSQEHQEKKTMHNLRQYTVPLQR YIAMMDLQERNERLFYKLLIDNVEELLPVVYTPVVGEACQKYGSIYRRPQGLYTSLKDKGKVLEVLKNWPERSIQVIVVTDGERILGLGDL GCQGMGIPVGKLSLYTALGGVRPSACLPITIDVGTNNQTLLDDEYYIGLKQRRATGEEYHELLQEFMNAVKQNYGEKVLVQFEDFANHNAF DLLAKYSKSHLVFNDDIQGTASVVLAGLLAALKVIGGGLADQTYLFLGAGEAGTGIAELIALEMSKHTDLPLDDCRKKIWLVDSKGLLVES RKESLQHFKKPFAHEHEPLTTLLEAVQSLKPTVLIGTSGVGKTFTQEVVEAMASFNEKPVIFSLSNPTSHSECTAEEAYTWTKGTAVFASG SPFDPVEYEGKTYVPGQSNNAYVFPGFGLGVVIEGAINVADDMLLAASEALAEQVSQENFDKGLIFPFFTNIRKIEANIAAKVAAKAYDLG LASRLPRPDDLVKYAESCMYPPLYRSYR 30 M.731 ..REMAGGGVEDVYGEDRATEEQFVTPWSFSVASGHSLLRDPRHNKGLAFSEAERDAHYLRGLLPPAIVSQEHQEKKTMHNLRQYTVPLQR YIAMMDLQERNERLFYKLLIDNVEELLPVVYTPVVGEACQKYGSIYRRPQGLYTSLKDKGKVLEVLKNWPERSIQVIVVTDGERILGLGDL GCQGMGIPVGKLSLYTALGGVRPSACLPITIDVGTNNQTLLDDEYYIGLKQRRATGEEYHELLQEFMNAVKQNYGEKVLVQFEDFANHNAF DLLAKYSKSHLVFNDDIQGTASVVLAGLLAALKVIGGGLADQTYLFLGAGEAGTGIAELIALEMSKHTDLPLDDCRKKIWLVDSKGLLVES RKESLQHFKKPFAHEHEPLTTLLEAVQSLKPTVLIGTSGVGKTFTQEVVEAMASFNEKPVIFSLSNPTSHSECTAEEAYTWTKGTAVFASG SPFDPVEYEGKTYVPGQSNNAYVFPGFGLG 30 M.735 ..REMAGGGVEDVYGEDRATEEQFVTPWSFSVASGHSLLRDPRHNKGLAFSEAERDAHYLRGLLPPAIVSQEHQEKKTMHNLRQYTVPLQR YIAMMDLQERNERLFYKLLIDNVEELLPVVYTPVVGEACQKYGSIYRRPQGLYTSLKDKGKVLEVLKNWPERSIQVIVVTDGERILGLGDL GCQGMGIPVGKLSLYTALGGVRPSACLPITIDVGTNNQTLLDDEYYIGLKQRRATGEEYHELLQEFMNAVKQNYGEKVLVQFEDFANHNAF DLLAKYSKSHLVFNDDIQGTASVVLAGLLAALKVIGGGLADQTYLFLGAGEAGTGIAELIALEMSKHTDLPLDDCRKKIWLVDSKGLLVES RKESLQHFKKPFAHEHEPLTTLLEAVQSLKPTVLIGTSGVGKTFTQEVVEAMASFNEKPVIFSLSNPTSHSECTAEEAYTWTKGTAVFASG SPFDPVEYEGKTYVPGQSNNAYVFPGFGLGVVIEGAINVADDMLLAASEALAEQVSQ 30 M.750 ..REMAGGGVEDVYGEDRATEEQFVTPWSFSVASGHSLLRDPRHNKGLAFSEAERDAHYLRGLLPPAIVSQEHQEKKTMHNLRQYTVPLQR YIAMMDLQERNERLFYKLLIDNVEELLPVVYTPVVGEACQKYGSIYRRPQGLYTSLKDKGKVLEVLKNWPERSIQVIVVTDGERILGLGDL GCQGMGIPVGKLSLYTALGGVRPSACLPITIDVGTNNQTLLDDEYYIGLKQRRATGEEYHELLQEFMNAVKQNYGEKVLVQFEDFANHNAF DLLAKYSKSHLVFNDDIQGTASVVLAGLLAALKVIGGGLADQTYLFLGAGEAGTGIAELIALEMSKHTDLPLDDCRKKIWLVDSKGLLVES RKESLQHFKKPFAHEHEPLTTLLEAVQSLKPTVLIGTSGVGKTFTQEVVEAMASFNEKPVIFSLSNPTSHSECTAEEAYTWTKGTAVFASG SPFDPVEYEGKTYVPGQSNNAYVFPGFGLGVVISGAIRVHDDMLLAASEALAEQVSQENFDKGLIFPFFTNIRKISANIAAKVAAKAYDLG LASRLPRPDDLVKYAESCMYPPLYRSYR 30 M.752 ...EMAGGGVEDVYGEDRATEEQFVTPWSFSVASGHSLLRDPRHNKGLAFSEAERDAHYLRGLLPPAIVSQEHQEKKTMHNLRQYTVPLQR YIAMMDLQERNERLFYKLLIDNVEELLPVVYTPVVGEACQKYGSIYRRPQGLYTSLKDKGKVLEVLKNWPERSIQVIVVTDGERILGLGDL GCQGMGIPVGKLSLYTALGGVRPSACLPITIDVGTNNQTLLDDEYYIGLKQRRATGEEYHELLQEFMNAVKQNYGEKVLVQFEDFANHNAF DLLAKYSKSHLVFNDDIQGTASVVLAGLLAALKVIGGGLADQTYLFLGAGEAGTGIAELIALEMSKHTDLPLDDCRKKIWLVDSKGLLVES RKESLQHFKKPFAHEHEPLTTLLEAVQSLKPTVLIGTSGVGKTFTQEVVEAMASFNEKPVIFSLSNPTSHSECTAEEAYTWTKGTAVFASG SPFDPVEYEGKTYVPGQSNNAYVFPGFGLGVVISGAIRVHDDMLLAASEALAEQVSQENFDKGLIFPFFTNIRKISANIAAKVAAKAYDLG LASRLPRPDDLVKYAESCMYPPLYRSYR 30 M.756 ...EMAGGGVEDVYGEDRATEEQFVTPWSFSVASGHSLLRDPRHNKGLAFSEAERDAHYLRGLLPPAIVSQEHQEKKTMHNLRQYTVPLQR YIAMMDLQERNERLFYKLLIDNVEELLPVVYTPVVGEACQKYGSIYRRPQGLYTSLKDKGKVLEVLKNWPERSIQVIVVTDGERILGLGDL GCQGMGIPVGKLSLYTALGGVRPSACLPITIDVGTNNQTLLDDEYYIGLKQRRATGEEYHELLQEFMNAVKQNYGEKVLVQFEDFANHNAF DLLAKYSKSHLVFNDDIQGTASVVLAGLLAALKVIGGGLADQTYLFLGAGEAGTGIAELIALEMSKHTDLPLDDCRKKIWLVDSKGLLVES RKESLQHFKKPFAHEHEPLTTLLEAVQSLKPTVLIGTSGVGKTFTQEVVEAMASFNEKPVIFSLSNPTSHSECTAEEAYTWTKGTAVFASG SPFDPVEYEGKTYVPGQSNNAYVFPGFGLGVVISGAIRVHDDMLLAASEALAEQVSQENFDKGLIFPFFTNIRKISANIAAKVAAKAYDLG LASRLPRPDDLVKYAESCMYTPLYRSYR 30 M.754 ...EMAGGGVEDVYGEDRATEEQFVTPWSFSVASGHSLLRDPRHNKGLAFSEAERDAHYLRGLLPPAIVSQEHQEKKTMHNLRQYTVPLQR YIAMMDLQERNERLFYKLLIDNVEELLPVVYTPVVGEACQKYGSIYRRPQGLYTSLKDKGKVLEVLKNWPERSIQVIVVTDGERILGLGDL GCQGMGIPVGKLSLYTALGGVRPSACLPITIDVGTNNQTLLDDEYYIGLKQRRATGEEYHELLQEFMNAVKQNYGEKVLVQFEDFANHNAF DLLAKYSKSHLVFNDDIQGTASVVLAGLLAALKVIGGGLADQTYLFLGAGEAGTGIAELIALEMSKHTDLPLDDCRKKIWLVDSKGLLVES RKESLQHFKKPFAHEHEPLTTLLEAVQSLKPTVLIGTSGVGKTFTQEVVEAMASFNEKPVIFSLSNPTSHSECTAEEAYTWTKGTAVFASG SPFDPVEYEGKTYVPGQSNNAYVFPGFGLGVVISGAIRVHDDMLLAASEALAEQVSQENFDKGLIFPFFTNIRKISANIAAKVAAKAYDLG LASRLPRPDDLVKYAESCMYTPLYRSYR 30 M.608 ....MAGGGVEDVYGEDRATEEQFVTPWSFSVASGHSLLRDPRHNKGLAFSEAERDAHYLRGLLPPAIVSQEHQEKKTMHNLRQYTVPLQR YIAMMDLQERNERLFYKLLIDNVEELLPVVYTPVVGEACQKYGSIYRRPQGLYTSLKDKGKVLEVLKNWPERSIQVIVVTDGERILGLGDL GCQGMGIPVGKLSLYTALGGVRPSACLPITIDVGTNNQTLLDDEYYIGLKQRRATGEEYHELLQEFMNAVKQNYGEKVLVQFEDFANHNAF DLLAKYSKSHLVFNDDIQGTASVVLAGLLA 30 M.740 .......GGVEDVYGEDRATEEQFVTPWSFSVASGHSLLRDPRHNKGLAFSEAERDAHYLRGLLPPAIVSQEHQEKKTMHNLRQYTVPLQR YIAMMDLQERNERLFYKLLIDNVEELLPVVYTPVVGEACQKYGSIYRRPQGLYTSLKDKGKVLEVLKNWPERSIQVIVVTDGERILGLGDL GCQGMGIPVGKLSLYTALGGVRPSACLPITIDVGTNNQTLLDDEYYIGLKQRRATGEEYHELLQEFMNAVKQNYGEKVLVQFEDFANHNAF DLLAKYSKSHLVFNDDIQGTASVVLAGLLAALKVIGGGLADQTYLFLGAGEAGTGIAELIALEMSKHTDLPLDDCRKKIWLVDSKGLLVES RKESLQHFKKPFAHEHEPLTTLLEAVQSLKPTVLIGTSGVGKTFTQEVVEAMASFNEKPVIFSLSNPTSHSECTAEEAYTWTKGTAVFASG SPFDPVEYEGKTYVPGQSNNAYVFPGFGLGVVISGAIRVHDDMLLAASEALAEQVSQENFDKGLIFPFFTNIRKISANIAA 31 M.39 ICASGQIIRKGFYLTKNVEHKGQVDLVTETDKACEDLIFNHLRKLYPDHKFIGE 32 M.303 ................................................IDFISTITRARFEEMKMDLFRLCMEPWERCLELAKMDKSTVH DVVLVGGSTRIPKWQQLLQDFFNGRELCRSTWPDEAVAYGAAVQAAILSGEGNFKVQDL 32 M.389 VQEFKRKNKKDISGNPRALRRLRTACERAKRTLSSTAQTTIEIDSLFEGIDFYSTITRARFEELNMDLFRKCMEPVEKCLRDAKMDKSTVH DVVLVGGSTRIPKVQQLLQDFFNGKELCKSINPDEAVAYGAAVQAAILSGEGNEKVQDL 32 M.390 VQEFNRKAKKDMTGNPRALRRLNTACERAKRTLSSTAQTTIEIDEIFECIDFYSTITRARFEELNMDLFRRCMEPVENCLRDARMDRSTVH DVVLVGGSTRIPKVQQLLQQFFNGKELCKSINPDEAVAYGAAVQAAILSGEGNEKVQDL 32 M.284 ................................................IDFYSTITRARFEEMNMDLFRKCMEPVEKCLRDAKMDKSTVH DVVLVGGSTRIPKVQQLLQDFFNGKELCKSINPDEAVAYGAAVQAAILSGE 32 M.201 .......................................................RARFEEMMMCFRECMEPVEKCLRDAKMDKSTVH DVVLVGGSTRIPKVQQLLQDFFNGKELCKSINPDEAVAYGA 32 M.28 .........................................................................VEKCLRDAKMDKSTVH DVVLVGGSTRIPKVQQLLQDFFNGKELCKSINPDE 32 M.364 ........................................................................................... ........................................................................ETAGGVMTTLIPRNTTIPIK KEQVFSTYSDNQPGVLIQVYEGERARTRDNNLLGKFELSGIPPAPRGVPQITVCFDIDANGILNVSAEDKTTGQKNKITITNDKGRLSKED IEKMVQEAERYKAEDEE 32 M.344 ........................................................................................... ...................................................................................RNTTIPTK KEQVFSTYSDNQPGVLIQVYEGERARIRDNNLLGKFELSGIPPAPRGVPQITVCFDIDANGILNVSAEDKTTGQKNKITITNDKGRLSKED IEKMVQEAERYKAEDEE 32 M.74 ..................................................................................AKMDKSTVH DVVLVGGSTRIPKVQQLLQDFFNGKELCKSINPDEAVAYGAAVQAAILSG 32 M.180 ........................................................................................... ...........................................AAILRGEGNEKVQDLLLLDVTPLSLGLETAGGVMTTLIPRNTTIPTK KEQVFSTYSDNQPGVLIQVYEGER 32 M.317 ........................................................................................... ..........................CNSTNPDEAVAYGAAVQAAILSGEGNFKVQQLLLLDVIFLSLGLETAGGVMTVLIPRNTTIPTK KEQVFSTYSDNQPGVLIQVYEGERARTADNNLLGKFELSGIP 32 M.298 ........................................................................................... ..................................RPWRTAPPSRPPSSAARATRRCRTCFLLDVIPLSLGLETAGGVMTTLIPRNTTIPTK KEQVFSTYSDNQPGVLIQVYEGERARTRDNNLLGKFELSGI 32 M.192 ........................................................................................... ..........................................................................................K KEQVFSTYSDNQPGVLIQVYEGERTRTRDNNLLGKFELSGIPAAPAGVPQITVCFDIGAKGILNVSAEDKITG 32 M.77 ........................................................................................... ...................................................................................RNTTIPTK KEQVFSTYSDNQPGVLIQVYEGERARTRDNNLLGKFELSGIPPAPRGVPQI 32 M.92 ...............................................................................LFRECMEPVLKCLRDAKMDKSTVH DVVLVGGSTRIPKVQQLLQDFFNGKELCKSIMPDEAV 32 M.144 ..............................................................EELNMDLFRKCMEPVEKCLRDAKMDKSTVH DVVLVGGSTRIPKVQQLLQDFFNGKELCKSINPDEAV 32 M.9 ........................................................................................... ..........................................................................................K KEQVFSTYSDNQPGVLIQVYEGERARTKIMNLLGKFELSGIP 33 M.296 .............................................ELIKATDSWMEASEMLYPDYDSMIPDYDTVITNVRRSLAVAKKNHL AWNCERCRKGESKKKIDAISEGNDLGKIIAVLSAFVDPPVTK 33 M.387 ....................................................................YDIVITNVRRSLAVAKKNHL AWNCERCRKGESKKIVDAISEGNDLEKITAILSAFVDAATK 33 M.172 ....................................................................YDIVITNVRRSLAVAKKNHL AWNCERCRKGESKKIVDAISEGNDLEKIVAILSAFVDAATK 33 M.72 ....................................................................YDIVITNVRRSLAVAKKNHL AWNCERCRKGESKKTVDAILSAFVDAATH 33 M.38 ................................................................................RSLAVAKKNHL AWNCERCRKGESKKTVDAISEGNDLEKIVAILSAFVDAATK 33 M.239 ..............................................................PDYDSMIPDYDTVITMNRRELAVAKRNHL AWNCERCRKGESKKTVDAISEGNDLGKITAVLSAFVDPPVTK 33 M.289 .......................................................KGYNISLASMIPDYDIVITNVRRSLAVAKKNHL AWNCERCRKGESKKTVDAISEGNDLEKIVAILSAFVDAATK 33 M.240 .............................................................YDSMTPDYDTVISNVRRSLAVAKKNHL AWNCERCRKGESKKTVDAISEGNDLEKIVAILSAFVDAATK 33 M.214 ........................................................GYNISLASMIPDYDTVITNVRRSLAVAKKNHL AWNCERCRKGESKKTVDAISEGNDLEKIVAILSAFVDAATK 33 M.365 QEMAYWSLKAAIEIGNGAADAASSLYLFGENLPRGADICYADCHTELLIKATIGWMEASEMLYPDYDSMIPDYDTVINVRRSLAVAKKNHL AWNCERCRKGESKKTVDAISEGNDLEKIVAILSAFVDA 34 M.614 .........................EEEVEVAPPQAMEVRVKILFTALCHTDVYFWEAKGQTPVFPRIFGHEAGGIVESVGEGVTDVAPGD HVLPVFTGECKECRHCKSAESNMCDLLRINTDRGVMISDGKSRFSIDGKPIFHFVGTSTFSEYTVMHVGCVAKINPEAPLDKVCVLSCGIS TGLGASINVAKPPKGSTVAIFGLGAVGLAAAEGARIAGASRIIGIDLNANRFEEARKFGCTEFVNPKDHTKPVQEVLAEMTDGGVDRSVEC TGNINAMIQAFECVHDGWGVAVLVGVPHKDAEFKTHPMNFLNERTLKGTFFGNFKPRIDLPNVVEMYMKKELEVEKFIIHSV 34 M.598 ....NWFCSWVIAAAVAMEAGNPLSIEEVEVAPPQAMEVRVKILFTALCHIDVYFNFAKGQIPVFPRIFGHEAGGTVESVGEGVTDVAPGD HVLPVFIGECKECPRCKSAESNMCKLLRINIDRGVMISDGNESRFSIDGNPPIEPFVGISTFSEYTVMHVGCVAKINPEAPLDKVCVLSCGIS TGLGASINVAKPPKGSTVAIFGLGAVGLAAAFGARTAGAERITGTDTNANRFEEARKEGCTEFVNPKDHTRPWQEVLAPMTDGGVDESVEC TGNTNAMTQAFECVRDGNGVAVLVGVFRKDAEFETRPMVFLNER 34 M.632 ...........CKAAVAWEAGKPLSIEEVEVAPRQAMEVRVKILFTALCHTDVYFWEAKGQTPVFPRIFGHEAGGIVESVGEGVTDVAPGD HVLPVFTGECKECRHCKSAESNMCDLLRINTDRGVMISDGKSRFSIDGKPIFHFVGTSTFSEYTVMHVGCVAKINPEAPLDKVCVLSCGIS TGLGASINVAKPPKGSTVAIFGLGAVGLAAAEGARIAGASRITGIDLNANRFEEARKFGCTEFVNPKDHTKPVQEVLAEMIDGGVDRSVEC TGNINAMIQAFECVHDGWGVAVLVGVPHKDAEFKIHPMNFLNERTLKGTFFGNFKPRTDLPNVVEMYMKKELEVEKFITHSV 34 M.633 .......................................................................EAGGIVESVGEGVIDVAPGD HVLPVFIGECKECRRCKSAESNMCDLLAINTDRGVMISDGKSRFSIDGKPIFHFPPVGISTFEEYTVMAVGCVAKINPEAPLLKVCVLSCGIS TGLGASINVAKPPKGSTVAIFGLGAVGLAAAEGARIAGASRTIGIDLNANRFEEARKFGCTEFVNPKDRTEPVQEVLPEMTDGGVDRSVEC TGNINAMICAFECVRQGWGVPRNDAEFKTHPMNELNERILKGTFFGNFKPRTDLPNVVEMYMERELEVEKFITNSVTISEINKAF DLMANGEGINCIINMER 34 M.616 .................................................................RIFGHEAGGIVESVGEGVTDVAPGD HVLPVFTGECKECRHCKSAESNMCDLLRINTDRGVMISDGKSRFSIDGKPIFHFVGTSTFSEYTVMHVGCVAKINPEAPLDKVCVLSCGIS TGLGASINVAKPPKGSTVAIFGLGAVGLAAAEGARIAGASRIIGIDLNANRFEEARKFGCIEFVNPKDHTKPVQEVLAEMIDGGVDRSVEC TGNINAMIQAFECVHDGWGVAVLVGVPHKDAEFKTRPMNFLNERTLKGTFFGNFEPRIDLPNVVEMYMKKELEVEKFITHSVTFSEINKAF DLMAKGEGIRCIIIIIRMER 34 M.690 ..SFEWICACVRAAAVAWEAGKPLSTEEVFVAPPQAMENRVEILFTALCHTDVIFWEAEGQTPVFPRIFGHEAGGTVESVGEGVTDVAPGG HVLPVFTGECKFCRHCKSAESNMCDLLRINIDRGVMISDGKSRFSIDGKPIFHFVGISTESEYTVMHVGCVAKINPEAPLDEVCVLSCGIS TGLGASINVAKPPKGSTVAIFGLGAVGLAAAEGARIAGASRIIGIDLNASRFEEAREFGGTEFVNPKDNTPVCEVLAEMIDGGVLSSVEC TGNINAMIQAFECVRDGWGVAVLVGVPRKDAEFETRPMNFLSERTLEGTFFGNFEPRIDLPNVVEMYMEKELEVEKPITHSVIFSEINKAF DLMAKGEQTRCIIRMEH 34 M.607 LMSFSWICACVRAAAVAWEAGKPLSTEEVEVAPPQAMEVRCKILFTALCHTDVYFWEAKGQTPVFPRIFGHEAGGIVESVGEGVTDVAPGD HVLPVFTGECKECRHCKSAESNMCDLLRINTDRGVMISDGKSRFSIDGKPIFHFVGTSTFSEYTVMHVGCVAKINPEAPLDKVCVLSCGIS TGLGASINVAKPPKGSTVAIFGLGAVGLAAAEGARTAGASRIIGIDLNANRFEEARKFGCTEFVNPKDHTKPVQEVLAEMTDGGVDRSVEC TGNINAMIQAFECVHDGWGVAVLVGVPHKDAEFKTHPMNFLNER 34 M.672 ..............VWAEAFKFLSTEEVEVAPPQMEVECKILFTALCHTDVYFWEAKGQTPVFPRIFGHEAGGIVESVGEGVTDVAPGD HVLPVFTGECKECRHCKSAESNMCDLLRINTDRGVMISDGKSRFSIDGKPIFHFVGTSTFSEYTVMHVGCVAKINPEAPLDKVCVLSCGIS TGLGASINVAKPPKGSTVAIFGLGAVGLAAAEGARTAGASRIIGIDLNANRFEEARKFGCTEFVNPKDHTKPVQEVLAEMTDGGVDRSVEC TGNINAMIQAFECVHDGWGVAVLVGVPHKDAEFKTHPMNFLNERTLKGTFFGNFKPKTDLPNVVEMTMKEELEVEKFITRSVTFSEINKAF DLMARGEGIKCIIRMER 34 M.545 ........................................................................................... ....VFTGECKECRHCKSAESNMCDLLRINTDRGVMISDGKSRFSIDGKPIFHFVGTSTFSEYTVMHVGCVAKINPEAPLDKVCVLSCGIS TGLGASINVAKPPKGSTVAIFGLGAVGLAAAEGARTAGASRIIGIDLNANRFEEARKFGCTEFVNPKDHTKPVQEVLAEMTDGGVDRSVEC TGNINAMIQAFECVHDGWGVAVLVGVPHKDAEFKTHPMNFLNERTLKGTFFGNFKPKTDLPNVVEMTMKEELEVEKFITRSVT 34 M.671 ...............................................................HEAGGIVESVGEGVTDVAPGD HVLPVFTGECKECRHCKSAESNMCDLLRINTDRGVMISDGKSRFSIDGKPIFHFVGTSTFSEYTVMHVGCVAKINPEAPLDKVCVLSCGIS TGLGASINVAKPPKGSTVAIFGLGAVGLAAAEGARTAGASRIIGIDLNANRFEEARKFGCTEFVNPKDHTKPVQEVLAEMTDGGVDRSVEC TGNINAMIQAFECVHDGWGVAVLVGVPHKDAEFKTHPMNFLNERTLKGTFFGNFKPKTDLPNVVEMTMKEELEVEKFITRSVTFSEINKAF DLMARGEGIKCIIRMER 35 M.272 ALRWNLQMGHSVLPKSVSEERIKQNLDVVYDWSIPDDLLAKFSETKQTRLMFNFIVNKDSVYTHEELWDGEI 36 M.301 QDFKKVNEIYAKYFPSPAPARSTYQVAALFLDARIEIECIAAL 36 M.202 QDFKKVNEIYAKYFPSPAPARSTYQVAALFLDARIEIECIAAL 37 M.492 MAEDEEAASTLPPGLSSIL 38 M.647 .....................................................................VRVAVDVATMPALSE TARSRGKDAGVSEKISGAVEEMGFLGAGADADGFPWSNAMLQWQRIGFHFQPEKNWMNDPNGPVFYRGWYHLFYQYNPEGAVWGNIAWGHA VSRDLIHWRHLPLAMVPDQWYDINGVWTGSATVFPDGSLNMLYIGSTNASVQVQCLAVPEDPNDSLLRNWTKHPANPVLLPPPGIGLKDFR DPTTAWFDDSDSTWRIVIGSKDDNGHAGTAMVYKTKDFVSYELIPGLLHRVDGIGMWECIDFYPVGGNSGEELYVIKESSDDDRHDYYALG SYDAAANKWTPQDPEADLGIGLRYDWGKFYASKTFYDPAKKRRVLWGWIAETDSERADVTKGWASLM 38 M.457 ........................................................................................... ........................................................................................... ........................................................................................... ..........................AGTAMVYKTKDFVSYELIPGLLHRVDGIGMWECIDFYPVGGNSGEELYVIKESSDDDRHDYYALG SYDAAANKWTPQDPEADLGIGLRYDWGKFYASKTFYDPAKKRRVLWGWIAETDSERADVTKGWASLMSIPRIVDLDEKTRINLIQWPVEEI ETLRINSTDLGGVTIDHGSVFPLPLRHATQLDIEA 38 M.686 ........................................................................................... ..GSRGKDAGVSEKISGAVEEMGFLGAGADADGFPWSNAMLQWQRIGFHFQPEKNWMNDPNGPVFYRGWYHLFYQYNPEGAVWGNIAWGHA VSRDLIHWRHLPLAMVPDQWYDINGVWTGSATVFPDGSLNMLYIGSTNASVQVQCLAVPEDPNDSLLRNWTKHPANPVLLPPPGIGLKDFR DPTTAWFDDSDSTWRIVIGSKDDNGHAGTAMVYKTKDFVSYELIPGLLHRVDGIGMWECIDFYPVGGNSGEELYVIKESSDDDRHDYYALG SYDAAANKWTPQDPEADLGIGLRYDWGKFYASKTFYDPAKKRRVLWGWIAETDSERADVTKGWASLMSIPRIVDLDEKTRINLIQWPVEEI ETLRINSTDLGGVTIDHGSVFPLPLRHATQLDIEAA 38 M.495 ........................................................................................... ........................................................................................... .......................................................................................KDFR DPTTAWFDDSDSTWRIVIGSKDDNGHAGTAMVYKTKDFVSYELIPGLLHRVDGIGMWECIDFYPVGGNSGEELYVIKESSDDDRHDYYALG SYDAAANKWTPQDPEADLGIGLRYDWGKFYASKTFYDPAKKRRVLWGWIAETDSERADVTKGWASLMSIPRIVDLDEKTRINLIQWPVEEI ETLRINSTDLGGVTIDHGSVFPLPLRHATQLDIE 38 M.486 ........................................................................................... ........................................................................................... .......................................................................................KDFR DPTTAWFDDSDSTWRIVIGSKDDNGHAGTAMVYKTKDFVSYELIPGLLHRVDGIGMWECIDFYPVGGNSGEELYVIKESSDDDRHDYYALG SYDAAANKWTPQDPEADLGIGLRYDWGKFYASKTFYDPAKKRRVLWGWIAETDSERADVTKGWASLMSIPRIVDLDEKTRINLIQWPVEEI ETLRINSTDLGGVTIDHGSVFPLPLRH 38 M.729 ........................................................................................... ........................................................................................... .....................................................................................GLKDFR DPTTAWFDDSDSTWRIVIGSKDDNGHAGTAMVYKTKDFVSYELIPGLLHRVDGIGMWECIDFYPVGGNSGEELYVIKESSDDDRHDYYALG SYDAAANKWTPQDPEADLGIGLRYDWGKFYASKTFYDPAKKRRVLWGWIAETDSERADVTKGWASLMSIPRIVDLDEKTRINLIQWPVEEI ETLRINSTDLGGVTIDHGSVFPLPLRHATQLDIEAAFRLDHAAVAALNEADVSYNCSISGGSANRGALGPFGLLVLADGKEEQTAVYFYVS RGLDGALRTHFCHDESRSSRAKDVVKRVVGYTVPVLDGEAFSVRVLVDHSIVESFAMGGRSTATSRVYPTEAIYAAAGVYLFNNAIGSTVI VEKLVVHEMDSSYNQIFMAEDL 38 M.760 ........................................................................................... ...........................................QRTGFHFQPEKNWMNDPNGPVFYRGWYHLFYQYNPEGAVWGNIAWGHA VSRDLIHWRHLPLAMVPDQWYDINGVWIGSATVFPDGSLNMLYTGSTNASVQVQCLAVPEDPNDSLLRNWTKHPANPVLLPPPGIGLKDFR DPTTAWFDDSDSTWRIVIGSKDDNGHAGTAMVYKTKDFVSYELIPGLLHRVDGIGMWECIDFYPVGGNSGEELYVIKESSDDDRHDYYALG SYDAAANKWTPQDPEADLGIGLRYDWGKFYASKTFYDPAKKRRVLWGWIAETDSERADVTKGWASLMSIPRIVDLDEKTRINLIQWPVEEI ETLRINSTDLGGVTIDHGSVFPLPLRHATQLDIEAAFRLDHAAVAALNEADVSYNCSISGGSANRGALGPFGLLVLADGKEEQTAVYFYVS RGLDGALRTHFCHDESRSSRAKDVVKRVVGYTVPVLDGEAFSVRVLVDHSIVESFAMGGRSTATSRVYPTEAIYAAAGVYLFNNAIGSTVI VEKLVVHEMDSSYNQIFMAEDL 38 M.668 ......................................GGVKWRAGAAVLAASAVYVLVYASSLAGERYVEVAVPVATMPALSE TARSRGKDAGVSEKISGAVEEMGFLGAGADADGFPWSNAMLQWQRIGFHFQPEKNWMNDPNGPVFYRGWYHLFYQYNPEGAVWGNIAWGHA VSRDLIHWRHLPLAMVPDQWYDINGVWTGSATVFPDGSLNMLYIGSTNASVQVQCLAVPEDPNDSLLRNWTKHPANPVLLPPPGIGLKDFR DPTTAWFDDSDSTWRIVIGSKDDNGHAGTAMVYKTKDFVSYELIPGLLHRVDGIGMWECIDFYPVGGNSGEELYVIKESSDDDRHDYYALG SYDAAANKWTPQDPEADLGIGLRYDWGKFYASKTFYDPAKKRRVLWGWIAETDSER 38 M.559 ........................................................................................... ................GAVEEMGFLGAGADADGFPWSNAMLQWQRIGFHFQPEKNWMNDPNGPVFYRGWYHLFYQYNPEGAVWGNIAWGHA VSRDLIHWRHLPLAMVPDQWYDINGVWTGSATVFPDGSLNMLYIGSTNASVQVQCLAVPEDPNDSLLRNWTKHPANPVLLPPPGIGLKDFR DPTTAWFDDSDSTWRIVIGSKDDNGHAGTAMVYKTKDFVSYELIPGLLHRVDGIGMWECIDFYPVGGNSGEELYVIKESSDDDRHDYYALG SYDAAANKWTPQDPEADLGIGLRYDWGKFYASKTFYDPAKKRRVLWGWIAETDSERAD 38 M.417 ........................................................................................... ........................................................................................... .....................................................................................GLKDER DPTTAWFDDSDSTWRIVIGSKDDNGHAGTAMVYKTKDFVSYELIPGLLHRVDGIGMWECIDFYPVGGNSGEELYVIKESSDDDRHDYYALG SYDAAANKWTPQDPEADLGIGLRYDWGKFYASKTFYDPAKKRRVLWGWIAETDSERADVTKGWASLM 38 M.635 ..............................................................................MPALSE TARSRGKDAGVSEKISGAVEEMGFLGAGADADGFPWSNAMLQWQRIGFHFQPEKNWMNDPNGPVFYRGWYHLFYQYNPEGAVWGNIAWGHA VSRDLIHWRHLPLAMVPDQWYDINGVWTGSATVFPDGSLNMLYIGSTNASVQVQCLAVPEDPNDSLLRNWTKHPANPVLLPPPGIGLKDFR DPTTAWFDDSDSTWRIVIGSKDDNGHAGTAMVYKTKDFVSYELIPGLLHRVDGIGMWECIDFYPVGGNSGEELYVIKESSDDDRHDYYALG SYDAAANKWTPQDPEADLGIGLRYDWGKFYASKTFYDPAKKRRVLWGWIAETDSERADVTKGWASLM 38 M.584 ........................................................................................... .......................................MLQWQRIGFHFQPEKNWMNDPNGPVFYRGWYHLFYQYNPEGAVWGNIAWGHA VSRDLIHWRHLPLAMVPDQWYDINGVWTGSATVFPDGSLNMLYIGSTNASVQVQCLAVPEDPNDSLLRNWTKHPANPVLLPPPGIGLKDFR DPTTAWFDDSDSTWRIVIGSKDDNGHAGTAMVYKTKDFVSYELIPGLLHRVDGIGMWECIDFYPVGGNSGEELYVIKESSDDDRHDYYALG SYDAAANKWTPQDPEADLGIGLRYDWGKFYASKTFYDPAKKRRVLWGWIAETDSERADVTKGWASLM 38 M.592 ........................................................................................... .......................................MLQWQRIGFHFQPEKNWMNDPNGPVFYRGWYHLFYQYNPEGAVWGNIAWGHA VSRDLIHWRHLPLAMVPDQWYDINGVWTGSATVFPDGSLNMLYTGSTNASVQVQCLAVPEDPNDSLLRNWTKHPANPVLLPPPGIGLKDFR DPTTAWFDDSDQTWRTVIGSKDDNGHAGIAMVYKTKDFVSYELIPGLLHRVDGTGMWECIDEYPVGGNSGEELYVIKESSDDDRHDYYALG SYDAAANKWTPQDPEADLGIGLRYWGKFYASKIFYDPAKKRRVLWGWIAETDSERADVTKGWASLM 38 M.709 SESTKIFLESSTMESRAIAGTPPLPYAYEPLPRSSDDAALDDREEGGVEWRACAAVLAASAVVVLVVASGLAGERADEVAVDVAIMFALSE IARSRGKDAGVSERTSGAVEEMGFLGAGADADGFPWSNAMLQNQRIGFRFQPEKNNMNDPNGPVFYRGWYHLFYQYNPEGAVWGNIAWGHA VSRDLIHWRHLPLAMVPDQWYDINGVWTGSATVFPDGSLNMLYTGSTNASVQVQCLAVPEDPNDSLLRNWTKHPANPVLLPPPGIGLKDFR DPTTAWFDDSDQTWRTVIGSKDDNGHAGIAMVYKTKDFVSYELIPGLLHRVDGTGMWECIDEYPVGGDSGEELYVIKESSDDDRRDYYALG SYDAAANKWTPQDPEADLGIGLRYWGKFYASKIFYDPAKKRRVLWGWIAETDSERADVTKGWASLM 38 M.489 ........................................................................................... ........................................................................................... ...............................TVFPDGSLNMLYTGSTNASVQVQCLAVPEDPNDSLLRNWTKHPANPVLLPPPGIGLKDFR DPTTAWFDDSDQTWRTVIGSKDDNGHAGIAMVYKTKDFVSYELIPGLLHRVDGTGMWECIDFYPVGGDSGEELYVIKESSDDDRHDYYALG SYDAAANKWTPQDPEADLGIGLRYWGKFYASKTFYDPAKKRRVLWGWIAETDSERADVTKGWASLM 39 M.392 ........................................................................................... .........................FVGDKVAYALAQGLKVIACVGEILEQEEAGETMTVVAEQTKAIADKITDNTNVVIAYEPVWAIGTGK VAIPAQAQEVHANLRDWLKTNVSPEVAETIRIIYGGSVTGASANELAAQPDVDGFLVGGASLKPEE 39 M.347 ........................................................................................... ..............................YALAQGLKVIACVGETLEQREAGSTMTVVAEQTKAIADKITDWTNVVIAYEPVWAIGTGK VAIPAQAQEVHANLRDWLKTNVSPEVAETIRIIYGGSVTGASANELAAQPDVDGFL 39 M.458 ........................................................................................... ..........................GDKVAYALAQGLKVIACVGETLEQREAGSTMTVVAEQTKAIADKITDWTNVVIAYEPVWAIGTGK VAIPAQAQEVHANLRDWLKTNVSPEVAEIIRIIYGGSVTGAEANELAAQPDVDGFLVGGASLKPEFIDIINAATVKSA 39 M.464 PLAVAVAMGRKFFVGGNWKCNGTIDQVDKIVKILNDGKIASTDIVEVVVSPPYVFLPTVKDKLRPEIQVAAQNCWVKKGGAFTGEVSAEML ANLGIPWVILGHSERRALLGESSEFVGDKVAYALAQGLKVIACVGETLEQREAGSTMTVVAEQTKAIADKITDWTNVVIAYEPVWAIGTGK VATPAQAQEVHANL 39 M.415 ...................................DGKIASTDIVEVVVSPPYVFLPTVKDKLRPEIQVAAQNCWVKKGGAFTGEVSAEML ANLGIPWVILGHSERRALLGESSEFVGDKVAYALAQGLKVIACVGETLEQREAGSTMTVVAEQTKAIADKITDWTNVVIAYEPVWAIGTGK VATPAQAQEVHANL 39 M.520 .LAVAVAMGRKFFVGGNWCNGTIDQVDKIVKILNDGKIASTDIVEVVVSPPYVFLPTVKDKLRPEIQVAAQNCWVKKGGAFTGEVSAEML ANLGIPWVILGHSERRALLGESSEFVGDKVAYALAQGLKVIACVGETLEQREAGSTMTVVAEQTKAIADKITDWTNVVIAYEPVWAIGTGK VATPAQAQEVHANLRDWLKTNVSPEVAETTRIIYGGSVTGASANELAAQPDVDGFLVGG 39 M.410 .........................................................................................ML ANLGVPWDILGHSERRALLGESSEFVGDKVAYALAQGLKVIACVGETLEQREAGSTMTVVAEQTKAIADKITDWTNVVIAYEPVWAIGTGK VATPAQAQEVHANLRDWLKTNVSPEVAETTRIIYGGSVTGASANELAAQPDVDGFLVGGASLKPEF 39 M.467 .................LSAEWNHRPVDKIVKILNDGKIASTDIVEVVVSPPYVFLPTVKDKLRPEIQVAAQNCWVKKGGAFTGEVSAEML ANLGVPWDILGHSERRALLGESSEFVGDKVAYALAQGLKVIACVGETLEQREAGSTMTVVAEQTKAIADKITDWTNVVIAYEPVWAIGTGK VAIPAQAQEVHAN 39 M.494 ..............................................LQKHKHFLPTVKDKLRPEIQVAAQNCWVKKGGAFTGEVSAEML ANLGVPWDILGHSERRALLGESSEFVGDKVAYALAQGLKVIACVGETLEQREAGSTMTVVAEQTKAIADKITDWTNVVIAYEPVWAIGTGK VATPAQAQEVHANLRDWLKTNVSPEVAETTRIIYGGSVTGASANELAAQPDVDGFLVGGASLKPEFIDIINAAIVKSA 39 M.374 ........................................................................................... ....................................GLKVIACVGETLEQREAGSTMTVVAEQTKAIADKITDWTNVVIAYEPVWAIGTGK VATPAQAQEVHANLRDWLKTNVSPEVAETTRIIYGGSVTGASANELAAQPDVDGFLVGGASLKPEFIDIINAAIVKSA 40 M.118 GVWQHDRVEIIANDQGNRTIPSYVAFIDSERLIGDAAKNQVAMNPINIVFGHLETCIPYTTHS 41 M.346 SSTRGWCSRRRAGRGTSS 42 M.318 LPGPAEKPMIVVKYKGEEKQFAAEEIEEMVLIEMREIAEAFLGNSIKNAVVIVPAYFNDSQHQAIKDAGVIAGLNVLRIINEPTAAAIAYG LDKKSISIGEKNVLIF 43 M.519 ...LDFVWYEPLTYNTEDEFAAHRAREFILGWFMHPITYGHYPETMQRLVADRLFNFTDEQTRLLQGSADIVGVNHYTTYYAKNHENLTHM SYANDWQVQLVYERNGIPIGKQGYSKWLYVVPWGFYKAVMHVKDYRNPLMIIGENGIDQSGSDILPHALYDKFRIDYFDQYLHEHKRAID DGARVIGYFAWSLLDNFEWRMGFTSKFGIVYVDRKTFTRYPKDSTRWFRKVIKNEE 43 M.600 ...LDFVWYEPLTYNTEDEFAAHRAREFILGWFMHPITYGHYPETMQRLVADRLFNFTDEQTRLLQGSADIVGVNHYTTYYAKNHENLTHM SYANDWQVQLVYERNGIPIGKQGYSKWLYVVPWGFYKAVMHVKDKYRNPLMIIGENGIDQSGSDILPHALYDKFRIDYFDQYLHELKRAID DGARVIGYFAWSLLDNFEWRMGFTSKFGIVYVDRKTFTRYPKDSTRWFRKVIKNEE 43 M.254 ........................................................................................... ...................................................................HALYDKFRIDYFDQYLHELKRATD DGARVTGYFAWSLLDNFEWRMGFTSKFGIVYVDRKTFTRYPKDSTRWFRKVIKNEE 43 M.438 ......................................................................IVGVNHYTTYYAKNREMLTHM SYANDWQVQLVYERNGIPIGKQGYSKWLYVVPWGFYKAVMHVKDKYRNPLMIIGENGIDQSGSDILPHALYDKFRIDYFDQYLHELKRAID DGARVIGYFAWSLLDNFEWRMGFTSKFGIVYVDRKTFTRYPKDSTRWFRKVIKNEE 43 M.479 ................................FMHPITYGHYPETMQRLVADRLFNFTDEQTRLLQGSADIVGVNHYTTYYAKNHENLTHM SYANDWQVQLVYERNGIPIGKQGYSKWLYVVPWGFYKAVMHVKDKYRNPLMIIGENGIDQSGSDILPHALYDKFRIDYFDQYLHELKRAID DGARVIGYFAWSLLDNFEWRMGFTSKFGIVYVDRKTFTRYPKDSTRWFRKVIKNEE 43 M.523 GILLDFVWYEPLTYNTEDEFAAHRAREFILGWFMHPITYGHYPETMQRLVADRLFNFTDEQTRLLQGSADIVGVNHYTTYYAKNHENLTHM SYANDWQVQLVYERNGIPIGKQGYSKWLYVVFWGFYKAVMHVKDKYRNPLMIIGENGIDQSGSDILPHALYDKFRIDYFDQYLHELKRAID DGARVIGYFAWSLLDNFEWRMGFTSKFGIVYVDRKTFTRYPKDSTRNFRKVIKNEE 43 M.380 ........................................................................................... ..........VYERNGIPIGKQGYSKWLYVVFWGFYKAVMHVKDKYRNPLMIIGENGIDQSGSDILPHALYDKFRIDYFDQYLHELKRAID DGARVIGYFAWSLLDNFEWRMGFTSKFGIVYVDRKTFTRYPKDSTRNFRKVIKNEE 43 M.480 ........................................................................................... ..........VYERNGIPIGKQGYSKWLYVVFWGFYKAVMHVKDKYRNPLMIIGENGIDQSGSDILPHALYDKFRIDYFDQYLHELKRAID DGARVIGYFAWSLLDNFEWRMGFTSKFGIVYVDRKTFTRYPKDSTRNFRKVIKNEE 43 M.371 ........................................................................................... ..........VYERNGIPIGKQGYSKWLYVVPWGFYKAVMHVKDKYRNPLMIIGENGIDQSGSDILPHALYDKFRIDYFDQYLHELKRATD DGARVIGYFAWSLLDNFEWRMGFTSKFGIVYVDRKTFTRYPKDSTRWFRKVI 43 M.482 ........................................................................................... ..........VYERNGIPIGKQGYSKWLYVVFWGFYKAVMHVKDKYRNPLMIIGENGIDQSGSDILPHALYDKFRIDYFDQYLHELKRAID DGARVIGYFAWSLLDNFEWRMGFTSKFGIVYVDRKTFTRYPKDSTRNFRKVIKNEE 43 M.261 ........................................................................................... ..................................................................PHALYDKFRIDYFDQYLHELKRAID DGARVIGYFAWSLLDNFEWRMGFTSKFGIVYVDRKTFTRYPKDSTRWFRKVIKNEE 43 M.108 ........................................................................................... ...................................................................PHALYDKFRIDYFDQYLHELKRAID DGARVIGYFAWSLLDNFEWRMGFTSKFGIVYVDRKTFI 43 M.260 ........................................................................................... ...................................................................HALYDKFRIDYFDQYLHELKRAID DGARVIGYFAWSLLDNFEWRMGFISKFGIVYVDRKTFTRYPKDSTRWFRKVIKNEE 43 M.556 ..................................................DRLFNFTDEQTRLLQGSADIVGVNHYTTYYAKNHENLTHM SYANDWQVQLVYERNGIPIGKQGYSKWLYVVPWGFYKAVMHVKDKYRNPLMIIGENGIDQSGSDTLPHALYDKFRIDYFDQYLHELKRATD DGARVIGYFAWSLLDNFEWRMGFTSKFGIVYVDRKTFTRYPKDSTRWFRKVIKNEE 43 M.461 ..................................................DRLFNFTDEQTRLLQGSADIVGVNHYTTYYAKNHENLTHM SYANDWQVQLVYERNGIPIGKQGYSKWLYVVPWGFYKAVMHVKDKYRNPLMIIGENGIDQSGSDTLPHALYDKFRIDYFDQYLHELKRATD DGARVTGYFAWSLLDNFEWRMGFTSKFGIVYVDRKTFTRYPKDSTRWFRKVIKNEE 44 M.400 .....GYDDTPKEVTDPDAKKPEDWDDEEDGEWTAPTIPNPEYKGPWKQKKIKNPNYQGKWKAPMIANPDFKDDPYIYAFDSLKYIGIELW QVKSGTLFDNILITDDAALAKTFAEETWAKHKDAEKAAFDEAEKKKEEEDASKAGEDDDDLDDEDADDE 44 M.474 .....GYDDTPKEVTDPDAKKPEDWDDEEDGEWTAPTIPNPEYKGPWKQKKIKNPNYQGKWKAPMIANPDFKDDPYIYAFDSLKYIGIELW QVKSGTLFDNILITDDAALAKTFAEETWAKHKDAEKAAFDEAEKKKEEEDASKAGEDDDDLDDEDADDEDKDDKAESDAEDHSDDEKHDEL 44 M.490 .....GYDDTPKEVTDPDAKKPEDWDDEEDGEWTAPTIPNPEYKGPWKQKKIKNPNYQGKWKAPMIANPDFKDDPYIYAFDSLKYIGIELW QVKSGTLFDNILITDDAALAKTFAEETWAKHKDAEKAAFDEAEKKKEEEDASKAGEDDDDLDDEDADDEDKDDKAESDAEDHSDDEKHDEL 44 M.491 .....GYDDTPKEVTDPDAKKPEDWDDEEDGEWTAPTIPNPEYKGPWKQKKIKNPNYQGKWKAPMIANPDFKDDPYIYAFDSLKYIGIELW QVKSGTLFDNILITDDAALAKTFAEETWAKHKDAEKAAFDEAEKKKEEEDASKAGEDDDDLDDEDADDEDKDDKAESDAEDHSDDEKHDEL 44 M.401 ..................................................KIKNPNYQGKWKAPMIANPDFKDDPYIYAFDSLKYIGIELW QVKSGTLFDNILITDDAALAKTFAEETWAKHKDAEKAAFDEAEKKKEEEDASKAGEDDDDLDDEDADDEDKDDKAESDAEDHSDDEKHDEL 44 M.470 ...........KEVTDPDAKKPEDWDDEEDGEWTAPTIPNPEYKGPWKQKKIKNPNYQGKWKAPMIANPDFKDDPYIYAFDSLKYIGIELW QVKSGTLFDNILITDDAALAKTFAEETWAKHKDAEKAAFDEAEKKKEEEDASKAGEDDDDLDDEDADDEDKDDKAESDAEDHSDDEKHDEL 44 M.409 ................................................................MIANPDFKDDPYIYAFDSLKYIGIELW QVKSGTLFDNILITDDAALAKTFAEETWAKHKDAEKAAFDEAEKKKEEEDASKAGEDDDDLDDEDADDE 44 M.435 ................................................................MIANPDFKDDPYIYAFDSLKYIGIELW QVKSGTLFDNILITDDAALAKTFAEETWAKHKDAEKAAFDEAEKKKEEEDASKAGEDDDDLDDEDADDE 44 M.553 ................................................................MIANPDFKDDPYIYAFDSLKYIGIELW QVKSGTLFDNILITDDAALAKTFAEETWAKHKDAEKAAFDEAEKKKEEEDASKAGEDDDDLDDEDADDEDKDDKAESDAEDHSDDEKHDEL 44 M.537 ................................................................MIANPDFKDDPYIYAFDSLKYIGIELW QVKSGTLFDNILITDDAALAKTFAEETWAKHKDAEKAAFDEAEKKKEEEDASKAGEDDDDLDDEDADDEDKDDKAESDAEDHSDDEKHDEL 45 M.402 MARMKRPPRCCQDLVVLPL 45 M.481 .........MNNMSSR 45 M.483 .........MNNMSSR 45 M.554 MARMKRPPRCCQDLVVLPL 45 M.538 MARMKRPPRCCQDLVVLPL 46 M.234 QARGLLRRARGGPHHRRQRGAHRRVPLRPLRHRVRVHGQEGRRAKLRSAGEVEIQFRRVKCKYPEGTKVTFHVEKGSNPN 46 M.237 QARGLLRRARGGPHHRRQRGAHRRVPLRPLRHRVRVHGQEGRRAKLRSAGEVEIQFRRVKCKYPEGTKVTFHHVVGVGPLLH 46 M.264 QARGLLRRARGGPHHRRQRGAHRRVPLRPLRHRVRVHGQEGRRAKLRSAGEVEIQFRRVKCKYPEGTKVTFHVEKGSNPNTWGCW 47 M.563 .TDAAAPAPAAAAASKWNLLTFDTEEDVAVSLAKYTAELSGKFAAERGAFTVVLSGGTLIDTLRKLAEPPYLETVQWSKWHVFWVDERVVP KDHVDSNYKLAVDGLLSKVPIPTDQVYATNDTLSAEGAAADYETVLKQLVKSGVLAMSTATGFPRFDLMLLGMGPDGHLASLFPGHPLLNE NQKWVTHTMDSPKPPPQRITFTFPVIKSSAYVAMVVTGPGEASAVKKVLSDDKTLPLLPTEMAILQDGEFTWFTDKPAVSMLQNK 47 M.566 ATDAAAPAPAAAAASKWNLLTFDTEEDVAVSLAKYTAELSGKFAAERGAFTVVLSGGTLIDTLRKLAEPPYLETVQWSKWHVFWVDERVVP KDHVDSNYKLAVDGLLSKVPIPTDQVYATNDTLSAEGAAADYETVLKQLVKSGVLAMSTATGFPRFDLMLLGMGPDGHLASLFPGHPLLNE NQKWVTHTMDSPKPPPQRITFTFPVIKSSAYVAMVVTGPGEASAVKKVLSDDKTLPLLPTEMAILQDGEFTWFTDKPAVSMLQNK 47 M.532 .......................................................GGTLIDTLRKLAEPPYLETVQWSKWHVFWVDERVVP KDHVDSNYKLAVDGLLSKVPIPTDQVYATNDTLSAEGAAADYETVLKQLVKSGVLAMSTATGFPRFDLMLLGMGPDGHLASLFPGHPLLNE NQKWVTHTMDSPKPPPQRITFTFPVIKSSAYVAMVVTGPGEASAVKKVLSDDKTLPLLPTEMAILQDGEFTWFTDKPAVSMLQNK 47 M.557 ...........AAASKWNLLTFDTEEDVAVSLAKYTAELSGKFAAERGAFTVVLSGGTLIDTLRKLAEPPYLETVQWSKWHVFWVDERVVP KDHVDSNYKLAVDGLLSKVPIPTDQVYATNDTLSAEGAAADYETVLKQLVKSGVLAMSTATGFPRFDLMLLGMGPDGHLASLFPGHPLLNE NQKWVTHTMDSPKPPPQRITFTFPVIKSSAYVAMVVTGPGEASAVKKVLSDDKTLPLLPTEMAILQDGEFTWFTDKPAVSMLQNK 47 M.573 ...........AAASKWNLLTFDTEEDVAVSLAKYTAELSGKFAAERGAFTVVLSGGTLIDTLRKLAEPPYLETVQWSKWHVFWVDERVVP KDHVDSNYKLAVDGLLSKVPIPTDQVYATNDTLSAEGAAADYETVLKQLVKSGVLAMSTATGFPRFDLMLLGMGPDGHLASLFPGHPLLNE NQKWVTHTMDSPKPPPQRITFTFPVIKSSAYVAMVVTGPGEASAVKKVLSDDKTLPLLPTEMAILQDGEFTWFTDKPAVSMLQNK 47 M.549 ...........AAASKWNLLTFDTEEDVAVSLAKYTAELSGKFAAERGAFTVVLSGGTLIDTLRKLAEPPYLETVQWSKWHVFWVDERVVP KDHVDSNYKLAVDGLLSKVPIPTDQVYATNDTLSAEGAAADYETVLKQLVKSGVLAMSTATGFPRFDLMLLGMGPDGHLASLFPGHPLLNE NQKWVTHTMDSPKPPPQRITFTFPVIKSSAYVAMVVTGPGEASAVKKVLSDDKTLPLLPTEMAILQDGEFTWFTDKPAVSMLQNK 47 M.550 ...........AAASKWNLLTFDTEEDVAVSLAKYTAELSGKFAAERGAFTVVLSGGTLIDTLRKLAEPPYLETVQWSKWHVFWVDERVVP KDHVDSNYKLAVDGLLSKVPIPTDQVYATNDTLSAEGAAADYETVLKQLVKSGVLAMSTATGFPRFDLMLLGMGPDGHLASLFPGHPLLNE NQKWVTHTMDSPKPPPQRITFTFPVIKSSAYVAMVVTGPGEASAVKKVLSDDKTLPLLPTEMAILQDGEFTWFTDKPAVSMLQNK 47 M.551 ...........AAASKWNLLTFDTEEDVAVSLAKYTAELSGKFAAERGAFTVVLSGGTLIDTLRKLAEPPYLETVQWSKWHVFWVDERVVP KDHVDSNYKLAVDGLLSKVPIPTDQVYATNDTLSAEGAAADYETVLKQLVKSGVLAMSTATGFPRFDLMLLGMGPDGHLASLFPGHPLLNE NQKWVTHTMDSPKPPPQRITFTFPVIKSSAYVAMVVTGPGEASAVKKVLSDDKTLPLLPTEMAILQDGEFTWFTDKPAVSMLQNK 47 M.558 .....TDAAAPAAASKWNLLTFDTEEDVAVSLAKYTAELSGKFAAERGAFTVVLSGGTLIDTLRKLAEPPYLETVQWSKWHVFWVDERVVP KDHVDSNYKLAVDGLLSKVPIPTDQVYATNDTLSAEGAAADYETVLKQLVKSGVLAMSTATGFPRFDLMLLGMGPDGHLASLFPGHPLLNE NQKWVTHTMDSPKPPPQRITFTFPVIKSSAYVAMVVTGPGEASAVKKVLSDDKTLPLLPTEMAILQDGEFTWFTDKPAVSMLQNK 47 M.463 ....ATDAAAPAAASKWNLLTFDTEGDVAVSLAKYTAELSGKFAAERGAFTVVLSGGTLIDTLRKLAEPPYLETVQWSKWHVFWVDERVVP KDHVDSNYKLAVDGLLSKVPIPTDQVYATNDTLSAEGAAADYETVLKQLVKSGVLAMSTATGFPRFDLMLLGMGPDGHLASLFPGHPLLNE NQKWVTHTMDSPKPPP 48 M.684 ................................................................RAHIAFYQVCFEQKGCDRDDILAAVDE AIEDGVDVLSLSLGGNPGADFSEDPVSLGGYTAALNGVFVSTAAGNIGPNPATLSNGAPWLLTVGASTSDRRFAATVKLGSGLEVDGESLT EPKDYGKEMVPLVRDMGGGQCTSESVLKAQNITGKIIICEAGGGVSTAKAKMVLRAGAFGMIVVAPAVFGPVIVPRPHVLPTVQVPYAVGQ KIKAYLEAESSPTANFIFKGTLFDTPRSPMMAPFSSRGPNVKSRGILKPDIIGPGVNVLAGVPGVVDMALQPKFVMPKFDIKSGTSMSCPH LAGIAALLKNAHPTWSPASIKSALMTTTETTDNTKKPIADVDGTQATYFATGAGHVNPKKAMDPGLVYNLTAAEYTPYLCGLKYTDQQVNS IIHP 48 M.739 ................................................................RAHIAFYQVCFEQKGCDRDDILAAVDE AIEDGVDVLSLSLGGNPGADFSEDPVSLGGYTAALNGVFVSTAAGNIGPNPATLSNGAPWLLTVGASTSDRRFAATVKLGSGLEVDGESLT EPKDYGKEMVPLVRDMGGGQCTSESVLKAQNITGKIIICEAGGGVSTAKAKMVLRAGAFGMIVVAPAVFGPVIVPRPHVLPTVQVPYAVGQ KIKAYLEAESSPTANFIFKGTLFDTPRSPMMAPFSSRGPNVKSRGILKPDIIGPGVNVLAGVPGVVDMALQPKFVMPKFDIKSGTSMSCPH LAGIAALLKNAHPTWSPASIKSALMTTTETTDNTKKPIADVDGTQATYFATGAGHVNPKKAMDPGLVYNLTAAEYTPYLCGLKYTDQQVNS IIHPEPPVTCDKLRKLDQKDLNYPSITVVVDKADSVVNASRAVTNVGVASSTYDVEVEVPKSVTVEVHPPKLTFKALEEVLNYTVTVKTAA VPLGATEGQLKWVSSKHIVRSPILILPGTGEEDTTEAAAPSAQP 48 M.637 ........................................................................................... ........................................................................................... ..........................................................FGMIVVAPAVFGPVIVPRPHVLPTVQVPYAVGQ KIKAYLEAESSPTANFIFKGTLFDTPRSPMMAPFSSRGPNVKSRGILKPDIIGPGVNVLAGVPGVVDMALQPKFVMPKFDIKSGTSMSCPH LAGIAALLKNAHPTWSPASIKSALMTTTETTDNTKKPIADVDGTQATYFATGAGHVNPKKAMDPGLVYNLTAAEYTPYLCGLKYTDQQVNS IIHPEPPVTCDKLRKLDQKDLNYPSITVVVDKADSVVNASRAVTNVGVASSTYDVEVEVPKSVTVEVHPPKLTFKALEEVLNYTVTVKTAA VPDGAIEGQLKWVEEKAIVRSPILILPGTGEEDTTEAAAPSAQP 48 M.517 .NKLIGARSFFESAKWKWKGLDDPVLPINEGQHGTHISSTAAGAFVRGANISGNAVGTAAGMAPRAHIAFYQVCFEQKGCDRDDILAAVDE AIEDGVDVLSLSLGGNPGADFSEDPVSLGGYTAALNGVFVSTAAGNIGPNPATLSNGAPWLLTVGASTSDRRFAATVKLGSGLEVDGESLT EPKDYGKEMVPLVRDMGGGQCTSESVLKAQNITGKIIICEAGGGVSTAKAKMVLRA 48 M.712 ........................................................................................... ..............................................................TVGASTSDRRFAATVKLGSGLEVDGESLT EPKDYGKEMVPLVRDMGGGQCTSESVLKAQNITGKTTTCEAGGGVSTAKAKMVLRAGAFGMIVVAPAVFGPVIVPRPHVLPTVQVPYAVGQ KIKAYLEAESSPTANFIFKGTLFDTPRSPTMAPFSSRGPNVKSRGILKPDIIGPGVNVLAGVPGVVDIVLQPKEVMPKFDIKSGTSMSCPH LAGIAALLKNAHPTWSPASIKSALMTTTETTDNTKKPIADVDGTQATYFAIGAGHVNPKKAMPDGLVYNLIAAEYIPYLGGLKYTDQQVNS ITHPEPPVTCDKLRKLDKDLNYPSITVVVKADSVNASAVTNVGVSSTASRAVINYVEVEVPKSVTVEVPPKLTFKALEEVLNYTVTVKTAA VPLGATEGQLKWVSSNHIVREPILILPGIGEEDTTEAAAPSAQP 48 M.732 ..................................................................HIAFYQVCFEQKGCDRDDILAAVDE AIEDGVDVLSLSLGGNPGADFSEDPVSLGGYTAALNGVFVSTAAGNIGPNPATLSNGAPWLLTVGASTSDRRFAATVKLGSGLEVDGESLT EPKDYGKEMVPLVRDMGGGQCTSESVLKAQNITGKTTTCEAGGGVSTAKAKMVLRAGAFGMIVVAPAVFGPVIVPRPHVLPTVQVPYAVGQ KIKAYLEAESSPTANFIFKGTLFDTPRSPTMAPFSSRGPNVKSRGILKPDIIGPGVNVLAGVPGVVDIVLQPKEVMPKFDIKSGTSMSCPH LAGIAALLKNAHPTWSPASIKSALMTTTETTDNTKKPIADVDGTQATYFAIGAGHVNPKKAMPDGLVYNLIAAEYIPYLGGLKYTDQQVNS ITHPEPPVTCDKLRKLDKDLNYPSITVVVKADSVNASAVTNVGVSSTASRAVINYVEVEVPKSVTVEVPPKLTFKALEEVLNYTVTVKTAA VPDGATE 48 M.711 ........................................................................................... ................................................................GASTSDRRFAATVKLGSGLEVDGESLT EPKDYGKEMVPLVRDMGGGQCTSESVLKAQNITGKTTTCEAGGGVSTAKAKMVLRAGAFGMIVVAPAVFGPVIVPRPHVLPTVQVPYAVGQ KIKAYLEAESSPTANFIFKGTLFDTPRSPTMAPFSSRGPNVKSRGILKPDIIGPGVNVLAGVPGVVDIVLQPKEVMPKFDIKSGTSMSCPH LAGIAALLKNAHPTWSPASIKSALMTTTETTDNTKKPIADVDGTQATYFAIGAGHVNPKKAMPDGLVYNLIAAEYIPYLGGLKYTDQQVNS ITHPEPPVTCDKLRKLDKDLNYPSITVVVKADSVNASAVTNVGVSSTASRAVINYVEVEVPKSVTVEVPPKLTFKALEEVLNYTVTVKTAA VPLGATEGQLKWVSSNHIVREPILILPGIGEEDTTEAAAPSAQP 48 M.730 ..............................................................................GCDRDDILAAVDE AIEDGVDVLSLSLGGNPGADFSEDPVSLGGYTAALNGVFVSTAAGNIGPNPATLSNGAPWLLTVGASTSDRRFAATVKLGSGLEVDGESLT EPKDYGKEMVPLVRDMGGGQCTSESVLKAQNITGKTTTCEAGGGVSTAKAKMVLRAGAFGMIVVAPAVFGPVIVPRPHVLPTVQVPYAVGQ KIKAYLEAESSPTANFIFKGTLFDTPRSPTMAPFSSRGPNVKSRGILKPDIIGPGVNVLAGVPGVVDIVLQPKEVMPKFDIKSGTSMSCPH LAGIAALLKNAHPTWSPASIKSALMTTTETTDNTKKPIADVDGTQATYFAIGAGHVNPKKAMPDGLVYNLIAAEYIPYLGGLKYTDQQVNS ITHPEPPVTCDKLRKLDKDLNYPSITVVVKADSVNASAVTNVGVSSTASRAVINYVEVEVPKSVTVEVPPKLTFKALEEVLNYTVTVKTAA VPLGATEGQLKWV 48 M.736 ..............................................................................GCDRDDILAAVDE AIEDGVDVLSLSLGGNPGADFSEDPVSLGGYTAALNGVFVSTAAGNIGPNPATLSNGAPWLLTVGASTSDRRFAATVKLGSGLEVDGESLT EPKDYGKEMVPLVRDMGGGQCTSESVLKAQNITGKTTTCEAGGGVSTAKAKMVLRAGAFGMIVVAPAVFGPVIVPRPHVLPTVQVPYAVGQ KIKAYLEAESSPTANFIFKGTLFDTPRSPTMAPFSSRGPNVKSRGILKPDIIGPGVNVLAGVPGVVDIVLQPKEVMPKFDIKSGTSMSCPH LAGIAALLKNAHPTWSPASIKSALMTTTETTDNTKKPIADVDGTQATYFAIGAGHVNPKKAMPDGLVYNLIAAEYIPYLGGLKYTDQQVNS ITHPEPPVTCDKLRKLDKDLNYPSITVVVKADSVNASAVTNVGVSSTASRAVINYVEVEVPKSVTVEVPPKLTFKALEEVLNYTVTVKTAA VPLGATEGQLKWVSSNHIVREPILILPGIGEEDTTEAAAPSAQP 48 M.737 ..............................................................................GCDRDDILAAVDE AIEDGVDVLSLSLGGNPGADFSEDPVSLGGYTAALNGVFVSTAAGNIGPNPATLSNGAPWLLTVGASTSDRRFAATVKLGSGLEVDGESLT EPKDYGKEMVPLVRDMGGGQCTSESVLKAQNITGKTTTCEAGGGVSTAKAKMVLRAGAFGMIVVAPAVFGPVIVPRPHVLPTVQVPYAVGQ KIKAYLEAESSPTANFIFKGTLFDTPRSPTMAPFSSRGPNVKSRGILKPDIIGPGVNVLAGVPGVVDIVLQPKEVMPKFDIKSGTSMSCPH LAGIAALLKNAHPTWSPASIKSALMTTTETTDNTKKPIADVDGTQATYFAIGAGHVNPKKAMPDGLVYNLIAAEYIPYLGGLKYTDQQVNS ITHPEPPVTCDKLRKLDKDLNYPSITVVVKADSVNASAVTNVGVSSTASRAVINYVEVEVPKSVTVEVPPKLTFKALEEVLNYTVTVKTAA VPLGATEGQLKWVSSNHIVREPILILPGIGEEDTTEAAAPSAQP 48 M.247 NNKLIGARSFFESARWKWRGLDDPVLPINEGQHGTATESTAAGAFVAGANISGNAVGIAAGMAPRANTAFYQVCFEQRGCD 49 M.13 ....................PRSWSAVMLTFDNAGMWNVRSNVWERHYLGEQLYISVISPARSL 49 M.57 ...........VSRHSIQVYPRSWSAVMLTFDNAGMWNVRSNVWERHYLGEQLYISVISPARSLRDEY 49 M.61 ELRKTYNLLDAVSRRSIQVYPRSWSAVMLTFDNAGMWNVRSNVWERHYLGEMTLM 49 M.47 ELRKTYNLLDAVSRRSIQVYPRSWSAVMLTFDNAGMWNVRSNVWERHYLAGEMTLM 49 M.43 ELRKTYNLLDAVSRRSIQVYPRSWSAVMLTFDNAGMWNVRSNVWERHYLGEQLYI 49 M.32 ....TYNLLDAVSRRSIQVYPRSWSAVMLTFDNAGMWNVRSNVWERHYLGEMTLM 50 M.518 RGGFSGLFPDSSEYAFRTAVSSSMPGVVLFCDLKFSSDGVGFCIGNLRLDNITLIDKDFASRGSTYQVNGQDVQGWFSLDFKSKELHEIPM IGNILSRSQIFDGIPNLMSLDNVVKIVDPNEIWVNVEYDSFYREHGLSSEDYILGLPKEFPVIWVSSPEVALLKSLAGKLRNSTKLIFRFL REDLVEPTTKMTYGELLKDLKSIKAFASGILVPKQFIWPMNKDMYLEPSTSLVKDAR 51 M.267 .....KIETELTKICEGILNLLETHLVPSSIAPESRVFYLNMKGDYHPYLAEFNSGAERKEAAESTMNSYNAAQDIALADLAPTHPIRLGL AL 51 M.73 ...........................................GDYHPYLAEFNSGAERKEAAESTMNSYNAAQDIALADLAPTHPIRLGL ALKIS 51 M.270 KDYHGKIETELTKICEGILNLLETHLVPSSIAPESRVFYLNMKGDYHPYLAEFNSGAERKEAAESTMNSYNAAQDIALADLAPTHPIHLG 51 M.150 ............................SAGAAESKVFYLKMKGDYHRYLAAEFKSGAERKEAAESTMNSYKAAQDIALADLAPTHPIRLGL ALNF 52 M.366 ........................................................................................... .............VECADIVALGTRDAVRISGGPAYEVPIGRRDELVSNREEADNNLPGPDIPIPKLTSEFLSEGFTPYEMVVLLAGGRSI GKVRCIFTEPDATPHDPGYQASISKLCDGPNRDTGFVNMDEHNPNVGEVA 52 M.679 LLGLLAPLASAQLSREFYKASCPDAEKIVAAVIEKKLKEDPGPAAGLLRLLFHDCFANGCDASILIDPLSNQSAEKEAGPNISVRGFEVID DIKKELEAKCPKTVSCADIVALGTRDAVRISGGPAYEVPTGRRDSLVSNREEADNNLPGPDIPIPKLTSEFLSRGFTPEEMVVLLAGGHSI GKVRCIFTEPDATPMDPGYQASISKLCDGPNRDTGFVNMDEHNPNVIDSSYFANVLAKKMPLTVDRLLGLDSKITPIIKNMLNKPNDFMPI FAKAMEKLSVLKVITGKDGEIRKSHCSEFNNPMPSTGGVIRISSANPEDLEGLSSGGTQVAGIVSQGTKDPWHVKTLKAAGAAHPKKVTGR HPKLRGAHPQ 52 M.680 LLGLLAPLASAQLSREFYKASCPDAEKIVAAVIEKKLKEDPGPAAGLLRLLFHDCFANGCDASILIDPLSNQSAEKEAGPNISVRGFEVID DIKKELEAKCPKTVSCADIVALGTRDAVRISGGPAYEVPTGRRDSLVSNREEADNNLPGPDIPIPKLTSEFLSRGFTPEEMVVLLAGGHSI GKVRCIFTEPDATPMDPGYQASISKLCDGPNRDTGFVNMDEHNPNVIDSSYFANVLAKKMPLTVDRLLGLDSKITPIIKNMLNKPNDFMPI FAKAMEKLSVLKVITGKDGEIRKSHCSEFNNPMPSTGGVIRISSANPEDLEGLSSGGTQVAGIVSQGTKDPWHVKTLKAAGAAHPKKVTGR HPKLRGAHPQ 52 M.230 ..........................................................GCDADILIDPLSNQSAEKEAGPNISVRGFEVID DIKKELEAKCPKTVSCADIVALGTRDAVRISG 52 M.530 ........................................................................................... ..........................................................PAYEVPTGRRDSLVSNREEADNNLPGPDIPIPKLTSEFLSRGFTPEEMVVLLAGGHSI GKVRCIFTEPDATPMDPGYQASISKLCDGPNRDTGFVNMDEHNPNVIDSSYFANVLAKKMPLTVDRLLGLDSKITPIIKNMLNKPNDFMPI FAKAMEKLSVLKVITGKDGEIRKHSCSEFNNPMPSTGGVIRISSANPEDLEGLSSGGTQVAGIVSQGTKDPWHVKTLKAAGAAHPKKVTGR HPKLRGAHPQ 52 M.667 LLGLLAPLASAQLSREFYKASCPDAEKIVAAVIEKKLKEDPGTAAGLLRLLFHDCFANGCDASILIDPLSNQSAEKEAGPNISVRGFEVID DIKKELEAKCPKTVSCADIVALGTRDAVRISGGPAYEVPTGRRDSLVSNREEADNNLPGPDIPIPKLTSEFLSRGFTPEEMVVLLAGGHSI GKVRCIFIEPDATPMDPGYQASISKLCDGPNRDTGFVNMDEHNPNVIDSSYFANVLAKKMPLTVDRLLGLDSKTTPIIKNMLNKPNDFMPT FAKAMEKLSVLKAIPGKDGEIRKSCSEFNNPMPSTGGSVIRISSANPEDLEGLSSGGTQVAGIVSQGTKDPWHVKTLKAAGAARPKKVTGR HPKLRGAHPQ 52 M.505 LLGLLAPLASAQLSREFYKASCPDAEKIVAAVIEKKLKEDPGTAAGLLRLLFHDCFANGCDASILIDPLSNQSAEKEAGPNISVRGFEVID DIKKELEAKCPKTVSCADIVALGTRDAVRISGGPAYEVPTGRRDSLVSNREEADNNLPGPDIPIPKLTSEFLSRGFTPEEMVVLLAGGHSI GKVRCIFIEPDATPMDPGYQASISKLCDGPNRDTGFVNMDEHNPN 52 M.488 ..................KASCPDAEKIVAAVIEKKLKEDPGTAAGLLRLLFHDCFANGCDASILIDPLSNQSAEKEAGPNISVRGFEVID DIKKELEAKCPKTVSCADIVALGTRDAVRISGGPAYEVPTGRRDSLVSNREEADNNLPGPDIPIPKLTSEFLSRGFTPEEMVVLLAGGHSI GKVRCIFIEPDATPMDPGYQASISKLCDGPNRDTGFVNMDEHNPNVIDSSYF 52 M.445 ..................................................LFHDCFANGCDASILIDPLSNQSAEKEAGPNISVRGFEVID DIKKELEAKCPKTVSCADIVALGTRDAVRISGGPAYEVPTGRRDSLVSNREEADNNLPGPDIPIPKLTSEFLSRGFTPEEMVVLLAGGHSI GKVRCIFIEPDATPMDPGYQASISKLCDGPNRDTGFVNMDEHNPN 53 M.436 WSEIQTLKPNLIGPFAAAGMDRNPVAKNAGKFMTLAGFLDYAKASNISGILIGIEHAAYLATRGLDVVDAVSNALIKSGYDKETKQQVFIQ SEDPPVLSAFKKFPKFNRVFEIEFDIRDVSKPSVVEIKEFANAVKLRRSSAAQVDGFYLTGFNAVVERLRDADIQVHVGVL 53 M.508 ...IQTLKPNLIGPFAAAGMDRNPVAKNAGKFMTLAGFLDYAKASNISGILIGIEHAAYLATRGLDVVDAVSNALIKSGYDKETKQQVFIQ SEDPPVLSAFKKFPKFNRVFEIEFDIRDVSKPSVVEIKEFANAVKLRRSSAAQVDGFYLTGFNAVVERLRDADIQVHVGVLKNEFMSLAFD YWADPMVEIATDTWSVLADGLVTEFPSTAAAYFSKWWYLLLDQRTV 53 M.688 ..EIQTLKPNLIGPFAAAGMDRNPVAKNAGKFMTLAGFLDYAKASNISGILIGIEHAAYLATRGLDVVDAVSNALIKSGYDKETKQQVFIQ SEDPPVLSAFKKFPKFNRVFEIEFDIRDVSKPSVVEIKEFANAVKLRRSSAAQVDGFYLTGFNAVVERLRDADIQVHVGVLKNEFMSLAFD YWADPMVEIATDTWSVLADGLVTEFPSTAAAYFRSPCSDIKRNMSYTIKPGPGALVDMAAYGALPPAPPPAPVLEPADVHRQPLPLCPTE PMFRTFRCRLPPKETGKNAEYTANLAADG 53 M.613 .SEIQTLKPNLIGPFAAAGMDRNPVAKNAGKFMTLAGFLDYAKASNISGILIGIEHAAYLATRGLDVVDAVSNALIKSGYDKETKQQVFIQ SEDPPVLSAFKKFPKFNRVFEIEFDIRDVSKPSVVEIKEFANAVKLRRSSAAQVDGFYLTGFNAVVERLRDADIQVHVGVLKNEFMSLAFD YWADPMVEIATDTWSVLADGLVTEFPSTAAAYFRSPCSDIKRNMSYTIKPGPGALVDMAAYGALPPAPPPAPVLEPADVHRQPLPLCPTE PMFRTFRCRLPPKETGKNAEYTANLAADG 53 M.487 .SEIQTLKPNLIGPFAAAGMDRNPVAKNAGKFMTLAGFLDYAKASNISGILIGIEHAAYLATRGLDVVDAVSNALIKSGYDKETKQQVFIQ SEDPPVLSAFKKFPKFNRVFEIEFDIRDVSKPSVVEIKEFANAVKLRRSSAAQVDGFYLTGFNAVVERLRDADIQVHVGVLKNEFMSLAFD YWADPMVEIATDTWSVLADGLVTEFPSTAAAYF 53 M.552 ..............................................ISGILIGIEHAAYLATRGLDVVDAVSNALIKSGYDKETKQQVFIQ SEDPPVLSAFKKFPKFNRVFEIEFDIRDVSKPSVVEIKEFANAVKLRRSSAAQVDGFYLTGFNAVVERLRDADIQVHVGVLKNEFMSLAFD YWADPMVEIATDTWSVLADGLVTEFPSTAAAYFRSPCSDIKRNMSYTIKPGPGALVDMAAYGALPPAPPPAPVLEPADVHRQPLPLCPTE PMFRTFRCRLPPKETGKNAEYTANLAADG 53 M.572 .......................................................HAAYLATRGLDVVDAVSNALIKSGYDKETKQQVFIQ SEDPPVLSAFKKFPKFNRVFEIEFDIRDVSKPSVVEIKEFANAVKLRRSSAAQVDGFYLTGFNAVVERLRDADIQVHVGVLKNEFMSLAFD YWADPMVEIATDTWSVLADGLVTEFPSTAAAYFRSPCSDIKRNMSYTIKPGPGALVDMAAYGALPPAPPPAPVLEPADVHRQPLPLCPTE PMFRTFRCRLPPKETGKNAEYTANLAADG 53 M.336 ................................................................LDVVDAVSNALIKSGYDKETKQQVFIQ SEDPPVLSAFKKFPKFNRVFEIEFDIRDVSKPSVVEIKEFANAVKLRRSSAAQVDGFYLTGFNAVVERLRDADIQVHVGVLKNEFMS 53 M.534 WSEIQTLKPNLIGPFAAAGMDRNPVAKNAGKFMTLAGFLDYAKASNISGILIGIEHAAYLATRGLDVVDAVSNALIKSGYDKETKQQVFIQ SEDPPVLSAFKKFPKFNRVFEIEFDIRDVSKPSVVEIKEFANAVKLRRSSAAQVDGFYLTGFNAVVERLRDADIQVHVGVLKNEFMSLAFD YWADPMVEIATDTWSVLADGLVTEFPSTAAAYFRSPCSDIKRNMSYTIKPGPGALVDMAAYGALPPAPP 54 M.213 ...................................................................DGLPGTNCPVAPGTNFTYKWQPKD QTGSFFYFPSTGMQRTVGGYGLTSVVSRLLTPVPFDPPADDLQVIIGDWYTKD 54 M.384 HVPLEEHVGTKTTVLGVPQKVTLINGEFPGPRINCSSNNNIVVNVFNQLDQPLLFTWNGTQHRKNSWQDGLPGTNCPVAPGTNFTYKWQPKD QTGSFFYFPSTGMQRTVGGYGLTSVVSRLLTPVPFDPPADDLQVIIGDWYTKDH 54 M.220 ...................................................................DGLPGTNCPVAPGTNFTYKWQPKD QTGSFFYFPSTGMQRTVGGYGLTSVVSRLLTPVPFDPPADDLQVIIGDWYTKDH 54 M.147 ............................................................................VAPGTNFTYKWQPKD QTGSFFYFPSTGMQRTVGGYGLTSVVSRLLTPVPFDPP 54 M.127 ................................................................................TNFTYKWQPKD QTGSFFYFPSTGMQRTVGGYGLTSVVSRLLTPVPFDPPADDLQVIIGDWYTKDH 54 M.145 ................................................................................TNFTYKWQPKD QTGSFFYFPSTGMQRTVGGYGLTSVVSRLLTPVPFDPPADDLQVIIGDWYTKDHTV 55 M.33 ...................PKFRRVLVIDPVISGASKPSIGEIKGFADAVMVSRGSLVRVNGFFLT 55 M.110 ..........SVLSVFKKFPKFRRVLVIDPVISGASKPSIGEIKGFADAVMVSRGSLVRVNGFFLT 55 M.173 ..VFIQSDDSSVLSVFKKFPKFRRVLVIDPVISGASKPSIGEIKGFADAVMVSRGSLVRVNGFFPT 55 M.50 ..........LNTESTEEFPKFRRVLVIDPVISGASKPSIGEIKGFADAVMVSRGSLVRVNGFFLT 55 M.249 QQVFIQSDDSSVLSVFKKFPKFRRVLVIDPVISGASKPSIGEIKGFADAVMVSRGSLVRVNGFFLTGFNDLVIEIHDANLSLH 55 M.18 ...............TEEFPKFRRVLVIDPVISGASKPSIGEIKGFADAVMVSRGSLVRVNGFF 56 M.5 .........RQPGPLPGLNTKIASFLDPDGWKVVLVDHADFLKELH 56 M.25 TKELGGKTLRQPGPLPGLNTKIASFLDPDGWKVVLVDHADFLKELH 57 M.394 ILQDNAKTVQIDSSTQARTVGAGSGGFSRIVCLRVHPTFTLLHPTEVVVAFTATNGSRQEVSPESGEVTLEGDTRPNGEWMLVDKCAGVAL VNRFEISQVQVSKCLVRWGTGDLNMELWSEEPVSKDTPLRICHQYELRQTS 58 M.329 .VRTTDSRCMDLADPCSEYFVEAYLNNPLVQKAIHANTALNYPWTGCRTRTYNLRRFGDSPPSMLAHIKALVTTGIRIWLYSGELYAMVPV TASKHSWKKLRLEVVKDWRPW 58 M.330 ..........DLADPCSEYFVEAYLNNPLVQKAIHANTALNYPWTGCRTRTYNLRRFGDSPPSMLAHIKALVTTGIRIWLYSGELYAMVPV TASRHSVEKLRLEVVKDWRPWSTAPGQDV 58 M.345 ...........................NPLVQKAIHANTALNYPWTGCRTRTYNLRRFGASPPSMLAHIKALVTTASASGCTAATWTRWCP 58 M.323 ...........................NPLVQKAIHANTALNYPWTGCRTRTYNLRRFGASPPSMLAHIKALVTTASASGCTAATWTRWCP 58 M.316 .........................NNPLVQKAIHANTALNYPWTGCRTRTYNLRRFGDSPPSMLAHIKALVTTGIRIWLYSGDLDAMVPV TASKHSVEKLRLEVVKDWRPWSIAPGQDVGGYVIEYKGLV 58 M.130 .........................NNPLVQKAIHANTALNYPWTGCRTRTYNLRRFGDSPPSMLAHIKALVTIGIRSPLYSQMRMRWCP 58 M.131 .........................NNPLVQKAIHANTALNYPWTGCRTRTYNLRRFGDSPPSMLAHIKALVTIGIRSPLYSQMRMRWCP 58 M.203 KVRITDSRCMDLADPCSEYFVEAYLNNPLVQKAIHANTALNYPWIGCRTRTYNLRRFGDSPPSMLAHIKALVTTGI 58 M.227 ................................AIHANTALNYPWTGCRTRTYNLRRFGDSPPSMLAHIKVLVTTGIRIWLYSGDLDAMVPV TASKHSVEKLRLEVVKDWRP 58 M.128 ...............................KAIHANTALNYPWTGCRTRTYNLRRFGDSPPSMLAHIKVLVTTGIRIWLYSGDLDAMVPV TASKHS 58 M.70 ..............................QKAIHANTALNYPWTGCRTRTYNLRRFGDSPPSMLAHIKALVTTGIRIWLYSGDLGAMV 58 M.292 ............................QKAIHANTALNYPWTGCRTRTYNLPRFGDSPPSMLAHIKALVTTGIRIWLYSGDLGAMVPV TASKHSVEKLRLEVVKDWRPWSTAPGQQVGGYVIEYK 59 M.526 ........................................................................................... .............................................................ACIGEILEQREAGTIMEVVAAQTKAIAEKI SDWINVVLAYEPVWAIGTGKVASRAQAQEVHDGLRKWLHANVGPAVAESTRIIYGGSVNGANCKELAAQPDLDGFLVGGASLKPEFVDIIK SATVKSSSA 59 M.585 ............PHTASDSPHRADQPMAPRKFFVGGNWKCNGASDDVKKIATVLNEAEVPSEDAVEVVVSPPVFLQQAKALLAPDFAVAA QNCWVRKGGAFTGEISAEMLVNLQVPWVILGHSERRALLSESNDFVADKVAYALAQGLKVIACIGETLEQREAGTTMEVVAAQTKAIAEKI SDWTNVVLAYEPVWAIGTGKVASRAQAQEVHDGLRKWLHANVGPAVAESTRIIYGGSVNGANCKELAAQPDLDGFLVGGASLKPEFVDIIK SATVKSSSA 59 M.681 ............PHTASDSPHRADQPMAPRKFFVGGNWKCNGASDDVKKIATVLNEAEVPSEDAVEVVVSPPVFLQQAKALLARPDFAVAA QNCWVRKGGAFTGEISAEMLVNLQVPWVILGHSERRALLSESNDFVADKVAYALAQGLKVIACIGETLEQREAGTTMEVVAAQTKAIAEKI SDWTNVVLAYEPVWAIGTGKVASRAQAQEVHDGLRKWLHANVGPAVAESTRIIYGGSVNGANCKELAAQPDLDGFLVGGASLKPEFVDIIK SATVKSSSA 59 M.885 ............PHTASDSPHRADQPMAPRKFFVGGNWKCNGASDDVKKIATVLNEAEVPSEDAVEVVVSPPVFLQQAKALLARPDFAVAA QNCWVRKGGAFTGEISAEMLVNLQVPWVIGLHSERRALLSESNDFVADKVAYALAQGLKVIACIGETLEQREAGTTMEVVAAQTKAIAEKI SDWTNVVLAYEPVWAIGTGKVASRAQAQEVHDGLRKWLHANVGPAVAESTRIIYGGSVNGANCKELAAQPDLDGFLVGGASLKPEFVDIIK SATVKSSSA 59 M.596 ..........................MAPRKFFVGGNWKCNGTSDDVKKIVTVLNEAEVPSEDAVEVVVSPPFVFLQQAKALLRPDFAVAA QNCWVRKGGAFTGEISAEMLVNLQVPWVILGHSERRALLSESNDFVADKVAYALAQGLKVIACIGETLEQREAGTTMEVVAAQTKAIAEKI SDWTNVVLAYEPVWAIGTGKVASRAQAQEVHDGLRKWLHANVGPAVAESTRIIYGGSVNGANCKELAAQPDLDGFLVGGASLKPEFVDIIK SATVKSSSA 59 M.660 .......................................MQNGTSDDVKKIVTVLNEAEVPSEDAVEVVVSPPFVFLQQAKALLRPDFAVAA QNCWVRKGGAFTGEISAEMLVNLQVPWVILGHSERRALLSESNDFVADKVAYALAQGLKVIACIGETLEQREAGTTMEVVAAQTKAIAEKI SDWTNVVLAYEPVWAIGTGKVASRAQAQEVHDGLRKWLHANVGPAVAESTRIIYGGSVNGANCKELAAQPDLDGFLVGGASLKPEFVDIIK SATVKSSSA 59 M.674 ...........RPHTASDSPHRADQPMAPRKFFVGGNWKCNGASDDVKKIVTVLNEAEVPSEDAVEVVVSPPFVFLQQAKALLRPDFAVAA QNCWVRKGGAFTGEISAEMLVNLQVPWVILGHSERRALLSESNDFVADKVAYALAQGLKVIACIGETLEQREAGTTMEVVAAQTKAIAEKI SDWTNVVLAYEPVWAIGTGKVASRAQAQEVHDGLRKWLHANVGPAVAESTRIIYGGSVNGANCKELAAQPDLDGFLVGGASLKPEFVDIIK SATVKSSSA 59 M.703 ...........RPHTASDSPHRADQPMAPRKFFVGGNWKCNGASDDVKKIVTVLNEAEVPSEDAVEVVVSPPFVFLQQAKALLRPDFAVAA QNCWVRKGGAFTGEISAEMLVNLQVPWVILGHSERRALLSESNDFVADKVAYALAQGLKVIACIGETLEQREAGTTMEVVAAQTKAIAEKI SDWTNVVLAYEPVWAIGTGKVASRAQAQEVHDGLRKWLHANVGPAVAESTRIIYGGSVNGANCKELAAQPDLDGFLVGGASLKPEFVDIIK SATVKSSSA 59 M.504 ..................................................................VVSPPFVFLQQAKALLRPDFAVAG QNCWVRKGGAFTGEISAEMLVNLQVPWVILGHSERRALLSESNDFVADKVAYALAQGLKVIACIGETLEQREAGTTMEVVAAQTKAIAEKI SDWTNVVLAYEPVWAIGTGKVASRAQAQEVHDGLRKWLHANVGPAVAESTRIIYGGSVNGANCKELAAQPDLDGFLVGGASLKPEFVDIIK SATVKSSSA 60 M.515 .....................................................................GGTWTRHSGPVKGGKSWIAFIE DPDGYKFELIERGPTPEPLCQVMLRVGDLDRAIKFYEKAFGMELLRRKDNPQYKYTIAMMGYGPEDKNAVLETYNYGVKEYDKGNAYAQI AIGTDDVYKTAEVVRQNGGQITREPGPLPGISTKITACTDPDGWKSVFVDNLDFLKELEE 60 M.521 ......................................................................................IAFIE DPDGYKFELIERGPTPEPLCQVMLRVDGLDRAIKFYEKAFGMELLRRKDNPQYKYTIAMMGYGPEDKNAVLELTYNYGVKEYDKGNAYAQI AIGTDDVYKTAEVVRQNGGQITREPGPLPGISTKITACTDPDGWKSVFVDNLDFLKELEE 60 M.493 ......................................................................................IAFIE DPDGYKFELIERGPTPEPLCQVMLRVDGLDRAIKFYEKAFGMELLRRKDNPQYKYTIAMMGYGPEDKNAVLELTYNYGVKEYDKGNAYAQI AIGTDDVYKTAEVVRQNGGQITREPGPLPGISTKITACTDPDGWKSVFVDNLDFLKELEE 60 M.497 ......................................................................................IAFIE DPDGYKFELIERGPTPEPLCQVMLRVDGLDRAIKFYEKAFGMELLRRKDNPQYKYTIAMMGYGPEDKNAVLELTYNYGVKEYDKGNAYAQI AIGTDDVYKTAEVVRQNGGQITREPGPLPGISTKITACTDPDGWKSVFVDNLDFLKELEE 60 M.509 LGMRLLRKRDIPEENYTNAFLGYGPEDSHFVVELTYNYGVESYDIGSGFGHFGIAVEDVELTVELIRAKGGTVTREPGPVKGGRSVIAFIE DPDGYKFELIERGPTPEPLCQVMLRVGDLDRAIKFYEKAFGMELLRRKDNPQYKYTIAMMGYGPEDKNAVLELIYNYGVKEYDKGNAYAQI AIGTDDVYKTAEVVRQNGGQITREPGPLPGISTKITACTDPAIWICAGS 60 M.533 ....................................................FGIAVEDVEKTVELIKAKGGTVIREPGPVKGGKSVIAFIE DPDGYKFELIERGPTPEPLCQVMLRVGDLDRAIKFYEKAFGMELLRRKDNPQYKYTIAMMGYGPEDKNAVLELTYNYGVKEYDKGNAYAQI AIGTDDVYKTAEVVRQNGGQITREPGPLPGISTKITACTDPDGWKSVFVDNLDFLKELEE 60 M.484 ....................................................FGIAVEDVEKTVELIKAKGGTVIREPGPVKGGKSVIAFIE DPDGYKFELIERGPTPEPLCQVMLRVGDLDRAIKFYEKAFGMELLRRKDNPQYKYTIAMMGYGPEDKNAVLELTYNYGVKEYDKGNAYAQI AIGTDDVYKTAEVVRQNGGQITREPGPLPGISTKITACTDPDGWKSVFVDNLDFLKELEE 60 M.302 ...................................................................................KSVIAFIE DPDGYKFELIERGPTPEPLCQVMLRVGDLDRAIKFYEKAFGMELLRRKDNPQYKYTIAMMGYGPEDKNAVLELTYNYGVKEYDKGNAYAQV DI 61 M.478 LQSRNCIDILCSIMICNGKVSKVLNTYIFLILYLEHI 62 M.222 ................................................................QSKQMANPTTAAGVLRIFFRDCFVSGC DASVLIAPTHYAKSEKDADINHSLPGDAFDAVVRSKLALELECPGVVSCADI 62 M.691 PKSHTRVGSTYQPAAMRRLSLILLAAAALLAAAVSAEPGPAPKLSPDFYSQTCPRAERIIAEVVQSKQMANPTTAAGVLRVFFHDCFVSGC DASVLIAPTHYAKSEKDADINHSLPGDAFDAVVRSKLALELECPGVVSCADILAIASRVLVTMTGGPRYPVPLGRKDSLSSNPAAPDVELP HSNFTVGRIIELFTAKGFTVQEMVALSGAHTLGFSRCQETASRIYNYRDKGGKPAPFDPSMNPIYAKGLQAACQDYCKDPTIAAFNDIMTP GKFDNIYSVNIERGLGLLSTDEDMWSDMRTKPFVQRYAANNTDFFEDFANAIEHLSMYGVKIGADGEIRRRCDAFNSGPNIQ 62 M.570 ...............MRRLSLILLAAAALLAAAVSAEPGPAPKLSPDFYSQTCPRAERIIAEVVQSKQMANPTTAAGVLRVFFHDCFVSGC DASVLIAPTHYAKSEKDADINHSLPGDAFDAVVRSKLALELECPGVVSCADILAIASRVLVTMTGGPRYPVPLGRKDSLSSNPAAPDVELP HSNFTV 62 M.119 ..........................................................................AAGVLRVFFHDCFVSGC DASVLIAPTHYAKSEKDADINHSLPGDAFDAVVRSKLALELECPGVV 62 M.535 PKSHTRVGSTYQPAAMRRLSLILLAAAALLAAAVSAEPGPAPKLSPDFYSQTCPRAERIIAEVVQSKQMANPTTAAGVLRVFFHDCFVSGC DASVLIAPTHYAKSEKDADINHSLPGDAFDAVVRSKLALELECPGVVSCADILAIASRVLVTMTGGPRYPVPLGRKDSLSSNPAAPDVELP HSNFTVGRIIELFTAKGFTVQEMVALSGAHTL 62 M.543 PKSHTRVGSTYQPAAMRRLSLILLAAAALLAAAVSAEPGPAPKLSPDFYSQTCPRAERIIAEVVQSKQMANPTTAAGVLRVFFHDCFVSGC DASVLIAPTHYAKSEKDADINHSLPGDAFDAVVRSKLALELECPGVVSCADILAIASRVLVTMTGGPRYPVPLGRKDSLSSNPAAPDVELP HSNFTVGRIIELFTAKGFTVQEMVALSGAHTL 62 M.528 PKSHTRVGSTYQPAAMRRLSLILLAAAALLAAAVSAEPGPAPKLSPDFYSQTCPRAERIIAEVVQSKQMANPTTAAGVLRVFFHDCFVSGC DASVLIAPTHYAKSEKDADINHSLPGDAFDAVVRSKLALELECPGVVSCADILAIASRVLVTMTGGPRYPVPLGRKDSLSSNPAAPDVELP HSNFTVGRIIELFTAKGFTVQEMVALSGAHT 62 M.529 PKSHTRVGSTYQPAAMRRLSLILLAAAALLAAAVSAEPGPAPKLSPDFYSQTCPRAERIIAEVVQSKQMANPTTAAGVLRVFFHDCFVSGC DASVLIAPTHYAKSEKDADINHSLPGDAFDAVVRSKLALELECPGVVSCADILAIASRVLVTMTGGPRYPVPLGRKDSLSSNPAAPDVELP HSNFTVGRIIELFTAKGFTVQEMVALSGAHTLG 62 M.373 .................................................................................FFHDCFVSGC DASVLIAPTHYAKSEKDADINHSLPGDAFDAVVRSKLALELECPGVVSCADILAIASRVLVTMTGGPRYPVPLGRKDSLSSNPAAPDVELP HSNFTVGRIIELFTAKGFTVQEMVALSGAHTLG 62 M.590 PKSHTRVGSTYQPAAMRRLSLILLAAAALLAAAVSAEPGPAPKLSPDFYSQTCPRAERIIAEVVQSKQMANPTTAAGVLRVFFHDCFVSGC DASVLIAPTHYAKSEKDADINHSLPGDAFDAVVRSKLALELECPGVVSCADILAIASRVLVTMTGGPRYPVPLGRKDSLSSNPAAPDVELP HSNFTVGRIIELFTAKGFTVQEMVALSGAHTLGFSRCQETASRIYNYRDKGGKPAPFDPSMNPIYAKGLQAACQDYCKDPTIAAFNDIMSS SVLEEP 63 M.361 .....PHMLLILLLLHGANAALDEPVQKWQTLDGSPPLVIARGGFSGLFPESSLYAYQFAMSNGLPDVVLHCDLQLSSDGKGFCRSGLRLD KSTLIAEVFPKRDKTYKLGTEDIHGWFAVDFTAAELVNNVT 63 M.432 MGGRYPHMLLILLLLHGANAALDEPVQKWQTLDGSPPLVIARGGFSGLFPESSLYAYQFAMSNGLPDVVLHCDLQLSSDGKGFCRSGLRLD KSTLIAEVFPKRDKTYKLGTEDIHGWFAVDFTAAELVNNVT 63 M.477 MGGRYPHMLLILLLLHGANAALDEPVQKWQTLDGSPPLVIARGGFSGLFPESSLYAYQFAMSNGLPDVVLHCDLQLSSDGKGFCRSGLRLD KSTLIAEVFPKRDKTYKLGTEDIHGWFAVDFTAAELVNNVTGMHPKLSNLL 63 M.408 MGGRYPHMLLILLLLHGANAALDEPVQKWQTLDGSPPLVIARGGFSGLFPESSLYAYQFAMSNGLPDVVLHCDLQLSSDGKGFCRSGLRLD KSTLIAEVFPKRDKTYKLGTEDIHGWFAVDFTAAELVNNVT 64 M.568 .HAANAGLGMLEPIKEEIPTISYSDLYQLAGVVAVEVSGGPVIPFHPGREDKPQPPPEGRLPDATKGSDHLRQVFGKQMGLSDQDIVALSG GHTLGRCHKERSGFEGPWTKNPLKFDNTYFTELLSGDKEGLIQLPSDKTLLTDPVFRPLVEKYAADEKAFFEDYKEAHLRLSELGYAEA 64 M.589 AHAANAGLGMLEPIKEEIPTISYSDLYQLAGVVAVEVSGGPVIPFHPGREDKPQPPPEGRLPDATKGSDHLRQVFGKQMGLSDQDIVALSG GHTLGRCHKERSGFEGPWTKNPLKFDNTYFTELLSGDKEGLIQLPSDKTLLTDPVFRPLVEKYAADEKAFFEDYKEAHLRLSELGYAEA 64 M.462 ..........................................................................................G GHTLGRCHKERSGFEGPWTKNPLKFDNTYFTELLSGDKEGLIQLPSDKTLLTDPVFRPLVEKYAADEKAFFEDYKEAHLRLSELGYAEA 64 M.516 ...............................................NLQDNPQPPPEGRLPDATKGSDHLRQVFGKQMGLSDQDIVALSG GHTLGRCHKERSGFEGPWTKNPLKFDNTYFTELLSGDKEGLIQLPSDKTLLTDPVFRPLVEKYAADEKAFFEDYKEAHLRLSELGYAEA 64 M.522 ...............................................................PQEGVDHLRQVFGKQMGLSDQDIVALSG GHTLGRCHKERSGFEGPWTKNPLKFDNTYFTELLSGDKEGLIQLPSDKTLLTDPVFRPLVEKYAADEKAFFEDYKEAHLRLSELGYAEA 64 M.412 ...............................................................PQEGVDHLRQVFGKQMGLSDQDIVALSG GHTLGRCHKERSGFEGPWTKNPLKFDNTYFTELLSGDKEGLIQLPSDKTLLTDPVFRPLVEKYAADEKAFFEDYKEAHLRLSELGYAEA 65 M.4 .................................................RVQVVGPDGKRVLETRIEGGSLFIVPRFHVVSKIADASGMEW 65 M.255 KEVGLGADLVRIDAHSNCSPGFSCDSAYQVTYIVRGSGRVQVVGPDGKRVLETRIEGGSLFIVPRFHVVSKIADASGMEWFSII 65 M.56 ......................................RVQVVGPDGKRVLETRIEGGSLFIVPRFHVVSKIADASGMEWFSIITTPNPIF SHLA 65 M.55 ...............................YIVRGSGRVQVVGPDGKRVLETRIEGGSLFIVPRFHVVSKIADASGMEWFSIITTP 65 M.64 ...........................YQVTYIVRGSGRVQVVGPDGKRVLETRIEGGSLFIVPRFHVVSKIADASGMEWFSIITT 65 M.22 ...................................GSGRVQVVGPDGKRVLETRIEGGSLFIVPRFHVVSKIADASGMEWFSIITT 65 M.148 .......................CDSAYQVTYIVRGSGRVQVVGPDGKRVLETRIEGGSLFIVPRFHVVSKIADASGMEWFSIITTPNPI 65 M.205 ...............SMCSPGFSCDSAYQVTYIVRGSGRVQVVGPDGKRVLETRIEGGSLFIVPRFHVVSKIADASGMEWFSIITTPNPI 65 M.332 ...................PGFSCDSAYQVTYIVRGSGRVQVVGPDGKRVLETRIEGGSLFIVPRFHVVSKIADASGMEWFSIITTPNPIF SHLAGKTSVWKAISPEVLEASFNTTPEMEKLFRSKRLDSEI 65 M.171 ...........IDAHSMCSPGFSCDSAYQVIYIVRGSGRVQVVGPDGKRVLETRIEGGSLFIVPRFHVVSKIADASGMEWF 66 ME.3566 PPRSCRGRCPCSLRTPAWGSCSRMAPCNCRCPCSTRGARRRLPGRTSS 67 ME.4276 AISPTIRITAPISRRSPSAPSPHTSPPPRASATTSSRDGTTRTCISTRRIPSRPTTSPWSTCRAARSPTPSATSASREPTPRPSRSSDTSS RRSLDRREIWLSEMVAWVGLQLAFWIQWQH 67 ME.4056 ..SPTIRITAPISRRSPSAPSPHTSPPPRASATTSSRDGTTRTCISTRRIPSRPTTSPWSTCRAARSPTPSATSASREPTPRPSRSSDTSS RRSLDRREIWLSEMVAWVGLQLAFWIQWQH 68 ME.3805 SSCSRRCPWRPPRRWSCCPLPWPGTRRWWFRCHQPPSSRTAPGSSRSLYGSPSTSC 68 ME.3720 SSCSRRCPWRPPRRWSCCPLPWPGTRRWWFRCHQPPSSRTAPGSSRSLYGSPSTSC 69 ME.3916 VKVAPAALVNVLEARSALTISVLRISSMPFSVYHSGKSFSPPLPTQVWNPGSLAAFWGKRYPLLSAGRSYGATDSLEMMASSPGWTPCLAN SLA 70 ME.3855 SSPSCAPESTHAVRALPSTHTARILLRSTTANVSGCKDRYERPS 71 ME.1412 QVQVPGGHQGDLPRGEGVQPQLPGAAGEVCRPRRRRGGGGHQGEGQGQVDRAQGVVGSHLEDRHSRQAHRPLHRPLH 72 ME.4234 FAAISNAKHLIYVTGWSVYTEITLLRDANRPKPAGGTVTLGELLKKKASEGVRVLMLVWDDRTSVGVLKKDGLMATHDEETMNYFQDTDVH CVLCPRDPDDSGSIVQDLQISTMFTHHQKIVVVDHDMPQPQSASRRRRIMSFVGGLDLCDGRYDTPFHSVFGTLDGAHHDDFHQPNFATSA ITKGGPREPWHDIHCRLEGPVAWDVLYNFEQRWRKQGGKDLLIQLRDLADEIIPPSPVVYAEDREAWNVQLFRSIDGGAAFGFPDTPEDAA RAGLVSGKDQIIDRSIQDAYICTIRRAKSFIYIENQYFLGSSYCWKPDGIKPDDVGALHLIPKELSMKVVSKIEAGERFTVYVVVPMWPEG IPASGSVQAILDWQRRTMEMMYTDIAQAIQAKGIDANPKDYLTFFCLGNREAKKAGEYEPPEPAEPDSDYLKAQQNRRFMIYVHTKMMIVD DEYIIVGSANINQRSMDGARDSEIAMGAYQPYHLAASRPARGQVHGFRMALWYEHLGMVDEAFQRPESVECVRKVNAMADRYWNLYAGDGP ERDLPGHLLTYPVGVTSDGTVTQLPGVEFFPDTQARILGAKSDYLPPILTT 72 ME.4088 ........................................................................................... ..................................................................................HQPNFATAA ITKGGPREPWHDIHCRLEGPVAWDVLYNFEQRWRKQGGKDLLIQLRDLADEIIPPSPVVYAEDREAWNVQLFRSIDGGAAFGFPDTPEDAA RAGLVSGKDQIIDRSIQDAYICAIRRAKSFIYIENQYFLGSSYCWKPDGIKPDDVGALHLIPKELSMKVVSKIEAGERFTVYVVVPMWPEG IPASGSVQAILDWQRRTMEMMYTDIAQAIQAKGIDANPKDYLTFFCLGNREAKKAGEYEPPEPAEPDSDYLKAQQNRRFMIYVHTKMMIVD DEYIIVGSANINQRSMDGARDSEIAMGAYQPYHLAASRPARGQVHGFRMALWYEHLGMVDEAFQRPESVECVRKVNAMADRYWNLYAGDGP ERDLPGHLLTYPVGVTSDGTVTQLPGVEFFPDTQARILGAKSDYLPPILTT 72 ME.4115 ........................................................................................... ........................................QSASRRRRIMSFVGGLDLCDGRYDTPFHSVFGTLDGAHHDDFHQPNFATSA ITKGGPREPWHDIHCRLEGPVAWDVLYNFEQRWRKQGGKDLLIQLRDLADEIIPPSPVVYAEDREAWNVQLFRSIDGGAAFGFPDTPEDAA RAGLVSGKDQIIDRSIQDAYICAIRRAKSFIYIENQYFLGSSYCWKPDGIKPDDVGALHLIPKELSMKVVSKIEAGERFTVYVVVPMWPEG IPASGSVQAILDWQRRTMEMMYTDIAQAIQAKGIDANPKDYLTFFCLGNREAKKAGEYEPPEPAEPDSDYLKAQQNRRFMIYVHTKMMIVD DEYIIVGSANINQRSMDGARDSEIAMGAYQPYHLAASRPARGQVHGFRMALWYEHLGMVDEAFQRPESVECVRKVNAMADRYWNLYAGDGP ERDLPGHLLTYPVGVTSDGTVTQLPGVEFFPDTQARILGAKSDYLPPILTT 72 ME.4210 ................................................SEGVRVLMLVWDDRTSVGVLKKDGLMATHDEETMNYFQDTDVH CVLCPRDPDDSGSIVQDLQISTMFTHHQKIVVVDHDMPQPQSASRRRRIMSFVGGLDLCDGRYDTPFHSVFGTLDGAHHDDFHQPNFATAA ITKGGPREPWHDIHCRLEGPVAWDVLYNFEQRWRKQGGKDLLIQLRDLADEIIPPSPVVYAEDREAWNVQLFRSIDGGAAFGFPDTPEDAA RAGLVSGKDQIIDRSIQDAYICAIRRAKSFIYIENQYFLGSSYCWKPDGIKPDDVGALHLIPKELSMKVVSKIEAGERFTVYVVVPMWPEG IPASGSVQAILDWQRRTMEMMYTDIAQAIQAKGIDANPKDYLTFFCLGNREAKKAGEYEPPEPAEPDSDYLKAQQNRRFMIYVHTKMMIVD DEYIIVGSANINQRSMDGARDSEIAMGAYQPYHLAASRPARGQVHGFRMALWYEHLGMVDEAFQRPESVECVRKVNAMADRYWNLYAGDGP ERDLPGHLLTYPVGVTSDGTVTQLPGVEFFPDTQARILGAKSDYLPPILTT 72 ME.3897 .......................................................................................TDVH CVLCPRDPDDSGSIVQDLQISTMFTHHQKIVVVDHDMPQPQSASRRRRIMSFVGGLDLCDGRYDTPFHSVFGTLDGAHHDDFHQPNFATAA ITKGGPREPWHDIHCRLEGPVAWDVLYNFEQRWRKQGGKDLLIQLRDLADEIIPPSPVVYAEDREAWNVQLFRSIDGGAAFGFPDTPEDAA RAGLVSGKDQIIDRSIQDAYICAIRRAKSFIYIENQYFLGSSYCWKPDGIKPDDVGALHLIPKELSMKVVSKIEAGERFTVYVVVPMWPEG IPASGSVQAILDWQRRTMEMMYTDIAQAIQAKGIDANPKDYLTFFCLGNREAKKAGEYEPPEPAEPDSDYLKAQQNRRFMIYVHTKMMIVD DEYIIVGSANINQRSM 73 ME.4229 ........................................................................................... ..PLLEGSGKLEVWCVDGSAKTALPKEDLGKFHSGDCYIVLYTYHSGEKREEFYLTYWIGKDSVLEDQHMALQIATTIWNSMKGRPVLGRI YQGKEPPQFIALFQPMVILKGGISSGYKKSIEENGLKDETYSGTGIALVHIHGTSIHNNKTLQVDAVSISLSSTDCFVLQSGNSMFTWIGN TSSYEQQQWAAKVAEFLKPGASVKHCKEGTESSAFWSALGGKQNYTSKNATQDVLREPHLYTFSFRNGKLEVTEVFNFSQDDLLTEDVMIL DTHAEVFVWMGQCVDTKEKQTAFETGQKYVEHAVNFEGLSPDVPLYKVSEGNEPCFFRTYFSWDNTRSVIHGNSFQKKLSLLFGMRSESGS KGSGDGGPTQRASALAALSSAFNPSSQDKQSNDRPKSSGDGGPTQRASALAALSSSLNPSSKPKSPHSQSRSGQGSQRAAAVAALSNVLTA EGSTLSPRNDAEKTELAPSEFHTDQDAPGDEVPSEGERTEPDVSQEETANENGGETTFSYDRLISKSTDPVRGIDYKRRETYLSDSEFETV FGVTKGGILPAAKVEAHIAEKKSRSFIRHSLLRTQRLHKFLVCSSMIGVMAHQKPMSGNLYMFQMQDHQLIYPLISPSFLVYSFFVRDLR 73 ME.4231 ........................................................................................... .PPLLEGSGKLEVWCVDGSAKTALPKEDLGKFHSGDCYIVLYTYHSGEKREEFYLTYWIGKDSVLEDQHMALQIATTIWNSMKGRPVLGRI YQGKEPPQFIALFQPMVILKGGISSGYKKSIEENGLKDETYSGTGIALVHIHGTSIHNNKTLQVDAVSISLSSTDCFVLQSGNSMFTWIGN TSSYEQQQWAAKVAEFLKPGASVKHCKEGTESSAFWSALGGKQNYTSKNATQDVLREPHLYTFSFRNGKLEVTEVFNFSQDDLLTEDVMIL DTHAEVFVWMGQCVDTKEKQTAFETGQKYVEHAVNFEGLSPDVPLYKVSEGNEPCFFRTYFSWDNTRSVIHGNSFQKKLSLLFGMRSESGS KGSGDGGPTQRASALAALSSAFNPSSQDKQSNDRPKSSGDGGPTQRASALAALSSSLNPSSKPKSPHSQSRSGQGSQRAAAVAALSNVLTA EGSTLSPRNDAEKTELAPSEFHTDQDAPGDEVPSEGERTEPDVSQEETANENGGETTFSYDRLISKSTDPVRGIDYKRRETYLSDSEFETV FGVTKEEFYQQPRWKQELQKRKADLF 73 ME.4280 VGRVTQVDDRKAASAAVEEFIVKQNRPKTIRVTQVIQGYENHTFKSLFESWPVSSTGNASTEEGRGKVAALLKKKGDVKGASKNSTPVNEE VPPLLEGSGKLEVWCVDGSAKTALPKEDLGKFHSGDCYIVLYTYHSGEKREEFYLTYWIGKDSVLEDQHMALQIATTIWNSMKGRPVLGRI YQGKEPPQFIALFQPMVILKGGISSGYKKSIEENGLKDETYSGTGIALVHIHGTSIHNNKTLQVDAVSISLSSTDCFVLQSGNSMFTWIGN TSSYEQQQWAAKVAEFLKPGASVKHCKEGTESSAFWSALGGKQNYTSKNATQDVLREPHLYTFSFRNGKLEVTEVFNFSQDDLLTEDVMIL DTHAEVFVWMGQCVDTKEKQTAFETGQKYVEHAVNFEGLSPDVPLYKVSEGNEPCFFRTYFSWDNTRSVIHGNSFQKKLSLLFGMRSESGS KGSGDGGPTQRASALAALSSAFNPSSQDKQSNDRPKSSGDGGPTQRASALAALSSSLNPSSKPKSPHSQSRSGQGSQRAAAVAALSNVLTA EGSTLSPRNDAEKTELAPSEFHTDQDAPGDEVPSEGERTEPDVSQEETANENGGETTFSYDRLISKSTDPVRGIDYKRRETYLSDSEFETV FGVTKEEFYQQPRWKQELQKRKADLF 73 ME.4281 VGRVTQVDDRKAASAAVEEFIVKQNRPKTIRVTQVIQGYENHTFKSLFESWPVSSTGNASTEEGRGKVAALLKKKGDVKGASKNSTPVNEE VPPLLEGSGKLEVWCVDGSAKTALPKEDLGKFHSGDCYIVLYTYHSGEKREEFYLTYWIGKDSVLEDQHMALQIATTIWNSMKGRPVLGRI YQGKEPPQFIALFQPMVILKGGISSGYKKSIEENGLKDETYSGTGIALVHIHGTSIHNNKTLQVDAVSISLSSTDCFVLQSGNSMFTWIGN TSSYEQQQWAAKVAEFLKPGASVKHCKEGTESSAFWSALGGKQNYTSKNATQDVLREPHLYTFSFRNGKLEVTEVFNFSQDDLLTEDVMIL DTHAEVFVWMGQCVDTKEKQTAFETGQKYVEHAVNFEGLSPDVPLYKVSEGNEPCFFRTYFSWDNTRSVIHGNSFQKKLSLLFGMRSESGS KGSGDGGPTQRASALAALSSAFNPSSQDKQSNDRPKSSGDGGPTQRASALAALSSSLNPSSKPKSPHSQSRSGQGSQRAAAVAALSNVLTA EGSTLSPRNDAEKTELAPSEFHTDQDAPGDEVPSEGERTEPDVSQEETANENGGETTFSYDRLISKSTDPVRGIDYKRRETYLSDSEFETV FGVTKEEFYQQPRWKQELQKRKADLF 73 ME.1571 ........................................................................................... ........................................................................................... ........................................................................................... ........................................................................................... ........................................................................................... ........................................................................................... ..........................................................................DYKRRETYLSDSEFQTV FGVTKEEFYQQPRWKQELQKRKADLF 73 ME.4190 ........................................................................................... ................................................................LEDQHMALQIATTIWNSMKGRPVLGRI YQGKEPPQFIGLFQPMVILKGGISSGYKKSIEENGLKDETYSGTGIALVHIHGTSIHNNKTLQVDAVSISLSSTDCFVLQSGNSMFTWIGN TSSYEQQQWAAKVAEFLKPGASVKHCKEGTESSAFWSALGGKQNYTSKNATQDVLREPHLYTFSFRNGKLEVTEVFNFSQDDLLTEDVMIL DTHAEVFVWMGQCVDTKEKQTAFETGQKYVEHAVNFEGLSPDVPLYKVSEGNEPCFFRTYFSWDNTRSVIHGNSFQKKLSLLFGMRSESGS KGSGDGGPTQRASALAALSSAFNPSSQDKQSNDRPKSSGDGGPTQRASALAALSSSLNPSSKPKSPHSQSRSGQGSQRAAAVAALSNVLTA EGSTLSPRNDAEKTELAPSEFHTDQDAPGDEVPSEGERTEPDVSQEETANENGGETTFSYDRLISKSTDPVRGIDYKRRETYLSDSEFETV FGVTKEEFYQQPRWKQELQKRKADLF 74 ME.4230 ITNAERLIYQTANSRLCSVLPKEFEYQQPRWKQELQKRKADLF 75 ME.3882 AIGAAAAMTTIRSTAIARPRAIV 76 MN.82 ........................................................................................... ......................................................................RVRPFYKANEISEEAYVSAIK EEISKVVKIQEELDTDVLVHGFPERNDMVEYFGEQLSGFAFIANGWVQSYGSRCVKPPTIYGDVSRPNPMTVEWSKMAQSMTPRPM 76 MN.124 ................IATAFLSVSNNYEYILSDKLVVSTSCSLMHTAVDLVNETKLDSEIKSWLAFAAQKVVEVNALGKALVGLKDEAYF AANAAAQASRRSSPRVNNEEVQKAAAALKGSDHRRATTVSARLDAQQKKLNLPVLPTTTIGSFPQTMDLRRVRREYKAKKISEEAYVSAIK EEISKVVKIQEELDTDVLVHGFPER 76 MN.159 YLFAGVVEGRNIWADDLAASLSTLESLEAIVGKDKLVVSTSGSLMHTAVDLVNETKLDSEIKSWLAFAAQKVVEVNALGKALVGLKDEAYF AANAAAQASRRSSPRVNNEEVQKAAAALKGSDHRRATTVSARLDAQQKKLNLPVLPTTTIGSFPQTMDLRRVRREYKAKKISEEAYVSAIK EEISKVVKIQEELDTDVLVHGFPERNDNVEYFGEQLSGFAFIAMGWYQSYGSRCVNPPIIYGDVSRPNPNIVFNSKMAQSMIPRPM 76 MN.185 ........................................................................................... ........................................................................................... .............................................................KVRSKILSEEFGWDKDLAKKIWCFGPETTG PNMVVDMCKGVQYLNEIKDSVVAGFQWASKEGALADENMRGICFEVCDVVLHTDAIHRGGGQVIPTARRVIFASQLTAKPRLLEPVYLVEI QAPEGALGGIYGVLNQKRGHVFEEMQRPGTPLYNIKAYLPVIESFGFSAILRAATSGQAFPQCVFDHWDVMNSDPLEVDSQSFNLVKEIRK RKGLKEQMTPLSDFEDKL 77 MN.140 ........................................................................................... ........................................................................................... ........................................................................................... ...............EIKDSVVAGFQWASKEGALADENMRGICFEVCDVVLHTDAIHRGGGQVIPTARRVIFASQLTAKPRLLEPVYLVEI QAPEGALGGIYGVLNQKRGHVFEEMQRPGTPLYNIKAYLPVIESFGFSAILRAATSGQAFPQCVFDHWDVMNSDPLEVDSQSFNLVKEIRK RKGLKEQMTPLSDFEDKL 77 MN.201 ........................................................................................... ......................................NAPKLVEGLKRLAKSDPMVLCSIEESGEHITAGAGELRLEICLKDLQDDFMGG AEIIVSPPVVSFRETVLDKSCRTVMSKSPNKHNRLYMEARPLEEGLPEAIDEGRIGPRDDPKVRSKILSEEFGWDKDLAKKIWCFGPETTG PNMVVDMCKGVQYLNEIKDSVVAGFQWASKEGALADENMRGICFEVCDVVLHTDAIHRGGGQVIPTARRVIFASQLTAKPRLLEPVYLVEI QAPEGALGGIYGVLNQKRGHVFEEMQRPGTPLYNIKAYLPVIESFGFSAILRAATSGQAFPQCVFDHWDVMNSDPLEVDSQSFNLVKEIRK RKGLKEQMTPLSDFEDKL 77 MN.193 ........................................................................................... ........................................................................................... ......................................................IGPRDDPKVRSKILSEEFGWDKDLAKKIWCFGPETTG PNMVVDMCKGVQYLNEIKDSVVAGFQWASKEGALADENMRGICFEVCDVVLHTDAIHRGGGQVIPTARRVIFASQLTAKPRLLEPVYLVEI QAPEGALGGIYGVLNQKRGHVFEEMQRPGTPLYNIKAYLPVIESFGFSAILRAATSGQAFPQCVFDHWDVMNSDPLEVDSQSFNLVKEIRK RKGLKEQMTPLSDFEDKL 77 MN.183 ........................................................................................... ........................................................................................... .....................................................RIGPRDDPKVRSKILSEEFGWDKDLAKKIWCFGPETTG PNMVVDMCKGVQYLNEIKDSVVAGFQWASKEGALADENMRGICFEVCDVVLHTDAIHRGGGQVIPTARRVIFASQLTAKPRLLEPVYLVEI QAPEGALGGIYGVLNQKRGHVFEEMQRPGTPLYNIKAYLPVIESFGFSAILRAATSGQAFPQCVFDHWDVMNSDPLEVDSQSFNLVKEIRK RKGLKEQMTPLSDFEDKL 77 MN.184 ........................................................................................... ........................................................................................... .....................................................RIGPRDDPKVRSKILSEEFGWDKDLAKKIWCFGPETTG PNMVVDMCKGVQYLNEIKDSVVAGFQWASKEGALADENMRGICFEVCDVVLHTDAIHRGGGQVIPTARRVIFASQLTAKPRLLEPVYLVEI QAPEGALGGIYGVLNQKRGHVFEEMQRPGTPLYNIKAYLPVIESFGFSAILRAATSGQAFPQCVFDHWDVMNSDPLEVDSQSFNLVKEIRK RKGLKEQMTPLSDFEDKL 77 MN.173 ........................................................................................... ........................................................................................... .......................................................................................ETTG PNMVVDMCKGVQYLNEIKDSVVAGFQWASKEGALADENMRGICFEVCDVVLHTDAIHRGGGQVIPTARRVIFASQLTAKPRLLEPVYLVEI QAPEGALGGIYGVLNQKRGHVFEEMQRPGTPLYNIKAYLPVIESFGFSAILRAATSGQAFPQCVFDHWDVMNSDPLEVDSQSFNLVKEIRK RKGLKEQMTPLSDFEDKL 77 MN.210 DPEGPLMLYVSKMIPASDKGRFFAFGRVFAGRVATGMKVRIMGPNFVPGQKKDLYTKSVQRTVIWMGKKQESVEDVPCGNTVALVGLDQFI TKNATLTGEKEVDACPIRAMKFSVSPVVRVAVQCKVASDLPKLVEGLKRLAKSDPMVLCSIEESGEHITAGAGELRLEICLKDLQDDFMGG AEIIVSPPVVSFRETVLDKSCRTVMSKSPNKHNRLYMEARPLEEGLPEAIDEGRIGPRDDPKVRSKILSEEFGWDKDLAKKIWCFGPETTG PNMVVDMCKGVQYLNEIKDSVVAGFQWASKEGALADENMRGICFEVCDVVLHTDAIHRGGGQVIPTARRVIFASQLTAKPRLLEPVYLVEI QAPEGALGGIYGVLNQKRGHVFEEMQRPGTPLYNIKAYLPVIESFGFSAILRAATSGQAFPQCVFDHWDVMNSDPLEVDSQSFNLVKEIRK RKGLKEQMTPLSDFEDKL 77 MN.206 DPEGPLMLYVSKMIPASDKGRFFAFGRVFAGRVATGMKVRIMGPNFVPGQKKDLYTKSVQRTVIWMGKKQESVEDVPCGNTVALVGLDQFI TKNATLTGEKEVDACPIRAMKFSVSPVVRVAVQCKVASDLPKLVEGLKRLAKSDPMVLCSIEESGEHITAGAGELRLEICLKDLQDDFMGG AEIIVSPPVVSFRETVLDKSCRTVMSKSPNKHNRLYMEARPLEEGLPEAIDEGRIGPRDDPKVRSKILSEEFGWDKDLAKKIWCFGPETTG PNMVVDMCKGVQYLNEIKDSVVAGFQWASKEGALADENMRGICFEVCDVVLHTDAIHRGGGQVIPTARRVIFASQLTAKPRLLEPVYLVEI QAPEGALGGIYGVLNQKRGHVFEEMQRPGTPLYNIKAYLPVIESFGFSAILRAATSGQAFPQCVFDHWDVMNSDPLEVDSQSFNLVKEIRK 77 MN.136 ........................................................................................... ........................................................................................... ........................................................................................... ......................AGFQWASKEGALADENMRGICFEVCDVVLHTDAIHRGGGQVIPTARRVIFASQLTAKPRLLEPVYLVEI QAPEGALGGIYGVLNQKRGHVFEEMQRPGTPLYNIKAYLPVIESFGFSAILRAATSGQAFPQCVFDHWDVMNSDPLEVDSQSFNLVKEIRK RKGLKEQMTPLSDFEDKL 78 MN.94 RHLARQFIPHLHQRFIHPPIRQPNTMENLSSTIFSFVILLSASASLVVAGDPIKEACGGTRFPETCASVLSANKDPRSTYADPGELAEMEV SAAFHLFSMAVTTTRSQQWNDEN 78 MN.83 RHLARQFIPHLHQRFIHPPIRQPNTMENLSSTIFSFVILLSASASLVVAGDPIKEACGGTRFPETCASVLSANKDPRSTYADPGELAEMEV S 78 MN.14 ......................PNTMENLSSTIFSFVILLSASASLVVAGDPIKEACRGTRFPETCASVLSANKDPR 78 MN.3 ........................................................................................... ................................................YYGKINLSKVRTFLTEAKAKHTEWNCDVCERGDDKKKVDEISK G 78 MN.46 .PHVARIRPHLHQRFIHPPIHQPNTMENLSSTIFSFVILLSASASLVVAGDPIKEACGGTRFPETCASVLSANKDPR 78 MN.17 .........................MENLSSTIFSFVILLSASASLVVAGDPIKEACGGTRFPETCASVLSANKDPRSAYVD 78 MN.20 .........................MENLSSTIFSFVILLSASASLVVAGDPIKEACGGTRFPETCASVLSANKDPRSTYVDP 78 MN.12 ........................................................................................... .....................................FTPHSLKLBKACEAFNPYDGKTISLSKVRSFLTEAKAKHIEWNCDVCRHGDDKKK 78 MN.35 ........................................................................................... ................QQWNDENMSKEDEDCFKECGVKLHKACEAFNPYDGKISLSKVRSFLTEAKAKHIEWNCDVCRHGDDKKK 78 MN.15 ........................................................................................... ....................................FTPHSLKLBKACEAFDPYYGKISLSKVRSFLTEAKAKHIEWNCDVCRHGDDKKKV 78 MN.38 ........................................................................................... ...............QQWNDENMSKEDEDCFKECGVKLHKACEAFDPYYGKISLSKVRSFLTEAKAKHIEWNCDVCRHGDDKKKV 78 MN.74 .......................NTNENLSSTIFSFVILLSASASLVVAGDQINEACGGTRFPEICASVLSANKDPRSTYADPVELAEMEV SAAFRLFSMAVTAARSQQWNDEN 78 MN.41 ........................................................................................... ...............SQQWNDENMSKEDEDCFKECGVKLHKACEAFDPYDGKISLSKVRSFLTEAKAKHIEWNCDVCRHGDDKKKVD 78 MN.67 ....................MENLSSTTFSFVILLSASASLVVAGDPIKEACGGTPSPETCASVLSANKDPRSBYADPVELAEMEV SAAFHLFSMAVTAARSQQWNDEN 78 MN.27 ........................................................................................... ...............QQWNDENMSKEDEDCFKECGVKLHKACEAFNPYDGKISLSKVRSFLAEAKAKHIEWNCDVCR 78 MN.75 ......................................LLSASASLVVAGDPTNEACGSSRYPETCASVLSANKDPRSTYADPGELAEMEC GTDEBLFSMTVIAAGSQQWNDCMMSKEDEDCFKECGVKL 78 MN.47 ........................................................................................... .............GSQQWNDENMSKEDEDCFKECGVKLHKACDAFNPYYGKTNLSKVRTFLTEAKAKHIEWNCDVCRHGDDKKTVDEISK 78 MN.33 .............DGGREILHQPNTMENLSSTIFSFVILLSASASLVVAGDSINEACGGSRYPEICVSVLSANRDPRST 78 MN.86 ....................................................IKEACGGTRFPETCASVLSANKDPRSTYADPVELAEMEV SAAFHLFSMAVTAARSQQWNDENMSKEKRWNAALTSISASSTGSAYVDLGSLLAERTEACASGKRVPPHASLI 78 MN.59 ....................................................IKEACGGTRYPETCASVLSANKDPRSYYADPVELAEMEV SAAFHLFSMAVTAARSQQWNDENMSKEDEMMSKEDEDCFKECGCKLHTLDR 78 MN.63 ....................................................IKEACGGTRFPETCASVLSANKDPRSTYADPVELAEMEV SAAFHLFSMAVTAARSQQWNDENMSKEDEDCFKECGVKLHKACEAFNP 78 MN.8 ..............................STIFSFVILLSASAELVVAGDPIKEACGGPRYPETCASVLSANKDPRSTYA 78 MN.51 ...................................................IKEACGGTRFPETCASVLSANKDPRSTYADPVELAEMEV SAAFHLFSMAVTAARSQQWNDENMSKEDEDCFKECGVRL 78 MN.62 ...................................................IKEACGGTRFPETCASVLSANKDPRSTYADPVELAEMEV SAAFHLFSMAVTAARSQQWNDZNMSKEDEDCFKECGMKLRKACEAFNP 78 MN.56 ...................................................IKEACGGTRFPETCASVLSANKDPRSTYADPVELAEMEV SAAFHLFSMAVTAARSQQWNDENMSKEDEDCFKECGLNASHAL 78 MN.30 ...................RAAVTTMENLSSTIFSFVILLSASASLVVAGDPIKEACGGTRZPETCASVLSANKDPREAYVDLG 79 MN.81 ........................................................................................... .........................................................................VKLKNVLNVYEARLTKFK YLAGDYLSLADLNHVSTILCLGATPHASLFDAYPHVKAWWTDLLAKPSVQKVAALMKP 79 MN.91 ........................................................................................... ....................................................................VEDNLVKENNVLNVYEARCIRSK YLAGDYLSLADLNHVSTILCLGATPHASLFDAYPHVKAWWTDLLAKPSVQKVAALMKP 79 MN.36 ........................................................................................... ...........................................................................LKKVLEVYEARLTKFK YLAGDYLSLADLNHVSTILCLGATPHASLFDAYPHVKAWWTDLLAKPSVQKVAA 79 MN.71 ........................................................................................... ........................................................................................... ..........DLNHVSTTLCLGATPHASLFDAYPHVKAWWTDLLAKPSVQKVAALMKP 79 MN.80 ........................................................................................... ......................................................................DNLVKLKNVLNVYEARLTKSK YLAGDYLSLADLNHVSTILCLGATPHASLFDAYPHVKAWWTDLLAKPSVQKVAALMKP 79 MN.76 ........................................................................................... ............................................................................KEVLEVYEARLTKFK YLAGDYLSLADLNHVSTILCLGATPHASLFDAYPHVKAWWTDLLAKFSVQKVAALMKP 79 MN.96 ........................................................................................... .........................................QYTAALSPILFECLIHPMLGGATNQKVVEDNLVKLKNVLNVYEARLTKSK YLAGDYLSLADLNHVSTTLCLGATPHASLFDAYPHVKAWWTDLLAKPSVQKVAALMKP 79 MN.106 ........................................................................................... .........................................QYTAALSPILFECLIHPMLGGATNQKVIEDNLVKLKNVLNVYEARLTKSK YLAGDYLSLADLNHVSTTLCLGATPHASLFDAYPHVKAWWTDLLAKPSVQKVAALMKP 79 MN.90 ........................................................................................... .........................................QYTAALSPILFECLIHPMLGGATNQKVVEDNLVKLKNVLNVYEARLTKFK YLAGDYLSLADLNHVSTTLCLGATPHASLFDAYPHVKAWWTDLLAKPSVQKVAALMKP 79 MN.57 AALEEAGVDYEIVPINFGTGEHKAPDHLARNBFGQVPALQDGDL CIFESRAICKYACRKNKPELLKEGDLKEAAMDEALEENG 79 MN.25 ........................................................................DHLARNPFGQVPALQDGDL CIFESRAICKYACRKNKPELLKEGDLKESAMVDVWLEVEANQY 79 MN.108 CIPYAESAGGEVTVLVISSRKKGAAAGVLFPKGGWCLDEIMECAARREALEEAGVDYEIVPINSGIGEAKGSDBLARNPIGQVPALQDGDL CIFESRAICKYACRKNRPELLNEGDLKESAMVDVWLEVEAQQYTAALSPILFFCLVHPMLGGATDDDQKVVEDNLIQ 80 MN.186 KLRFTCLSSTGSSCLFVLILF 81 MN.58 ERLKKVIEVYEAKLSNHSYLAGDFVSEADINRFPKTFYYFYMATPRASLFDSYYYPRVKQWWERIMARPPAVKKIAAAMVPPKA 82 MN.6 ........................................................................................... PDHLARNPFGQVPALQDGDLYIFESRAICKYACRKNKPELLKEGDL 82 MN.77 .....................................................................LEEAGVDYEIVPINFGTGERKG PDHLARNPFGQVPALQDGDLYIFESRAICKYACRKNKPELLKEGDLKESAMVDVWLEVEANQYTAALGPILFE 82 MN.107 PAPRRLFKPGPPASSSPSHPIHPAATSLPPPRKRKVRGFWRVHQISARMAPVKLYGATLSWNVTRCVAALEEAGVDYEIVPINFGTGEBKG PDHLARNPFGQVPALQDGDLYIFESRAICKYACRKNKPELLKEGDLKESAMVDVWLEVEANQYTAALGPILFE 83 MN.203 ..........................RLKKLKSEHGKVQLGNITVDMVLGGMRGMTGMLWETSLLDPEEGIRFRGLSIPECQKVLPTAVKG GEPLPEGLLWLLLTGKVPTKEQVDALSKDLLSRSTVPGYVYKAIDALPVTAHPMTQFTTGVMALQVESEFAKAYDKGMPKSKFWEPTYEDC LNLIARLPQVASYVYRRIFKDGTIAADNSLDYAANFSHMLGFDDPKMLELMRLYITIHTDHEGGNVSAHTGHLVGSALSDPYLSFAAALN GLAGPLHGLANQEVLLWIKSVMEETGSNITTDQLKEYVWKTLKSGKVVPGYGHGVLRNTDPRYSCQREFALKHLPEEPLFQLVSKLYEVVP GILTELGKVKNPWPNVDAHSGVLLNHFGLVEARYHTVLFGVSRSMGIGSQLIWDRALGLPLERPKSVTMEWLGNHCKKVAA 83 MN.204 ..........................RLKKLKSEHGKVQLGNITVDMVLGGMRGMTGMLWETSLLDPEEGIRFRGLSIPECQKVLPTAVKG GEPLPEGLLWLLLTGKVPTKEQVDALSKDLLSRSTVPGYVYKAIDALPVTAHPMTQFTTGVMALQVESEFAKAYDKGMPKSKFWEPTYEDC LNLIARLPQVASYVYRRIFKDGTIAADNSLDYAANFSHMLGFDDPKMLELMRLYITIHTDHEGGNVSAHTGHLVGSALSDPYLSFAAALN GLAGPLHGLANQEVLLWIKSVMEETGSNITTDQLKEYVWKTLKSGKVVPGYGHGVLRNTDPRYSCQREFALKHLPEEPLFQLVSKLYEVVP GILTELGKVKNPWPNVDAHSGVLLNHFGLVEARYHTVLFGVSRSMGIGSQLIWDRALGLPLERPKSVTMEWLGNHCKKVAA 83 MN.211 AYPEACSLFLNTAVSPNYFVCNLLQERLKKLKSEHGKVQLGNITVDMVLGGMRGMTGMLWETSLLDPEEGIRFRGLSIPECQKVLPTAVKG GEPLPEGLLWLLLTGKVPIKEQVDALSKDLLSRSTVPGYVYKAIDALPVIARPMIGFIIGVMALQVESEFAKAYDKGMPKSWEPIYEDC LNLIRLPQVASTVIRRIFKDGKIIAADNSLDYAANFSHMLGFDDPKMLELMRLYITIHTDHOGGNVSAHIGHLVGSALSDPYLSPAALN GLAGPLHGLANQEVLLWIKSVMEETGSNITIDQLKEYVWKTLKSGKVVPGYGHGALRDTDFRYSCQREFALKELPEDDPLFQLVSKLYEVVP GILTELGRVKNPNPNVDAHSGVLLNHFGLVEARYDTVLFGVSRSMGIGSQLIWDRAL 83 MN.205 AYPEACSLFLNTAVSPNYFVCNLLQERLKKLKSEHGKVQLGNITVDMVLGGMRGMTGMLWETSLLDPEEGIRFRGLSIPECQKVLPTAVKG GEPLPEGLLWLLLTGKVPIKEQVDALSKDLLSRSTVPGYVYKAIDALPVIARPMIGFIIGVMALQVESEFAKAYDKGMPKSWEPIYEDC LNLIRLPQVASTVIRRIFKDGKIIAADNSLDYAANFSHMLGFDDPKMLELMRLYITIHTDHOGGNVSAHIGHLVGSALSDPYLSPAALN GLAGPLHGLANQEVLLWIKSVMEETGSNITIDQLKEYVWKTLKSGKVVPGYGHGALRDTDPRYSCQREFALKELPEDDPLFQLVSKLYEVVP GILTELGRVKNPNPNVDAHSGVLLNHFGLVEARYDTVLFGVSRSMGIGSQLIWDRALGLPLERPKSVIMEWLGNHCKKGA 83 MN.68 ........................................................................................... ........................................................................................... ........................................................................................... ...................................................................................VEKLYEVVP GILTELGRVKNPNPNVDAHSGVLLNHFGLVEARYDTVLFGVSRSMGIGSQLIWDRALGLPLERPKSVIMEWLGNHCKKGA 83 MN.98 ........................................................................................... ........................................................................................... ........................................................................................... ...........................................................TDPRYSCQREFALKELPEDDPLFQLVSKLYEVVP GILTELGRVKNPNPNVDAHSGVLLNHFGLVEARYDTVLFGVSRSMGIGSQLIWDRALGLPLERPKSVIMEWLENHCKKVAA 83 MN.93 ........................................................................................... ........................................................................................... ........................................................................................... ...................................................................................VEKLYEVVP GILTELGRVKNPNPNVDAHSGVLLNHFGLVEARYDTVLFGVSRSMGIGSQLIWDRALGLPLERPKSVIMEWLGNHCKKVAA 83 MN.113 ........................................................................................... ........................................................................................... ........................................................................................... ...................................................................................VEKLYEVVP GILTELGRVKNPNPNVDAHSGVLLNHFGLVEARYDTVLFGVSRSMGIGSQLIWDRALGLPLERPKSVIMEWLGNHCKKVAA 83 MN.123 ........................................................................................... ........................................................................................... ........................................................................................... ...........................................................TDPRYSCQREFALKELPEDPLFQLVSKLYEVVP GILTELGRVKNPNPNVDAHSGVLLNHFGLVEARYDTVLFGVSRSMGIGSQLIWDRALGLPLERPKSVIMEWLENHCKKVAA 83 MN.69 ........................................................................................... ........................................................................................... ........................................................................................... ...........................................................................EDPLFQLVSKLYEVVP GILTELGRVKNPNPNVDAHSGVLLNHFGLVEARYDTVLFGVSRSMGIGSQLIWDRALGLPLERPKSVTMEWLG 84 MN.178 PRPMKGMLTGPVTILNNSTVSSDQPRFETCTQIALAIKKIVEDLEAGGIQVIQIDEAALREGLPLKKSTHAFTYLDWAVHSEFRITNCGVQDT TQIHTHMCYSWPNDLIWSTINMDADVITINNKKRDEKLLSVFGVTIGMGIGPGVYDIHSPRIPTAETADMVNMMLAVLDTNILWVNPD CGLKIRKYAEVMPALTINMVTAAKLIRIQLASTK 84 MN.182 ....KGMLTGPVTILNNSTVSSDQPRFETCTQIALAIKKIVEDLEAGGIQVIQIDEAALREGLPLKKSTHAFTYLDWAVHSEFRITNCGVQDT TQIHTHMCYSWPNDLIWSTINMDADVITINSRSDEKLLSVFGVTIGMGIGPGVYDIHSPRIPTAETADMVNMMLAVLDTNILWVNPD CGLKIRKYAEVMPALTINMVTAAKLIRIQLASTK 84 MN.4 ........................................................................................... ......................................VFGVTIGMGIGPGVYDIHSPRIPTAETADMVNMMLAVLDTNI 84 MN.166 ....KGMLTGPVTILNNSTVSSDQPRFETCTQIALAIKKIVEDLEAGGIQVIQIDEAALREGLPLKKSTHAFTYLDWAVHSEFRITNCGVQDT TQIHTHMCYSWPNDLIWSTINMDADVITINSRSDEKLLSVFGVTIGMGIGPGVYDIHSPRIPTAETADMVNMMLAVLDTNILWVNPD CGLKIRKYAEVMPALTINMVTAAKLIRIQLASTK 84 MN.167 ....KGMLTGPVTILNNSTVSSDQPRFETCTQIALAIKKIVEDLEAGGIQVIQIDEAALREGLPLKKSTHAFTYLDWAVHSEFRITNCGVQDT TQIHTHMCYSWPNDLIWSTINMDADVITINSRSDEKLLSVFGVTIGMGIGPGVYDIHSPRIPTAETADMVNMMLAVLDTNILWVNPD CGLKIRKYAEVMPALTINMVTAAKLIRIQLASTK 84 MN.172 PEPMKGMLTGPVTILNNSTVSSDQPRFETCTQIALAIKKIVEDLEAGGIQVIQIDEAALREGLPLKKSTHAFTYLDWAVHSEFRITNCGVQDT TQIHTHMCYSWPNDLIWSTINMDADVITINNKKRDEKLLSVFGVTIGMGIGPGVYDIHSPRIPTAETADMVNMMLAVLDTNILWVNPD CGLKIRKYAEVMPALTINMVTAAKLIRIQLASTK 84 MN.158 ...............LNNSTVSSDQPRFETCTQIALAIKKIVEDLEAGGIQVIQIDEAALREGLPLKKSTHAFTYLDWAVHSEFRITNCGVQDT TQIHTHMCYSWPNDLIWSTINMDADVITINNKKRDEKLLSVFGVTIGMGIGPGVYDIHSPRIPTAETADMVNMMLAVLDTNILWVNPD CGLKIRKYAEVMPALTINMVTAAKLIRIQLASTK 84 MN.105 PRPMKGMLTGPVTILNNSTVSSDQPRFETCTQIALAIKKIVEDLEAGGIQVIQIDEAALREGLPLKKSTHAFTYLDWAVHSEFRITNCGVQDT TQIHTHMCYSWPNDLIWSTINMDADVITINNKKRDEKLLSVFGVTIGMGIGPGVYDIHSPRIPTAEEI 85 MN.39 LAETHMCYSWPNDLIWSTINMDADVITINNKKRDEKLLSVFGVTIGMGIGPGVYDIHSPRIP 86 MN.194 ......MSTAEATREENVYMAKLAEQAERYEEMVEFMEKVAKTADVGELIVEERNLLSVAYKNVIGARRASWRIISSIEQKEESRGNEAYVA SIKEYRIRIELSKICDGILKLLDSHLVPSATAAESKVFYLKMKGDYHRYYLAEFKAGAERKEAAENTLVAYKSAQDIALADLPITHPIRL GLALNFSVFYYEILNSPDRACNLAKQAFDEAIAELDSLGEESYKDSTLIMQLLRLNLTLWTSDNADEGGDEIKEASKPEGECH 86 MN.195 ......MSTAEATREENVYMAKLAEQAERYEEMVEFMEKVAKTADVGELIVEERNLLSVAYKNVIGARRASWRIISSIEQKEESRGNEAYVA SIKEYRIRIELSKICDGILKLLDSHLVPSATAAESKVFYLKMKGDYHRYYLAEFKAGAERKEAAENTLVAYKSAQDIALADLPITHPIRL GLALNFSVFYYEILNSPDRACNLAKQAFDEAIAELDSLGEESYKDSTLIMQ 86 MN.101 ...........................................................................SIEQKEESRGNEAYVA SIKEYRIRIELSKICDGILKLLDSHLVPSATAAESKVFYLKMKGDYHRYYLAEFKAGAERKEAAENTLVAYKSAQDIALADLPITHPIRL GLALNFSVFYYEILNSPDRACNLAKQAFDEAIAELDSLGEESYKDSTLIMQ 86 MN.116 ......MSTAEATREENVYMAKLAEQAERYEEMVEFMEKVAKTADVGELIVEERNLLSVAYKNVIGARRASWRIISSIEQKEESRGNEAYVA SIKEYRIRIELSKICDGILKLLDSHLVPSATAAESKVFYLKMKGDYHRYYLAEFKAGAERKEAAENTLVAYKS 86 MN.181 ......MSTAEATREENVYMAKLAEQAERYEEMVEFMEKVAKTADVGELIVEERNLLSVAYKNVIGARRASWRIISSIEQKEESRGNEAYVA SIKEYRIRIELSKICDGILKLLDSHLVPSATAAESKVFYLKMKGDYHRYYLAEFKAGAERKEAAENTLVAYKSAQDIALADLPITHPIRL GLALNFSVFYYEILNSPDRACNLAKQAFDEAIAELDSLGEESYKDSTLIMQLLRLNLTLWTSDNADEGGDEIKEASKPEGECH 86 MN.97 ........................................................................................... ........................................................RKEAAENTLVAYKSAQDIALADLPITHPIRL GLALNFSVFYYEILNSPDRACNLAKQAFDEAIAELDSLGEESYKDSTLIMQLLRLNLTLWTSDNADEGGDEIKEASKPEGECH 86 MN.54 ........................................................................................... ........................................................................................... ......FSVFTYYEILNSPDRACNLAKQAFDEAISELDSLGEESYKDSTLIMQLLRDNLTLWISDTNEDCGGDEIKEAPAPKESGDCQ 86 MN.156 ..................YMAKLAEQAERYEEMVEFMEKVAKTADVGELIVEERNLLSVAYKNVIGARRASWRIISSIEQKEESRGNEAYVA SIKEYRIRIELSKICDGILKLLDSHLVPSATAAESKVFYLKMKGDYHRYYLAEFKAGAERKEAAENTLVAYKSAQDIALADLPITHPIRL GLALNFSVFYYEILNSPDRACNLAKQAFDEAIAELDSLGEESYKDSTLIMQLLRLNLTLWTSDNADEGGDEIKEASK 86 MN.117 ......MSTAEATREENVYMAKLAEQAERYEEMVEFMEKVAKTADVGELIVEERNLLSVAYKNVIGARRASWRIISSIEQKEESRGNEAYVA SIKEYRIRIELSKICDGILKLLDSHLVPSATAAESKVFYLKMKGDYHRYLAEFKA 86 MN.163 ........................................................................................... .......................................................GAERKEAAENTLVAYKSAQDIALADLPITHPIRL GLALNNFSVFYYEILNSPDHACNLAKQAFDEAIAELDSLGEESYKDSILIMQLLRDNLTLWISDNADEGGDEIKEASKPEGEGH 86 MN.175 .......................................................................................... .........................................................GAERKEAAENTLVAYKSAQDIALADLPITHPIRL GLALNNFSVFYYEILNSPDHACNLAKQAFDEAIAELDSLGEESYKDSILIMQLLRDNLTLWISDNADEGGDEIKEASKPEGEGH 86 MN.102 .....METAEATREENVYMAKLAEQAERYEEMVEFMEKVAKTADVGELTVEERNLLSVAYKNVIGARRASWRIISSIEQKEESRGNEAYVA SIKEYRTRIETELSKICDGILKLLDSHLVPSATAAESKVTYLKMKGDYHRYLAEFKAG 86 MN.202 .....METAEATREENVYMAKLAEQAERYEEMVEFMEKVAKTADVGELTVEERNLLSVAYKNVIGARRASWRIISSIEQKEESRGNEAYVA SIKEYRTRIETELSKICDGLKLLDSHLVPSATAAESKVTYLKMKGDYHRYLAETKAGAERKEAAENILVAYKSAQDIALADLPIIHPIRL GLALNNFSVFYYEILNSPDHACNLAKQAFDEAIAELDSLGEESYKDSILIMQLLRDNLTLWISDNADEGGDEIKEASKPEGEGH 87 MN.157 ........................RPSSVLPFDLKEAEAELQPPSRTPMGTVSSYYNYLYIIFIKSVFGTVGIFHKJHKKGSVYEVHEI LAEEVLGKMGAPPKIDVPIISPQELLKEADGILFGFPTHFGMMASQMKAFDATGGLWREQSLAGFFAGVFFSTGIQGGGQEITPLIAVTQL THHGMVFVPVGYTFGAKMFDMEKVQGGSPYGAGTFAGDGSRWPSEMELEHAFHQGKYFYGIAKKLKGSSA 87 MN.119 ........................................................................................PEI LAEEVLGKMGAPPKIDVPIISPQELLKEADGILFGFPTHFGMMASQMKAFDATGGLWREQSLAGFFAGVFFSTGIQGGGQEITPLIAVTQL THHGMVFVPVGYTFGAKMFDMEKVQGGSPYGAGTFAGDGSRWPSEMELEHAFHQGKYFYGIAKKLKGSSA 87 MN.114 ........................................................................................PEI LAEEVLGKMGAPPKIDVPIISPQELLKEADGILFGFPTHFGMMASQMKAFDATGGLWREQSLAGFFAGVFFSTGIQGGGQEITPLIAVTQL THHGMVFVPVGYTFGAKMFDMEKVQGGSPYGAGTFAGDGSRWPSEMELEHAFHQGKYFYGIAKKLKGSSA 87 MN.92 ..............................................................VGKLAEEIKKGASSVEGVEVKVWQVFEI LAEEVLGKMGAPPKIDVPIISPQELLKEADGILFGFPTHFGMMASQMKAFDATGGLWREQSLAGFFAGVFFSTGIQGGGQEITPLIAVTQL THHGMVFVPVGY 87 MN.88 .......................................................................................... .............................GILFGFPTHFGMMASQMKAFDATGGLWREQSLAGFFAGVFFSTGIQGGGQEITPLIAVTQL THHGMVFVPVGYTFGAKMFDMEKVQGGSPYGAGTFAGDGSRWPSEMELEHAFH 87 MN.153 QGTATSAGSRALPFLLQLTKQPATRPSSVLFFDLRSAEAELQPPRRPPHAVKVYVVYYSMYGHVGKLAEEIKKGASSVEGVEVRAKQVPEI LAEEVLGKMGAPPKIDVPIISPQELLKEADGILFGFPTHFGMMASQMKAFDATGGLWREQSLAGFFAGVFFSTGIQGGGQEITPLIAVTQL THHGMVFVPVGYTFGAKMFDMEKVQGGSPYGAGTFAGDGSRWPSEMELEHAFH 87 MN.95 ...............................................MAVKVYVVYYSMYGHVGKLAEEIKKGASSVEGVEVRAKQVPEI LAEEVLGKMGAPPKIDVPIISPQELLKEADGILFGFPTHFGMMASQMKAFDATGGLWREQSLAGFFAGVFFSTGIQGGGQEITPLIAVTQL TQHGMVF 87 MN.128 ......................................................................IKKGASSVEGVEVRAKQVPEI LAEEVLGKMGAPPKIDVPIISPQELLKEADGILFGFPTHFGMMASQMKAFDATGGLWREQSLAGFFAGVFFSTGIQGGGQEITPLIAVTQL THHGMVFVPVGYTFGAKMFDMEKVQGGSPYGAGTFAGDGSRWPSEMELEHAFHQGKYFYGIAKKLKGSSA 87 MN.122 ......................................................................IKKGASSVEGVEVRAKQVPEI LAEEVLGKMGAPPKIDVPIISPQELLKEADGILFGFPTHFGMMASQMKAFDATGGLWREQSLAGFFAGVFFSTGIQGGGQEITPLIAVTQL THHGMVFVPVGYTFGAKMFDMEKVQGGSPYGAGTFAGDGSRWPSEMELEHAFHQGKYFYGIAKKLKGSSA 87 MN.118 .............................................................................VEGVEVKVKQVPEI LAEEVLGKMGAPPKIDVPIISPQELLKEADGILFGFPTHFGMMASQMKAFDATGGLWREQSLAGFFAGVFFSTGIQGGGQEITPLIAVTQL THHGMVFVPVGYTFGAKMFDMEKVQGGSPYGAGTFAGDGSRWPSEMELEHAFHQGKYFYGIAKKLKGSSA 87 MN.99 ........................................................................................... .............KIDVPIISPQELLKEADGILFGFPTHFGMMASQMKAFDATGGLWREQSLAGFFAGVFFSTGIQGGGQEITPLIAVTQL THHGMVFVPVGYTFGAKMFDMEKVQGGSPYGAGTFAGDGSRWPSEMELEHAFHQGKYFYGIAKKLKGSSA 88 MN.72 ADVYFIVCLPMCVCVLFVICS 89 MN.214 ........................................................................................... ...............GLGRLAACFLDSMAILNLPAWGYGLRYRYGLFKQRIAKEGQEEIAEDWLEKFSPWEIVRHDVVYPVRFFGHVEILP DGRRKSAGGEVLNALAYDVPIPGYKTKNAISLRLWDAKASAEDFNLEQFNDGQYESAAQLHSRAQQICAVLYPGDATEEGKLLRLKQQFFL CSASLQDIIFRFKERKSDRVSGKWSEFPSKVAVQMNDTHPTLAIPELMRLLMDEEGLGWDEAWDVTNKTVAYTNHTVLPEALEKWSQSVMR KLLPRQMEIIEEIDKRFREMVISTRKDMEGKLDSMSVLDNSPQKPVVRMANLCVVSAHTVNGVAELHSNILKEELFADYVSIWPKKFQNKT NGITPRRWLRFCNPELSEIVTKWLNTDQWTSNLDLLTGLRKFADDEKLHAEWAAAKLASKKRLAKHVLDATGVTIDPTSLFDIQIKRIHEY KRQLMNILGAVYRYKKLKEMSAEEKQKVIPRIVMVGGKAFATYTNAKRIVKVLNDVGAVVNNDPDVNKYLKVVFIPNYNVSVAEVLIPGSE LSQHISTAGMEASGTSNMKFSLNGCVIIGTLDGANVEIREEVGEDNFFLFGAKADQVAGLRKDRENGLFKPDPRFEEAKQYIRSGTFGTYD YIPLLDSLEGSGFGRGDYFLVGYDFPSYIDAQARVDEAYKDKKRWIKMSILNTAGSGKFSSDRTIDQYAKEIWGITANPVP 89 MN.219 ........................................................................................... ...............GLGRLAACFLDSMAILNLPAWGYGLRYRYGLFKQRIAKEGQEEIAEDWLEKFSPWEIVRHDVVYPVRFFGHVEILP DGRRKSAGGEVLNALAYDVPIPGYKTKNAISLRLWDAKASAEDFNLEQFNDGQYESAAQLHSRAQQICAVLYPGDATEEGKLLRLKQQFFL CSASLQDIIFRFKERKSDRVSGKWSEFPSKVAVQMNDTHPTLAIPELMRLLMDEEGLGWDEAWDVTNKTVAYTNHTVLPEALEKWSQSVMR KLLPRQMEIIEEIDKRFREMVISTRKDMEGKLDSMSVLDNSPQKPVVRMANLCVVSAHTVNGVAELHSNILKEELFADYVSIWPKKFQNKT NGITPRRWLRFCNPELSEIVTKWLNTDQWTSNLDLLTGLRKFADDEKLHAEWAAAKLASKKRLAKHVLDATGVTIDPTSLFDIQIKRIHEY KRQLMNILGAVYRYKKLKEMSAEEKQKVIPRIVMVGGKAFATYTNAKRIVKVLNDVGAVVNNDPDVNKYLKVVFIPNYNVSVAEVLIPGSE LSQHISTAGMEASGTSNMKFSLNGCVIIGTLDGANVEIREEVGEDNFFLFGAKADQVAGLRKDRENGLFKPDPRFEEAKQYIRSGTFGTYD YIPLLDSLEGSGFGRGDYFLVGYDFPSYIDAQARVDEAYKDKKRWIKMSILNTAGSGKFSSDRTIDQYAKEIWGITANPVP 89 MN.220 ........................................................................................... ...............GLGRLAACFLDSMAILNLPAWGYGLRYRYGLFKQRIAKEGQEEIAEDWLEKFSPWEIVRHDVVYPVRFFGHVEILP DGRRKSAGGEVLNALAYDVPIPGYKTKNAISLRLWDAKASAEDFNLEQFNDGQYESAAQLHSRAQQICAVLYPGDATEEGKLLRLKQQFFL CSASLQDIIFRFKERKSDRVSGKWSEFPSKVAVQMNDTHPTLAIPELMRLLMDEEGLGWDEAWDVTNKTVAYTNHTVLPEALEKWSQSVMR KLLPRQMEIIEEIDKRFREMVISTRKDMEGKLDSMSVLDNSPQKPVVRMANLCVVSAHTVNGVAELHSNILKEELFADYVSIWPKKFQNKT NGITPRRWLRFCNPELSEIVTKWLNTDQWTSNLDLLTGLRKFADDEKLHAEWAAAKLASKKRLAKHVLDATGVTIDPTSLFDIQIKRIHEY KRQLMNILGAVYRYKKLKEMSAEEKQKVIPRIVMVGGKAFATYTNAKRIVKVLNDVGAVVNNDPDVNKYLKVVFIPNYNVSVAEVLIPGSE LSQHISTAGMEASGTSNMKFSLNGCVIIGTLDGANVEIREEVGEDNFFLFGAKADQVAGLRKDRENGLFKPDPRFEEAKQYIRSGTFGTYD YIPLLDSLEGSGFGRGDYFLVGYDFPSYIDAQARVDEAYKDKKRWIKMSILNTAGSGKFSSDRTIDQYAKEIWGITANPVP 89 MN.199 GNISYHAHYSPHFSPLAFGPEPAYFATAESVKDHLLQRWNDTYLHFHKTDPKQTYYLSMEYLQGRALTNAVGNLGITGAYAEAVKKFGYEL EALAGQERDMALGNGGLGRLAACFLDSMAILNLPAWGYGLRYRYGLFKQRIAKEGQEEIAEDWLEKFSPWEIVRHDVVYPVRFFGHVEISP DGRRKSAGGEVLNALAYDVPIPGYKTKNAISLRLWDAKASAEDFNLEQFNDGQYESAAQLHSRAQQICAVLYPGDATEEGKLLRLKQQFFL CSASLQDIIFRFKERKSDRVSGKWSEFPSKVAVQMNDTHPTLAIPELMRLLMDEEGLGWDEAWDVTNKTVAYTNHTVLPEALEKWSQSVMR KLLPRQMEIIEEIDKR 89 MN.224 GNISYHAHYSPHFSPLAFGPEPAYFATAESVKDHLLQRWNDTYLHFHKTDPKQTYYLSMEYLQGRALTNAVGNLGITGAYAEAVKKFGYEL EALAGQERDMALGNGGLGRLAACFLDSMAILNLPAWGYGLRYRYGLFKQRIAKEGQEEIAEDWLEKFSPWEIVRHDVVYPVRFFGHVEISP DGRRKSAGGEVLNALAYDVPIPGYKTKNAISLRLWDAKASAEDFNLEQFNDGQYESAAQLHSRAQQICAVLYPGDATEEGKLLRLKQQFFL CSASLQDIIFRFKERKSDRVSGKWSEFPSKVAVQMNDTHPTLAIPELMRLLMDEEGLGWDEAWDVTNKTVAYTNHTVLPEALEKWSQSVMR KLLPRQMEIIEEIDKRFREMVISTRKDMEGKLDSMSVLDNSPQKPVVRMANLCVVSAHTVNGVAELHSNILKEELFADYVSIWPKKFQNKT NGITPRRWLRFCNPELSEIVTKWLNTDQWTSNLDLLTGLRKFADDEKLHAEWAAAKLASKKRLAKHVLDATGVTIDPTSLFDIQIKRIHEY KRQLMNILGAVYRYKKLKEMSAEEKQKVIPRIVMVGGKAFATYTNAKRIVKVLNDVGAVVNNDPDVNKYLKVVFIPNYNVSVAEVLIPGSE LSQHISTAGMEASGTSNMKFSLNGCVIIGTLDGANVEIREEVGEDNFFLFGAKADQVAGLRKDRENGLFKPDPRFEEAKQYIRSGTFGTYD YIPLLDSLEGSGFGRGDYFLVGYDFPSYIDAQARVDEAYKDKKRWIKMSILNTAGSGKFSSDRTIDQYAKEIWGITANPVP 89 MN.218 ........................................................................................... ..................RLAACFLDSMAILNLPAWGYGLRYRYGLFKQRIAKEGQEEIAEDWLEKFSPWEIVRHDVVYPVRFFGHVEISP DGRRKSAGGEVLNALAYDVPIPGYKTKNAISLRLWDAKASAEDFNLEQFNDGQYESAAQLHSRAQQICAVLYPGDATEEGKLLRLKQQFFL CSASLQDIIFRFKERKSDRVSGKWSEFPSKVAVQMNDTHPTLAIPELMRLLMDEEGLGWDEAWDVTNKTVAYTNHTVLPEALEKWSQSVMR KLLPRQMEIIEEIDKRFREMVISTRKDMEGKLDSMSVLDNSPQKPVVRMANLCVVSAHTVNGVAELHSNILKEELFADYVSIWPKKFQNKT NGITPRRWLRFCNPELSEIVTKWLNTDQWTSNLDLLTGLRKFADDEKLHAEWAAAKLASKKRLAKHVLDATGVTIDPTSLFDIQIKRIHEY KRQLMNILGAVYRYKKLKEMSAEEKQKVIPRIVMVGGKAFATYTNAKRIVKVLNDVGAVVNNDPDVNKYLKVVFIPNYNVSVAEVLIPGSE LSQHISTAGMEASGTSNMKFSLNGCVIIGTLDGANVEIREEVGEDNFFLFGAKADQVAGLRKDRENGLFKPDPRFEEAKQYIRSGTFGTYD YIPLLDSLEGSGFGRGDYFLVGYDFPSYIDAQARVDEAYKDKKRWIKMSILNTAGSGKFSSDRTIDQYAKEIWGITANPVP 89 MN.217 ........................................................................................... ........................................RYRYGLFKQRIAKEGQEEIAEDWLEKFSPWEIVRHDVVYPVRFFGHVEISP DGSRKSAGGEVLNALAYDVPIPGYKTKNAISLRLWDAKASAEDFNLEQFNDGQYESAAQLHSRAQQICAVLYPGDATEEGKLLRLKQQFFL CSASLQDIIFRFKERKSDRVSGKWSEFPSKVAVQMNDTHPTLAIPELMRLLMDEEGLGWDEAWDVTNKTVAYTNHTVLPEALEKWSQSVMR KLLPRQMEIIEEIDKRFREMVISTRKDMEGKLDSMSVLDNSPQKPVVRMANLCVVSAHTVNGVAELHSNILKEELFADYVSIWPKKFQNKT NGITPRRWLRFCNPELSEIVTKWLNTDQWTSNLDLLTGLRKFADDEKLHAEWAAAKLASKKRLAKHVLDATGVTIDPTSLFDIQIKRIHEY KRQLMNILGAVYRYKKLKEMSAEEKQKVIPRIVMVGGKAFATYTNAKRIVKVLNDVGAVVNNDPDVNKYLKVVFIPNYNVSVAEVLIPGSE LSQHISTAGMEASGTSNMKFSLNGCVIIGTLDGANVEIREEVGEDNFFLFGAKADQVAGLRKDRENGLFKPDPRFEEAKQYIRSGTFGTYD YIPLLDSLEGSGFGRGE 89 MN.215 ........................................................................................... ........................................RYRYGLFKQRIAKEGQEEIAEDWLEKFSPWEIVRHDVVYPVRFFGHVEISP DGSRKSAGGEVLNALAYDVPIPGYKTKNAISLRLWDAKASAEDFNLEQFNDGQYESAAQLHSRAQQICAVLYPGDATEEGKLLRLKQQFFL CSASLQDIIFRFKERKSDRVSGKWSEFPSKVAVQMNDTHPTLAIPELMRLLMDEEGLGWDEAWDVTNKTVAYTNHTVLPEALEKWSQSVMR KLLPRQMEIIEEIDKRFREMVISTRKDMEGKLDSMSVLDNSPQKPVVRMANLCVVSAHTVNGVAELHSNILKEELFADYVSIWPKKFQNKT NGITPRRWLRFCNPELSEIVTKWLNTDQWTSNLDLLTGLRKFADDEKLHAEWAAAKLASKKRLAKHVLDATGVTIDPTSLFDIQIKRIHEY KRQLMNILGAVYRYKKLKEMSAEEKQKVIPRIVMVGGKAFATYTNAKRIVKVLNDVGAVVNNDPDVNKYLKVVFIPNYNVSVAEVLIPGSE LSQHISTAGMEASGTSNMKFSLNGCVIIGTLDGANVEIREEVGEDNFFLFGAKADQVAGLRKDRENGLFKPDPRFEEAKQYIRSGTFGTYD YIPLLDSLEGSGFGRGE 89 MN.207 ..ISYRAHYSPHFSPLAEGPEPAYFATAESVRDHLLQNWNDTYLRFHETDFKQTYYISMEYLWSRALTNAVGNLGILGAYAEAVKKFGYEL EALAGQERDMALGNGGLGRLAACFLDSMAILNLPAWGYGLRYRYGLFKQRIAKEGQEEIAEDWLEKFSPWEIVRHDVVYPVRFFGHVEILP DGRRKSAGGEVLNALAYDVPIPGYKTKNAISLRLWDAKASAEDFNLEQFNDGQYESAAQLHSRAQQICAVLYPGDATEEGKLLRLKQQFFL CSASLQDIIFRFKERKSDRVSGKWSEFPSKVAVQMNDTHPTLAIPELMRLLMDEEGLGWDEAWDVTNKTVAYTNHTVLPEALEKWSQSVMR KLLPRQMEIIEEIDKRFREMVISTRKDMEGKLDSMSVLDNSPQKPVVRMANLCVVSAHTVNGVAELHSNILKEELFADYVSIWPKKFQNKT NGIIPFRWLRFCNPHLSEIVINWLKT 89 MN.223 ...................................................................................VKKFGYEL EALAGQERDMALGNGGLGRLAACFLDSMAILNLPAWGYGLRYRYGLFKQRIAKEGQEEIAEDWLEKFSPWEIVRHDVVYPVRFFGHVEILP DGRRKSAGGEVLNALAYDVPIPGYKTKNAISLRLWDAKASAEDFNLEQFNDGQYESAAQLHSRAQQICAVLYPGDATEEGKLLRLKQQFFL CSASLQDIIFRFKERKSDRVSGKWSEFPSKVAVQMNDTHPTLAIPELMRLLMDEEGLGWDEAWDVTNKTVAYTNHTVLPEALEKWSQSVMR KLLPRQMEIIEEIDKRFREMVISTRKDMEGKLDSMSVLDNSPQKPVVRMANLCVVSAHTVNGVAELHSNILKEELFADYVSIWPKKFQNKT NGITPRRWLRFCNPELSEIVTKWLNTDQWTSNLDLLTGLRKFADDEKLHAEWAAAKLASKKRLAKHVLDATGVTIDPTSLFDIQIKRIHEY KRQLMNILGAVYRYKKLKEMSAEEKQKVIPRIVMVGGKAFATYTNAKRIVKVLNDVGAVVNNDPDVNKYLKVVFIPNYNVSVAEVLIPGSE LSQHISTAGMEASGTSNMKFSLNGCVIIGTLDGANVEIREEVGEDNFFLFGAKADQVAGLRKDRENGLFKPDPRFEEAKQYIRSGTFGTYD YIPLLDSLEGSGFGRGDYFLVGYDFPSYIDAQARVDEAYKDKKRWIKMSILNTAGSGKFSSDRTIDQYAKEIWGITANPVP 89 MN.221 ........................................................................................... ..............RPRRRLAACFLDSMAILNLPAWGYGLRYRYGLFKQRIAKEGQEEIAEDWLEKFSPWEIVRHDVVYPVRFFGHVEILP DGRRKSAGGEVLNALAYDVPIPGYKTKNAISLRLWDAKASAEDFNLEQFNDGQYESAAQLHSRAQQICAVLYPGDATEEGKLLRLKQQFFL CSASLQDIIFRFKERKSDRVSGKWSEFPSKVAVQMNDTHPTLAIPELMRLLMDEEGLGWDEAWDVTNKTVAYTNHTVLPEALEKWSQSVMR KLLPRQMEIIEEIDKRFREMVISTRKDMEGKLDSMSVLDNSPQKPVVRMANLCVVSAHTVNGVAELHSNILKEELFADYVSIWPKKFQNKT NGITPRRWLRFCNPELSEIVTKWLNTDQWTSNLDLLTGLRKFADDEKLHAEWAAAKLASKKRLAKHVLDATGVTIDPTSLFDIQIKRIHEY KRQLMNILGAVYRYKKLKEMSAEEKQKVIPRIVMVGGKAFATYTNAKRIVKVLNDVGAVVNNDPDVNKYLKVVFIPNYNVSVAEVLIPGSE LSQHISTAGMEASGTSNMKFSLNGCVIIGTLDGANVEIREEVGEDNFFLFGAKADQVAGLRKDRENGLFKPDPRFEEAKQYIRSGTFGTYD YIPLLDSLEGSGFGRGDYFLVGYDFPSYIDAQARVDEAYKDKKRWIKMSILNTAGSGKFSSDRTIDQYAKEIWGITANPVP 89 MN.222 ........................................................................................... ..............RPRRRLAACFLDSMAILNLPAWGYGLRYRYGLFKQRIAKEGQEEIAEDWLEKFSPWEIVRHDVVYPVRFFGHVEILP DGRRKSAGGEVLNALAYDVPIPGYKTKNAISLRLWDAKASAEDFNLEQFNDGQYESAAQLHSRAQQICAVLYPGDATEEGKLLRLKQQFFL CSASLQDIIFRFKERKSDRVSGKWSEFPSKVAVQMNDTHPTLAIPELMRLLMDEEGLGWDEAWDVTNKTVAYTNHTVLPEALEKWSQSVMR KLLPRQMEIIEEIDKRFREMVISTRKDMEGKLDSMSVLDNSPQKPVVRMANLCVVSAHTVNGVAELHSNILKEELFADYVSIWPKKFQNKT NGITPRRWLRFCNPELSEIVTKWLNTDQWTSNLDLLTGLRKFADDEKLHAEWAAAKLASKKRLAKHVLDATGVTIDPTSLFDIQIKRIHEY KRQLMNILGAVYRYKKLKEMSAEEKQKVIPRIVMVGGKAFATYTNAKRIVKVLNDVGAVVNNDPDVNKYLKVVFIPNYNVSVAEVLIPGSE LSQHISTAGMEASGTSNMKFSLNGCVIIGTLDGANVEIREEVGEDNFFLFGAKADQVAGLRKDRENGLFKPDPRFEEAKQYIRSGTFGTYD YIPLLDSLEGSGFGRGDYFLVGYDFPSYIDAQARVDEAYKDKKRWIKMSILNTAGSGKFSSDRTIDQYAKEIWGITANPVP 89 MN.216 ........................................................................................... ..............RPRRRLAACFLDSMAILNLPAWGYGLRYRYGLFKQRIAKEGQEEIAEDWLEKFSPWEIVRHDVVYPVRFFGHVEILP DGRRKSAGGEVLNALAYDVPIPGYKTKNAISLRLWDAKASAEDFNLEQFNDGQYESAAQLHSRAQQICAVLYPGDATEEGKLLRLKQQFFL CSASLQDIIFRFKERKSDRVSGKWSEFPSKVAVQMNDTHPTLAIPELMRLLMDEEGLGWDEAWDVTNKTVAYTNHTVLPEALEKWSQSVMR KLLPRQMEIIEEIDKRFREMVISTRKDMEGKLDSMSVLDNSPQKPVVRMANLCVVSAHTVNGVAELHSNILKEELFADYVSIWPKKFQNKT NGITPRRWLRFCNPELSEIVTKWLNTDQWTSNLDLLTGLRKFADDEKLHAEWAAAKLASKKRLAKHVLDATGVTIDPTSLFDIQIKRIHEY KRQLMNILGAVYRYKKLKEMSAEEKQKVIPRIVMVGGKAFATYTNAKRIVKVLNDVGAVVNNDPDVNKYLKVVFIPNYNVSVAEVLIPGSE LSQHISTAGMEASGTSNMKFSLNGCVIIGTLDGANVEIREEVGEDNFFLFGAKADQVAGLRKDRENGLFKPDPRFEEAKQYIRSGTFGTYD YIPLLDSLEGSGFGRGDYFLVGYDFPSYIDAQARVDEAYKDKKRWIKMSILNTAGSGKFSSDRTIDQYAKEIWGITANPVP 90 MN.162 SIHIDTHARHAQSLPRKQKTHEAMALRILASKKTLAVALGGARPLATRGVATFTLPDLPYDYGALEPAISGEIMRLHHQKHHATYVANYNK ALEQLDAAVSKGDASAVVQLQGAIKFNGGGHVNHSIFWKNLKPTNEGGGEAPHGKLGWAIDEDFGSFDKLVKKMNAEGAALQGSGWVWLAL DKEAKKLSVETTANQDPLVIKGANLIPLLGIDVWEHAYYLQYKNVRPDYLTNIWKVVNWKYAGEEYENVAA 90 MN.142 ...............RKQKTHEAMALRILASKKTLAVALGGARPLATRGVATFTLPDLPYDYGALEPAISGEIMRLHHQKHHATYVANYNK ALEQLDAAVSKGDASAVVQLQGAIKFNGGGHVNHSIFWKNLKPTNEGGGEAPHGKLGWAIDEDFGSFDKLVKKMNAEGAALQGSGWVWLAL DKEAKKLSVETTANQDPLVIKGANLIPLLGIDVWEHAYYLQYKNVRPDYLTNIWKVVNWKYAGEEYENVAA 90 MN.158 .......ARHAQSLPRKQKTHEAMALRILASKKTLAVALGGARPLATRGVATFTLPDLPYDYGALEPAISGEIMRLHHQKHHATYVANYNK ALEQLDAAVSKGDASAVVQLQGAIKFNGGGHVNHSIFWKNLKPTNEGGGEAPHGKLGWAIDEDFGSFDKLVKKMNAEGAALQGSGWVWLAL DKEAKKLSVETTANQDPLVIKGANLIPLLGIDVWEHAYYLQYKNVRPDYLTNIWKVVNWKYAGEEYENVAA 90 MN.141 ............................................LATRGVATFTLPDLPYDYGALEPAISGEIMRLHHQKHHATYVANYNK ALEQLDAAVSKGDASAVVQLQGAIKFNGGGHVNHSIFWKNLKPTNEGGGEAPHGKLGWAIDEDFGSFDKLVKKMNAEGAALQGSGWVWLAL DKEAKKLSVETTANQDPLVIKGANLIPLLGIDVWEHAYYLQYKNVRPDYLTNIWKVVNWKYAGEEYENVAA 90 MN.53 ........................................................................................... ..................................................................................GSGWVWLAL DKEAKKLSVETTANQDPLVIKGANLIPLLGIDVWEHAYYLQYKNVRPDYLTNIWKVVNWKYAGEEFFFFF 90 MN.111 ........RHAQSLPRKQKTHEAMALRILASKKTLAVALGGARPLATRGVATFTLPDLPYDYGALEPAISGEIMRLHHQKHHATYVANYNK ALEQLDAAVSKGDASAVVQLQGAIKFNGGGHVNHSIFWKNLKPTNEGGGEAPHGKLGWAIDEDFGSFDKLVKKMNAEGAALQGSGWVWLAL 90 MN.112 ........................................................................................... .................................HSIFWKNLKPTNEGGGEAPHGKLGWAIDEDFGSFDKLVKKMNAEGAALQGSGWVWLAL DKEAKKLSVETTANQDPLVIKGANLIPLLGIDVWEHAYYLQYKNVRPDYLTNIWKVVNWKYAGEEYENVAAEYFV 91 MN.120 ............PGDRPSEMANNPKVFFDVTIGGAPAGRIVMELYADVVPKTAENFRALCTGEKGVGKMGKPLHYKGSSFHRVIPGFMCQG GDFTAGNGTGGESIYGAKFADENFIKKHTGEGVLSMANAGPGINGSQFFLCTAKTAWLDGKHVVFGQVVEGMDVVKAVEKVGSQSGRCSKP VVIADCGQL 91 MN.130 RNPNPQTPASTDPGDRASEMANNPKVFFDVTIGGAPAGRIVMELYADVVPKTAENFRALCTGEKGVGKMGKPLHYKGSSFHRVIPGFMCQG GDFTAGNGTGGESIYGAKFADENFIKKHTGEGVLSMANAGPGINGSQFFLCTAKTAWLDGKHVVFGQVVEGMDVVKAVEKVGSQSGRCSKP VVIADCGQL 91 MN.132 ...................MAPNPKVFFDVTIGGAPAGRIVMELYADVVPKTAENFRALCTGEKGVGKMGKPLHYKGSSFHRVIPGFMCQG GDFTAGNGTGGESIYGAKFADENFIKKHTGEGVLSMANAGPGINGSQFFLCTAKTAWLDGKHVVFGQVVEGMDVVKAVEKVGSQSGRCSKP VVIADCGQL 91 MN.127 ...................MAPNPKVFFDVTIGGAPAGRIVMELYADVVPKTAENFRALCTGEKGVGKMGKPLHYKGSSFHRVIPGFMCQG GDFTAGNGTGGESIYGAKFADENFIKKHTGEGVLSMANAGPGINGSQFFLCTAKTAWLDGKHVVFGQVVEGMDVVKAVEKVGSQSGRCSKP VVIADCGQL 91 MN.121 ...................MAPNPKVFFDVTIGGAPAGRIVMELYADVVPKTAENFRALCTGEKGVGKMGKPLHYKGSSFHRVIPGFMCQG GDFTAGNGTGGESIYGAKFADENFIKKHTGEGVLSMANAGPGINGSQFFLCTAKTAWLDGKHVVFGQVVEGMDVVKAVEKVGSQSGRCSKP VVIADCGQL 91 MN.139 ...................MAPNPKVFFDVTIGGAPAGRIVMELYADVVPKTAENFRALCTGEKGVGKMGKPLHYKGSSFHRVIPGFMCQG GDFTAGNGTGGESIYGAKFADENFIKKHTGEGVLSMANAGPGINGSQFFLCTAKTAWLDGKHVVFGQVVEGMDVVKAVEKVGSQSGRCSKP VVIADCGQL 91 MN.146 ...................MAPNPKVFFDVTIGGAPAGRIVMELYADVVPKTAENFRALCTGEKGVGKMGKPLHYKGSSFHRVIPGFMCQG GDFTAGNGTGGESIYGAKFADENFIKKHTGEGVLSMANAGPGINGSQFFLCTAKTAWLDGKHVVFGQVVEGMDVVKAVEKVGSQSGRCSKP VVIADCGQL 91 MN.64 ........................................................................................... ................AKFADENFIKKHTGEGVLSMANAGPGINGSQFFLCTAKTAWLDGKHVVFGQVVEGMDVVKAVEKVGSQSGRCSKP VVIADCGQL 91 MN.87 .................................................................................PLKWSGFMCQG GDFTKGNGTGGESIYGAKFADENFIKKHTGEGVLSMANAGPGINGSQFFLCTAKTAWLDGKHVVFGQVVEGMDVVKAVEKVGSQSGRCSKP VVIADCGQL 91 MN.89 ............................................................................GSSFHRVIPDFMCQG GDFTKGNGTGGESIYGAKFADENFIKKHTGEGVLSMANAGPGINGSQFFLCTAKTAWLDGKHVVFGQVVEGMDVVKAVEKVGSQSGRCSKP VVIADCGQL 92 MN.37 EQVHIRRPGGAGEDGGQLLLLRIPSLLHGGHGCAWPAMEREKRIEWNCDVCRHGDDKKKVD 93 MN.164 WITVMRASCGHHRFRDCVISSLADFKLFPVLQHIISIAVLAIFIGLLMIEDIGA

TABLE 2 Panel of peptides predicted from protein sequences identified by transcriptomic anaylsis of Timothy Grass (TG) pollen. peptide_sequence (SEQ ID NOS. 621-1442) protein_Id ORF (start-stop) SDGTFAFAAVPSGAS 1 M.125 (11-25), M.151 (38-52), M.226 (44-58), M.291 (11-25), M.331 (11-25), M.399 (44-58), M.414 (39-53), M.418 (43-57), M.498 (38-52), M.617 (8-22), M.624 (31-25), M.689 (37-51), M.704 (8-22), M.714 (33-47), M.721 (11-25) FAAVPSGASTGVYEA 1 M.125 (17-31), M.151 (44-58), M.266 (50-64), M.291(17-31), M.331(17-31), M.399 (50-64), M.414 (45-59), M.418 (49-63) M.498 (44-58), M.617 (14-28), M.624 (17-31), M.689 (43-57), M.704 (14-28), M.714 (39-53), M.721 (17-31) GASTGVYEALELRDG 1 M.125 (23-37), M.151 (50-64), M.226 (56-70), M.291 (23-37), M.331 (23-37), M.399 (56-70), M.414 (51-65), M.418 (55-69) M.498 (50-64), M.617 (20-34), M.624 (23-37), M.689 (49-63), M.704 (20-34), M.714 (45-59), M.723 (23-37) LGKGVLKGNRANVEL 1 M.125 (42-56) NRANVELFMIAVLLA 1 M.125 (50-64) QTELDNFMVHQLDGT 1 M.291 (69-83), M.331 (69-83), M.399 (102-116), M.414 (97-111), M.418(101-115), M.498 (96-110), M.617 (66-80), M.624 (69-83), M.644 (30-44), M.689 (95-109), M.692 (29-43), M.693 (30-44), M.704 (66-80), M.705 (29-43), M.714 (91-105), M.721(69-83) CKQKVFFNISADADA 1 M.331 (90-104) PAMAATIQSVKARQI 1 M.151 (8-22), M.226 (14-28), M.399 (14-28), M.418 (13-27), M.498 (8-22), M.689 (7-21), M.714 (3-17) M.291 (50-64), M.331 (50-64), M.399 (83-97), M.414 (78-92), M.498 (77-91), M.617 (47-63), M.624 (50-64), M.644 (11-25) VDNVNEIIGFALIGK 1 M.692 (10-24), M.693 (11-25), M.704 (47-61), M.714 (72-86) KLGANAILAVSLAVC 1 M.414 (121-135), M.418 (125-139), M.498 (120-134), M.617 (90-104), M.624 (93-107), M.644 (54-68), M.689 (119-133), M.692 (53-67), M.693 (54-68), M.704 (90-104), M.705 (53-67), M.714 (115-129), M.721 (93-107) KKIFLYQKIANLAGN 1 M.414 (142-156), M.418 (146-160), M.498 (141-155), M.561 (12-26), M.603(12-26), M.604 (16-30), M.617 (111-125), M.624 (114-128), M.644 (75-89), M.689 (140-154), M.692 (74-88), M.693 (75-89), M.704 (111-125), M.705 (74-88), M.714 (136-150), M.721 (114-128) GNKQLVLPVPAFNVI 1 M.498 (154-168), M.561 (25-39), M.591 (4-18), M.603 (25-39), M.604 (29-43), M.617 (124-138), M.624 (127-141), M.644 (88-102), M.689 (153-167), M.692 (87-101), M.693 (88-102), M.704 (124-138), M.705 (87-101), M.714 (149-163), M.721 (127-141) KLAMQEFMILPTGAS 1 M.498 (177-191), M.561 (48-62), M.591 (27-41), M.603 (48-62), M.604 (52-66), M.617 (147-161), M.624 (150-164), M.644 (111-125), M.689 (176-190), M.692 (110-124), M.693 (111-125), M.704 (147-161), M.705 (110-124), M.714 (172-186), M.721 (150-164) KMGVEVYHNLKSVIK 1 M.498 (198-212), M.561 (69-83), M.591 (48-62), M.603 (69-83), M.604 (73-87), M.617 (168-182), M.624 (171-185), M.644 (132-146), M.689 (197-211), M.692 (131-145), M.693 (132-146), M.704 (168-182), M.705 (131-145), M.714 (193-207), M.721 (171-185) GKVVIGMDVAASEFY 1 M.561 (124-136), M.591 (101-117), M.603 (124-136), M.604 (126-142), M.617 (223-237), M.624(226-240), M.644 (187- 201), M.689 (252-266), M.692 (186-200), M.693 (187-201), M.704 (223-237), M.705 (186-200), M.714 (248-262), M.721 (226-240) VYKSFVSEYPIVSIE 1 M.561 (168-182), M.591 (147-161), M.603 (168-182), M.604 (172-186), M.617 (267-281), M.624 (270-284), M.644 (231- 245), M.689 (296-310), M.692 (230-244), M.693 (231-245), M.704 (267-281), M.705 (230-244), M.714 (292-603), M.721 (270-284) IVGDDLLVTNPTRVA 1 M.561 (206-220), M.591 (185-199), M.603 (206-220), M.604 (210-224), M.617 (305-319), M.624 (308-122), M.644 (269- 283), M.689 (334-348), M.692 (268-282), M.693 (269-283), M.704 (305-319), M.705 (268-282), M.714 (330-344), M.721 (308-322) NALLLKVNQIGSVTE 1 M.561 (229-243), M.591 (208-222), M.603 (229-243), M.604 (233-247), M.644 (292-306), M.689 (357-371), M.692 (291- 305), M.693 (292-306), M.704 328-342), M.705 (291-305), M.714 (353-367), M.721 (331-345) ETEDIFTALLAVGLS 1 M.591 (245-259), M.603 (266-280), M.604 (270-284), M.644 (329-343), M.692 (328-342), M.693 (329-343), M.704 (635- 379), M.708 (328-342), M.714 (390-404), M.721 (368-382) ERLAKYNQLLRIEEE 1 M.591 (272-286), M.603 (293-307), M.604 (297-311), M.692 (355-369), M.693 (356-370), M.704 (392-406), M.705 (355- 369), M.714 (417-431), M.721 (395-409) LGAAAVYAGLKERAE 1 M.692 (370-384), M.693 (371-385), M.705 (370-384), M.721 (410-424) ADPCSEYFVEAYLNN 58 M.203 (12-26), M.329 (11-25), M.330 (2-16) YFVEAYLNNPLVQKA 58 M.203 (18-32), M.329 (17-31), M.330 (8-27) VQKATHANTALNYPW 58 M.130 (4-18), M.131 (4-18), M.203 (29-43), M.316 (4-18), M.323 (3-17), M.329 (28-42), M.330 (19-33), M.345 (3-17) PSMLAHIKALVIFGI 58 M.130 (36-50), M.131 (38-50), M.203 (61-75), M.292 (31-45), M.316 (36-50), 329 (60-74), M.70 (31-45) LYSGDLDAMVPVTAS 58 M.128 (48-62), M.227 (47-61), M.316 (54-68) LNYPWTGCFTFTYNL 58 M.128 (8-22), M.330 (14-28), M.131 (14-28), M.203 (39-53), M.227 (7-21), M.292 (9-23), M.316 (14-28), M.123 (13-27), M.329 (38-52), M.330 (29-43), M.345 (13-27), M.70 (9-23) YLNRRFGASPPSMLA 58 M.345 (25-39) HIKALVTTASAEGCT 58 M.323 (40-54), M.345 (40-54) QEMAYWSLKAAIETG 33 M.365 (0-14) DAASSLYLFGENLPR 33 M.365 (19-33) GYNISLASMIPDYDT 33 M.241 (0-14), M.289 (1-15) YDIVITNVRRSLAVA 33 M.172 (0-14), M.214 (12-26), M.239 (9-23), M.240 (7-21), M.289 (13-27), M.296 (26-40), M.365 (71-85), M.72 (0-14) LEKIVAILSAFVDAA 33 M.172 (44-58), M.214 (56-70), M.240 (51-65), M.289 (57-71), M.38 (35-49) NVFFSLAVAKKNHLA 33 M.172 (6-20), M.214 (16-32), M.239 (18-29), M.240 (13-27), M.289 (19-33), M.296 (32-46), M.365 (77-91), M.72 (6-20) VAKKNHLAWNCERCR 33 M.172 (13-27), M.187 (13-27), M.214 (25-39), M.239 (22-36), M.240 (20-34), M.289 (26-40), M.296 (39-53), M.365 (84-98), M.38 (4-18), M.72 (13-27) LAWNCEPCRKGESKK 33 M.172 (19-33), M.187 (19-33), M.214 (31-45), M.239 (28-42), M.240 (26-40), M.289 (32-45), M.295 (45-59), M.385 (90- 304), M.38 (10-24), M.72 (19-38) KKTVDAILSAFVDAA 33 M.72 (32-46) GSGDEKTIKEALAKV 21 M.178 (0-14), M.191 (0-14), M.29 (1-15) MYVMYIKEGTYKEYV 21 M.107 (9-23), M.133 (7-21), M.166 (10-24), M.123 (9-23), M.129 (10-24), M.149 (10-24), M.164 (10-24), M.174 (3-17), M.178 (21-35), M.191 (21-35), M.29 (22-36), M.3 (4-18) YKEYVTVPRTVTNLV 21 M.107 (19-33), M.113 (17-31), M.116 (20-34), M.123 (19-33), M.129 (20-34), M.149 (20-34), M.164 (20-34), M.174 (3-17), M.178 (31-45), M.191 (31-45), M.29 (32-45), M.3 14-28) VTNLVMIGDGAAKTI 21 M.107 (29-43), M.113 (27-41), M.116 (30-44), M.123 (29-43), M.129 (30-44), M.149 (30-44), M.164 (30-44), M.174 (23-37), M.178 (41-55), M.191 (41-55) NFKMNLTSMVAVSLV 21 M.123 (49-63) YQDTLYTHAQRQFFR 21 M.101 (36-50), M.146 (49-63), M.165 (51-65), M.183 (36-50), M.204 (49-63), M.34 (19-33) M.6 (17-31) GTIDFTFGNEQVVIQ 21 M.183 (56-70) AKTIILKFLLPVMIV 21 M.178 (52-66) ALTHTTIVASGTENM 8 M.763 (0-14) MKIFTRIWVLLLLVV 8 M.763 (14-28), M.765 (11-25) LLLLVVLLFEGCLAK 8 M.763 (23-37), M.765 (20-34) KDTHYTLSAWLQLSK 8 M.733 (16-30), M.759 (57-71), M.763 (109-123), M.765 (106-120) GKGELFFETNVIAEL 8 M.653 (28-42), M.728 (34-48), M.733 (72-86), M.759 (113-127), M.763 (165-179), M.765 (162-176) VTAELMVDSMSLQPF 8 M.653 (38-52), M.728 (44-58), M.733 (82-96), M.763 (175-189) YEKWFTSRFTVATME 8 M.653 (115-129), M.728 (121-135), M.733 (159-173), M.747 (73-87), M.759 (199-213), M.763 (252-266), M.765 (248-262) KQMDWVSKLSAPQLK 8 M.653 (175-189), M.728 (181-195), M.733 (219-233), M.747 (133-147), M.759 (259-273), M.763 (312-326), M.765 (308- 322) KPILFMNEYNTIEEP 8 M.653 (244-258), M.728 (250-264), M.733 (288-302), M.747 (202-216), M.759 (328-342), M.763 (318-395), M.765 (377- 391) TKYLAKLKQIQSYPG 8 M.653 (266-280), M.728 (272-286), M.733 (310-324), M.747 (224-238), M.759 (350-364), M.763 (403-417), M.763 (403-417), M.765 (399-413) PYVRGELDTLAQAKV 8 M.653 (300-314), M.728 (306-320), M.733 (344-358), M.747 (258-272), M.759 (384-398), M.763 (437-451), M.765 (433- 447) PKQVEYLEEVMREGF 8 M.653 (327-341), M.728 (333-347), M.733 (371-385), M.747 (285-299), M.759 (411-425), M.763 (464-478), M.765 (460- 474) NVTAELVDSMSLQPF 8 M.759 (122-136), M.765 (171-185) NIPATWGAMEKLYDA 18 M.8 (0-14) GAMENLYDAGKRAT 18 M.8 (6-20) KARAIGVSNLASKKL 18 M.8 (16-30) VSNLASNKLGDLLAV 18 M.8 (22-36) KKLGDLLAVAARIPPA 18 M.8 (28-42) SVFKKFPKFRRVLVI 55 M.110 (3-17), M.173 (11-25), M.249 (13-27) PKFRRVLVIDPVISG 55 M.110 (9-23), M.173 (17-31), M.18 (4-18), M.249 (19-33), M.33 (0-14), M.50 (9-23) IGEINGFADAVMVEA 55 M.110 (29-43), M.173 (37-51), M.18 (24-38), M.249 (39-53), M.33 (20-34), M.50 (29-43) FADAVMVSRGSLVRV 55 M.110 (35-49), M.173 (43-57), M.18 (30-44), M.249 (45-59), M.33 (26-40), M.50 (35-49) VSRGSLVAVNGFFLT 55 M.110 (41-55), M.249 (51-65), M.33 (32-45), M.50 (41-55) VNGFFLTGFNDLVTE 55 M.249 (59-73) QIIRNGFYLTKNVEH 31 M.39 (5-19) FYLTRNVEHKGQVDL 31 M.39 (11-25) VENKGQVDLVTETDK 31 M.39 (17-31) TDKACEDLIFNHLRK 31 M.39 (29-43) DLIFNHLAKLYPDHK 31 M.39 (35-49) AEFEGVFLDFARQQA 2 M.574 (0-14) VDKLFKLAEAAKLKE 2 M.574 (19-33) ENRSVLHVALRAPRD 2 M.422 (8-22), M.431 (8-22), M.473 (0-14), M.574 (48-62), M.634 (24-38), M.676 (24-38) FLGPLFVATALQTDP 2 M.367 (54-68), M.422 (75-89), M.431 (75-89), M.437 (36-50), M.473 (67-81), M.574 (115-129), M.610 (32-46), M.634 (91- 105), M.676 (91-105), M.722 (32-46) RQLRFLANVDPVDVA 2 M.387 (77-91), M.422 (98-112), M.431 (98-112), 437 (59-73), M.473 (90-140), M.531 (8-22), M.574 (138-152), M.610 (55-69), M.634 (114-128), M.676 (114-128), M.722 (55-69) VVSKIFTTAETMLNA 2 M.387 (106-120), M.422 (127-141), M.431 (127-141), M.437 (88-102), M.473 (119-133), M.531 (37-51), M.574 (167-181), M.610 (84-98), M.634 (143-157), M.676 (143-157), M.722 (84-98) IKEWVSSLGPQAVS 2 M.387 (123-137), M.431 (144-158), M.437 (105-119), M.473 (136-150), M.531 (54-68), M.574 (184-198), M.610 (101-115), M.634 (160-174), M.676 (160-174), M.722 (101-115) VSKHMIAVSTNLKLV 2 M.473 (118-132), M.473 (149-163), M.531 (67-81), M.574 (197-211), M.610 (114-128), M.634 (173-187), M.676 (173-187) M.722 (114-128) RYSVCSAVGVLPLSL 2 M.473 (152-166), M.473 (183-197), M.531 (101-115), M.574 (231-245), M.610 (148-162), M.634 (207-221), M.676 (207- 221), M.722 (148-162) AVGVLPLSLQYGFPI 2 M.533 (107-121), M.574 (237-251), M.610 (154-168), M.534 (213-227), M.676 (213-227), M.722 (154-168) LSLQYGFPIVQRFLE 2 M.531 (113-127), M.574 (243-257), M.610 (160-174), M.634 (219-233), M.676 (219-233), M.722 (160-174) FFIVQRFLEGASSTD 2 M.531 (119-133), M.574 (249-263), M.610 (166-180), M.634 (226-239), M.636 (2-16), M.676 (225-239), M.722 (166-180) HFRTASFEKNIPVLL 2 M.531 (135-149), M.574 (265-279), M.610 (182-196), M.634 (241-255), M.636 (18-32), M.676 (241-255), M.722 (182-196) VLLGLLSVWNVSELQ 2 M.531 (147-161), M.610 (194-208), M.634 (253-267), M.636 (30-44), M.676 (253-267), M.722 (194-208) SVWNVSFLGYPARAI 2 M.531 (153-167), M.610 (200-214), M.634 (259-273), M.636 (36-50), M.676 (259-273), M.722 (200-214) ARAILFYSQALENLA 2 M.531 (164-178), M.610 (211-255), M.634 (270-284), M.636 (47-61), M.676 (270-284), M.277 (211-225) NGQHSFYQLIHQGRV 2 M.531 (215-299), M.610 (262-276), M.634 (321-355), M.636 (98-112), M.676 (321-335), M.722 (262-276) CQFIGVIKSQQPVYL 2 M.531 (232-246), M.610 (279-293), M.636 (115-129), M.676 (338-352), M.722 (279-293) ELMSNFFAQPDALAY 2 M.610 (303-317), M.636 (139-153), M.676 (362-376) NTEKGNRPSLSFLLS 2 M.363 (173-187), M.722 (337-351) PSLSFLLSSLSAYEI 2 M.636 (180-194), M.722 (355-358) AYEIGQLLAIYEHRI 2 M.636 (191-205), M.722 (358-369) LLAIYEHRIAVQGFI 2 M.636 (197-211), M.722 (631-375) QQFIWGTNSFDQWQV 2 M.636 (208-222), M.722 (372-386) PVEGFNPSSASLLAR 2 M.636 (245-259), M.722 (409-423) PSSASSLLARYLAVEP 2 M.636 (251-265), M.722 (415-429) NELGGKILRQPGPLP 56 M.25 (1-15) ILRQPGPLPGLNTRI 56 M.25 (7-21) LRGNLTNIASFLDPD 56 M.25 (5-19) NIASFLDPLGWRVVL 56 M.25 (20-34), M.5 (11-25) GWKVVLVDHADFLKE 56 M.25 (29-43), M.5 (20-34) QDNAKIVQTDSSIQA 57 M.394 (2-16) RLVCLRVHPTFTLLH 57 M.394 (28-42) HFTFILLHPTEVVVA 57 M.394 (35-49) TEVVVAFTAINGSRQ 57 M.394 (44-58) LVNRFEISQVSKCLV 57 M.394 (90-104) ILLVFAETAEPEVKV 3 M.305 (0-14) EPEVKVVDLTILSPD 3 M.212 (7.21), M.271 (3-17), M.282 (14-28), M.288 (3-17), M.305 (9-23) LKDGSTYSFRFSFIV 3 M.212 (42-56), M.271 (38-52), M.282 (49-63) M.288 (38-52) M.305 (44-58) SFRFSFIVSNNIVEG 3 M.212 (49-63), M.271 (45-59), M.282 (56-70), M.285 (1-15), M.288 (45-59), M.305 (51-65), M.348 (1-15) DDGKVYLEMSYYFEI 3 M.519 (45-59), M.285 (74-88), M.287 (51-65), M.348 (74-88), M.83 (27-41) VKNIVIVLNEAHVPS 59 M.596 (20-34), M.660 (8-22), M.674 (35-49), M.685 (35-49), M.703 (34-48) EDAVEVVVSPPFVFL 59 M.585 (49-63), M.596 (35-49), M.660 (23-37), M.674 (50-64), M.681 (49-63), M.685 (50-64), M.703 (49-63) VSPPFVFLQQAKALL 59 M.504 (1-15), M.585 (56-70), M.596 (42-56), M.660 (30-44), M.674 (57-71), M.681 (56-70), M.685 (57-71), M.703 (56-70) FLQQAKALLRPDFAV 59 M.504 (7-21), M.585 (62-76), M.596 (48-62), M.660 (36-50), M.674 (63-77), M.681 (62-76), M.685 (63-77), M.703 (62-76) ALLRPDFAVAAQNCW 59 M.585 (68-82), M.596 (54-68), M.660 (42-56), M.674 (69-83), M.681 (68-82), M.685 (69-83), M.703 (68-82) GAFTGEISAEMLVNL 59 M.504 (32-46), M.585 (87-101), M.596 (73-87), M.660 (61-75), M.674 (88-102), M.681 (87-101), M.685 (88-102), M.703 (87-101) ISAEMLVNLQVPWVI 59 M.504 (38-52), M.585 (93-107), M.596 (79-93), M.660 (67-81), M.674 (94-108), M.681 (93-107), M.685 (94-108), M.703 (93-107) ESNDFVADKVAYALA 59 M.504 (64-78), M.585 (119-133), M.596 (105-119), M.660 (93-107), M.674 (120-134), M.681 (119-133), M.685 (120-134), M.703 (119-133) ADKVAYALAQGLKVI 59 M.504 (70-84), M.585 (125-139), M.596 (111-125), M.660 (99-113), M.674 (126-140), M.681 (125-139), M.685 (126-140), M.703 (125-139) IIMEVVAAQTKAIAE 59 M.504 (98-112), M.526 (13-27), M.585 (153-167), M.596 (139-153), M.660 (127-141), M.674 (154-168), M.681 (153-167), M.685 (154-168), M.703 (153-167) WINVVLAYEPVWAIG 59 M.504 (117-131), M.526 (32-46), M.585 (172-186), M.596 (158-172), M.660 (146-160), M.674 (173-187), M.681 (172-185), M.685 (173-187), M.703 (172-186) LRKWLHANVGPAVAE 59 M.504 (148-162), M.526 (63-77), M.585 (203-217), M.596 (189-203), M.660 (177-191), M.674 (204-218), M.681 (203-217), M.685 (204-218), M.703 (203-217) PEFVDIIKEATVKSS 59 M.504 (198-232), M.526 (113-127) M.585 (253-267), M.596 (239-253), M.660 (227-241), M.674 (254-268), M.681 (253-267), M.685 (254-268), M.703 (253-267) LNGPFIATVQQRGAA 19 M.235 (25-39) QQRGAAIIKARKLSS 19 M.235 (34-48) IIKARKLSSALSAAS 19 M.235 (40-54) LSSALSAASSACDHI 19 M.235 (46-60) GTPEGTFVSMGVYSD 19 M.235 (66-80) IEIDSLFEGIDFYST 32 M.389 (40-54), M.390 (40-54) IDFYSTITRARFEEL 32 M.389 (49-63), M.390 (49-63) IPKVQQLLQDFFNGK 32 M.144 (40-54), M.201 (44-58), M.28 (26-40), M.284 (52-56), M.303 (52-66), M.389 (101-115), M.390 (101-115), M.74 (19-33), M.92 (34-48) EAVAYGAAVQAAILS 32 M.284 (76-90), M.303 (76-90), M.317 (7-21), M.389 (125-139), M.390 (125-139), M.74 (43-57) VQDLLLIDVIFLSLG 32 M.180 (11-25), M.317 (28-42) LMSFSWICACVRAAA 34 M.607 (0-14) ICACVRAAAVAWEAG 34 M.607 (6-20), M.690 (4-18) VRVKILFTALCHIDV 34 M.598 (34-48), M.607 (68-52), M.614 (13-27), M.632 (27-41), M.672 (23-37), M.690 (36-50) MCDLLRINTDRGVMI 34 M.545 (18-32), M.598 (109-123), M.607 (113-127), M.614 (88-102), M.616 (47-61), M.632 (102-116), M.633 (42-56), M.671 (43-57), M.672 (98-112), M.690 (111-125) KPIFHFVGTSTFSEY 34 M.545 (44-58), M.598 (135-149), M.607 (139-153), M.614 (114-128), M.616 (73-87), M.632 (128-142), M.633 (68-82), M.671 (69-83), M.672 (124-138), M.690 (137-151) VGISTFSEYTVMHVG 34 M.545 (50-64), M.598 (141-155), M.607 (145-159), M.614 (120-134), M.616 (79-93), M.632 (134-148), M.633 (74-88) M.671 (75-89), M.672 (130-144), M.690 (143-157) VAIFGLGAVGLAAAE 34 M.545 (104-118), M.598 (195-209), M.607 (199-213), M.614 (174-188), M.616 (133-147), M.632 (188-202), M.633 (128-142), M.671 (129-143), M.672 (184-198), M.690 (197-211) GAVGLAAAEGARIAG 34 M.545 (110-124), M.598 (201-215), M.607 (205-219), M.614 (180-194), M.616 (139-153), M.632 (184-208), M.633 (134-148), M.671 (135-149), M.672 (190-204), M.690 (203-217) GNINAMIQAFECVHD 34 M.545 (179-193), M.598 (270-284), M.607 (274-288), M.614 (249-263), M.616 (208-222), M.622 (263-277), M.633 (203-217), M.671 (204-218), M.672 (259-273), M.690 (272-286) LEGTFFGNFKPRTDL 34 M.545 (223-237), M.614 (293-307), M.616 (252-266), M.632 (307-321), M.633 (247-261), M.671 (248-262), M.672 (303-317), M.690 (316-330) KFITHSVTFSEINKA 34 M.616 (282-296), M.633 (277-291), M.671 (278-292), M.672 (333-347), M.690 (346-360) VIFSEINKAFDLMAK 34 M.616 (288-302), M.633 (283-297), M.671 (284-298), M.672 (339-353), M.690 (352-366) ALRWNLQMGHSVLPK 35 M.272 (0-14) NLDVYDWSIPDDLLA 35 M.272 (24-38) DDLLAKFSEIKQTRL 35 M.272 (34-48) FSEIKQTRLLMGNFI 35 M.272 (40-54) IRLLMGNFIVNKDSV 35 M.272 (46-60) MKIIFDEESIKELLA 4 M.595 (2-16), M.648 (2-16), M.715 (0-14), M.718 (2-16), M.720 (2-16), M.725 (0-14) FESIKKLLASPKFSF 4 M.595 (8-22), M.648 (8-22), M.662 (7-21), M.694 (11-25), M.701 (11-25), M.715 (6-20), M.718 (8-22), M.720 (8-22), M.723 (5-19), M.725 (6-20) RMFVDELGASESSLL 4 M.595 (37-51), M.648 (67-51), M.662 (36-50), M.694 (40-54), M.701 (40-54), M.715 (35-49), M.718 (37-51), M.720 (37-51), M.273 (34-48), M.725 (35-49) PNLTYAKELVERMGL 4 M.595 (66-80), M.648 (66-80), M.662 (65-79), M.694 (69-83), M.701 (69-83), M.715 (64-78), M.718 (66-80), M.720 (66-820), M.723 (63-77), M.725 (64-78) RNMVLGNRFFVTPSD 4 M.595 (102-116), M.648 (102-116), M.662 (101-115), M.594 (105-119), M.701 (105-119), M.715 (100-114), M.718 (102-116), M.720 (102-116), M.723 (99-113), M.725 (100-114) KRFFVTPSDSVAIIA 4 M.595 (108-122), M.648 (108-122), M.662 (107-121), M.694 (111-125), M.701 (111-125), M.715 (106-120), M.718 (108-122), M.720 (108-122), M.723 (105-119), M.725 (106-120) SDSVAIIAANAVQSI 4 M.595 (115-129), M.648 (115-129), M.662 (114-128), M.694 (118-132), M.701 (118-132), M.715 (113-127), M.718 (115-129) M.720 (115-129), M.723 (112-126), M.725 (113-127) AVQSIPYFASGLKGV 4 M.595 (125-139), M.648 (125-139), M.662 (124-138), M.694 (128-142), M.701 (128-142), M.715 (123-137), M.718 (125-139), M.720 (125-139), M.723 (122-136), M.725 (123-137) ENLNLKFEEVPIGWK 4 M.595 (154-168), M.648 (154-168), M.662 (153-167), M.694 (157-171), M.701 (157-171), M.715 (152-166), M.718 (154-168), M.720 (154-168), M.723 (151-165), M.725 (152-166) GIWAVLAWLSTTAYK 4 M.576 (33-47), M.595 (199-213), M.648 (199-213), M.662 (198-212), M.694 (202-216), M.701 (202-216), M.715 (197-211), M.718 (199-213), M.720 (199-213), M.723 (196-210), M.725 (197-211) NLGGDKLVSVEDIVL 4 M.576 (51-65), M.595 (217-231), M.648 (217-231), M.662 (216-230), M.694 (220-234), M.701 (220-234), M.715 (215-229), M.718 (217-231), M.720 (217-231), M.723 (214-228), M.725 (215-229) LVSVEDIVLQHWATY 4 M.576 (57-71), M.595 (223-237), M.648 (223-237), M.662 (222-236), M.694 (226-240), M.701 (226-240), M.715 (221-235), M.718 (223-237), M.720 (223-237), M.723 (220-234), M.725 (221-235) KELMANLVKMOSALS 4 M.576 (90-104), M.595 (256-270), M.648 (256-270), M.662 (255-269), M.694 (259-273), M.701 (259-273), M.715 (254-268), M.718 (256-270), M.720 (256-270), M.723 (253-267), M.725 (254-268) LVKMQSALSDVNKLI 4 M.576 (96-110), M.595 (262-276), M.648 (262-276), M.662 (261-275), M.694 (265-279), M.701 (265-279), M.715 (260-274), M.718 (262-276), M.720 (262-276), M.723 (259-273), M.725 (260-274) HQGTRYLFGDGSRLV 4 M.576 (139-153), M.648 (305-319), M.662 (304-318), M.694 (308-322), M.701 (308-322), M.715 (303-317), M.718 (305-319), M.720 (305-319), M.723 (302-316), M.725 (303-317) SRLVFRLSGTGSVGA 4 M.576 (150-164), M.648 (316-330), M.662 (315-329), M.694 (319-333), M.701 (319-333), M.715 (314-328), M.718 (316-330), M.720 (316-330), M.723 (313-327), M.725 (314-328) GATTRIYTEQYENDS 4 M.576 (163-177), M.648 (329-343), M.662 (328-342), M.694 (332-346), M.701 (332-346), M.715 (327-341), M.718 (329-343), M.720 (329-343), M.723 (326-340), M.725 (327-341) DALSPLVDVALKLSK 4 M.576 (186-200), M.662 (351-365), M.694 (355-369), M.701 (355-369), M.715 (350-364), M.718 (352-366), M.720 (352-366), M.723 (349-363), M.725 (350-364) QDFKKVNETYAKYFP 36 M.202 (0-14), M.301 (0-14) NEIYAKYFPSPAPAR 36 M.202 (6-20), M.301 (6-20) YFPSPAPARSTYQVA 36 M.202 (12-26), M.301 (12-26) ARSTYQVAALPLDAR 36 M.202 (19-33), M.301 (19-33) LPLDARIEIECIAAL 36 M.202 (28-42), M.301 (28-42) PPPGOHIAMAASSRR 20 M.675 (19-33), M.678 (24-38) ASQLLGSAASRFLHB 20 M.675 (34-48), M.678 (39-53) SRFLHSRGYAAAAAA 20 M.675 (43-57), M.678 (48-62) RGYAAAAAAPSFAVF 20 M.675 (49-63), M.678 (54-68) LGLPVFNSVAEAKAE 20 M.583 (15-29), M.641 (53-67), M.649 (22-36), M.675 (108-122), M.678 (113-127), TKANAZVLYVPPPFA 20 M.583 (30-44), M.641 (68-82), M.649 (37-51), M.675 (123-137), M.678 (128-142), VIYVPPPFAAAAIME 20 M.583 (36-50), M.641 (74-88), M.649 (43-57), M.675 (129-143), M.678 (134-148), PFAAAAIMEALEAEL 20 M.583 (42-56), M.641 (80-94), M.649 (49-63), M.675 (135-149), M.678 (140-154), QHDMVKVKAALNRQS 20 M.583 (68-82), M.641 (106-120), M.649 (75-89), M.675 (161-175), M.678 (166-180), ILIYEAVFQTTAVEL 20 M.499 (18-32), M.583 (123-137), M.641 (161-175), M.649 (130-144), M.675 (216-290), M.678 (221-235), DKPVVAFIAGLTAPP 20 M.499 (90-104), M.583 (195-209), M.641 (233-247), M.649 (202-216), M.675 (228-302), M.678 (293-307), KIKALREAGVTVVES 20 M.499 (125-139), M.583 (230-244), M.641 (266-282), M.649 (237-251), M.675 (323-337), M.678 (328-342), GSTMFEIFKQRGMVE 20 M.499 (144-158), M.583 (249-263), M.641 (287-301), M.649 (256-270), M.675 (342-356), M.678 (347-361), IVSDEYLAAVAKARR 5 M.423 (4-18), M.625 (15-29), M.631 (9-23), M.654 (5-19), M.655 (26-40), M.682 (4-18) LDIAVRLLEPIKEQV 5 M.393 (58-72), M.421 (71-85), M.618 (64-78), M.625 (82-96), M.631 (76-90), M.654 (72-86), M.655 (93-107), M.669 (58-72), M.682 (71-85) IKEQVPILSYADFYQ 5 M.393 (68-82), M.421 (81-95), M.618 (74-88), M.625 (92-106), M.631 (86-100), M.654 (82-96), M.655 (103-117), M.669 (68-82), M.682 (81-95) ILSYADFYQLAGVVA 5 M.393 (74-88), M.421 (87-101), M.618 (80-94), M.625 (98-112), M.631 (92-106), M.654 (88-102), M.655 (109-123), M.669 (74-88), M.682 (87-101) FYOLAGVVAVEITGG 5 M.393 (80-94), M.421 (93-107), M.618 (86-100), M.625 (104-118), M.631 (98-112), M.654 (94-108), M.655 (115-129), M.669 (80-94), M.682 (93-107) DHLRQVFTAQMGLSD 5 M.393 (123-137), M.421 (136-150), M.524 (30-44), M.618 (129-143), M.625 (147-161), M.631 (141-155), M.654 (137-151), M.655 (158-172), M.669 (123-137), M.682 (136-150) NPLIFDNSYFTELLT 5 M.524 (73-87), M.618 (172-186), M.625 (190-204), M.631 (184-198), M.654 (180-194), M.655 (201-215), M.669 (166-180), M.682 (179-193) EDAFFADYAEARLKL 5 M.524 (119-133), M.618 (218-232), M.625 (236-250), M.631 (230-244), M.654 (226-240), M.655 (247-261), M.669 (212-226), M.682 (225-239) EDSHFVVELIYNYGV 60 M.509 (25-39) RAIKFYEKAFGMELL 60 M.302 (38-52), M.484 (70-84), M.493 (35-49), M.497 (35-49), M.509 (121-135), M.515 (52-66), M.521 (35-49), M.533 (70-84) NPQYKYTTAMMGYGP 60 M.302 (57-71), M.484 (89-103), M.493 (54-68), M.497 (54-68), M.509 (140-154), M.515 (71-85), M.521 (54-68), M.533 (89-103) KNAVLELTYNYGVKE 60 M.302 (74-88), M.484 (106-120), M.493 (71-85), M.497 (71-85), M.509 (157-171), M.515 (88-102), M.521 (71-85), M.533 (106-120) DGWKSVFVDNLDFLK 60 M.484 (172-185), M.493 (137-151), M.497 (137-151), M.515 (154-168), M.521 (137-151), M.533 (172-186) EEAASTLPGLSSSTL 37 M.492 (4-18) TLLFPHTQTSLPSVR 6 M.639 (0-14) VRTRKHLAATMADEK 6 M.639 (13-27) DNEKSGFTSLVSRYL 6 M.570 (7-21), M.639 (43-67) FISLVSRYLSGEEEH 6 M.570 (13-27) EATKALLNKLAVLKL 6 M.555 (11-25), M.639 (91-105) IEVRNGFTFLDLIVL 6 M.546 (34-48), M.555 (42-56), M.570 (86-100), M.639 (122-136) FLDLIVLQIESLNKK 6 M.546 (42-56), M.555 (50-64), M.570 (94-108), M.639 (130-144) LNKKYGSNVPLLLMN 6 M.546 (53-67), M.555 (61-75), M.570 (105-119), M.639 (141-155) NVPLLLMNSFNIHED 6 M.546 (60-74), M.555 (68-82), M.570 (112-126), M.639 (148-162) LKIVEKYANSSIDIH 6 M.546 (76-90), M.555 (94-98), M.570 (128-142), M.639 (164-178) SIDIHTFNQSQYPRV 6 M.546 (86-100), M.555 (94-105), M.570 (138-152), M.639 (174-188) GKLDLLLSQGKEYVF 6 M.546 (135-149), M.555 (143-157), M.570 (187-201), M.639 (223-237) GKEYVFIANSDNLGA 6 M.546 (144-158), M.555 (152-166), M.570 (196-210), M.639 (232-246) SDNLGALVDMKILNH 6 M.450 (4-18), M.546 (153-167), M.555 (161-175), M.570 (205-219), M.639 (241-255) IVDMKTLNHLIRKON 6 M.450 (10-24), M.546 (159-173), M.555 (167-181), M.570 (211-225), M.639 (247-261) ISYEGRVQLLEIAQV 6 M.450 (44-58), M.546 (193-207), M.555 (201-215), M.570 (245-259), M.639 (281-295) VQLLEIAQVPDAHVD 6 M.450 (50-64), M.546 (199-213), M.555 (207-271), M.570 (251-265), M.639 (287-301) FKSIEKFKIFNINNL 6 M.450 (66-80), M.546 (215-229), M.555 (223-237), M.639 (303-317) FKIFNTNNLWVNLKA 6 M.450 (72-86), M.546 (221-235), M.555 (229-243), M.639 (309-323) NNLWVNLKAIKRLVE 6 M.450 (78-92), M.546 (227-241), M.555 (235-249), M.639 (315-329) IKRLVEADALKMEIL 6 M.450 (87-101), M.546 (236-250), M.555 (244-258), M.639 (324-338) VKVLQLETAAGAAIR 6 M.341 (4-18), M.342 (4-18), M.343 (4-18), M.450 (110-124) AAIRFFDHAIGINVP 6 M.341 (15-29), M.342 (15-29), M.343 (15-29), M.450 (121-135) GINVPRSRFLPVKAT 6 M.341 (25-39), M.342 (25-39), M.343 (25-39), M.450 (131-145) RFLPVKATSDLQLVQ 6 M.341 (32-46), M.342 (32-46), M.343 (32-46), M.450 (138-152) TSDLQLVQSDLYTLV 6 M.341 (39-53), M.342 (39-53), M.343 (39-53), M.450 (145-159) VQSDLYTLVDGFVTR 6 M.341 (45-59), M.342 (45-59), M.343 (45-59), M.450 (151-165) GPEFKKVDSFLGRFK 6 M.342 (74-88), M.343 (74-88) GRFKSIPSIVELDSL 6 M.341 (85-99), M.342 (85-99), M.343 (85-99) LQSKNCILYLCSIMI 61 M.478 (0-14) ILYLCSINICNCKVS 61 M.478 (6-20) IMICNCKVSKVLNTY 61 M.478 (12-26) KVSKVINTYIFLLYL 61 M.478 (18-32) GTIRNIINGTVFREP 7 M.658 (30-44) VFNFIGAGGVALAMY 7 M.548 (7-21), M.560 (7-21), M.606 (17-31), M.628 (26-40) M.658 (100-114), M.695 (71-85) IQGFAEASMAIAYEK 7 M.548 (27-41), M.560 (27-41), M.606 (37-51), M.628 (46-60) M.658 (120-134), M.695 (91-105) ASMAIAYEKKWFLYL 7 M.548 (33-47), M.560 (33-47), M.606 (43-57), M.628 (52-66) M.658 (126-140), M.695 (97-111) EKKWPLYLSIKNTIL 7 M.548 (40-54), M.560 (40-54), M.606 (50-64), M.628 (59-73) M.658 (133-147), M.695 (104-118) GRKKDIFQAVYEADW 7 M.548 (59-73), M.560 (59-73), M.606 (69-83), M.628 (78-92) M.658 (152-166), M.695 (123-137) WYEHRLIDDMVAYAL 7 M.248 (28-42), M.548 (83-97), M.560 (83-97), M.606 (93-107), M.628 (102-116) M.658 (176-190), M.695 (147-161) VQSDFLAQGFGELGL 7 M.248 (59-73), M.548 (114-128), M.560 (114-128), M.606 (124-138), M.628 (133-147), M/658 (207-221), M.695 (178-192) NSIASIFAWTRGLAH 7 M.269 (2-16), M.328 (2-16), M.466 (25-39), M.548 (166-180), M.560 (166-180), M.606 (176-190), M.628 (185-199), M.658 (259-273), M.695 (230-244) DNARLLDFTQKLZDA 7 M.269 (22-36), M.328 (22-36), M.466 (45-59), M.548 (186-200), M.560 (186-200), M.606 (196-210), M.628 (205-219) M.658 (279-293), M.695 (250-264) MTKDLALLVHGSSKV 7 M.269 (46-60), M.328 (46-60), M.466 (69-83), M.548 (210-224), M.560 (210-224), M.606 (220-234), M.628 (229-243) M.658 (303-317), M.695 (274-288) LNTEEFIDAVAAELQ 7 M.269 (66-80), M.328 (66-80), M.466 (89-103), M.548 (230-244), M.560 (230-244), M.606 (240-254), M.628 (249-263) M.658 (323-337), M.695 (294-308) NTRVLLLRRTSPFSA 22 M.615 (14-28) DGYYTHGQCATIMFD 22 M.352 (75-89), M.514 (75-89), M.539 (95-109), M.569 (88-102), M.578 (87-101), M.580 (84-88), M.587 (96-110), M.588 (97-111), M.594 (104-118), M.615 (123-137) QCATIMFDVTSRLTY 22 M.352 (82-96), M.514 (82-96), M.539 (102-116), M.569 (95-109), M.578 (94-108), M.580 (91-105), M.587 (103-117), M.588 (104-118), M.594 (111-125), M.615 (130-144) RKKNLQYYETSAKSN 22 M.514 (138-152), M.539 (158-172), M.569 (151-165), M.578 (150-164), M.580 (147-161), M.587 (159-173), M.588 (160-174), M.594 (167-181), M.615 (186-200) SAKSNYNFEKPFLYL 22 M.514 (148-162), M.539 (168-182), M.569 (161-175), M.578 (160-174), M.580 (157-171), M.587 (169-183), M.588 (170-184), M.594 (177-191), M.615 (196-210) KPFLYLARKLAGDAN 22 M.514 (157-171), M.539 (177-191), M.569 (170-184), M.578 (169-183), M.580 (166-180), M.587 (178-192), M.588 (179-193), M.594 (188-200), M.615 (205-219) ANIHFVEALKPPE 22 M.514 (170-184), M.539 (190-204), M.569 (183-197), M.578 (182-196), M.580 (179-193), M.587 (191-205), M.588 (192-206), M.594 (199-213), M.615 (218-232) EAELAAAAAQPLPDD 22 M.514 (196-210), M.539 (216-230), M.569 (209-223), M.578 (208-222), M.580 (205-219), M.587 (217-231), M.588 (218-232), M.594 (225-239), M.615 (244-258) YQPAAMRRLSLILLA 62 M.528 (10-24), M.529 (10-24), M.535 (10-24), M.543 (10-24), M.590 (10-24), M.691 (10-24) RRLSLILLAAAALLA 62 M.528 (16-30), M.529 (16-30), M.535 (16-30), M.543 (16-30), M.590 (16-30), M.691 (16-30) LLAAAALLAAAVSAE 62 M.510 (7-21), M.528 (22-36), M.529 (22-36), M.535 (22-36), M.543 (22-36), M.590 (22-36), M.691 (22-36) CPRAERIIAEVVQSK 62 M.510 (37-51), M.528 (52-66), M.529 (52-66), M.535 (52-66), M.543 (52-66), M.590 (52-66), M.691 (22-66) AFDAVVRSKLALELE 62 M.119 (44-58), M.222 (54-68), M.373 (37-51), M.510 (103-117), M.528 (118-132), M.529 (118-132), M.535 (118-132), M.543 (118-132), M.590 (118-132), M.691 (118-132) CADILAIASRVLVIM 62 M.373 (58-72), M.510 (124-138), M.528 (139-153), M.529 (139-153), M.535 (139-153), M.543 (139-153), M.590 (139-153), M.691 (139-153) NFTVGRIIELFTAKG 62 M.373 (103-117), M.528 (184-198), M.529 (184-198), M.535 (184-198), M.543 (184-198), M.590 (184-198), M.691 (184-198) IIELFTAKGFTVQEM 62 M.373 (109-123), M.528 (190-204), M.529 (190-204), M.535 (190-204), M.543 (190-204), M.590 (190-204), M.691 (190-204) FIVQEMVALSGAHTL 62 M.373 (118-132), M.529 (199-213), M.535 (199-213), M.543 (199-213), M.590 (199-213), M.691 (199-213) IAAFNDIMSSVLSS 62 M.590 (263-277) FDNIYSVNIERGLGL 62 M.691 (275-289) NIDFFEDFAKAIEEL 62 M.691 (313-327) TDTIVYCAGRTFFFR 9 M.547 (38-52), M.562 (55-69), M.761 (42-56) GRIFFFRRLDAPLDA 9 M.547 (46-60), M.562 (63-77), M.761 (50-64) KSLVRAFMWDSGSTV 9 M.547 (134-148), M.562 (151-165), M.571 (151-165), M.741 (44-58), M.761 (138-152) RVLSCDFXPTRPFRI 9 M.547 (157-171), M.562 (174-188), M.571 (174-188), M.734 (50-64), M.738 (49-63), M.741 (67-81), M.761 (161-175) HTGSIYAVSWSADSK 9 M.547 (242-256), M.562 (259-273), M.571 (259-273), M.734 (135-149), M.738 (134-148), M.741 (152-166), M.761 (246-260) AGHLKTVSSLITFPQ 9 M.597 (72-86), M.621 (45-59), M.651 (70-84), M.657 (81-95), M.677 (73-87), M.734 (224-238), M.738 (223-237), M.741 (241-255), M.761 (335-349) VSSLTYFPQSNPRTM 9 M.597 (78-92), M.621 (51-65), M.651 (76-90), M.657 (87-101), M.677 (79-93), M.734 (230-244), M.738 (229-243), M.741 (247-261), M.761 (341-355) SYDGVIIRWIGGVGY 9 M.597 (96-110), M.621 (69-83), M.651 (94-108), M.657 (105-119), M.677 (97-111), M.734 (248-262), M.738 (247-261), M.741 (265-279), M.761 (359-373) TQIKCFVAAEELIT 9 M.597 (120-134), M.621 (93-107), M.651 (118-132), M.657 (129-143), M.677 (121-135), M.734 (272-286), M.738 (271-285), M.741 (289-303), M.761 (383-397) NALNIAVCQPEFLI 9 M.597 (164-178), M.621 (137-151), M.651 (162-176), M.657 (173-187), M.677 (165-179), M.734 (316-330), M.738 (315-329), M.741 (333-347), M.761 (427-441) PEFALITIDSAIVLL 9 M.597 (173-187), M.621 (146-160), M.651 (171-185), M.657 (182-196), M.677 (174-188), M.734 (325-339), M.738 (324-338), M.741 (342-356), M.761 (436-450) TDSAIVLLRKSIVTS 9 M.597 (180-194), M.621 (153-167), M.651 (178-192), M.657 (189-203), M.677 (181-195), M.734 (332-346), M.738 (331-345), M.741 (349-363), M.761 (443-457) IKVSYTITSSAVSPD 9 M.597 (196-210), M.621 (169-183), M.651 (194-208), M.657 (205-219), M.677 (197-211), M.734 (348-362), M.738 (347-361), M.741 (365-379), M.761 (459-473) KLRIYSISGDILTEE 9 M.597 (222-236), M.621 (195-209), M.651 (220-234), M.657 (231-245), M.677 (223-237), M.734 (374-388), M.738 (373-387), M.741 (391-261), M.761 (485-499) IRYSPDVSMFASADA 9 M.597 (249-263), M.621 (222-236), M.651 (247-261), M.657 (258-272), M.677 (250-264), M.734 (401-415), M.738 (400-414), M.741 (418-432), M.761 (512-526) IKLKNMLEHTARINC 9 M.597 (277-291), M.621 (250-264), M.651 (275-289), M.657 (286-300), M.677 (278-292), M.734 (429-443), M.738 (428-442), M.741 (446-460), M.761 (540-554) STKIFLESSTMESRA 38 M.709 (2-16) CAAVLAASAVVVLVV 38 M.668 (7-21), M.709 (52-66) VVVLVVASGLAGSRV 38 M.668 (16-30) LAGSRVVRVAVDVAT 38 M.668 (25-39) GWYHLFYQYNPEGAV 38 M.584 (28-42), M.592 (28-42), M.599 (51-65), M.635 (73-87), M.647 (82-96), M.668 (113-127), M.686 (65-79), M.709 (158-172), M.760 (24-38) SRDLIHWRHLPLAMV 38 M.584 (53-67), M.592 (53-67), M.599 (76-90), M.635 (98-112), M.647 (107-121), M.668 (138-152), M.686 (90-104), M.709 (183-197), M.760 (49-63) LNMLYTGSTNASVQV 38 M.489 (7-21), M.584 (90-104), M.592 (90-104), M.599 (113-127), M.635 (135-149), M.647 (144-158), M.668 (175-189), M.686 (127-141), M.709 (220-234), M.760 (86-100) IANVYKIKDFVSYEL 38 M.417 (34-48), M.457 (2-16), M.486 (33-47), M.489 (88-102), M.495 (32-46), M.584 (171-185), M.592 (171-185), M.599 (194-208), M.635 (216-230), M.647 (225-239) M.668 (256-270), M.686 (208-222), M.709 (301-315), M.729 (34-48), M.760 (167-181) TKDFVSYELIPGLLH 38 M.417 (40-54), M.457 (8-22), M.486 (39-53), M.489 (94-108), M.495 (38-52), M.584 (177-191), M.592 (177-191), M.599 (200-214), M.635 (222-236), M.647 (231-245) M.668 (262-276), M.686 (214-228), M.709 (307-321), M.729 (40-54), M.760 (173-187) WGKFYASKTFYDPAK 38 M.417 (122-136), M.457 (90-104), M.486 (121-135), M.489 (176-190), M.495 (120-134), M.584 (259-273), M.592 (259-273), M.599 (282-296), M.635 (304-318), M.647 (313-327) M.668 (344-358), M.686 (296-310), M.709 (389-403), M.729 (122-136), M.760 (265-269) KGWASLMSIPRTVDL 38 M.457 (125-139), M.486 (156-170), M.495 (155-169), M.686 (331-345), M.729 (157-171), M.760 (290-304) LRRAICLDIEAAFHL 38 M.729 (212-226), M.760 (345-359) EAAFRLDHAAVAALN 38 M.729 (221-235), M.760 (354-368) ECIAVYFYYSRGLDG 38 M.729 (269-283), M.760 (402-435) VKRVVGYTVPVLDGE 38 M.729 (303-317), M.760 (435-450) EAFSVRVLVDRSIVE 38 M.729 (317-332), M.760 (450-464) EAIYAAAGVYLFNNA 38 M.729 (349-363), M.760 (482-496) VYLFNNAISGIVTVE 38 M.729 (357-371), M.760 (490-504) TDIVEVVVSPPYVFL 39 M.415 (6-20), M.464 (41-55) M.467 (24-38), M.520 (40-54) SPPYVFLPIVKDKLR 39 M.415 (14-28), M.464 (49-63) M.467 (32-46), M.520 (48-62) GAFTGEVSAENLANL 39 M.415 (44-58), M.464 (79-93) M.467 (62-76), M.494 (33-47), M.520 (78-92) VSAEMLANLGIFNVI 39 M.415 (50-64), M.464 (85-99) M.520 (84-98) GESSEFVGDKVAYAL 39 M.410 (21-35) M.415 (75-89), M.464 (110-124) M.467 (93-107), M.494 (64-78), M.520 (109-123) GDKVAYALACGLKVI 39 M.392 (2-16) M.410 (28-42), M.415 (82-96) M.458 (0-14), M.464 (117-131), M.467 (100-114), M.494 (71-85), M.520 (116-130) STMTVVAEQTKAIAD 39 M.347 (23-37) M.374 (18-32), M.392 (30-44) M.410 (56-70), M.415 (110-124), M.458 (28-42), M.464 (145-159), M.467 (128-142), M.494 (99-113), M.520 (144-158) DWTNVVIAYEEVWAI 39 M.347 (41-55) M.374 (36-50), M.392 (48-62) M.410 (74-88), M.415 (128-142), M.458 (46-60), M.464 (163-177), M.467 (146-160), M.494 (117-131), M.520 (162-176) IAYEPVWAIGTGKVA 39 M.347 (47-61) M.374 (42-56), M.392 (54-68) M.410 (80-94), M.415 (134-148), M.458 (52-66), M.464 (169-183), M.467 (152-166), M.494 (123-137), M.520 (168-182) LRPEFIDIINAATVK 39 M.374 (116-130), M.458 (126-140), M.494 (197-211) RTSSWGSGASLKIDR 23 M.419 (0-14), M.443 (0-14) SLKIDRRELVIRIY 23 M.419 (9-23), M.443 (9-23) RFLHAAVAMATKRSV 24 M.540 (10-24), M.640 (8-22), M.642 (8-22), M.645 (18-32) EGKKVFLRADLNVPL 24 M.540 (33-47) M.622 (16-30), M.626 (16-30) M.627 (21-35), M.640 (31-45), M.642 (31-45), M.645 (41-55), M.646 (32-46), M.650 (34-48), M.652 (34-48) TRIRASIPTIKFLLE 24 M.540 (57-71) M.581 (10-24), M.622 (40-54), M.626 (40-54) M.627 (45-59), M.640 (55-69), M.642 (55-69), M.645 (65-79), M.646 (56-70), M.650 (58-72), M.652 (58-72) IIFFLLEKGAKVILA 24 M.540 (65-79) M.581 (18-32), M.622 (48-62), M.626 (48-62) M.627 (53-67), M.640 (63-77), M.642 (63-77), M.645 (73-87), M.646 (64-78), M.650 (66-80), M.652 (66-80) EKGAKVILASHLGRP 24 M.540 (71-85) M.581 (24-38), M.622 (54-68), M.626 (54-68) M.627 (59-73), M.640 (69-83), M.642 (69-83), M.645 (79-93), M.646 (70-84), M.650 (72-86), M.652 (72-86) VPRLSELLGVEVVMA 24 M.540 (98-112) M.559 (17-31), M.565 (22-36), M.567 (22-36) M.581 (51-65), M.622 (81-95), M.626 (81-95), M.627 (86-100), M.640 (96-110), M.642 (96-110), M.645 (106-120), M.646 (97-111), M.650 (99-113), M.652 (99-113) GGVLLLENVRFYKEE 24 M.540 (130-144) M.559 (49-63), M.565 (54-68), M.567 (54-68) M.581 (83-97), M.622 (113-127), M.626 (113-127), M.627 (118-132), M.640 (128-142), M.642 (128-142), M.645 (138-152), M.646 (129-143), M.650 (131-145), M.652 (131-145) PEFAKKLASVADLYV 24 M.540 (149-163) M.559 (68-82), M.565 (73-87), M.567 (73-87) M.581 (102-116), M.622 (132-146), M.626 (132-146), M.627 (137-151), M.640 (147-161), M.642 (147-161), M.645 (157-171), M.646 (148-162), M.650 (150-164), M.652 (150-164) KFLRPSVAGFLMQKE 24 M.540 (182-196) M.559 (101-115), M.565 (106-120), M.567 (106-120) M.581 (135-149), M.622 (165-179), M.626 (165-179), M.627 (170-184), M.640 (180-194), M.642 (180-194), M.645 (190-204), M.646 (181-195), M.650 (183-197), M.652 (183-197) VGFLMOKELDYLVG 24 M.540 (188-202) M.559 (107-121), M.565 (112-126), M.567 (112-126) M.581 (141-155), M.622 (171-185), M.626 (171-185), M.627 (176-190), M.640 (186-200), M.642 (186-200), M.645 (196-210), M.646 (187-201), M.650 (189-203), M.652 (189-203) KELDYLGAVANPKK 24 M.540 (195-209) M.559 (114-128), M.565 (119-133), M.567 (119-133) M.581 (148-162), M.622 (178-192), M.626 (178-192), M.627 (183-197), M.640 (193-207), M.642 (193-207), M.645 (203-217), M.646 (194-208), M.650 (196-210), M.652 (196-210) KIGVIESLLAKVDIL 24 M.540 (223-237) M.559 (142-156), M.565 (147-161), M.567 (147-161) M.581 (176-190), M.622 (206-220), M.626 (206-220), M.627 (211-225), M.640 (221-235), M.642 (221-235), M.645 (231-245), M.646 (222-236), M.650 (224-238), M.652 (224-238) GMIFTFYKAQGKAVG 24 M.559 (161-175) M.565 (166-180), M.567 (166-180), M.581 (195-209), M.622 (225-239), M.626 (225-239), M.627 (230-244), M.640 (240-254), M.642 (240-254), M.645 (250-264), M.646 (241-255), M.650 (243-257), M.652 (243-257) EEDKLELAISLIEIA 24 M.559 (180-194), M.565 (185-199), M.567 (185-199), M.581 (214-228), M.622 (244-258), M.626 (244-258), M.627 (249-263), M.640 (259-273), M.642 (259-273), M.645 (269-283), M.646 (260-274), M.650 (262-276), M.652 (262-276) GVSLLLPIDVVVADK 24 M.559 (198-212), M.565 (203-217), M.567 (203-217), M.581 (232-246), M.622 (262-276), M.626 (262-276), M.627 (267-281), M.640 (277-291), M.642 (277-291), M.645 (287-301), M.646 (278-292), M.650 (280-294), M.652 (280-294) SAPALRILRSFPSRS 25 M.609 (1-15) VELVANDPFITIDY 26 M.255 (1-15), M.471 (1-15), M.496 (1-15), M.575 (1-15) DYMTYMFRYDIVHGQ 26 M.255 (14-28), M.471 (14-28), M.496 (14-28), M.575 (14-28), M.586 (8-22) GGAKKVIISAPSKDA 26 M.471 (89-103), M.496 (89-103), M.575 (89-103) M.586 (83-97) TISDITIVSNASCIT 26 M.471 (115-129), M.496 (115-129), M.575 (115-129) M.586 (109-123) KVINDRFGIVEGLMT 26 M.471 (137-151), M.496 (137-151), M.575 (137-151) M.586 (131-145) FGIVEGLMTTBAMT 26 M.471 (143-157), M.496 (143-157), M.575 (143-157) M.586 (137-151) GGRAASFNIIPSSTG 26 M.367 (15-29), M.471 (173-187), M.496 (173-187), M.575 (173-187) M.586 (167-181) LIVRLENAAIYEQIK 26 M.367 (62-76), M.575 (220-234), M.586 (214-228) ALNDNFVKLVSWYDN 26 M.182 (43-57), M.189 (38-52), M.283 (50-64), M.297 (43-57) M.586 (271-285) VWQHDRVEIIANDQG 40 M.118 (1-15) VEIIANDQGNRTTPS 40 M.118 (7-21) TIPSYVAFIDSERLI 40 M.118 (18-32) KNQVAMNPINTVFGE 40 M.118 (37-51) NPINTVFGEHLSTCT 40 M.118 (43-57) SSTRGWCSRRRAGRG 41 M.346 (0-14) EEKGFAAEEISSMVL 42 M.318 (16-30) SSMVLIKMREIAEAF 42 M.318 (26-40) SIKNAVVTVPAYEND 42 M.318 (44-58) GVIAGLNVLRIINEP 42 M.318 (68-82) VLRIINEPTAAAIAY 42 M.318 (75-89) GRYFSKDAVQIITKM 10 M.177 (9-23) DAYQIITRNAAANGV 10 M.177 (15-29) GVRRVWVGQDSLLST 10 M.177 (28-42) SLLSTPAVSAIIRER 10 M.177 (38-52) AVSAIIRERIAADGS 10 M.177 (44-58) YPSMLLILLLLBGAN 63 M.408 (4-18), M.432 (4-18), M.477 (4-18) ILLLLHGANAALDEP 63 M.361 (5-19), M.408 (10-24), M.432 (10-24) M.477 (10-24) ESSLYAYOFAMSNGL 63 M.361 (45-59), M.408 (50-64), M.432 (50-64) M.477 (50-64) SGLRLDRSTLIAEVF 63 M.361 (80-94), M.408 (85-99), M.432 (85-99) M.477 (85-99) IRGWFAVDFTAAELV 63 M.361 (108-122), M.408 (113-127), M.432 (113-127) M.477 (113-127) IGKRFASINVENVED 27 M.469 (45-59) ALRELLFTIFGALQH 27 M.469 (63-77) LQHISGVILFEETLY 27 M.469 (75-89) TEAGARFARWRAVLK 27 M.104 (18-32) M.469 (143-157) GLARYAIICQENGLV 27 M.206 (26-40) M.469 (174-188), M.472 (10-24) RCAYVTEVVLAACYK 27 M.206 (57-71) M.472 (41-55) NDQHVLLEGSLLKPN 27 M.472 (58-72) WFLSFSFGRALQQST 27 M.294 (68-80) M.314 (61-75), M.472 (135-149) SVGFVETLENDLAQL 11 M.372 (57-71), M.466 (7-21), M.513 (56-70) M.579 (35-49), M.593 (50-64) LGEAPYRFKSALEAV 11 M.372 (110-124), M.395 (25-39), M.446 (60-74) M.506 (30-44), M.513 (109-123), M.579 (88-102), M.593 (103-117) KFKSALEAVKTLRAE 11 M.372 (116-130), M.395 (31-45), M.446 (66-80) M.513 (115-129), M.579 (94-108), M.593 (109-123) QYLOAFVIVDESGKS 11 M.395 (51-65), M.446 (86-100), M.506 (56-70) M.513 (135-149), M.579 (114-128), M.593 (129-143) VVTIFNFRADRMVMLA 11 M.381 (2-16), M.388 (2-16), M.391 (2-16) M.395 (75-89), M.446 (110-124), M.506 (80-94) M.513 (159-173), M.579 (138-152), M.593 (153-167) ADEMVMLAFALEFAD 11 M.381 (9-23), M.388 (9-23), M.391 (9-23) M.395 (82-96), M.446 (117-131), M.506 (87-101) M.513 (166-180), M.579 (145-159), M.593 (160-174) FDKFDRVRVPKIKYA 11 M.381 (24-38), M.391 (24-38) M.395 (97-111), M.446 (132-146), M.506 (102-116) M.513 (181-195), M.579 (160-174), M.593 (175-189) PKIKYAGMIQYDEL 11 M.381 (33-47), M.388 (33-47), M.391 (33-47) M.395 (106-120), M.446 (141-155), M.506 (111-125) M.513 (190-204), M.579 (169-183), M.593 (184-198) LKLPNKFLVSPPLIE 11 M.381 (47-61), M.388 (47-61), M.391 (47-61) M.395 (120-134), M.446 (155-169), M.506 (125-139) M.513 (204-218), M.579 (183-197), M.593 (198-212) GILLDFVNYEPLTYN 43 M.523 (0-14) ETMQRLVADRLPNFT 43 M.479 (11-25), M.519 (40-54), M.523 (43-57) M.600 (40-54) GYSKWLYVVPWGEYK 43 M.371 (12-26), M.380 (12-26), M.438 (43-57) M.461 (62-76), M.479 (81-95), M.480 (12-26) M.482 (12-26), M.519 (110-124), M.523 (113-127), M.556 (62-76) M.600 (110-124) YVVPWGFYKAVMHVK 43 M.371 (18-32), M.380 (18-32), M.438 (49-63) M.461 (68-82), M.479 (87-101), M.480 (18-26) M.482 (18-32), M.519 (116-130), M.523 (119-133), M.556 (68-82) M.600 (116-130) KFRIDYFDQYLRELK 43 M.108 (6-20), M.254 (5-19), M.260 (9-19) M.253 (6-20), M.371 (62-76), M.380 (62-76) M.438 (93-107), M.461 (112-126), M.479 (131-145), M.480 (62-76) M.482 (62-76), M.519 (160-174), M.523 (163-177), M.556 (112-126) M.600 (160-174) ARVTGYFAWSLLDNF 43 M.108 (27-41), M.254 (26-40), M.260 (26-40) M.261 (27-41), M.371 (83-97), M.380 (83-97) M.438 (114-128), M.461 (113-147), M.479 (152-166), M.480 (83-97) M.482 (83-97), M.519 (181-195), M.523 (184-198), M.556 (133-147) M.600 (181-195) FAWSLLDNFENAMGF 43 M.108 (33-47), M.254 (32-46), M.260 (32-46) M.261 (33-47), M.371 (89-103), M.380 (89-103) M.438 (120-134), M.461 (139-153), M.479 (158-172), M.480 (89-103) M.482 (89-103), M.519 (187-201), M.523 (190-204), M.556 (139-153) M.600 (187-201) EIPTISYSDLYQLAG 64 M.568 (15-29) M.589 (16-30) YSDLYQLAGVVAVEV 64 M.568 (21-35) M.589 (22-36) DHLRQVFGKQMGLSD 64 M.412 (5-19) M.516 (21-35) M.522 (5-19) M.568 (67-81), M.589 (68-82) NNPLKFDNTYFIELL 64 M.412 (47-61), M.462 (20-34), M.516 (63-77), M.522 (47-61), M.568 (109-123), M.589 (110-124) KAFFEDYKEAHLRLS 64 M.412 (95-109), M.462 (68-82), M.516 (111-125), M.522 (95-109), M.568 (157-171), M.589 (158-172) YKLLCSSFPVITYHQ 12 M.525 (4-18), M.656 (4-18) FPVITYHQGRNGNLS 12 M.525 (11-25), M.656 (11-25) RNGNLSALACPLNQK 12 M.525 (20-34), M.619 (20-34), M.656 (20-34) IPPAPHLKRWNRVVD 28 M.420 (1-15), M.444 (1-15) LKRWNKVVDTNLEEP 28 M.420 (7-21), M.444 (7-21) VVDINLESPNDIVPE 28 M.420 (13-27), M.444 (13-27) GAPFIGSGYRIAPYS 28 M.420 (28-42), M.444 (28-42) GYRIAPYSSILLKAT 28 M.420 (35-49), M.444 (35-49) ECILSGLLSVDGLKV 13 M.620 (15-29), M.630 (16-30), M.698 (16-30), M.599 (16-30) LLSVDGLKVLHMDRN 13 M.620 (21-35), M.630 (22-36), M.698 (22-36), M.699 (22-36), M.708 (0-14) VPKFMMANGALVRVL 13 M.620 (75-89), M.630 (76-90), M.698 (76-90), M.699 (76-90), M.708 (54-68) VRVLIRTSVTKYLNF 13 M.620 (86-100), M.630 (87-101), M.698 (87-101), M.699 (87-101), M.708 (65-79) TKYLNFKAVDGSFVY 13 M.620 (95-109), M.630 (96-100), M.698 (96-100), M.699 (96-100), M.708 (74-88) IDVEALKSNLMGLFE 13 M.620 (120-134), M.630 (121-135), M.698 (121-135), M.699 (121-135), M.708 (99-113) EKRRARRFFIVVQDY 13 M.620 (134-148), M.630 (135-149), M.698 (134-149), M.699 (134-149), M.708 (113-127) KFFIYVQDYEEEDPK 13 M.620 (140-154), M.630 (141-155), M.698 (141-155), M.699 (141-155), M.708 119-133) TVDFIGHALAHRDD 13 M.439 (14-28), M.620 (179-193), M.630 (180-194), M.698 (180-194), M.699 (180-194), M.708 (158-172) VKRMKLYAESLARFQ 13 M.439 (39.53), M.620 (204-218), M.630 (205-219), M.698 (205-219), M.699 (205-219), M.708 (183-197) GELPQAFARLSAVYG 13 M.439 (66.80), M.620 (231-245), M.630 (232-245), M.598 (232-246), M.699 (232-246), M.708 (210-224) FARLSAVYGGTYMLN 13 M.439 (72-86), M.620 (237-251), M.630 (238-252), M.698 (238-252), M.699 (238-252), M.708 (216-230) KGNFIAFVSIEAEID 13 M.698 (347-361), M.699 (347-361), M.708 (325-339) ETTVKVLALYSKIT 13 M.708 (390-404) LDLSVDLNAASAGES 13 M.708 (408-422) FKDDPYIYAFDSLKY 44 M.400 (65-79), M.401 (20-34), M.409 (6-20), M.435 (6-20), M.470 (59-73), M.474 (65-79), M.490 (65-79), M.491 (65-79), M.537 (6.20), M.553 (6.20) AFDSLKYIGIELWQV 44 M.400 (73-87), M.401 (28-42), M.409 (14-28), M.435 (14-28), M.470 (57-81), M.474 (73-87), M.490 (79-87), M.491 (73-87), M.537 (14-28), M.553 (14-28) IELWQVKSGTLFDNI 44 M.400 (82.96), M.401 (37-81), M.409 (23-37), M.435 (23-37), M.470 (76-90), M.474 (82.96), M.490 (82.96), M.491 (82.96) M.537 (23-37), M.553 (23-37) GTLFDNILITDDAAL 44 M.400 (90-104), M.401 (45-59), M.409 (31-45), M.435 (31-45), M.470 (84-98), M.474 (90-104), M.490 (90-104), M.491 (90-104), M.537 (31-45), M.553 (31-45) ILITDDAALAKTPAE 44 M.400 (96-100), M.401 (51-65), M.409 (37-51), M.435 (37-51), M.470 (90-104), M.474 (96-110), M.490 (96-110), M.491 (96-110), M.537 (37-51), M.553 (37-51) FPPPRCCQDLVVIPI 45 M.402 (4-38), M.538 (4-18), M.594 (4-18) RGLLRRARGGPHHRR 46 M.234 (2-16), M.237 (2-16), M.264 (2-16) RGAHRRVPLRPLRHR 46 M.234 (18-32), M.237 (18-32), M.264 (18-32) EGRRAKLRSAGEVEI 46 M.234 (39-53), M.237 (39-53), M.264 (39-53) GEVEIQERVKCKYF 46 M.234 (49-63), M.237 (49-63), M.264 (49-63) TKVTFHVVGVGPLLH 46 M.237 (66-80) EDVAVSLAKYTAELS 47 M.549 (14-28), M.550 (14-28), M.551 (14-28), M.557 (14-28), M.563 (24-38), M.566 (25-39), M.573 (14-28) GKFAAERGAFTVVLS 47 M.463 (36-50), M.549 (29-43), M.550 (29-43), M.551 (29-43), M.557 (29-43), M.558 (35-49), M.563 (39-53), M.566 (40-54), M.573 (29-43) AFIVVLSGGTLIDTL 47 M.463 (44-58), M.551 (37-51), M.557 (37-51), M.558 (43-57), M.566 (48-62), M.573 (37-51) DSNYKLAVDGLLSKV 47 M.463 (91-105), M.532 (40-54), M.549 (84-98), M.550 (84-98), M.551 (84-98), M.557 (84-98), M.558 (90-104), M.563 (94-108), M.566 (95-109), M.573 (84-98) IVLKQLVKSGVLAMS 47 M.463 (130-144), M.550 (123-137), M.551 (123-137), M.558 (129-143), M.563 (133-147), M.566 (134-148) KSGVLAMSTATGFPR 47 M.463 (137-151), M.550 (130-144), M.551 (130-144), M.558 (136-150), M.563 (140-154), M.566 (141-155) PPPQRTIFIFPVIKS 47 M.532 (140-154), M.549 (184-198), M.550 (184-198), M.551 (184-198), M.557 (184-198), M.558 (190-204), M.563 (194-208), M.565 (195-209), M.573 (184-198) IFTFPVIKSSAYVAM 47 M.532 (146-160), M.549 (190-204), M.550 (190-204), M.551 (190-204), M.557 (190-204), M.558 (196-210), M.563 (200-214), M.566 (201-215), M.573 (190-204) KTLPLLPTEMAILQP 47 M.532 (179-193), M.549 (223-237), M.550 (223-237), M.551 (223-237), M.557 (223-237), M.558 (229-243), M.563 (233-247), M.566 (234-248), M.573 (223-237) NKLIGARSFFESAKW 48 M.247 (1-15), M.517 (0-14) RAHIAFYQVCFEQKG 48 M.247 (64-78), M.517 (63-77), M.684 (0-14), M.739 (0-14) AALNGVFVSTAAGNI 48 M.517 (122-136), M.684 (5-73), M.730 (45-59), M.732 (57-71), M.736 (45-59), M.737 (45-59), M.739 (59-73) APWLLTVQASTSDRR 48 M.517 (147-161), M.684 (84-98), M.730 (70-84), M.732 (82-96), M.736 (70-84), M.737 (70-84), M.739 (84-98) STSDRRFAATVKLGS 48 M.517 (156-170), M.684 (93-107), M.711 (2-16), M.712 (4-18), M.730 (79-93), M.732 (91-105), M.736 (79-93), M.737 (79-93), M.739 (93-107) VLRAGAFGMIVVAPA 48 M.684 (170-184), M.711 (79-93), M.712 (81-95), M.732 (168-182), M.736 (156-170), M.739 (170-184) FGMIVVAPAVFGPVI 48 M.637 (0-14), M.684 (176-190), M.711 (85-99), M.712 (87-101), M.730 (162-176), M.732 (174-188), M.736 (162-176), M.737 (162-176), M.739 (176-190) YAVGQKIKAYLEAES 48 M.637 (28-42), M.684 (204-238), M.711 (113-127), M.712 (115-129), M.730 (190-204), M.732 (202-216), M.736 (190-204), M.737 (190-204), M.739 (204-218) VPGVVDIVLQPKEVM 48 M.637 (94-108), M.712 (181-195), M.730 (256-270), M.732 (268-282), M.736 (256-270), M.737 (256-270) CPHLAGIAALLRNAH 48 M.637 (121-135), M.684 (297-311), M.711(206-220), M.712 (208-222), M.730 (283-297), M.732 (295-309), M.736 (283-297), M.737 (283-297), M.739 (297-311) GLVYNLTAAEYIPYL 48 M.637 (188-202), M.684 (364-378), M.711 (273-287), M.712 (275-289), M.730 (350-364), M.732 (362-376), M.736 (350-364), M.737 (350-364), M.739 (364-378) KADSVVNASRAVINV 48 M.637 (246-260), M.711 (331-345), M.712 (333-347), M.730 (408-422), M.732 (420-434), M.736 (408-422), M.737 (408-422), M.739 (422-436) KLTFKALEEVLNYTV 48 M.637 (285-299), M.711 (370-384), M.712 (372-386), M.730 (447-461), M.732 (459-473), M.736 (447-461), M.737 (447-461), M.739 (461-475) EEVINYIVIVKTAAV 48 M.637 (292-306), M.711 (377-391), M.712 (379-393), M.730 (454-468), M.732 (456-480), M.736 (454-468), M.737 (454-468), M.739 (468-482) IEGQLKWVSSKHIVR 48 M.637 (311-325), M.711 (396-410), M.712 (398-412), M.736 (473-487), M.737 (473-487), M.739 (487-501) WVSSWHIVRSPILIL 48 M.637 (317-331), M.711 (402-416), M.712 (404-418), M.736 (479-493), M.737 (479-493), M.739 (493-507) SPRFFLAHSSHPST 29 M.707 (0-14), M.710 (1-15) EKAFKYLLGGGVAA 29 M.702 (14-28), M.707 (24-38), M.710 (25-39), M.713 (19-33) TEKGIELILSTEIVK 29 M.638 (70-84), M.673 (49-63), M.683 (63-77), M.687 (70-84), M.697 (70-84), M.700 (68-82), M.702 (94-108), M.707 (104-118), M.710 (105-119), M.713 (99-113) ASNILISAAGATFIY 29 M.638 (88-302), M.673 (67-81), M.683 (81-95), M.687 (88-102), M.697 (88-102), M.700 (86-100), M.702 (112-326), M.707 (122-136), M.710 (123-137), M.713 (117-131) FTYEILLIATGSSTI 29 M.638 (100-114), M.673 (79-93), M.683 (93-107), M.687 (100-114), M.697 (100-114), M.700 (98-112), M.702 (124-138), M.707 (134-148), M.710 (135-149), M.713 (129-143) GGGYIGLELSAALKL 29 M.638 (157-171), M.673 (136-150), M.683 (150-164), M.687 (157-171), M.697 (157-171), M.700 (155-169), M.702 (181-195), M.707 (191-205), M.710 (192-206), M.713 (186-200) LELSAALKLNNFDVT 29 M.638 (163-177), M.673 (142-156), M.683 (156-170), M.687 (163-177), M.697 (163-177), M.700 (161-175), M.702 (187-201), M.707 (197-211), M.710 (198-212), M.713 (192-206) LKLNNFDVTMVYFEP 29 M.638 (169-183), M.673 (148-162), M.683 (162-176), M.687 (169-183), M.697 (169-183), M.700 (167-181), M.702 (193-207), M.707 (203-217), M.710 (204-218), M.713 (198-212) MPRLFTAGIAHFYEG 29 M.638 (186-200), M.673 (165-179), M.683 (179-193), M.687 (186-200), M.697 (186-200), M.700 (184-198), M.702 (210-224), M.707 (220-234), M.710 (221-235), M.713 (215-229) HFYEGYYASKGINIV 29 M.638 (196-210), M.873 (175-189), M.687 (196-210), M.697 (196-210), M.700 (194-208), M.702 (220-234), M.707 (230-244), M.710 (233-245), M.713 (225-239) SKGINIVKGIVASGF 29 M.638 (204-218), M.673 (183-197), M.687 (204-218), M.697 (204-218), M.700 (202-216), M.702 (228-242), M.707 (238-252), M.710 (239-253), M.713 (233-247) KANIVIVGVGGRPHT 29 M.638 (238-252), M.673 (217-231), M.683 (231-245), M.687 (238-252), M.697 (238-252), M.700 (236-250), M.702 (262-276), M.707 (272-286), M.710 (273-287), M.713 (267-281) KTDTFFETSVAGVYA 29 M.638 (267-281), M.673 (246-260), M.683 (260-274), M.687 (267-281), M.697 (267-281), M.700 (265-279), M.702 (291-305), M.707 (301-315), M.710 (302-316), M.713 (296-310) VYAIGDVASFPMKLY 29 M.638 (279-293), M.673 (258-272), M.683 (272-286), M.687 (279-293), M.697 (279-293), M.700 (277-291), M.702 (303-317), M.707 (313-327), M.710 (314-328), M.713 (308-322) DYLPYFYSRSFDIAW 29 M.638 (329-343), M.673 (308-322), M.683 (322-336), M.687 (329-343), M.697 (329-343), M.700 (327-341), M.702 (353-367), M.707 (363-377), M.710 (364-378), M.713 (358-372) LLGYLLWVVAIHRPR 14 M.746 (0-34), M.758 (0.14), M.762 (0.14), M.764 (0.14) WVVAIRRPRPVRCFS 14 M.746 (6-20), M.758 (6-20), M.762 (6-20), M.764 (6-20) EQFVIPWSFSVASGH 30 M.608 (17-31), M.643 (19-33), M.663 (17-31), M.664 (17-31), M.666 (17-31), M.670 (17-31), M.731 (19-33), M.735 (19-33), M.740 (14-28), M.748 (19-33), M.750 (19-33), M.752 (18-32), M.754 (18-32), M.756 (18-32) RDAHYLRGLLPPAIV 30 M.608 (50-64), M.643 (52-66), M.663 (50-64), M.664 (50-64), M.666 (50-64), M.670 (50-64), M.731 (52-66), M.735 (52-66), M.740 (47-61), M.748 (52-66), M.750 (52-66), M.752 (51-65), M.754 (51-65), M.756 (51-65) MHNLRQYIVFLQRYI 30 M.608 (74-88), M.643 (76-90), M.663 (74-88), M.664 (74-88), M.666 (74.88), M.670 (74-88), M.731 (76-90), M.735 (76-90), M.740 (71-85), M.748 (76-90), M.750 (76-90), M.752 (75-89), M.754 (75-89), M.756 (75-89) VPLQRYIAMMDLQER 30 M.608 (82-96), M.643 (84-98), M.663 (82-96), M.664 (82-96), M.666 (82-96), M.670 (82-96), M.731 (84-98), M.735 (84-98), M.740 (79-93), M.748 (84-98), M.750 (84-98), M.752 (83-97), M.754 (83-97), M.756 (83-97) ERLFHKILLIDNVEHL 30 M.608 (98-112), M.643 (100-114), M.663 (98-112), M.664 (98-112), M.666 (98-112), M.670 (98-112), M.731 (100-114), M.735 (100-114), M.740 (95-109), M.748 (100-114), M.750 (100-114), M.752 (99-113), M.754 (99-113), M.756 (99-113) EELLPVVYIPVVGEA 30 M.608 (110-124), M.643 (112-126), M.663 (110-124), M.664 (110-124), M.666 (110-124), M.670 (110-124), M.731 (112-126), M.735 (112-126), M.740 (107-121), M.748 (112-126), M.750 (112-126), M.752 (111-125), M.754 (111-125), M.756 (111-125) RSIQVIVVIDGERIL 30 M.608 (158-172), M.643 (160-174), M.663 (158-172), M.664 (158-172), M.666 (158-172), M.670 (158-172), M.731 (160-174), M.735 (160-174), M.740 (155-169), M.748 (160-174), M.750 (160-174), M.752 (159-173), M.754 (159-173), M.756 (159-173) EEYHELLQEFMNAVK 30 M.608 (234-248), M.643 (236-250), M.663 (234-248), M.664 (234-248), M.666 (234-248), M.670 (234-248), M.731 (236-250), M.735 (236-250), M.740 (231-245), M.748 (236-250), M.750 (236-250), M.752 (235-249), M.754 (235-249), M.756 (235-249) GERVLVQFEDFANHN 30 M.608 (252-266), M.643 (254-268), M.663 (252-266), M.664 (252-266), M.666 (252-266), M.670 (252-266), M.731 (254-268), M.735 (254-268), M.740 (249-263), M.748 (254-268), M.750 (254-268), M.752 (253-267), M.754 (253-267), M.756 (253-267) FDLLAKYSKSHLVFN 30 M.608 (268-282), M.643 (270-284), M.663 (268-282), M.664 (268-282), M.666 (268-282), M.260 (268-282), M.731 (270-284), M.735 (270-284), M.740 (265-279), M.748 (270-284), M.750 (270-284), M.752 (269-283), M.754 (269-283), M.756 (269-283) VFNDDIQGIASVVLA 30 M.608 (280-294), M.643 (282-296), M.663 (280-294), M.664 (280-294), M.666 (280-294), M.670 (280-294), M.731 (282-296), M.735 (282-296), M.740 (277-291), M.748 (282-296), M.750 (282-296), M.752 (281-295), M.754 (281-295), M.756 (281-295) SVVLAGLLAALKVIG 30 M.643 (292-306), M.663 (290-304), M.664 (290-304), M.666 (290-304), M.670 (290-304), M.731 (292-306), M.735 (292-306), M.740 (287-301), M.748 (292-306), M.750 (292-306), M.752 (291-305), M.754 (291-305), M.756 (291-305) GLADQTYLFLGAGEA 30 M.643 (308-322), M.663 (306-320), M.664 (306-320), M.666 (306-320), M.670 (306-320), M.731 (308-322), M.735 (308-322), M.740 (303-317), M.748 (308-322), M.750 (308-322), M.752 (307-323), M.754 (307-321), M.756 (307-321) TGTAELTALEMSKHT 30 M.643 (324-338), M.663 (322-336), M.664 (322-336), M.666 (322-336), M.670 (322-336), M.731 (324-338), M.735 (324-338), M.740 (319-333), M.748 (324-338), M.750 (324-338), M.752 (323-337), M.754 (323-337), M.756 (323-337) CRKKTWLVDSKGLLV 30 M.731 (345-359), M.735 (345-359), M.740 (340-354), M.748 (345-359), M.750 (345-359), M.752 (344-358), M.754 (344-358), M.755 (344-358) HEPLTTLLEAVQSLK 30 M.731 (377-391), M.735 (377-391), M.740 (372-386), M.748 (377-391), M.750 (377-391), M.752 (376-390), M.754 (376-390), M.756 (376-390) LLEAVQSLKPTVLIG 30 M.731 (383-397), M.735 (383-397), M.740 (378-392), M.748 (383-397), M.750 (383-397), M.752 (382-396), M.754 (382-396), M.756 (382-396) NELPVIFSLSNPTSH 30 M.731 (417-431), M.735 (417-431), M.740 (412-426), M.748 (417-431), M.750 (417-431), M.752 (416-430), M.754 (416-430), M.756 (416-430) EEAYTWTKGTAVFAS 30 M.731 (437-451), M.735 (437-451), M.740 (432-446), M.748 (437-451), M.750 (437-451), M.752 (436-450), M.754 (438-450), M.756 (436-450) GFGLGVVISGAIRVH 30 M.735 (478-492), M.740 (473-487), M.748 (478-492), M.750 (478-492), M.752 (477-491), M.754 (477-491), M.756 (477-491) VISGAIRVHDDMLLA 30 M.735 (484-498), M.740 (479-493), M.748 (484-498), M.750 (484-498), M.752 (483-497), M.754 (483-497), M.756 (483-497) HDDMLLAASEALAEQ 30 M.735 (492-506), M.740 (487-501), M.748 (492-506), M.750 (492-506), M.752 (491-505), M.754 (491-505), M.756 (491-505) FPPFTNIRKTSANTA 30 M.740 (513-527), M.748 (518-532), M.750 (518-532), M.752 (517-531), M.754 (517-531), M.756 (517-531) IRKISANIAAKVAAK 30 M.748 (524-538), M.750 (524-538), M.752 (523-537), M.754 (523-537), M.754 (523-537) PRVNFFKKYNLTCVF 15 M.716 (0-14), M.726 (0-14) KRYNLTCVWSKKKK 15 M.726 (6-20) TIVASGTENMKTFTR 8 M.763 (5-19), M.765 (2-16) FSCDSATQVTYTVRG 65 M.171 (10-24), M.205 (6-20), M.256 (21-35), M.332 (2-16) YQVTYTVRGSGRVQV 65 M.148 (4-38), M.171 (16-30), M.205 (32-25), M.255 (27-41), M.332 (8-22), M.64 (0-14) IEGGSLFIVPRFHVV 65 M.148 (31-45), M.171 (43-57), M.205 (39-53), M.22 (19-33), M.256 (54-68), M.332 (35-49), M.4 (16-30), M.55 (23-37), M.56 (16-30), M.64 (27-41) GNEWFSTTTTPNFIF 65 M.332 (57-71), M.58 (38-52) GKTSVWKATSPEVLE 65 M.332 (76-90) ELRKTYNLLDAVSRH 48 M.43 (0-14), M.47 (0-14), M.61 (0-14) QVYPRSWSAVMLTFD 49 M.32 (13-27), M.43 (17-31), M.47 (17-31), M.57 (6-20), M.61 (17-31) AVMLTFDNAGMWNVR 49 M.13 (5-19), M.32 (21-35), M.43 (25-39), M.47 (25-39), M.57 (14-28), M.61 (25-39) NVWERHYLAGEMTLM 49 M.32 (37-51), M.47 (41-55) GEQLYISVISPARSL 49 M.33 (29-43), M.57 (38-52) DSSEYAFRTAVSSM 50 M.518 (9-23) TGNLRLDNTTLIDKD 50 M.538 (43-57) EIPMIQNILSRSQIF 50 M.518 (87-101) SRSQIFDGIPNLMSL 50 M.518 (96-110) DGIPNLMSLDNVVKI 50 M.518 (102-116) IWVNVEYDSFYREHG 50 M.518 (122-136) EFPVIWVSSPEVALL 50 M.518 (149-163) SPEVALLKSLAGKLR 50 M.518 (157-171) AGKLRNSTKLIFRFL 50 M.518 (167-181) ETKLIFRFLREDLVE 50 M.518 (173-187) GELLKDLKSIKAFAS 50 M.518 (195-209) LKSIKAFASGILVPK 50 M.538 (201-215) CEGILKLLETHLVPS 51 M.267 (9-23), M.270 (14-28) LTETHLVPSSTAPHS 51 M.267 (15-29), M.270 (20-34) PESKVFYLKMKGDYH 51 M.267 (27-41), M.270 (32-46) MNSYKAAQDIALADL 51 M.150 (38-52), M.267 (81-75), M.270 (66-80), M.73 (23-37) AFTHPIRLGLALKIS 51 M.73 (38-52) LLGLLAPLASAQLSR 52 M.505 (0-14), M.667 (0-14), M.679 (0-14), M.680 (0-14) PDAEKIVAVIEKKL 52 M.488 (4-18), M.505 (22-36), M.667 (22-36), M.679 (22-36), M.680 (22-36) AGLLFLLFHDCFANG 52 M.488 (26-40), M.505 (44-58), M.667 (44-58), M.679 (44-58), M.680 (44-58) CDASILIDPLSNQSA 52 M.230 (1-15), M.445 (9-23), M.488 (41-55), M.505 (59-73), M.667 (59-73), M.679 (59-73), M.680 (59-73) IDSSYFANYLAKKMP 52 M.530 (104-118), M.667 (228-242), M.679 (228-242), M.680 (228-242) KPNDFMPTFAKAMEK 52 M.530 (141-155), M.667 (265-279), M.679 (265-279), M.680 (265-279) PTFANAMEMLSVLKV 52 M.530 (147-161), M-679 (271-285), M.680 (271-285) GGSVIRISSANPEDL 52 M.530 (184-198), M.667 (308-322), M.679 (308-322), M.680 (308-322) DPWHVKTLKAAGAAH 52 M.530 (218-232), M.667 (342-385), M.679 (342-356), M.680 (342-356) WSEIQTLKPNLIGPF 53 M.436 (0-14), N.534 (0-14) NEMTLAGFLDYANAS 53 M.436 (30-44), M.487 (29-43), M.508 (27-41), M.534 (30-44), M.613 (29-43), M.688 (28-42) NISGILIGIENAAYL 53 M.436 (45-59), M.487 (44-58), M.508(42-56), M.534(45-59), M.613(44-58), M.688(43-57) AAYLATRGLDVVDAV 53 M.436 (56-70), M.487 (55-69), M.508 (53-67), M.534 (56-70), M.562(10-24), M.572 (1-15), M.613 (55-69), M.688(54-68) GLDVVDAVSNALIKS 53 M.436 (63-77), M.487 (62-76), M.508 (60-74), M.534 (63-77), M.552 (17-31), M.572 (8-22), M.613 (62-76), M.688 (61-75) IKQQVFIQSEDFPVL 53 M.336 (19-33), M.436 (83-97), M.487 (82-96), M.508 (80-54), M.534 (83-97), M.552 (37-51), M.572 (28-42), M.613 (82-96) M.688 (81-95) PVLSAFKKEPKFNRV 53 M.336 (31-45), M.436 (95-109), M.487 (94-108), M.508 (92-106), M.534 (95-109), M.552 (49-63), M.572 (40-54), M.613 (94-108), M.688 (93-107) KFPKFNRVFEIEFDI 53 M.336 (38-52), M.436 (102-116), M.487 (101-115), M.508 (89-113), M.534 (102-116), M.552 (56-70), M.572 (47-61), M.613 (101-115), M.688 (100-114) VEIKEFANAVKLRRS 53 M.336 (61-75), M.436 (125-139), M.487 (124-138), M.508 (122-136), M.534 (125-139), M.552 (79-93), M.572 (70-84) M.613 (124-138), M.688 (123-137) VKLRRSSAAQVDFGFY 53 M.336 (70-84), M.436 (114-146), M.487 (133-147), M.508 (131-145), M.534 (134-148), M.552 (88-102), M.572 (79-93) M.613 (133-147), M.688 (132-146) GFYLTGFNAVVERLR 53 M.336 (82-96), M.436 (146-160), M.487 (145-159), M.508 (143-157), M.534 (146-160), M.552 (100-114), M.572 (91-105) M.613 (145-159), M.688 (144-158) GVLKNEEMSLAFDYW 53 M.487 (168-182), M.508 (166-180), M.534 (169-183), M.552 (123-137), M.572 (114-128), M.613 (168-182), M.668 (167-181) GLVTEFPSTAAAYFR 53 M.534 (201-215), M.552 (155-169), M.572 (146-160), M.613 (200-214), M.688 (199-213) NIVVNVFNQLDQPLL 54 M.384 (38-52) QPLLFTWNVIQRRKN 54 M.384 (49-63) IGSFFYFPSIGMQRT 54 M.127 (12-26), M.145 (12-126), M.147 (36-80), M.213 (26-39), M.220 (25-39), M.384 (92-106) GYGLISVVSRLLIPV 54 M.127 (29-43), M.145 (29-43), M.147 (33-47), M.213 (42-26), M.220 (42-56), M.384 (109-123) VVSRLLIPVFFDFPA 54 M.127 (35-49), M.145 (35-49), M.213 (48-62), M.220 (48-62), M.384 (115-128) VCTRLSPFCCLYCIL 17 M.577 (1-15), M.717 (1-15), M.719 (1-15), M.724 (1-15), M.727 (1-15 YCILCCWYSMRLVTV 17 M.577 (12-26), M.717 (12-26), M.719 (12-26), M.724 (12-26), M.727 (12-26) NIWADDLAASLSTLE 76 MN.169 (10-24) TAIAFLSVSNNYEYI 76 MN.124 (0-14) VSNNYEYILSDKLVV 76 MN.124 (7-21) KDKLVVSISCSLMHT 76 MN.169 (32-46) TSCSLMHTAVDLVNE 76 MN.124 (23-37), MN.169 (39-53) TKLDSETKSKLAFAA 76 MN.124 (38-52), MN.169 (54-68) IKSWLAFAAQKVVEV 76 MN.124 (44-58), MN.169 (60-74) KVVEVNALGKALVGL 76 MN.124 (54-68), MN.169 (70-84) LKDEAYFAANAAAQA 76 MN.124 (68-82), MN.169 (84-98) EAYVSAIKEEISKVV 76 MN.124 (158-172), MN.169 (174-188), MN.82 (13-37) ISKVVKIQEELDIDV 76 MN.124 (168-182), MN.169 (184-198), MN.82 (23-37) MVEYFGEQLSGFATT 76 MN.169 (209-223), MN.82 (48-62) LSGFAFTANGWVQSY 76 MN.169 (217-221), MN.82 (56-70) NPMIVFWSFMAWSMT 76 MN.169 (249-263), MN.82 (88-102) EGPLMLYVSKMIPAS 77 MN.206 (2-16), MN.210 (2-16) NGRFFAFGRVFAGHR 77 MN.208 (18-32), MN.210 (18-32) GNTVALVGLDQFITK 77 MN.206 (78-92), MN.210 (78-92) VGLDQFITKNATLTG 77 MN.206 (84-98), MN.210 (84-98) PIRAMKFSVSPVVRV 77 MN.206 (106-120), MN.210 (106-120) FNGGAEIIVSPPVVS 77 MN.201 (49-63), MN.206 (178-192), MN.210 (178-192) SPPVVSFRETVLDKS 77 MN.201 (58-72), MN.206 (187-201), MN.210 (187-201) NKHNRLYMEARPLEE 77 MN.201 (82-96), MN.206 (213-225), MN.210 (211-225) PTARRVIFASQTAK 77 MN.136 (42-56), MN.140 (49-63), MN.173 (68-82), MN.183 (102-116), MN.184 (102-116), MN.185 (94-108), MN.193 (101-115), MN.201 (208-222), MN.206 (337-351), MN.210 (337-351) AKPRLLEFVYLVEIQ 77 MN.136 (55-69), MN.140 (62-76), MN.173 (81-95), MN.183 (135-129), MN.184 (115-129), MN.185 (107-121), MN.193 (114-128), MN.201 (221-235), MN.206 (350-364), MN.210 (350-364) EPVYLVEIQAPEGAL 77 MN.136 (61-75), MN.140 (68-82), MN.173 (87-101), MN.183 (121-135), MN.184 (121-135), MN.185 (113-127), MN.193 (120-134), MN.201 (227-241), MN.206 (356-370), MN.210 (356-370) PLYNIKAYLPVIESF 77 MN.136 (99-113), MN.140 (106-120), MN.173 (125-139), MN.183 (159-173), MN.184 (159-173), MN.185 (191-169), MN.193 (158-172), MN.201 (265-279), MN.206 (394-408), MN.210 (394-408) LPVIESFGFSATLRA 77 MN.136 (107-121), MN.140 (114-128), MN.173 (133-147), MN.183 (167-181), MN.184 (167-181), MN.185 (159-173), MN.193 (166-180), MN.201 (273-287), MN.206 (402-416), MN.210 (402-416) FGFSATLRAATSGQA 77 MN.136 (113-127), MN.140 (120-134), MN.173 (139-153), MN.183 (173-187), MN.184 (173-187), MN.185 (165-179), MN.193 (172-185), MN.201 (229-293), MN.206 (408-422), MN.210 (408-422) SLKLHKACEAFNPYD 78 MN.12 (4-18) CAFDPYYGKISLSKV 78 MN.15 (32-25), MN.38 (27-41) SKVRSFLTEAKAKHI 78 MN.12 (24-38), MN.15 (24-38), MN.35 (39-53), MN.38 (39-53), MN.41 (40-54) LTEAHAKHIEWNCDV 78 MN.12 (30-44), MN.15 (30-44), MN.3 (13-27), MN.35 (45-59), MN.38 (45-59), MN.41 (46-60), MN.47 (47-61) KEKRWNAALTSISAS 78 MN.86 (64-78) GSAYVDLGSLLAERT 78 MN.86 (81-95) RHLARQFIPHLHQRF 78 MN.83 (0-14), MN.94 (0-14) FIPHLHQRFIHPPIH 78 MN.83 (6-20), MN.94 (6-20) NTMENLSSTIFSFVI 78 MN.14 (1-15), MN.33 (10-24), MN.46 (22-36), MN.74 (0-14), MN.83 (23-37), MN.94 (23-37) TIFSFVILLSASASL 78 MN.14 (9-23), MN.17 (6-20), MN.20 (6-20), MN.30 (12-26), MN.33 (18-32), MN.46 (30-44), MN.67 (6-20), MN.74 (8-22), MN.8 (1-19), MN.83 (31-45), MN.94 (31-45) ILLSASAELVVAGDP 78 MN.14 (15-29), MN.17 (12-26), MN.20 (12-26), MN.30 (18-32), MN.33 (24-38), MN.45 (36-50), MN.67 (12-26), MN.8 (7-21), MN.83 (37-51), MN.94 (37-51) ELAEMEVSAAFRLTS 78 MN.51 (32-46), MN.56 (32-46), MN.59 (32-46), MN.62 (32-46), MN.63 (32-46), MN.67 (59-73), MN.74 (61-75), MN.86 (32-46), MN.94 (84-98) SAAFHLFSMAVTAAR 78 MN.51 (39-53), MN.56 (39-53), MN.59 (39-53), MN.62 (39-53), MN.63 (39-53), MN.67 (66-80), MN.74 (68-82), MN.86 (39-53) FSMAVTAARSCQWND 78 MN.51 (45-59), MN.56 (49-59), MN.59 (45-59), MN.62 (45-59), MN.63 (45-59), MN.67 (72-86), MN.74 (74-88), MN.86 (45-59) KISLSKVRSFLTEAK 78 MN.12 (20-34), MN.15 (20-34), MN.35 (35-49), MN.38 (35-49), MN.41 (36-50) QQYTAALSPILFECL 79 MN.108 (131-145) LSPILFECLIHPMLG 79 MN.106 (5-19), MN.90 (5-19), MN.96 (5-19) VEDNLVKLKNVLNVY 79 MN.90 (27-41), MN.91 (0-14), MN.96 (27-41) KLKNVLNVYEARLTK 79 MN.106 (33-47), MN.80 (4-18), MN.81 (1-15), MN.90 (33-47), MN.91 (6-20), MN.96 (33-47) EVYEARLTKFNILAG 79 MN.36 (5-19), MN.26 (4-18) IKFKYLAGDYLSLAD 79 MN.36 (12-26), MN.76 (11-25), MN.81 (14-28), MN.90 (46-60) AGDYLSLADLNBVSI 79 MN.106 (52-56), MN.35 (18-32), MN.76 (17-31), MN.80 (23-37), MN.81 (20-34), MN.90 (52-66), MN.91 (25-39), MN.95 (52-66) VKAWWIDLLAKPSVQ 79 MN.106 (85-99), MN.36 (51-65), MN.71 (25-39), MN.76 (50-64), MN.80 (56-70), MN.81 (53-67), MN.90 (85-99), MN.91 (58-72), MN.96 (85-99) KLRTICLSSIGSSCL 80 MN.186 (0-14) LSSTGSSCLFVLILF 80 MN.186 (6-20) EKLKFVLEVYEARLS 81 MN.58 (0-14) SYLAGDFVSFADLNH 81 MN.58 (17-31) FVSFADLNHFPRTFY 81 MN.58 (23-37) FPKTFYFMAIPHASL 81 MN.58 (32-46) HVKAWWERIMARPAV 81 MN.58 (52-66) IMARPAVKKIAAMV 81 MN.58 (60-74) MRKVRGFNRVHQISA 82 MN.107 (32-46) FWRVHQISARMAPVK 82 MN.107 (38-52) MAPVKLYGATLSWNV 82 MN.107 (48-62) GDLYIFESRAICNYA 82 MN.107 (108-122), MN.6 (17-31), MN.77 (39-53) EANQYTAALGPILFE 82 MN.107 (149-163), MN.77 (80-94) ACSLFLNYAVSFNYF 83 MN.205 (4-18), MN.211 (4-18) YAVSFNYFVCNLLQE 83 MN.205 (11-25), MN.211 (11-25) NLLQERLKKLKSEHG 83 MN.205 (21-35), MN.211 (21-35) GMTGMLWETSLLDPE 83 MN.203 (27-43), MN.204 (27-41), MN.205 (53-67), MN.211 (53-67) PEGLLWLLLTGKVPT 83 MN.203 (69-83), MN.204 (69-83), MN.205 (95-109), MN.211 (95-109), YVYKAIDALPVIAHP 83 MN.203 (103-117), MN.204 (103-117), MN.205 (129-143), MN.211 (129-143) QFTTGVMALQVESEF 83 MN.203 (120-134), MN.204 (120-134), MN.205 (146-160), MN.211 (145-160) EDCLNLIARLOQVAS 83 MN.203 (153-167), MN.204 (153-167), MN.205 (179-193), MN.211 (179-193) IARLPQVASYVYRRI 83 MN.203 (159-173), MN.204 (159-173), MN.205 (185-199), MN.211 (185-199) ADNSLDYAANFSHML 83 MN.203 (182-196), MN.204 (182-196), MN.205 (208-222), MN.211 (208-222) DPKMLELMRLYITIH 83 MN.203 (200-214), MN.204 (200-214), MN.205 (226-240), MN.211 (226-240) ALSDPYLSFAAALNG 83 MN.203 (233-247), MN.204 (238-247), MN.205 (259-273), MN.211 (259-273) LSFAAALNGLAGPLH 83 MN.203 (239-253), MN.204 (239-253), MN.205 (265-279), MN.211 (265-279) PLHGLANQEVLLWIN 83 MN.203 (251-265), MN.204 (251-265), MN.205 (277-291), MN.211 (277-291) QEVLLWIKSVMEETG 83 MN.203 (258-272), MN.204 (258-272), MN.205 (184-298), MN.211 (284-298) QLKEYVWKTLKSGKV 83 MN.203 (279-293), MN.204 (279-293), MN.205 (905-319), MN.211 (909-319) EDPLFQLVSKLYEVV 83 MN.123 (17-31), MN.203 (322-336), MN.204 (322-336), MN.205 (348-362), MN.211 (348-362), MN.69 (0-14), MN.98 (17-31) LVSKLYEVVFGILTE 83 MN.123 (23-37), MN.203 (328-342), MN.204 (328-342), MN.205 (354-368), MN.211 (364-368), MN.69 (6-20), MN.98 (23-37) SGVLLNHFGLVEARY 83 MN.113 (28-42), MN.123 (52-66), MN.203 (357-371), MN.204 (357-371), MN.205 (383-397), MN.211 (383-397), MN.68 (28-42), MN.69 (35-49), MN.93 (28-42), MN.98 (52-66) IVLFGVSRSMGIGSQ 83 MN.113 (44-58), MN.123 (68-82), MN.203 (979-387), MN.204 (373-387), MN.205 (399-419), MN.211 (399-413), MN.68 (44-58), MN.69 (51-65), MN.93 (44-58), MN.98 (68-82) GSQLIWDRALGLPLE 83 MN.113 (56-70), MN.123 (80-94), MN.203 (385-399), MN.204 (385-399), MN.205 (411-425), MN.211 (411-425), MN.68 (56-70), MN.69 (63-77), MN.93 (56-70), MN.98 (80-94) GPVTILNWSFVENDQ 84 MN.105 (9-23), MN.166 (5-19), MN.167 (6-20), MN.172 (9-23), MN.178 (9-23), MN.182 (5-19) PRFETCYQIALAIKK 84 MN.105 (24-38), MN.166 (20-34), MN.167 (21-35), MN.168 (10-24), MN.172 (24-38), MN.178 (24-38), MN.182 (20-34) GIQVIQIDEAALREG 84 MN.105 (47-61), MN.166 (43-57), MN.167 (44-58), MN.168 (33-47), MN.172 (47-61), MN.178 (47-61), MN.182 (43-57) EHAFYLDWAVHSFRI 84 MN.105 (68-82), MN.166 (64-78), MN.167 (65-79), MN.168 (54-68), MN.172 (68-82), MN.178 (68-82), MN.182 (64-78) FNDITHSITNMDADV 84 MN.105 (102-115), MN.166 (98-112), MN.167 (99-113), MN.168 (88-102), MN.172 (102-316), MN.178 (302-115), MN.182 (98-112) SDEKLLSVFREGVTY 84 MN.105 (124-138), MN.166 (120-134), MN.167 (121-135), MN.168 (110-124), MN.172 (124-138), MN.178 (124-138), MN.182 (120-134) VNKMLAVLDTNILWV 84 MN.166 (160-174), MN.167 (161-175), MN.168 (150-164), MN.172 (164-178), MN.178 (164-178), MN.182 (160-174) TRKYAEVMPALTNMV 84 MN.166 (182-196), MN.167 (183-197), MN.168 (172-186), MN.172 (186-200), MN.178 (186-200), MN.182 (182-196) PALTNMVTAAKLIPT 84 MN.166 (190-204), MN.167 (191-205), MN.168 (180-194), MN.172 (194-208), MN.178 (194-208), MN.182 (190-204) VTAAKLIRTQLASTK 84 MN.166 (196-210), MN.167 (197-211), MN.168 (186-200), MN.172 (200-214), MN.178 (200-214), MN.182 (196-210) GRGIKDFGLVVAPGG 85 MN.39 (9-23) LTVGNIIAGDRFSMA 85 MN.39 (28-42) DRFSMAYDRTPEEIL 85 MN.39 (37-51) YDRTPEEILAIVYGT 85 MN.39 (43-57) EILAIVYGIGNPAQA 85 MN.39 (49-63) TREENVYMAKLAEQA 86 MN.102 (6-20), MN.116 (6-20), MN.117 (6-20), MN.181 (6-20), MN.194 (6-20), MN.195 (6-20), MN.202 (6-20) YEEMVEFMEKVAKTA 86 MN.102 (23-37), MN.116 (23-37), MN.117 (23-37), MN.156 (11-25), MN.181 (23-37), MN.194 (23-37), MN.195 (23-37), MN.202 (23-37) EERNLLSVAYKNVIG 86 MN.102 (45-59), MN.116 (45-59), MN.117 (45-59), MN.156 (33-47), MN.181 (45-59), MN.194 (45-59), MN.195 (45-59), MN.202 (45-59) AYKNVIGARRASWRI 86 MN.102 (53-67), MN.116 (53-67), MN.117 (53-67), MN.156 (41-55), MN.181 (53-67), MN.194 (53-67), MN.195 (53-67), MN.202 (53-67) RRASWRIISSIEQKE 86 MN.102 (61-75), MN.116 (61-75), MN.117 (61-75), MN.156 (49-63), MN.181 (61-75), MN.194 (61-75), MN.195 (61-75), MN.202 (61-75) NEAYVASINEYRTRI 86 MN.101 (10-24), MN.102 (80-94), MN.116 (80-94), MN.117 (80-94), MN.156 (68-82), MN.181 (80-94), MN.194 (80-94), MN.195 (80-94), MN.202 (80-94) SKICDGILKLLDSHL 86 MN.101 (29-43), MN.102 (99-113), MN.116 (99-113), MN.117 (99-113), MN.156 (87-101), MN.181 (99-113), MN.194 (99-113), MN.195 (99-113), MN.202 (99-113) ILKLLDSRLVFSATA 86 MN.101 (35-49), MN.102 (105-119), MN.116 (105-119), MN.117 (105-119), MN.156 (93-107), MN.181 (105-119), MN.194 (105-119), MN.195 (105-119), MN.202 (105-119) AESKVFYLKMKGDYH 86; 51 M.150 (4-18), MN.101 (50-64), MN.102 (120-134), MN.116 (120-134), MN.117 (120-134), MN.156 (108-122), MN.181 (120-134), MN.194 (120-134), MN.195 (120-134), MN.202 (120-134) GDYRRYLAEFKAGAE 86 MN.101 (61-75), MN.116 (131-145), MN.156 (119-139), MN.183 (131-145), MN.194 (131-145), MN.195 (131-145), MN.202 (131-145) NILVAYKSAQDIALA 86 MN.101 (82-96), MN.156 (140-154), MN.163 (9-23), MN.175 (9-23), MN.181 (152-166), MN.194 (152-166), MN.195 (152-166), MN.202 (152-166), MN.97 (6-20) LPTTAPIRLGLALNF 86 MN.101 (98-112), MN.156 (156-170), MN.163 (25-39), MN.175 (25-39), MN.181 (158-182), MN.194 (168-182), MN.195 (168-182), MN.202 (168-182), MN.97 (22-36) IRLGLALNFSVFYYE 86 MN.101 (104-118), MN.156 (162-176), MN.163 (31-45), MN.175 (31-45), MN.181 (174-188), MN.194 (174-188), MN.195 (174-188), MN.202 (174-188), MN.97 (28-42) LNPSVFYYETLNSPD 86 MN.101 (110-124), MN.156 (168-182), MN.163 (37-53), MN.175 (37-51), MN.181 (180-194), MN.194 (180-194), MN.195 (180-194), MN.202 (180-194), MN.97 (34-48) YKDSTLIMQLLRDNL 86 MN.156 (207-221), MN.163 (76-90), MN.175 (76-90), MN.181 (219-233), MN.194 (219-233), MN.195 (219-233), MN.202 (219-233), MN.54 (37-51), MN.97 (73-84) TMQLLRDNLTLWTSD 86 MN.156 (213-227), MN.163 (82-96), MN.175 (82-96), MN.181 (225-239), MN.194 (225-239), MN.195 (225-239), MN.202 (225-239), MN.54 (43-37), MN.97 (79-93) GSRALPFLLQLTKQP 87 MN.153 (7-21) VKVYVVYYSMYGHVG 87 MN.153 (50-64), MN.157 (26-40), MN.95 (2-16) GVEVKVWQVPEILSE 87 MN.118 (2-16), MN.122 (9-23), MN.128 (9-23), MN.153 (79-93), MN.92 (16-30), MN.95 (31-45) ADGILFGFPTRFGMM 87 MN.114 (30-44), MN.118 (41-55), MN.119 (30-44), MN.122 (48-62), MN.128 (48-62), MN.153 (118-132), MN.157 (94-108), MN.92 (55-69), MN.95 (70-84), MN.99 (14-28) FHQGKYFAGIAKKLK 87 MN.114 (145-159), MN.118 (156-170), MN.119 (145-159), MN.122 (163-177), MN.128 (163-177), MN.157 (209-223), MN.99 (129-143) DVYPIVCLPMCVCVL 88 MN.72 (3-15) EPAYFATAESVRDHL 89 MN.199 (20-34), MN.207 (18-32), MN.224 (20-34) QTYYLSMEYLQGRAL 89 MN.199 (62-66), MN.207 (50-64), MN.224 (52-68) AVGNLGITGAYAEAV 89 MN.199 (69-83), MN.207 (67-81), MN.224 (69-83) AEAVKKFGYELEALA 89 MN.199 (80-94), MN.207 (78-92), MN.224 (80-94) RLAACFLDSMATLNL 89 MN.199 (109-123), MN.207 (107-121), MN.214 (3-17), MN.218 (0-14), MN.219 (3-17), MN.220 (3-17), MN.221 (4-18), MN.222 (4-18), MN.223 (26-40), MN.224 (109-123) LRYRYGLSKQRIAKC 89 MN.199 (130-144), MN.207 (128-142), MN.214 (24-38), MN.218 (21-35), MN.219 (24-38), MN.220 (24-38), MN.221 (25-39), MN.222 (25-39), MN.223 (47-61), MN.224 (130-144) FSPWEIVRHDVVYPV 89 MN.199 (157-171), MN.207 (155-169), MN.214 (51-65), MN.215 (26-40), MN.216 (25-39), MN.217 (26-40), MN.218 (48-62), MN.219 (51-65), MN.220 (51-65), MN.221 (52-66), MN.222 (52-66), MN.223 (74-88), MN.222 (157-171) VYPVRFFGHVEILPD 89 MN.207 (166-180), MN.214 (62-76), MN.216 (36-50), MN.219 (62-76), MN.220 (62-76), MN.221 (63-77), MN.222 (63-77), MN.223 (85-99) GEVLNALAYDVPIPG 89 MN.199 (190-204), MN.207 (188-202), MN.214 (84-98), MN.215 (59-73), MN.216 (58-72), MN.217 (59-73), MN.218 (81-95), MN.219 (84-98), MN.220 (84-98), MN.221 (85-99), MN.222 (85-99), MN.223 (107-121), MN.224 (190-204) IPGYKTKNAISLRLW 89 MN.199 (202-216), MN.207 (200-214), MN.214 (96-110), MN.215 (71-85), MN.216 (70-84), MN.217 (73-85), MN.218 (93-107), MN.219 (96-110), MN.220 (96-110), MN.221 (97-111), MN.222 (97-111), MN.223 (119-133), MN.224 (202-216) AEDFNLFQFNDGQYE 89 MN.199 (222-236), MN.207 (220-234), MN.214 (116-130), MN.215 (91-105), MN.216 (90-104), MN.217 (91-105), MN.218 (113-127), MN.219 (116-130), MN.220 (116-130), MN.221 (117-131), MN.222 (117-131), MN.223 (139-153), MN.224 (222-236) EGKLLRLKQQFFLCS 89 MN.199 (260-274), MN.207 (258-272), MN.214 (154-168), MN.215 (129-143), MN.216 (128-142), MN.217 (129-143), MN.218 (151-165), MN.219 (154-168), MN.220 (154-168), MN.221 (155-169), MN.222 (155-169), MN.223 (177-191) MN.224 (260-274) LKQQFFLCSASLQDI 89 MN.199 (266-280), MN.207 (264-278), MN.214 (160-174), MN.215 (135-149), MN.216 (134-148), MN.217 (135-149), MN.218 (157-171), MN.219 (160-174), MN.220 (160-174), MN.221 (161-175), MN.222 (161-175), MN.223 (183-197), MN.224 (266-280) PTLAIPELMRLLMDE 89 MN.199 (312-325), MN.207 (310-324), MN.234 (206-220), MN.215 (181-195), MN.216 (180-194), MN.217 (181-195), MN.218 (203-217), MN.219 (206-220), MN.220 (206-220), MN.221 (207-221), MN.222 (207-221), MN.223 (229-243) MN.224 (312-326) QSVMRKLLPRQMEII 89 MN.199 (359-373), MN.207 (357-371), MN.214 (253-267), MN.215 (228-242), MN.216 (227-241), MN.217 (228-242), MN.218 (250-264), MN.219 (253-267), MN.220 (253-267), MN.221 (254-268), MN.222 (254-268), MN.223 (276-290) MN.224 (359-373) EEIDKRPREMVISTR 89 MN.207 (372-385), MN.214 (268-282), MN.235 (243-257), MN.216 (242-256), MN.217 (243-257), MN.238 (265-279), MN.219 (268-282), MN.220 (268-282), MN.221 (269-283), MN.222 (269-283), MN.223 (291-305), MN.224 (374-386) PQKPVVRMANLCVVS 89 MN.207 (403-417), MN.214 (299-313), MN.215 (274-288), MN.216 (273-287), MN.217 (274-288), MN.218 (296-310), MN.219 (299-313), MN.220 (299-313), MN.221 (300-314), MN.222 (300-314), MN.223 (322-336), MN.224 (405-419) ILKEELFADYVSIWP 89 MN.207 (431-445), MN.214 (327-341), MN.215 (302-316), MN.216 (301-315), MN.217 (302-316), MN.218 (324-338), MN.207 (327-341), MN.220 (327-341), MN.221 (328-342), MN.222 (328-342), MN.223 (350-364), MN.224 (433-447) PRRWLRFCNPELSEI 89 MN.207 (457-471), MN.214 (353-367), MN.215 (328-342), MN.216 (327-341), MN.217 (328-342), MN.218 (350-364), MN.219 (353-367), MN.220 (353-367), MN.221 (354-368), MN.222 (354-368), MN.223 (376-390), MN.224 (459-473) EKLHAEWAAAKLASK 89 MN.214 (394-408), MN.215 (369-383), MN.216 (368-382), MN.217 (369-383), MN.218 (391-405), MN.219 (394-408), MN.220 (394-408), MN.221 (385-408), MN.222 (395-409), MN.223 (417-431), MN.224 (500-514) IKRIHEYKRQLMNTL 89 MN.214 (433-447), MN.215 (408-422), MN.216 (407-421), MN.217 (408-422), MN.218 (430-444), MN.219 (433-447), MN.220 (433-447), MN.221 (434-448), MN.222 (434-448), MN.223 (456-470), MN.224 (539-553) YKRQLMNTLGAVYRY 89 MN.214 (439-453), MN.215 (414-428), MN.216 (413-427), MN.217 (414-428), MN.218 (436-450), MN.219 (439-453), MN.220 (439-453), MN.221 (440-454), MN.222 (440-454), MN.223 (462-476), MN.224 (545-559) LGAVYRYKKLKEMSA 89 MN.214 (447-461), MN.215 (422-436), MN.216 (421-435), MN.217 (422-436), MN.218 (444-458), MN.219 (447-461), MN.220 (447-461), MN.221 (448-462), MN.222 (448-462), MN.223 (470-484), MN.224 (553-567) GKAFATYTNAKRIVK 89 MN.214 (476-490), MN.215 (451-465), MN.216 (450-464), MN.217 (451-465), MN.218 (473-487), MN.219 (476-490), MN.220 (476-490), MN.221 (477-491), MN.222 (477-493), MN.223 (499-513), MN.224 (582-596) KRIVKLVNDVGAVVN 89 MN.214 (486-500), MN.215 (461-475), MN.216 (460-474), MN.217 (461-475), MN.218 (483-497), MN.219 (486-500), MN.220 (486-500), MN.221 (487-501), MN.222 (487-501), MN.223 (509-523), MN.224 (592-606) VNKYLKVVFIPNYNV 89 MN.214 (505-519), MN.215 (480-494), MN.216 (479-493), MN.217 (480-494), MN.218 (502-516), MN.219 (505-519), MN.220 (505-519), MN.221 (506-520), MN.222 (506-520), MN.223 (528-542), MN.224 (611-625) VFIPNYNVSVAEVLI 89 MN.214 (512-526), MN.215 (487-501), MN.216 (486-500), MN.217 (487-501), MN.218 (509-523), MN.219 (512-526), MN.220 (512-526), MN.221 (513-527), MN.222 (513-527), MN.223 (535-549), MN.224 (618-632) EDNFFLFQAKADQVA 89 MN.214 (574-588), MN.215 (549-563), MN.216 (548-562), MN.217 (549-563), MN.218 (571-585), MN.219 (574-588), MN.220 (574-568), MN.221 (575-589), MN.222 (575-589), MN.223 (597-611), MN.224 (680-694) TFGTYDYTPLLDSLE 89 MN.214 (616-630), MN.215 (591-605), MN.216 (590-604), MN.217 (591-605), MN.218 (613-627), MN.219 (616-630), MN.220 (616-630), MN.221 (617-631), MN.222 (617-631), MN.223 (639-653), MN.224 (722-736) FLVGYDFPSYIDAQA 89 MN.214 (641-655), MN.216 (615-629), MN.218 (638-652), MN.219 (641-655), MN.220 (641-655), MN.221 (642-656), MN.222 (642-650), MN.223 (664-678), MN.224 (747-761) KRWIKMSILNTAGSG 89 MN.216 (639-653), MN.218 (662-676), MN.219 (665-679), MN.220 (665-679), MN.221 (666-680), MN.222 (666-680), MN.223 (688-702), MN.224 (771-785) QYAKEIWGITANPVP 89 MN.216 (663-677), MN.218 (686-700), MN.219 (689-703), MN.220 (689-703), MN.221 (690-704), MN.222 (690-704), MN.223 (712-726), MN.224 (795-809) KTLAVALGGARPLAT 90 MN.111 (24-38), MN.142 (17-31), MN.158 (25-39), MN.162 (32-46) LAIRGVATFTLPDLP 90 MN.111 (36-50), MN.141 (0-14), MN.142 (29-43), MN.158 (37-51), MN.162 (44-58) PDLPYDYGALEPAIS 90 MN.111 (47-61), MN.141 (11-25), MN.142 (40-54), MN.158 (48-62), MN.162 (55-69) HATYVANYNKALEQL 90 MN.111 (73-87), MN.141 (37-51), MN.142 (66-80), MN.158 (74-88), MN.162 (81-95) GDASAVVQLQGAIKF 90 MN.111 (94-108), MN.141 (58-72), MN.142 (87-101), MN.158 (95-109), MN.162 (102-116) DPLVTKGANLIPLLG 90 MN.112 (73-87), MN.141 (153-167), MN.142 (182-196), MN.158 (190-204), MN.162 (197-211), MN.53 (24-38) ANLIPLLGIDVWEHA 90 MN.112 (80-94), MN.141 (160-174), MN.142 (189-203), MN.158 (197-211), MN.162 (204-218), MN.53 (31-45) HAYYLQYKNVRPDYL 90 MN.112 (93-107), MN.141 (173-187), MN.158 (210-224), MN.162 (217-231), MN.53 (44-58) PDYLTNIWKVVNWKY 90 MN.112 (104-118), MN.141 (184-198), MN.158 (221-235), MN.162 (228-242), MN.53 (55-69) APSGRIVMELYADVV 91 MN.121 (15-29), MN.127 (15-29), MN.132 (15-29), MN.139 (15-29), MN.146 (15-29) VMELYADVVPKTAEN 91 MN.120 (28-42), MN.121 (21-35), MN.127 (21-35), MN.130 (40-54), MN.132 (21-35), MN.139 (21-35), MN.146 (21-35) HYKGSSFHRVIPGFM 91 MN.120 (61-75), MN.121 (54-68), MN.127 (54-68), MN.130 (73-87), MN.132 (54-68), MN.139 (54-68), MN.146 (54-68) SIYGAKFADENFIKK 91 MN.120 (91-105), MN.121 (84-98), MN.127 (84-98), MN.130 (103-117), MN.132 (84-98), MN.139 (84-98), MN.146 (84-98) NGSQFFLCTAKTAWL 91 MN.120 (122-136), MN.121 (115-129), MN.127 (115-129), MN.130 (134-148), MN.132 (115-129), MN.139 (115-129), MN.146 (115-129), MN.64 (27-41), MN.87 (54-68), MN.89 (58-72) SQVHIRRPGGAGRDG 92 MN.37 (0-14) PPGGAGRDGGQLRIP 92 MN.37 (6-20) RDGGQLRIPSLLHGG 92 MN.37 (12-26) GHGCAQPAMERRKHI 92 MN.37 (26-40) RKHIEWNCDVCRHGD 92 MN.37 (37-51) WTTVMRASCGHHRFR 93 MN.164 (0-14) RFRDCVISSLADFKL 93 MN.164 (12-26) ISSLADFKLFPVLQH 93 MN.164 (18-32) PVLQHIISIAVLAIF 93 MN.164 (28-42) ISIAVLAIFIGLLMI 93 MN.164 (34-48) DEKLLSVFREGVVYG 16 MN.66 (2-16) GPGVYDIHSPRIPSK 84; 16 MN.4 (12-26), MN.66 (20-34) EEIADDFALFRGTRP 16 MN.66 (35-49) FALFRGTRPPRRPKK 16 MN.66 (41-55) LCPGFCLADVTPETY 16 MN.66 (67-81) SCRGRCPCSLRTPAW 66 ME.3566 (3-17) SLRTPAWGSCSRMAP 66 ME.3566 (11-25) WGSCSRMAPCNCRCP 66 ME.3566 (17-31) NCRCPCSTRGARRRL 66 ME.3566 (27-41) STRGARRRLPGRTSS 66 ME.3566 (33-47) PWRPPRRWSCCPLPW 68 ME.3720 (7-21), ME.3805 (7-21) SCCPLPWPGTRRWWF 68 ME.3720 (15-29), ME.3805 (15-29) GTRRWWFRCHQPPSS 68 ME.3720 (23-37), ME.3805 (23-37) FRCHQPPSSRTAPGS 68 ME.3720 (29-43), ME.3805 (29-43) PGSSRSLYGSPSTSC 68 ME.3720 (41-55), ME.3805 (41-55) KHLIYVIGWSVYTEI 72 ME.4234 (7-21) TGWSVYTEITLLRDA 72 ME.4234 (13-27) SEGVRVLMLVWDDHI 72 ME.4210 (0-14), ME.4234 (48-62) DDSGSIVQDLQISTM 72 ME.3897 (12-26), ME.4210 (51-65), ME.4234 (99-113) LQISIMFTHKQKIVV 72 ME.3897 (21-35), ME.4210 (60-74), ME.4234 (108-122) RRRRIMSFVGGLDLC 72 ME.3897 (48-62), ME.4115 (4-18), ME.4210 (87-101), ME.4234 (135-149) PVAWDVLYNFEQRWR 72 ME.3897 (114-128), ME.4088 (28-42), ME.4115 (70-84), ME.4210 (153-167), ME.4234 (201-215) GKDLLIQLRDLADEI 72 ME.3897 (132-146), ME.4088 (46-60), ME.4115 (88-102), ME.4210 (171-185), ME.4234 (219-233) AKNVQLFRSIDGGAA 72 ME.3897 (160-174), ME.4088 (74-88), ME.4115 (116-130), ME.4234 (247-261) DAYICAIRRAKSFIY 72 ME.3897 (203-217), ME.4088 (117-131), ME.4115 (159-173), ME.4210 (242-256) IERAKSFIYISNQYF 72 ME.3897 (209-223), ME.4088 (123-137), ME.4115 (165-179), ME.4210 (248-262), ME.4234 (296-310) FIYIENQYFLGSSYC 72 ME.3897 (215-229), ME.4088 (129-143), ME.4115 (171-185), ME.4210 (254-268), ME.4234 (302-316) RFIVYVVVPMWPEGI 72 ME.3897 (263-277), ME.4088 (177-191), ME.4115 (219-233), ME.4210 (302-316), ME.4234 (350-364) RRTMEMMYIDIAQAI 72 ME.3897 (291-305), ME.4088 (205-219), ME.4115 (247-261), ME.4210 (330-344), ME.4234 (378-392) MYTDIAQAICARGID 72 ME.3897 (297-311), ME.4088 (211-225), ME.4115 (253-267), ME.4210 (336-350), ME.4234 (384-398) DYLKAQQNRRFMIYV 72 ME.3897 (345-359), ME.4088 (259-273), ME.4115 (301-315), ME.4210 (384-398), ME.4234 (432-446) FMIYVRTKMMIVDDE 72 ME.3897 (355-359), ME.4088 (259-283), ME.4115 (311-325), ME.4210 (394-408), ME.4234 (442-445) IVDDEYIIVGSANIN 72 ME.3897 (365-379), ME.4088 (279-293), ME.4115 (321-335), ME.4210 (404-418), ME.4234 (452-466) YDPYELRASRPARGQ 72 ME.4088 (310-324), ME.4115 (352-356), ME.4210 (435-449), ME.4234 (483-497) GQVHGFRMALWYEHL 72 ME.4088 (323-337), ME.4115 (365-379), ME.4210 (448-462), ME.4234 (496-510) RMALWYERLGMVDEA 72 ME.4088 (329-343), ME.4115 (371-385), ME.4210 (454-468), ME.4234 (502-616) CVRKVNAMADRYWNL 72 ME.4088 (325-366), ME.4115 (394-408), ME.4210 (477-491), ME.4234 (525-539) LPGVEFFFDTQARTL 72 ME.4088 (396-410), ME.4115 (438-452), ME.4210 (521-535), ME.4234 (569-583) TAPTSRRSPSAPSPH 67 ME.4056 (6-20), ME.4276 (8-22) THTCIETRRIPSRPI 67 ME.4056 (38-52), ME.4276 (40-54) PWSTCRAARSPTPSA 67 ME.4056 (55-69), ME.4276 (57-71) DRKEINLSEMVAWVG 67 ME.4056 (93-107), ME.4276 (95-109) SEMVAWVGLQLAFWI 67 ME.4056 (100-114), ME.4276 (102-116) VKVAPAALVNVLEAR 69 ME.3916 (0-14) LVNVLEARSALTISV 69 ME.3916 (7-21) ARSALTISWLRISSM 69 ME.3916 (13-27) ISVLRISSMPFSVYH 69 ME.3916 (19-33) LAAFWGKEYPLLSAG 69 ME.3916 (52-66) SSPSCAPESTHAVRA 70 ME.3855 (0-14) PESTHAVRALPSTHT 70 ME.3855 (6-20) VRALPSIHTARILLR 70 ME.3855 (12-26) THIARILLRSTTANV 70 ME.3855 (18-32) LLRSITANVSGCKDR 70 ME.3855 (24-38) VDVPGGHQGDLPRGE 71 ME.1412 (1-15) LPGAAGEVCRRRRRR 71 ME.1412 (21-35) GQGDVDRAQGVVGSH 71 ME.1412 (44-58) GVVGSHLEDRHSRQA 71 ME.1412 (53-67) LEDRRSRQAHRRLHR 71 ME.1412 (59-73) HTFKSLFESWPVSST 73 ME.4280 (41-55), ME.4281 (41-55) DCTIVLTTYHSGEKR 73 ME.4229 (33-47), ME.4231 (34-48), ME.4280 (126-140), ME.4281 (126-140) FYLTYWIGKDSVLED 73 ME.4229 (50-64), ME.4231 (51-65), ME.4280 (143-157), ME.4281 (143-157) QRMALQIATTIWNSM 73 ME.4190 (3-17), ME.4229 (65-79), ME.4231 (66-80), ME.4280 (158-172), ME.4281 (158-172) EPPQFIALFQPMVIL 73 ME.4229 (93-107), ME.4231 (94-108), ME.4280 (186-200), ME.4281 (186-200) KDETYEGTGIALVHI 73 ME.4190 (63-77), ME.4229 (125-139), ME.4231 (126-140), ME.4280 (218-232), ME.4281 (218-232) GTGIALVHIHGTSIH 73 ME.4190 (69-83), ME.4229 (131-145), ME.4231 (132-146), ME.4280 (224-238), ME.4281 (224-238) NNNTLQVDAVSISLS 73 ME.4190 (84-98), ME.4229 (348-160), ME.4231 (147-181), ME.4280 (239-253), ME.4281 (239-253) IDCFVLQSGNSMFTW 73 ME.4190 (100-114), ME.4229 (162-176), ME.4231 (163-177), ME.4280 (255-269), ME.4281 (255-269) QQQWAAKVAEFLEPG 73 ME.4190 (123-137), ME.4229 (185-199), ME.4231 (186-200), ME.4280 (278-292), ME.4281 (278-292) DVLREPHLYTFSFRN 73 ME.4190 (170-184), ME.4229 (232-246), ME.4231 (233-247), ME.4280 (325-339), ME.4281 (325-339) LEVTEVFNFSQDGLL 73 ME.4190 (187-201), ME.4229 (249-253), ME.4231 (250-264), ME.4280 (342-386), ME.4281 (342-356) FNFSQDDLLTEDVMI 73 ME.4190 (193-207), ME.4229 (255-269), ME.4231 (256-270), ME.4280 (348-362), ME.4281 (348-362) DVMLLDTRAEVFVWM 73 ME.4190 (204-218), ME.4229 (266-280), ME.4231 (267-281), ME.4280 (359-373), ME.4281 (359-373) CFFRTYFSWDNTRSV 73 ME.4190 (263-277), ME.4229 (325-339), ME.4231 (326-340), ME.4280 (418-432), ME.4281 (418-432) NSFQKKLELLFGMRS 73 ME.4190 (281-299), ME.4229 (343-357), ME.4231 (344-358), ME.4280 (436-450), ME.4281 (436-450) RASALAALSSAFNPS 73 ME.4190 (310-324), ME.4229 (372-386), ME.4231 (373-387), ME.4280 (465-479), ME.4281 (465-479) QRASALAALSSSLNP 73 ME.4190 (344-358), ME.4229 (406-420), ME.4231 (407-421), ME.4280 (499-513), ME.4281 (499-513) SQRAAAVAALSNVLT 73 ME.4190 (375-389), ME.4229 (437-451), ME.4231 (438-452), ME.4280 (530-544), ME.4281 (530-544) VAALSNVLIAEGSTL 73 ME.4190 (381-395), ME.4229 (449-457), ME.4231 (444-458), ME.4280 (536-550), ME.4281 (536-550) ETTFSYDRLISKSTD 73 ME.4190 (445-459), ME.4229 (507-521), ME.4231 (508-522), ME.4280 (600-614), ME.4281 (600-614) YKRRETYLSDSEFET 73 ME.4190 (466-480), ME.4229 (528-542), ME.4231 (529-543), ME.4280 (621-635), ME.4281 (621-635) SEFETVFGVTKEEFY 73 ME.4190 (476-490), ME.4231 (539-553), ME.4280 (631-645), ME.4281 (631-645) SRSFLKRSLLRTQRL 73 ME.4229 (566-880) HSLLRTQRLHKFLVC 73 ME.4229 (572-586) LRKFLVCESMIGVMA 73 ME.4229 (580-594) SGNLVMFQMQDHQLI 73 ME.4229 (600-614) QRIIPLISPEFLVIS 73 ME.4229 (612-626) ISPSFLVYSFFVHDL 73 ME.4229 (618-632) ERLIYGTANSRLCSV 74 ME.4230 (4-18) ANSRLCSVLPKEEFY 74 ME.4230 (11-25) VLPKEEFYQQPRNKQ 74 ME.4230 (18-32) FYQQPRWKQELQKRK 74; 73 ME.1571 (24-388), ME.4190 (489-503), ME.4230 (24-38), ME.4231 (552-566), ME.4280 (644-658), ME.4281 (644-658) IGAAAAMTTTIRSTA 75 ME.3882 (1-15) TTIRSTATARPRAIV 75 ME.3882 (9-23)

TABLE 3 Panel of 25 MHC II molecules for which peptide binding affinities were predicted. Locus Allele HLA DP DPA1*01-DPB1*0401 DPA1*0103-DPB1*0201 DPA1*0201-DPB1*0101 DPA1*0201-DPB1*0501 DPA1*0301-DPB1*0402 HLA DQ DQA1*0101-DQB1*0501 DQA1*0102-DQB1*0602 DQA1*0301-DQB1*0302 DQA1*0401-DQB1*0402 DQA1*0501-DQB1*0201 DQA1*0501-DQB1*0301 HLA DR DRB1*0101 DRB1*0301 DRB1*0401 DRB1*0404 DRB1*0405 DRB1*0701 DRB1*0802 DRB1*0901 DRB1*1101 DRB1*1302 DRB1*1501 DRB3*0101 DRB4*0101 DRB5*0101

TABLE 4 Panel of 822 peptides predicted from 93 novel Timothy Grass (TG) proteins tested for T cell recognition in TG allergic patients. Total Total response response Antibody reactvity SEQ ID NOS: 1443-2264 IL-5 IFNg Antigen Peptide IgE/IgG Sequence Events SFC Events SFC 1 1₁₂ E+G+ SDGTFARAAVPSGAS 0 — 0 — 1₁₈ E+G+ RAAVPSGASTGVYEA 0 — 0 — 1₂₄ E+G+ GASTGVYEALELRDG 0 — 0 — 1₄₃ E+G+ LGKGVLKGNRANVEL 0 — 0 — 1₅₁ E+G+ NRANVELFHIAVLLA 0 — 0 — 1₇₀ E+G+ QTELDNFMVHQLDGT 0 — 0 — 1₉₁ E+G+ CKQKVFFNISADADA 0 — 0 — 1₁₅ E+G+ PAMAATIQSVKARQI 0 — 0 — 1₈₄ E+G+ VDNVNSIIGPALIGK 0 — 0 — 1₁₂₇ E+G+ KLGANAILAVSLAVC 0 — 0 — 1₁₄₈ E+G+ KKIPLYQHIANLAGN 0 — 0 — 1₁₆₁ E+G+ GNKQLVLPVPAFNVI 0 — 1 190 1₁₈₄ E+G+ KLAMQEFMILPTGAS 0 — 0 — 1₂₀₅ E+G+ KMGVEVYHNLKSVIK 0 — 0 — 1₂₆₀ E+G+ GKVVIGMDVAASEFY 0 — 0 — 1₃₀₄ E+G+ VYKSFVSEYPIVSIE 1 40 0 — 1₃₄₂ E+G+ IVGDDLLVTNPTRVA 0  0 1 193 1₃₆₅ E+G+ NALLLKVNQIGSVTE 1 40 1 170 1₄₀₂ E+G+ ETEDTFIADLAVGLS 0 — 0 — 1₄₂₉ E+G+ ERLAKYNQLLRIEEE 0 — 0 — 1₄₄₄ E+G+ LGAAAVYAGLKFRAP 0 — 1 153 2 2₁ E+G+ AEFEGVFLDFARQQA 2 58 0 — 2₂₀ E+G+ VDKLFKLAEAAKLKE 2 88 2 247 2₄₉ E+G+ ENRSVLHVALRAPRD 2 63 1  27 2₁₁₆ E+G+ FLGPLFVHTALQTDP 1 63 0 — 2₁₃₉ E+G+ RQLRFLANVDPVDVA 1 20 1  20 2₁₆₈ E+G+ VVSKTFTTAETMLNA 0 — 1  97 2₁₈₅ E+G+ IKEWIVSSLGPQAVS 0 — 0 — 2₁₉₈ E+G+ VSKHMIAVSTNLKLV 2 80 1  20 2₂₃₂ E+G+ RYSVCSAVGVLPLSL 3 83 3 238 2₂₃₈ E+G+ AVGVLPLSLQYGFPI 3 71 4 121 2₂₄₄ E+G+ LSLQYGFPIVQRFLE 1 127  1  50 2₂₅₀ E+G+ FPIVQRFLEGASSID 2 92 1  90 2₂₆₆ E+G+ HFRTASFEKNIPVLL 1 33 0 — 2₂₇₈ E+G+ VLLGLLSVWNVSFLG 2 50 0 — 2₂₈₄ E+G+ SVWNVSFLGYPARAI 1 100  1  53 2₂₉₅ E+G+ ARAILPYSQALEKLA 1 120  1  27 2₃₄₆ E+G+ NGQHSFYQLIHQGRV 1 27 2  95 2₃₆₃ E+G+ CDFIGVIKSQQPVYL 2 98 2 238 2₃₈₇ E+G+ ELMSNFFAQPDALAY 2 102  3  99 2₄₂₁ E+G+ KTFKGNRPSLSFLLS 2 42 5 363 2₄₂₈ E+G+ PSLSFLLSSLSAYEI 1 67 1  53 2₄₃₉ E+G+ AYEIGQLLAIYEHRI 1 40 0 — 2₄₄₅ E+G+ LLAIYEHRIAVQGFI 1 77 2  42 2₄₅₆ E+G+ QGFIWGINSFDQWGV 1 113  0 — 2₄₉₃ E+G+ PVEGFNPSSASLLAR 1 143  1  47 2₄₉₉ E+G+ PSSASLLARYLAVEP 1 127  0 — 3 3₆ E+G+ ILLVFAETAEPEVKV 0 — 0 — 3₁₅ E+G+ EPEVKVVDLTILSPD 0 — 0 — 3₅₀ E+G+ LKDGSTYSFRFSFIV 1 20 0 — 3₅₇ E+G+ SFRFSFIVSNNIVSG 0 — 0 — 3₁₃₀ E+G+ DDGKVYLEMSYYFEI 0 — 0 — 4 4₆ E+G+ MKTIFDFESIKKLLA 0 — 1  43 4₁₂ E+G+ FESIKKLLASPKFSF 1 47 2 245 4₄₁ E+G+ RMFVDELGASESSLL 1 47 1  30 4₇₀ E+G+ PNLTYAKELVERMGL 0 — 1  33 4₁₀₆ E+G+ RNMVLGKRFFVTPSD 1 33 1  27 4₁₁₂ E+G+ KRFFVTPSDSVAIIA 0 — 0 — 4₁₁₉ E+G+ SDSVAIIAANAVQSI 0 — 0 — 4₁₂₉ E+G+ AVQSIPYFASGLKGV 0 — 1  37 4₁₅₈ E+G+ KNLNLKFFEVPTGWK 0 — 0 — 4₂₀₃ E+G+ GIWAVLAWLSIIAYK 0 — 1 107 4₂₂₁ E+G+ NLGGDKLVSVEDIVL 0 — 0 — 4₂₂₇ E+G+ LVSVEDIVLQHWATY 0 — 0 — 4₂₆₀ E+G+ KELMANLVKMQSALS 1 327  1  97 4₂₆₆ E+G+ LVKMQSALSDVNKLI 2 35 0 — 4₃₀₉ E+G+ HQGIRYLFGDGSRLV 0 — 0 — 4₃₂₀ E+G+ SRLVFRLSGTGSVGA 0 — 0 — 4₃₃₃ E+G+ GATIRIYIEQYEKDS 0 — 0 — 4₃₅₆ E+G+ DALSPLVDVALKLSK 0 — 0 — 5 5₂₇ E+G+ TVSDEYLAAVAKARR 0 — 1  73 5₉₄ E+G+ LDIAVRLLEPIKEQV 0 — 0 — 5₁₀₄ E+G+ IKEQVPILSYADFYQ 0 — 0 — 5₁₁₀ E+G+ ILSYADFYQLAGVVA 0 — 0 — 5₁₁₆ E+G+ FYQLAGVVAVEITGG 0 — 0 — 5₁₅₉ E+G+ DHLRQVFTAQMGLSD 0 — 0 — 5₂₀₂ E+G+ NPLIFDNSYFTELLT 0 — 0 — 5₂₄₈ E+G+ EDAFFADYAEAHLKL 0 — 0 — 6 6₁ E+G+ TLLFPHTQISLPSVR 2 32 0 — 6₁₄ E+G+ VRTRKHLAATMADEK 0 — 0 — 6₄₄ E+G+ DNEKSGFISLVSRYL 2 38 0 — 6₅₀ E+G+ FISLVSRYLSGEEEH 0 — 0 — 6₉₂ E+G+ EATKALLNKLAVLKL 1 33 0 — 6₁₂₃ E+G+ IEVRNGFTFLDLIVL 1 27 0 — 6₁₃₁ E+G+ FLDLIVLQIESLNKK 1 33 0 — 6₁₄₂ E+G+ LNKKYGSNVPLLLMN 1 353  0 — 6₁₄₉ E+G+ NVPLLLMNSFNTHED 1 153  0 — 6₁₆₅ E+G+ LKIVEKYANSSIDIH 3 196  3 654 6₁₇₅ E+G+ SIDIHTFNQSQYPRV 2 113  1 243 6₂₂₄ E+G+ GKLDLLLSQGKEYVF 1 87 2  65 6₂₃₃ E+G+ GKEYVFIANSDNLGA 2 115  0 — 6₂₄₂ E+G+ SDNLGAIVDMKILNH 2 28 1  30 6₂₄₈ E+G+ IVDMKILNHLIHKQN 3 101  2 160 6₂₈₂ E+G+ ISYEGRVQLLEIAQV 0 — 0 — 6₂₈₈ E+G+ VQLLEIAQVPDAHVD 1 73 0 — 6₃₀₄ E+G+ FKSIEKFKIFNTNNL 1 30 1 357 6₃₁₀ E+G+ FKIFNTNNLWVNLKA 2 60 0 — 6₃₁₆ E+G+ NNLWVNLKAIKRLVE 3 517  2 823 6₃₂₅ E+G+ IKRLVEADALKMEII 2 103  1 397 6₃₄₈ E+G+ VKVLQLETAAGAAIR 3 60 1  50 6₃₅₉ E+G+ AAIRFFDHAIGINVP 4 105  4 344 6₃₆₉ E+G+ GINVPRSRFLPVKAT 1 23 0 — 6₃₇₆ E+G+ RFLPVKATSDLQLVQ 2 60 1  83 6₃₈₃ E+G+ TSDLQLVQSDLYTLV 1 40 1  87 6₃₈₉ E+G+ VQSDLYTLVDGFVTR 2 82 1  60 6₄₁₈ E+G+ GPEFKKVGSFLGRFK 2 182  2 147 6₄₂₉ E+G+ GRFKSIPSIVELDSL 3 247  0 — 7 7₃₁ E+G+ GTIRNIINGTVFREP 3 109  2 523 7₁₀₁ E+G+ VFNFTGAGGVALAMY 3 118  3 968 7₁₂₁ E+G+ IQGFAEASMAIAYEK 2 33 1  50 7₁₂₇ E+G+ ASMAIAYEKKWPLYL 2 52 1  80 7₁₃₄ E+G+ EKKWPLYLSTKNTIL 1 63 1 117 7₁₅₃ E+G+ GRFKDIFQAVYEADW 1 57 2  63 7₁₇₇ E+G+ WYEHRLIDDMVAYAL 1 43 0 — 7₂₀₈ E+G+ VQSDFLAQGFGSLGL 2 35 1  80 7₂₆₀ E+G+ NSIASIFAWTRGLAH 0 — 1  63 7₂₈₀ E+G+ DNARLLDFTQKLEDA 2 37 0 — 7₃₀₄ E+G+ MTKDLALLVHGSSKV 1 40 2 128 7₃₂₄ E+G+ LNTEEFIDAVAAELQ 3 60 3  92 8 8₁ E+G+ ALTHTTIVASGIENM 0 — 0 — 8₃ E+G+ TIVASGIENMKIFTR 0 — 1 293 8₁₅ E+G+ MKIFTRTWVLLLLVV 0 — 0 — 8₂₄ E+G+ LLLLVVLLFEGCLAK 0 — 0 — 8₁₁₀ E+G+ KDTHYTLSAWLQLSK 0 — 0 — 8₁₆₆ E+G+ GKGELFFETNVTAEL 0 — 0 — 8₁₇₆ E+G+ VTAELMVDSMSLQPF 0 — 0 — 8₂₅₃ E+G+ YEKWFTSRFTVATME 0 — 0 — 8₃₁₃ E+G+ KQMDWVSKLSAPQLK 0 — 0 — 8₃₈₂ E+G+ KPILFMNEYNTIEEP 0 — 0 — 8₄₀₄ E+G+ TKYLAKLKQIQSYPG 0 — 0 — 8₄₃₈ E+G+ PYVRGSLDTLAQAKV 0 — 0 — 8₄₆₅ E+G+ PKQVEYLEEVMREGF 0 — 0 — 8₁₇₂ E+G+ NVTAELVDSMSLQPF 0 — 0 — 9 9₅₆ E+G+ TDTIVYCAGRTFFFR 0 — 1 180 9₆₄ E+G+ GRTFFFRRLDAPLDA 0 — 1 383 9₁₅₂ E+G+ KSLVRAFMWDSGSTV 0 — 0 — 9₁₇₅ E+G+ RVLSCDFKPTRPFRI 0 — 1  97 9₂₆₀ E+G+ HTGSIYAVSWSADSK 0 — 0 — 9₃₄₉ E+G+ AGHLKTVSSLTYFPQ 0 — 0 — 9₃₅₅ E+G+ VSSLTYFPQSNPRTM 1 23 0 — 9₃₇₃ E+G+ SYDGVIIRWIQGVGY 0 — 0 — 9₃₉₇ E+G+ TQIKCFVAAEEELIT 1 20 0 — 9₄₄₁ E+G+ NALNIAVQQPEFALI 1 60 0 — 9₄₅₀ E+G+ PEFALITTDSAIVLL 1 33 0 — 9₄₅₇ E+G+ TDSAIVLLHKSTVTS 0 — 0 — 9₄₇₃ E+G+ TKVSYTITSSAVSPD 0 — 0 — 9₄₉₉ E+G+ KLRIYSISGDTLTEE 0 — 1  53 9₅₂₆ E+G+ IHYSPDVSMFASADA 1 30 0 — 9₅₅₄ E+G+ IKLKNMLFHTARINC 1 33 1  20 10 10₁₀ E+G+ GRYFSKDAVQIITKM 1 43 1 170 10₁₆ E+G+ DAVQIITKMAAANGV 1 160  1  83 10₂₉ E+G+ GVRRVWVGQDSLLST 0 — 2  30 10₃₉ E+G+ SLLSTPAVSAIIRER 1 37 2  30 10₄₅ E+G+ AVSAIIRERIAADGS 1 60 1  47 11 11₅₈ E+G+ SVGFVETLENDLAQL 1 30 1  47 11₁₁₁ E+G+ LGEAPYKFKSALEAV 1 53 2 488 11₁₁₇ E+G+ KFKSALEAVKTLRAE 1 43 1  73 11₁₃₇ E+G+ QYLPAFVIVDESGKS 1 23 0 — 11₁₆₁ E+G+ VVTFNFRADRMVMLA 2 50 0 — 11₁₆₈ E+G+ ADRMVMLAKALEFAD 1 40 0 — 11₁₈₃ E+G+ FDKFDRVRVPKIKYA 0 — 0 — 11₁₉₂ E+G+ PKIKYAGMLQYDGEL 0 — 0 — 11₂₀₆ E+G+ LKLPNKFLVSPPLIE 1 30 0 — 12 12₅ E+G+ YKLLCSSFPVITYHQ 2 60 0 — 12₁₂ E+G+ FPVITYHQGRNGNLS 1 103  0 — 12₂₁ E+G+ RNGNLSALACPLNQK 1 20 0 — 13 13₂₁ E+G+ ECILSGLLSVDGLKV 0 — 0 — 13₂₇ E+G+ LLSVDGLKVLHMDRN 0 — 0 — 13₈₁ E+G+ VPKFMMANGALVRVL 0 — 0 — 13₉₂ E+G+ VRVLIRTSVTKYLNF 0 — 0 — 13₁₀₁ E+G+ TKYLNFKAVDGSFVY 0 — 0 — 13₁₂₆ E+G+ TDVEALKSNLMGLFE 0 — 0 — 13₁₄₀ E+G+ EKRRARKFFIYVQDY 0 — 0 — 13₁₄₆ E+G+ KFFIYVQDYEEEDPK 0 — 0 — 13₁₈₅ E+G+ TVDFIGHALALHRDD 0 — 0 — 13₂₁₀ E+G+ VKRMKLYAESLARFQ 0 — 0 — 13₂₃₇ E+G+ GELPQAFARLSAVYG 0 — 0 — 13₂₄₃ E+G+ FARLSAVYGGTYMLN 0 — 0 — 13₃₅₂ E+G+ KGKFIAFVSTEAETD 0 — 0 — 13₄₁₇ E+G+ ETTVKDVLALYSKIT 0 — 0 — 13₄₃₅ E+G+ LDLSVDLNAASAGES 0 — 0 — 14 14₁ E+G+ LLGYLLWVVAIRRPR 1 110  0 — 14₇ E+G+ WVVAIRRPRPVRCFS 0 — 0 — 15 15₁ E+G+ PRVNFFKRYNLTCVF 0 — 0 — 15₇ E+G+ KRYNLTCVFWSKKKK 0 — 0 — 16 16₃ E−G− DEKLLSVFREGVVYG 0 — 1 113 16₂₁ E−G− GPGVYDIHSPRIPSK 0 — 2  80 16₃₆ E−G− EEIADDFALFRGTRP 0 — 2 207 16₄₂ E−G− FALFRGTRPPRRPKK 0 — 1  97 16₆₈ E−G− LCPGFCLADVTPETY 0 — 2  45 17 17₂ E+G+ VCTRLSPFCCLYCIL 2 52 0 — 17₁₃ E+G+ YCILCCWYSMRLVTV 1 63 0 — 18 18₁ E+G− NIPATWGAMEKLYDA 0 — 0 — 18₇ E+G− GAMEKLYDAGKARAI 0 — 0 — 18₁₇ E+G− KARAIGVSNLASKKL 0 — 0 — 18₂₃ E+G− VSNLASKKLGDLLAV 0 — 0 — 18₂₉ E+G− KKLGDLLAVARIPPA 0 — 0 — 19 19₂₆ E+G− LNGPFIATVQQRGAA 0 — 0 — 19₃₅ E+G− QQRGAAIIKARKLSS 0 — 0 — 19₄₁ E+G− IIKARKLSSALSAAS 0 — 0 — 19₄₇ E+G− LSSALSAASSACDHI 0 — 0 — 19₆₇ E+G− GTPEGTFVSMGVYSD 0 — 0 — 20 20₂₅ E+G− PPPGQHIAMAASSRR 0 — 0 — 20₄₀ E+G− ASQLLGSAASRFLHS 0 — 0 — 20₄₉ E+G− SRFLHSRGYAAAAAA 0 — 0 — 20₅₅ E+G− RGYAAAAAAPSPAVF 0 — 0 — 20₁₁₄ E+G− LGLPVFNSVAEAKAE 0 — 0 — 20₁₂₉ E+G− TKANASVIYVPPPFA 0 — 0 — 20₁₃₅ E+G− VIYVPPPFAAAAIME 0 — 0 — 20₁₄₁ E+G− PFAAAAIMEALEAEL 0 — 0 — 20₁₆₇ E+G− QHDMVKVKAALNRQS 0 — 0 — 20₂₂₂ E+G− TLTYEAVFQTTAVGL 0 — 0 — 20₂₉₄ E+G− DKPVVAFIAGLTAPP 1 23 0 — 20₃₂₉ E+G− KIKALREAGVTVVES 1 23 0 — 20₃₄₈ E+G− GSTMFEIFKQRGMVE 0 — 0 — 21 21₂ E+G− GSGDFKTIKEALAKV 0 — 0 — 21₂₃ E+G− MYVMYIKEGTYKEYV 0 — 0 — 21₃₃ E+G− YKEYVTVPRTVTNLV 0 — 0 — 21₄₃ E+G− VTNLVMIGDGAAKTI 0 — 0 — 21₆₃ E+G− NFKMNLTSMVAVSLV 0 — 0 — 21₁₀₉ E+G− YQDTLYTHAQRQFFR 0 — 0 — 21₁₂₉ E+G− GTIDFIFGNSQVVIQ 0 — 0 — 21₅₃ E+G− AKTIILKFLLPVMIV 0 — 0 — 22 22₁₅ E+G− NTRVLLLRRTSPFSA 1 — 0 — 22₁₂₄ E+G− DGYYIHGQCAIIMFD 1 — 0 — 22₁₃₁ E+G− QCAIIMFDVTSRLTY 1 27 0 — 22₁₈₇ E+G− RKKNLQYYEISAKSN 0 — 0 — 22₁₉₇ E+G− SAKSNYNFEKPFLYL 0 — 0 — 22₂₀₆ E+G− KPFLYLARKLAGDAN 2 88 1 603 22₂₁₉ E+G− ANIHFVEAVALKPPE 0 — 1  63 22₂₄₅ E+G− EAELAAAAAQPLPDD 1 20 0 — 23 23₁ E+G− RTSSWGSGASLKIDR 1 27 0 — 23₁₀ E+G− SLKIDRRELVTTRIY 2 35 0 — 24 24₂₁ E+G− RFLHAAVAMATKRSV 0 — 1 150 24₄₄ E+G− KGKKVFLRADLNVPL 1 30 3 234 24₆₈ E+G− TRIRASIPTIKFLLE 0 — 0 — 24₇₆ E+G− TIKFLLEKGAKVILA 2 47 0 — 24₈₂ E+G− EKGAKVILASHLGRP 1 63 0 — 24₁₀₉ E+G− VPRLSELLGVEVVMA 2 70 2 118 24₁₄₁ E+G− GGVLLLENVRFYKEE 2 45 1  23 24₁₆₀ E+G− PEFAKKLASVADLYV 2 45 0 — 24₁₉₃ E+G− KFLRPSVAGFLMQKE 3 38 1 177 24₁₉₉ E+G− VAGFLMQKELDYLVG 1 90 0 — 24₂₀₆ E+G− KELDYLVGAVANPKK 1 37 1 143 24₂₃₄ E+G− KIGVIESLLAKVDIL 1 57 0 — 24₂₅₃ E+G− GMIFTFYKAQGKAVG 0 — 2 397 24₂₇₂ E+G− EEDKLELATSLIETA 2 52 1  23 24₂₉₀ E+G− GVSLLLPTDVVVADK 1 90 0 — 25 25₂ E+G− SAPALRILRSFPSHS 1 97 1 143 26 26₂ E+G− VELVAVNDPFITTDY 0 — 0 — 26₁₅ E+G− DYMTYMFKYDTVHGQ 0 — 0 — 26₉₀ E+G− GGAKKVIISAPSKDA 0 — 0 — 26₁₁₆ E+G− YTSDITIVSNASCTT 0 — 0 — 26₁₃₈ E+G− KVINDRFGIVEGLMT 0 — 1  37 26₁₄₄ E+G− FGIVEGLMTTVHAMT 0 — 0 — 26₁₇₄ E+G− GGRAASFNIIPSSTG 0 — 0 — 26₂₂₁ E+G− LTVRLEKAATYEQIK 0 — 0 — 26₂₇₈ E+G− ALNDNFVKLVSWYDN 0 — 0 — 27 27₄₆ E+G− IGKRFASINVENVED 0 — 0 — 27₆₄ E+G− ALRELLFTTPGALQH 0 — 0 — 27₇₆ E+G− LQHISGVILFEETLY 1 53 0 — 27₁₄₄ E+G− YEAGARFAKWRAVLK 1 33 0 — 27₁₇₅ E+G− GLARYAIICQENGLV 2 33 1 140 27₂₀₆ E+G− RCAYVTEVVLAACYK 1 27 0 — 27₂₂₃ E+G− NDQHVLLEGSLLKPN 1 27 0 — 27₃₀₀ E+G− WFLSFSFGRALQQST 1 23 0 — 28 28₂ E+G− IPPAPHLKRWNRVVD 1 127  0 — 28₈ E+G− LKRWNRVVDTNLESP 0 — 0 — 28₁₄ E+G− VVDTNLESPNDIVPE 0 — 0 — 28₂₈ E+G− GAPFTGSGYRIAPYS 1 107  0 — 28₃₆ E+G− GYRIAPYSSILLKAT 1 — 2 477 29 29₂ E+G− SFRFFLAHSSIHPST 2 83 0 — 29₂₆ E+G− EKHFKYVILGGGVAA 0 — 0 — 29₁₀₆ E+G− TEKGIELILSTEIVK 1 50 1 247 29₁₂₄ E+G− ASKTLTSAAGATFTY 1 30 0 — 29₁₃₆ E+G− FTYETLLIATGSSTI 0 — 0 — 29₁₉₃ E+G− GGGYIGLELSAALKL 0 — 0 — 29₁₉₉ E+G− LELSAALKLNNFDVT 1 133  0 — 29₂₀₅ E+G− LKLNNFDVTMVYPEP 0 — 0 — 29₂₂₂ E+G− MPRLFTAGIAHFYEG 0 — 0 — 29₂₃₂ E+G− HFYEGYYASKGINIV 0 — 0 — 29₂₄₀ E+G− SKGINIVKGTVASGF 0 — 0 — 29₂₇₄ E+G− DANIVIVGVGGRPLT 0 — 0 — 29₃₀₃ E+G− KTDTFFETSVAGVYA 0 — 0 — 29₃₁₅ E+G− VYAIGDVASFPMKLY 0 — 0 — 29₃₆₅ E+G− DYLPYFYSRSFDIAW 0 — 0 — 30 30₂₂ E+G− EQFVTPWSFSVASGH 0 — 0 — 30₅₅ E+G− RDAHYLRGLLPPAIV 0 — 0 — 30₇₉ E+G− MHNLRQYTVPLQRYI 0 — 0 — 30₈₇ E+G− VPLQRYIAMMDLQER 0 — 0 — 30₁₀₃ E+G− ERLFYKLLIDNVEEL 0 — 0 — 30₁₁₅ E+G− EELLPVVYTPVVGEA 0 — 0 — 30₁₆₃ E+G− RSIQVIVVTDGERIL 0 — 0 — 30₂₃₉ E+G− EEYHELLQEFMNAVK 0 — 0 — 30₂₅₇ E+G− GEKVLVQFEDFANHN 0 — 0 — 30₂₇₃ E+G− FDLLAKYSKSHLVFN 0 — 0 — 30₂₈₅ E+G− VFNDDIQGTASVVLA 1 67 0 — 30₂₉₅ E+G− SVVLAGLLAALKVIG 0 — 0 — 30₃₁₁ E+G− GLADQTYLFLGAGEA 0 — 0 — 30₃₂₇ E+G− TGIAELIALEMSKHT 0 — 0 — 30₃₄₈ E+G− CRKKIWLVDSKGLLV 0 — 0 — 30₃₈₀ E+G− HEPLTTLLEAVQSLK 0 — 0 — 30₃₈₆ E+G− LLEAVQSLKPTVLIG 0 — 0 — 30₄₂₀ E+G− NEKPVIFSLSNPTSH 0 — 0 — 30₄₄₀ E+G− EEAYTWTKGTAVFAS 0 — 0 — 30₄₈₁ E+G− GFGLGVVISGAIRVH 0 — 0 — 30₄₈₇ E+G− VISGAIRVHDDMLLA 0 — 0 — 30₄₉₅ E+G− HDDMLLAASEALAEQ 0 — 0 — 30₅₂₁ E+G− FPPFTNIRKISANIA 0 — 0 — 30₅₂₇ E+G− IRKISANIAAKVAAK 0 — 0 — 31 31₆ E−G+ QIIRKGFYLTKNVEH 0 — 0 — 31₁₂ E−G+ FYLTKNVEHKGQVDL 0 — 0 — 31₁₈ E−G+ VEHKGQVDLVTETDK 0 — 0 — 31₃₀ E−G+ TDKACEDLIFNHLRK 0 — 0 — 31₃₆ E−G+ DLIFNHLRKLYPDHK 0 — 0 — 32 32₄₁ E−G+ IEIDSLFEGIDFYST 0 — 1  27 32₅₀ E−G+ IDFYSTITRARFEEL 1 20 0 — 32₁₀₂ E−G+ IPKVQQLLQDFFNGK 0 — 0 — 32₁₂₆ E−G+ EAVAYGAAVQAAILS 0 — 1  30 32₁₄₇ E−G+ VQDLLLLDVTPLSLG 0 — 1  47 33 33₁ E−G+ QEMAYWSLKAAIEIG 0 — 0 — 33₂₀ E−G+ DAASSLYLFGENLPR 0 — 0 — 33₆₀ E−G+ GYNISLASMIPDYDT 0 — 0 — 33₇₂ E−G+ YDTVITNVRRSLAVA 0 — 0 — 33₁₁₆ E−G+ LEKIVAILSAFVDAA 0 — 0 — 33₇ E−G+ NVRRSLAVAKKNHLA 0 — 0 — 33₁₄ E−G+ VAKKNHLAWNCERCR 0 — 0 — 33₂₀ E−G+ LAWNCERCRKGESKK 0 — 0 — 33₃₃ E−G+ KKTVDAILSAFVDAA 0 — 0 — 34 34₁ E−G+ LMSFSWICACVRAAA 0 — 0 — 34₇ E−G+ ICACVRAAAVAWEAG 0 — 0 — 34₃₉ E−G+ VRVKILFTALCHTDV 0 — 0 — 34₁₁₄ E−G+ MCDLLRINTDRGVMI 0 — 0 — 34₁₄₀ E−G+ KPIFHFVGTSTFSEY 1 40 0 — 34₁₄₆ E−G+ VGTSTFSEYTVMHVG 0 — 0 — 34₂₀₀ E−G+ VAIFGLGAVGLAAAE 0 — 0 — 34₂₀₆ E−G+ GAVGLAAAEGARIAG 0 — 0 — 34₂₇₅ E−G+ GNINAMIQAFECVHD 0 — 0 — 34₃₁₉ E−G+ LKGTFFGNFKPRTDL 0 — 0 — 34₃₄₉ E−G+ KFITHSVTFSEINKA 1 50 1 103 34₃₅₅ E−G+ VTFSEINKAFDLMAK 0 — 1 103 35 35₁ E−G+ ALRWNLQMGHSVLPK 1 47 0 — 35₂₅ E−G+ NLDVYDWSIPDDLLA 1 90 1  67 35₃₅ E−G+ DDLLAKFSEIKQTRL 1 30 0 — 35₄₁ E−G+ FSEIKQTRLLMGNFI 0 — 0 — 35₄₇ E−G+ TRLLMGNFIVNKDSV 0 — 0 — 36 36₁ E−G+ QDFKKVNEIYAKYFP 0 — 0 — 36₇ E−G+ NEIYAKYFPSPAPAR 0 — 0 — 36₁₃ E−G+ YFPSPAPARSTYQVA 0 — 0 — 36₂₀ E−G+ ARSTYQVAALPLDAR 0 — 0 — 36₂₉ E−G+ LPLDARIEIECIAAL 0 — 0 — 37 37₅ E−G+ EEAASTLPGLSSSTL 0 — 0 — 38 38₃ E−G+ STKIFLESSTMESRA 0 — 0 — 38₅₃ E−G+ CAAVLAASAVVVLVV 0 — 0 — 38₆₂ E−G+ VVVLVVASGLAGSRV 0 — 0 — 38₇₁ E−G+ LAGSRVVRVAVDVAT 0 — 0 — 38₁₅₉ E−G+ GWYHLFYQYNPEGAV 0 — 0 — 38₁₈₄ E−G+ SRDLIHWRHLPLAMV 0 — 0 — 38₂₂₁ E−G+ LNMLYTGSTNASVQV 0 — 0 — 38₃₀₂ E−G+ IAMVYKTKDFVSYEL 0 — 0 — 38₃₀₈ E−G+ TKDFVSYELIPGLLH 0 — 0 — 38₃₉₀ E−G+ WGKFYASKTFYDPAK 0 — 0 — 38₄₂₅ E−G+ KGWASLMSIPRTVDL 0 — 0 — 38₄₈₀ E−G+ LRHATQLDIEAAFRL 0 — 0 — 38₄₈₉ E−G+ EAAFRLDHAAVAALN 0 — 0 — 38₅₃₇ E−G+ EQTAVYFYVSRGLDG 0 — 0 — 38₅₇₁ E−G+ VKRVVGYTVPVLDGE 0 — 0 — 38₅₈₅ E−G+ EAFSVRVLVDHSIVE 0 — 0 — 38₆₁₇ E−G+ EAIYAAAGVYLFNNA 0 — 0 — 38₆₂₅ E−G+ VYLFNNATSGTVTVE 0 — 0 — 39 39₄₂ E−G+ TDIVEVVVSPPYVFL 0 — 0 — 39₅₀ E−G+ SPPYVFLPTVKDKLR 0 — 0 — 39₈₀ E−G+ GAFTGEVSAEMLANL 0 — 0 — 39₈₆ E−G+ VSAEMLANLGIPWVI 0 — 0 — 39₁₁₁ E−G+ GESSEFVGDKVAYAL 0 — 1  30 39₁₁₈ E−G+ GDKVAYALAQGLKVI 1 67 1  73 39₁₄₆ E−G+ STMTVVAEQTKAIAD 0 — 0 — 39₁₆₄ E−G+ DWTNVVIAYEPVWAI 0 — 0 — 39₁₇₀ E−G+ IAYEPVWAIGTGKVA 0 — 0 — 39₂₄₄ E−G+ LKPEFIDIINAATVK 0 — 0 — 40 40₂ E−G+ VWQHDRVEIIANDQG 1 40 0 — 40₈ E−G+ VEIIANDQGNRTTPS 1 27 0 — 40₁₉ E−G+ TTPSYVAFTDSERLI 0 — 0 — 40₃₈ E−G+ KNQVAMNPINTVFGE 0 — 0 — 40₄₄ E−G+ NPINTVFGEHLSTCT 0 — 0 — 41 41₁ E−G+ SSTRGWCSRRRAGRG 0 — 0 — 42 42₁₇ E−G+ EEKQFAAEEISSMVL 0 — 0 — 42₂₇ E−G+ SSMVLIKMREIAEAF 0 — 0 — 42₄₅ E−G+ SIKNAVVTVPAYFND 0 — 0 — 42₆₉ E−G+ GVIAGLNVLRIINEP 0 — 1  33 42₇₆ E−G+ VLRIINEPTAAAIAY 0 — 0 — 43 43₁ E−G+ GILLDFVWYEPLTYN 0 — 0 — 43₄₄ E−G+ ETMQRLVADRLPNFT 0 — 0 — 43₁₁₄ E−G+ GYSKWLYVVPWGFYK 0 — 0 — 43₁₂₀ E−G+ YVVPWGFYKAVMHVK 1 20 0 — 43₁₆₄ E−G+ KFRIDYFDQYLHELK 0 — 0 — 43₁₈₅ E−G+ ARVTGYFAWSLLDNF 0 — 0 — 43₁₉₁ E−G+ FAWSLLDNFEWRMGF 1 27 0 — 44 44₇₁ E−G+ FKDDPYIYAFDSLKY 0 — 0 — 44₇₉ E−G+ AFDSLKYIGIELWQV 0 — 0 — 44₈₈ E−G+ IELWQVKSGTLFDNI 0 — 0 — 44₉₆ E−G+ GTLFDNILITDDAAL 0 — 0 — 44₁₀₂ E−G+ ILITDDAALAKTFAE 0 — 0 — 45 45₅ E−G+ KRPPRCCQDLVVLPL 0 — 0 — 46 46₃ E−G+ RGLLRRARGGPHHRR 1 40 0 — 46₁₉ E−G+ RGAHRRVPLRPLRHR 0 — 1  60 46₄₀ E−G+ EGRRAKLRSAGEVEI 1 177  0 — 46₅₀ E−G+ GEVEIQFRRVKCKYP 4 60 0 — 46₆₇ E−G+ TKVTFHVVGVGPLLH 1 70 1 160 47 47₂₆ E−G+ EDVAVSLAKYTAELS 0 — 0 — 47₄₁ E−G+ GKFAAERGAFTVVLS 1 30 0 — 47₄₉ E−G+ AFTVVLSGGTLIDTL 1 43 0 — 47₉₆ E−G+ DSNYKLAVDGLLSKV 1 53 0 — 47₁₃₅ E−G+ TVLKQLVKSGVLAMS 2 22 0 — 47₁₄₂ E−G+ KSGVLAMSTATGFPR 1 40 0 — 47₁₉₆ E−G+ PPPQRITFTFPVIKS 0 — 0 — 47₂₀₂ E−G+ TFTFPVIKSSAYVAM 0 — 0 — 47₂₃₅ E−G+ KTLPLLPTEMAILQD 0 — 0 — 48 48₂ E−G+ NKLIGARSFFESAKW 0 — 0 — 48₆₅ E−G+ RAHIAFYQVCFEQKG 0 — 0 — 48₁₂₄ E−G+ AALNGVFVSTAAGNI 0 — 0 — 48₁₄₉ E−G+ APWLLTVGASTSDRR 0 — 0 — 48₁₅₈ E−G+ STSDRRFAATVKLGS 0 — 0 — 48₂₃₅ E−G+ VLRAGAFGMIVVAPA 0 — 0 — 48₂₄₁ E−G+ FGMIVVAPAVFGPVI 0 — 0 — 48₂₆₉ E−G+ YAVGQKIKAYLEAES 0 — 1 297 48₃₃₅ E−G+ VPGVVDIVLQPKEVM 0 — 0 — 48₃₆₂ E−G+ CPHLAGIAALLKNAH 0 — 0 — 48₄₂₉ E−G+ GLVYNLTAAEYIPYL 0 — 0 — 48₄₈₇ E−G+ KADSVVNASRAVTNV 0 — 0 — 48₅₂₆ E−G+ KLTFKALEEVLNYTV 0 — 0 — 48₅₃₃ E−G+ EEVLNYTVTVKTAAV 0 — 0 — 48₅₅₂ E−G+ IEGQLKWVSSKHIVR 0 — 0 — 48₅₅₈ E−G+ WVSSKHIVRSPILIL 0 — 0 — 49 49₁ E−G+ ELRKTYNLLDAVSRH 4 847  1 100 49₁₈ E−G+ QVYPRSWSAVMLTFD 2 602  0 — 49₂₆ E−G+ AVMLTFDNAGMWNVR 3 899  1 503 49₄₂ E−G+ NVWERHYLAGEMTLM 1 130  0 — 49₅₀ E−G+ GEQLYISVISPARSL 0 — 1  80 50 50₁₀ E−G+ DSSEYAFRTAVSSSM 0 — 0 — 50₄₄ E−G+ IGNLRLDNTTLIDKD 1 40 0 — 50₈₈ E−G+ EIPMIQNILSRSQIF 0 — 2 158 50₉₇ E−G+ SRSQIFDGIPNLMSL 0 — 1  87 50₁₀₃ E−G+ DGIPNLMSLDNVVKI 0 — 2 158 50₁₂₃ E−G+ IWVNVEYDSFYREHG 0 — 0 — 50₁₅₀ E−G+ EFPVTWVSSPEVALL 0 — 1  97 50₁₅₈ E−G+ SPEVALLKSLAGKLR 1 27 1  87 50₁₆₈ E−G+ AGKLRNSTKLIFRFL 0 — 0 — 50₁₇₄ E−G+ STKLIFRFLREDLVE 1 30 0 — 50₁₉₆ E−G+ GELLKDLKSIKAFAS 0 — 1  43 50₂₀₂ E−G+ LKSIKAFASGILVPK 0 — 0 — 51 51₁₅ E−G+ CEGILKLLETHLVPS 0 — 0 — 51₂₁ E−G+ LLETHLVPSSTAPES 0 — 1  47 51₃₃ E−G+ PESKVFYLKMKGDYH 1 27 1  53 51₆₇ E−G+ MNSYKAAQDIALADL 0 — 1  43 51₈₂ E−G+ APTHPIRLGLALKIS 0 — 0 — 52 52₁ E−G+ LLGLLAPLASAQLSR 0 — 1  33 52₂₃ E−G+ PDAEKIVAAVIEKKL 1 20 0 — 52₄₅ E−G+ AGLLRLLFHDCFANG 1 113  1  37 52₆₀ E−G+ CDASILIDPLSNQSA 3 91 5 151 52₂₂₉ E−G+ IDSSYFANVLAKKMP 1 50 1  50 52₂₆₆ E−G+ KPNDFMPTFAKAMEK 0 — 1  33 52₂₇₇ E−G+ PTFAKAMEKLSVLKV 2 53 2  62 52₃₀₉ E−G+ GGSVIRISSANPEDL 1 70 2  72 52₃₄₃ E−G+ DPWHVKTLKAAGAAH 0 — 0 — 53 53₁ E−G+ WSEIQTLKPNLIGPF 0 — 1 103 53₃₁ E−G+ KFMTLAGFLDYAKAS 0 — 0 — 53₄₆ E−G+ NISGILIGIEHAAYL 0 — 0 — 53₅₇ E−G+ AAYLATRGLDVVDAV 1 880  1 1030  53₆₄ E−G+ GLDVVDAVSNALIKS 1 23 0 — 53₈₄ E−G+ TKQQVFIQSEDPPVL 3 42 0 — 53₉₆ E−G+ PVLSAFKKFPKFNRV 1 53 0 — 53₁₀₃ E−G+ KFPKFNRVFEIEFDI 1 30 3 499 53₁₂₆ E−G+ VEIKEFANAVKLRRS 1 87 1 797 53₁₃₅ E−G+ VKLRRSSAAQVDGFY 3 104  0 — 53₁₄₇ E−G+ GFYLTGFNAVVERLR 0 — 0 — 53₁₇₀ E−G+ GVLKNEFMSLAFDYW 1 83 0 — 53₂₀₂ E−G+ GLVTEFPSTAAAYFR 1 63 1 153 54 54₃₉ E−G+ NIVVNVFNQLDQPLL 1 43 0 — 54₅₀ E−G+ QPLLFTWNGIQHRKN 0 — 0 — 54₉₃ E−G+ IGSFFYFPSIGMQRT 5 447  4 183 54₁₁₀ E−G+ GYGLISVVSRLLIPV 0 — 0 — 54₁₁₆ E−G+ VVSRLLIPVPFDPPA 1 307  1 133 55 55₁₄ E−G− SVFKKFPKFRRVLVI 0 — 0 — 55₂₀ E−G− PKFRRVLVIDPVISG 0 — 0 — 55₄₀ E−G− IGEIKGFADAVMVSR 0 — 1 167 55₄₆ E−G− FADAVMVSRGSLVRV 0 — 0 — 55₅₂ E−G− VSRGSLVRVNGFFLT 0 — 0 — 55₆₀ E−G− VNGFFLTGFNDLVTE 0 — 1 903 56 56₂ E−G− KELGGKILRQPGPLP 0 — 0 — 56₈ E−G− ILRQPGPLPGLNTKI 0 — 0 — 56₁₅ E−G− LRGLNTKIASFLDPD 0 — 0 — 56₂₁ E−G− KIASFLDPDGWKVVL 0 — 1 343 56₃₀ E−G− GWKVVLVDHADFLKE 0 — 0 — 57 57₃ E−G− QDNAKIVQIDSSIQA 0 — 0 — 57₂₉ E−G− RLVCLRVHPTFTLLH 0 — 0 — 57₃₆ E−G− HPTFTLLHPTEVVVA 0 — 0 — 57₄₅ E−G− TEVVVAFTAINGSRQ 0 — 0 — 57₉₁ E−G− LVNRFEISQVSKCLV 0 — 0 — 58 58₁₃ E−G− ADPCSEYFVEAYLNN 0 — 0 — 58₁₉ E−G− YFVEAYLNNPLVQKA 0 — 0 — 58₃₀ E−G− VQKAIHANTALNYPW 0 — 0 — 58₆₂ E−G− PSMLAHIKALVTTGI 0 — 0 — 58₈₀ E−G− LYSGDLDAMVPVTAS 0 — 0 — 58₁₄ E−G− LNYPWTGCRTRTYNL 0 — 0 — 58₂₆ E−G− YNLRRFGASPPSMLA 0 — 0 — 58₄₁ E−G− HIKALVTTASASGCT 0 — 0 — 59 59₄₇ E−G− VKKIVTVLNEAEVPS 0 — 0 — 59₆₂ E−G− EDAVEVVVSPPFVFL 0 — 0 — 59₆₉ E−G− VSPPFVFLQQAKALL 0 — 0 — 59₇₅ E−G− FLQQAKALLRPDFAV 0 — 1  33 59₈₁ E−G− ALLRPDFAVAAQNCW 0 — 1  23 59₁₀₀ E−G− GAFTGEISAEMLVNL 0 — 0 — 59₁₀₆ E−G− ISAEMLVNLQVPWVI 0 — 1  37 59₁₃₂ E−G− ESNDFVADKVAYALA 0 — 0 — 59₁₃₈ E−G− ADKVAYALAQGLKVI 1 47 2  45 59₁₆₆ E−G− TTMEVVAAQTKAIAE 0 — 1  23 59₁₈₅ E−G− WTNVVLAYEPVWAIG 1 20 0 — 59₂₁₆ E−G− LRKWLHANVGPAVAE 0 — 2 138 59₂₆₆ E−G− PEFVDIIKSATVKSS 0 — 1 137 60 60₂₆ E−G− EDSHFVVELTYNYGV 0 — 0 — 60₁₂₂ E−G− RAIKFYEKAFGMELL 0 — 0 — 60₁₄₁ E−G− NPQYKYTIAMMGYGP 0 — 0 — 60₁₅₈ E−G− KNAVLELTYNYGVKE 0 — 0 — 60₂₂₄ E−G− DGWKSVFVDNLDFLK 0 — 0 — 61 61₁ E−G− LQSKNCILYLCSIMI 0 — 0 — 61₇ E−G− ILYLCSIMICNCKVS 0 — 0 — 61₁₃ E−G− IMICNCKVSKVLNTY 0 — 0 — 61₁₉ E−G− KVSKVLNTYIFLLYL 1 27 0 — 62 62₁₁ E−G− YQPAAMRRLSLILLA 1 63 0 — 62₁₇ E−G− RRLSLILLAAAALLA 0 — 0 — 62₂₃ E−G− LLAAAALLAAAVSAE 0 — 0 — 62₅₃ E−G− CPRAERIIAEVVQSK 0 — 0 — 62₁₁₉ E−G− AFDAVVRSKLALELE 0 — 0 — 62₁₄₀ E−G− CADILAIASRVLVTM 1 43 0 — 62₁₈₅ E−G− NFTVGRIIELFTAKG 4 200  6 223 62₁₉₁ E−G− IIELFTAKGFTVQEM 2 298  4 179 62₂₀₀ E−G− FTVQEMVALSGAHTL 0 — 1 537 62₂₆₄ E−G− IAAFNDIMSSSVLSS 0 — 0 — 62₂₇₆ E−G− FDNIYSVNIERGLGL 0 — 1  73 62₃₁₄ E−G− NTDFFEDFAKAIEKL 0 — 0 — 63 63₅ E−G− YPHMLLILLLLHGAN 0 — 0 — 63₁₁ E−G− ILLLLHGANAALDEP 0 — 1  47 63₅₁ E−G− ESSLYAYQFAMSNGL 0 — 0 — 63₈₆ E−G− SGLRLDKSTLIAEVF 0 — 0 — 63₁₁₄ E−G− IHGWFAVDFTAAELV 1 120  2 227 64 64₁₇ E−G− EIPTISYSDLYQLAG 0 — 0 — 64₂₃ E−G− YSDLYQLAGVVAVEV 0 — 0 — 64₆₉ E−G− DHLRQVFGKQMGLSD 0 — 0 — 64₁₁₁ E−G− KNPLKFDNTYFTELL 1 100  1  47 64₁₅₉ E−G− KAFFEDYKEAHLRLS 0 — 0 — 65 65₂₂ E−G− FSCDSAYQVTYIVRG 1 23 1  47 65₂₈ E−G− YQVTYIVRGSGRVQV 1 87 1 367 65₅₅ E−G− IEGGSLFIVPRFHVV 1 130  1 113 65₇₇ E−G− GMEWFSIITTPNPIF 0 — 0 — 65₉₆ E−G− GKTSVWKAISPEVLE 0 — 0 — 66 66₄ n.d. SCRGRCPCSLRTPAW 0 — 0 — 66₁₂ n.d. SLRTPAWGSCSRMAP 0 — 0 — 66₁₈ n.d. WGSCSRMAPCNCRCP 0 — 0 — 66₂₈ n.d. NCRCPCSTRGARRRL 0 — 0 — 66₃₄ n.d. STRGARRRLPGRTSS 0 — 0 — 67 67₉ n.d. TAPTSRRSPSAPSPH 0 — 0 — 67₄₁ n.d. TRTCISTRRIPSRPT 0 — 0 — 67₅₈ n.d. PWSTCRAARSPTPSA 0 — 0 — 67₉₆ n.d. DRREIWLSEMVAWVG 0 — 0 — 67₁₀₃ n.d. SEMVAWVGLQLAFWI 0 — 0 — 68 68₈ n.d. PWRPPRRWSCCPLPW 0 — 0 — 68₁₆ n.d. SCCPLPWPGTRRWWF 0 — 0 — 68₂₄ n.d. GTRRWWFRCHQPPSS 0 — 0 — 68₃₀ n.d. FRCHQPPSSRTAPGS 0 — 0 — 68₄₂ n.d. PGSSRSLYGSPSTSC 0 — 0 — 69 69₁ n.d. VKVAPAALVNVLEAR 0 — 0 — 69₈ n.d. LVNVLEARSALTISV 0 — 0 — 69₁₄ n.d. ARSALTISVLRISSM 0 — 0 — 69₂₀ n.d. ISVLRISSMPFSVYH 0 — 0 — 69₅₃ n.d. LAAFWGKRYPLLSAG 0 — 0 — 70 70₁ n.d. SSPSCAPESTHAVRA 0 — 0 — 70₇ n.d. PESTHAVRALPSTHT 0 — 0 — 70₁₃ n.d. VRALPSTHTARILLR 0 — 0 — 70₁₉ n.d. THTARILLRSTTANV 0 — 0 — 70₂₅ n.d. LLRSTTANVSGCKDR 0 — 0 — 71 71₂ n.d. VQVPGGHQGDLPRGE 0 — 0 — 71₂₂ n.d. LPGAAGEVCRRRRRR 0 — 0 — 71₄₅ n.d. GQGQVDRAQGVVGSH 0 — 0 — 71₅₄ n.d. GVVGSHLEDRHSRQA 0 — 0 — 71₆₀ n.d. LEDRHSRQAHRPLHR 0 — 0 — 72 72₈ n.d. KHLIYVTGWSVYTEI 0 — 0 — 72₁₄ n.d. TGWSVYTEITLLRDA 0 — 0 — 72₄₉ n.d. SEGVRVLMLVWDDRT 0 — 0 — 72₁₀₀ n.d. DDSGSIVQDLQISTM 0 — 0 — 72₁₀₉ n.d. LQISTMFTHHQKIVV 0 — 0 — 72₁₃₆ n.d. RRRRIMSFVGGLDLC 0 — 0 — 72₂₀₂ n.d. PVAWDVLYNFEQRWR 0 — 0 — 72₂₂₀ n.d. GKDLLIQLRDLADEI 0 — 0 — 72₂₄₈ n.d. AWNVQLFRSIDGGAA 0 — 0 — 72₂₉₁ n.d. DAYICAIRRAKSFIY 1 40 1  77 72₂₉₇ n.d. IRRAKSFIYIENQYF 0 — 0 — 72₃₀₃ n.d. FIYIENQYFLGSSYC 0 — 0 — 72₃₅₁ n.d. RFTVYVVVPMWPEGI 0 — 0 — 72₃₇₉ n.d. RRTMEMMYTDIAQAI 0 — 0 — 72₃₈₅ n.d. MYTDIAQAIQAKGID 0 — 0 — 72₄₃₃ n.d. DYLKAQQNRRFMIYV 1 190  1  33 72₄₄₃ n.d. FMIYVHTKMMIVDDE 0 — 0 — 72₄₅₃ n.d. IVDDEYIIVGSANIN 0 — 0 — 72₄₈₄ n.d. YQPYHLAASRPARGQ 0 — 0 — 72₄₉₇ n.d. GQVHGFRMALWYEHL 0 — 0 — 72₅₀₃ n.d. RMALWYEHLGMVDEA 0 — 0 — 72₅₂₆ n.d. CVRKVNAMADRYWNL 0 — 0 — 72₅₇₀ n.d. LPGVEFFPDTQARIL 0 — 0 — 73 73₄₂ n.d. HTFKSLFESWPVSST 0 — 0 — 73₁₂₇ n.d. DCYIVLYTYHSGEKR 0 — 0 — 73₁₄₄ n.d. FYLTYWIGKDSVLED 0 — 0 — 73₁₅₉ n.d. QHMALQIATTIWNSM 0 — 0 — 73₁₈₇ n.d. EPPQFIALFQPMVIL 0 — 0 — 73₂₁₉ n.d. KDETYSGTGIALVHI 0 — 0 — 73₂₂₅ n.d. GTGIALVHIHGTSIH 0 — 0 — 73₂₄₀ n.d. NNKTLQVDAVSISLS 0 — 0 — 73₂₅₆ n.d. TDCFVLQSGNSMFTW 0 — 0 — 73₂₇₉ n.d. QQQWAAKVAEFLKPG 0 — 0 — 73₃₂₆ n.d. DVLREPHLYTFSFRN 1 77 0 — 73₃₄₃ n.d. LEVTEVFNFSQDDLL 1 63 0 — 73₃₄₉ n.d. FNFSQDDLLTEDVMI 1 90 0 — 73₃₆₀ n.d. DVMILDTHAEVFVWM 0 — 0 — 73₄₁₉ n.d. CFFRTYFSWDNTRSV 0 — 0 — 73₄₃₇ n.d. NSFQKKLSLLFGMRS 0 — 0 — 73₄₆₆ n.d. RASALAALSSAFNPS 0 — 0 — 73₅₀₀ n.d. QRASALAALSSSLNP 0 — 0 — 73₅₃₁ n.d. SQRAAAVAALSNVLT 0 — 0 — 73₅₃₇ n.d. VAALSNVLTAEGSTL 0 — 0 — 73₆₀₁ n.d. ETTFSYDRLISKSTD 0 — 0 — 73₆₂₂ n.d. YKRRETYLSDSEFET 0 — 0 — 73₆₃₂ n.d. SEFETVFGVTKEEFY 0 — 0 — 73₆₆₀ n.d. SRSFLKHSLLRTQRL 1 73 0 — 73₆₆₆ n.d. HSLLRTQRLHKFLVC 1 87 0 — 73₆₇₄ n.d. LHKFLVCSSMIGVMA 1 — 0 — 73₆₉₄ n.d. SGNLVMFQMQDHQLI 1 157  0 — 73₇₀₆ n.d. QLIYPLISPSFLVYS 1 200  0 — 73₇₁₂ n.d. ISPSFLVYSFFVHDL 1 77 0 — 74 74₅ n.d. ERLIYQTANSRLCSV 0 — 0 — 74₁₂ n.d. ANSRLCSVLPKEEFY 0 — 0 — 74₁₉ n.d. VLPKEEFYQQPRWKQ 0 — 0 — 74₂₅ n.d. FYQQPRWKQELQKRK 0 — 0 — 75 75₂ n.d. TGAAAAMTTTIRSTA 0 — 0 — 75₁₀ n.d. TTIRSTATARPRAIV 0 — 0 — 76 76₁₁ E−G− NIWADDLAASLSTLE 0 — 1 390 76₁₇ E−G− IAIAFLSVSNNYEYI 1 47 0 — 76₂₄ E−G− VSNNYEYILSDKLVV 0 — 0 — 76₃₃ E−G− KDKLVVSTSCSLMHT 0 — 0 — 76₄₀ E−G− TSCSLMHTAVDLVNE 1 160  0 — 76₅₅ E−G− TKLDSEIKSWLAFAA 1 200  1 323 76₆₁ E−G− IKSWLAFAAQKVVEV 0 — 0 — 76₇₁ E−G− KVVEVNALGKALVGL 0 — 0 — 76₈₅ E−G− LKDEAYFAANAAAQA 1 203  1 153 76₁₇₅ E−G− EAYVSAIKEEISKVV 0 — 0 — 76₁₈₅ E−G− ISKVVKIQEELDIDV 0 — 0 — 76₂₁₀ E−G− MVEYFGEQLSGFAFT 0 — 0 — 76₂₁₈ E−G− LSGFAFTANGWVQSY 0 — 0 — 76₂₅₀ E−G− NPMTVFWSKMAQSMT 2 138  0 — 77 77₃ E−G− EGPLMLYVSKMIPAS 0 — 0 — 77₁₉ E−G− KGRFFAFGRVFAGRV 0 — 0 — 77₇₉ E−G− GNTVALVGLDQFITK 0 — 0 — 77₈₅ E−G− VGLDQFITKNATLTG 0 — 0 — 77₁₀₇ E−G− PIRAMKFSVSPVVRV 0 — 0 — 77₁₇₉ E−G− FMGGAEIIVSPPVVS 0 — 0 — 77₁₈₈ E−G− SPPVVSFRETVLDKS 1 107  0 — 77₂₁₂ E−G− NKHNRLYMEARPLEE 1 107  0 — 77₃₃₈ E−G− PTARRVIFASQLTAK 0 — 0 — 77₃₅₁ E−G− AKPRLLEPVYLVEIQ 0 — 0 — 77₃₅₇ E−G− EPVYLVEIQAPEGAL 0 — 0 — 77₃₉₅ E−G− PLYNIKAYLPVIESF 0 — 0 — 77₄₀₃ E−G− LPVIESFGFSATLRA 0 — 1 333 77₄₀₉ E−G− FGFSATLRAATSGQA 0 — 0 — 78 78₅ E−G− SLKLHKACEAFNPYD 0 — 0 — 78₁₃ E−G− EAFDPYYGKISLSKV 0 — 0 — 78₂₅ E−G− SKVRSFLTEAKAKHI 0 — 0 — 78₃₁ E−G− LTEAKAKHIEWNCDV 0 — 0 — 78₁₁₆ E−G− KEKRWNAALTSISAS 0 — 0 — 78₁₃₃ E−G− GSAYVDLGSLLAERT 0 — 0 — 78₁ E−G− RHLARQFIPHLHQRF 0 — 0 — 78₇ E−G− FIPHLHQRFIHPPIH 0 — 0 — 78₂₄ E−G− NTMENLSSTIFSFVI 0 — 0 — 78₃₂ E−G− TIFSFVILLSASASL 0 — 0 — 78₃₈ E−G− ILLSASASLVVAGDP 0 — 0 — 78₈₅ E−G− ELAEMEVSAAFHLFS 0 — 2 217 78₉₂ E−G− SAAFHLFSMAVTAAR 0 — 0 — 78₉₈ E−G− FSMAVTAARSQQWND 0 — 0 — 78₁₄₃ E−G− KISLSKVRSFLTEAK 0 — 1 783 79 79₁₃₂ E−G− QQYTAALSPILFECL 1 183  0 — 79₁₃₈ E−G− LSPILFECLIHPMLG 1 83 0 — 79₁₆₀ E−G− VEDNLVKLKNVLNVY 1 100  0 — 79₁₆₆ E−G− KLKNVLNVYEARLTK 0 — 0 — 79₁₁ E−G− EVYEARLTKFKYLAG 0 — 1  47 79₁₈ E−G− TKFKYLAGDYLSLAD 1 37 0 — 79₂₄ E−G− AGDYLSLADLNHVST 0 — 0 — 79₅₇ E−G− VKAWWTDLLAKPSVQ 1 100  1  23 80 80₁ E−G− KLRFTCLSSTGSSCL 1 133  0 — 80₇ E−G− LSSTGSSCLFVLILF 1 147  1  63 81 81₁ E−G− EKLKKVLEVYEARLS 2 100  0 — 81₁₈ E−G− SYLAGDFVSFADLNH 1 40 0 — 81₂₄ E−G− FVSFADLNHFPKTFY 0 — 0 — 81₃₃ E−G− FPKTFYFMATPHASL 0 — 0 — 81₅₃ E−G− HVKAWWERIMARPAV 0 — 0 — 81₆₁ E−G− IMARPAVKKIAAAMV 0 — 0 — 82 82₃₃ E−G− KRKVRGFWRVHQISA 0 — 0 — 82₃₉ E−G− FWRVHQISARMAPVK 0 — 0 — 82₄₉ E−G− MAPVKLYGATLSWNV 0 — 0 — 82₁₀₉ E−G− GDLYIFESRAICKYA 1 290  0 — 82₁₅₀ E−G− EANQYTAALGPILFE 0 — 0 — 83 83₅ E−G− ACSLFLNYAVSFNYF 1 57 0 — 83₁₂ E−G− YAVSFNYFVCNLLQE 1 70 1  37 83₂₂ E−G− NLLQERLKKLKSEHG 1 83 1  47 83₅₄ E−G− GMTGMLWETSLLDPE 1 107  0 — 83₉₆ E−G− PEGLLWLLLTGKVPT 1 93 1  33 83₁₃₀ E−G− YVYKAIDALPVTAHP 0 — 0 — 83₁₄₇ E−G− QFTTGVMALQVESEF 0 — 0 — 83₁₈₀ E−G− EDCLNLIARLPQVAS 0 — 0 — 83₁₈₆ E−G− IARLPQVASYVYRRI 1 187  1  33 83₂₀₉ E−G− ADNSLDYAANFSHML 1 130  1  53 83₂₂₇ E−G− DPKMLELMRLYITIH 1 63 1  40 83₂₆₀ E−G− ALSDPYLSFAAALNG 1 130  1  70 83₂₆₆ E−G− LSFAAALNGLAGPLH 1 103  0 — 83₂₇₈ E−G− PLHGLANQEVLLWIK 0 — 0 — 83₂₈₅ E−G− QEVLLWIKSVMEETG 0 — 0 — 83₃₀₆ E−G− QLKEYVWKTLKSGKV 1 90 1  40 83₃₄₉ E−G− EDPLFQLVSKLYEVV 1 160  0 — 83₃₅₅ E−G− LVSKLYEVVPGILTE 1 207  0 — 83₃₈₄ E−G− SGVLLNHFGLVEARY 1 140  0 — 83₄₀₀ E−G− TVLFGVSRSMGIGSQ 1 123  0 — 83₄₁₂ E−G− GSQLIWDRALGLPLE 1 37 1  57 84 84₁₀ E−G− GPVTILNWSFVRNDQ 1 47 0 — 84₂₅ E−G− PRFETCYQIALAIKK 0 — 0 — 84₄₈ E−G− GIQVIQIDEAALREG 0 — 0 — 84₆₉ E−G− EHAFYLDWAVHSFRI 1 53 1 303 84₁₀₃ E−G− FNDIIHSIINMDADV 1 50 0 — 84₁₂₅ E−G− SDEKLLSVFREGVTY 0 — 0 — 84₁₆₅ E−G− VNKMLAVLDTNILWV 1 47 0 — 84₁₈₇ E−G− TRKYAEVMPALTNMV 0 — 0 — 84₁₉₅ E−G− PALTNMVTAAKLIRT 0 — 0 — 84₂₀₁ E−G− VTAAKLIRTQLASTK 0 — 0 — 85 85₁₀ E−G− GRGIKDEGLVVAPGQ 0 — 0 — 85₂₉ E−G− LTVGNIIAGDRFSMA 0 — 0 — 85₃₈ E−G− DRFSMAYDRTPEEIL 0 — 0 — 85₄₄ E−G− YDRTPEEILAIVYGT 0 — 0 — 85₅₀ E−G− EILAIVYGTGNPAQA 0 — 0 — 86 86₁₂ E−G− TREENVYMAKLAEQA 0 — 0 — 86₂₉ E−G− YEEMVEFMEKVAKTA 0 — 0 — 86₅₁ E−G− EERNLLSVAYKNVIG 0 — 0 — 86₅₉ E−G− AYKNVIGARRASWRI 0 — 0 — 86₆₇ E−G− RRASWRIISSIEQKE 0 — 0 — 86₈₆ E−G− NEAYVASIKEYRTRI 0 — 0 — 86₁₀₅ E−G− SKICDGILKLLDSHL 0 — 0 — 86₁₁₁ E−G− ILKLLDSHLVPSATA 0 — 0 — 86₁₂₆ E−G− AESKVFYLKMKGDYH 0 — 0 — 86₁₃₇ E−G− GDYHRYLAEFKAGAE 0 — 0 — 86₁₅₈ E−G− NTLVAYKSAQDIALA 0 — 0 — 86₁₇₄ E−G− LPTTHPIRLGLALNF 0 — 0 — 86₁₈₀ E−G− IRLGLALNFSVFYYE 0 — 0 — 86₁₈₆ E−G− LNFSVFYYEILNSPD 0 — 0 — 86₂₂₅ E−G− YKDSTLIMQLLRDNL 0 — 0 — 86₂₃₁ E−G− IMQLLRDNLTLWTSD 0 — 1  73 87 87₈ E−G− GSRALPFLLQLTKQP 0 — 0 — 87₅₁ E−G− VKVYVVYYSMYGHVG 0 — 0 — 87₈₀ E−G− GVEVKVWQVPEILSE 0 — 0 — 87₁₁₉ E−G− ADGILFGFPTRFGMM 0 — 0 — 87₂₃₄ E−G− FHQGKYFAGIAKKLK 0 — 0 — 88 88₂ E−G− DVYPTVCLPMCVCVL 0 — 0 — 89 89₂₁ E−G− EPAYFATAESVRDHL 1 37 0 — 89₅₃ E−G− QTYYLSMEYLQGRAL 1 37 0 — 89₇₀ E−G− AVGNLGITGAYAEAV 0 — 0 — 89₈₁ E−G− AEAVKKFGYELEALA 1 33 0 — 89₁₁₀ E−G− RLAACFLDSMATLNL 0 — 0 — 89₁₃₁ E−G− LRYRYGLFKQRIAKE 0 — 1 663 89₁₅₈ E−G− FSPWEIVRHDVVYPV 0 — 0 — 89₁₆₉ E−G− VYPVRFFGHVEILPD 0 — 0 — 89₁₉₁ E−G− GEVLNALAYDVPIPG 2 288  1 1247  89₂₀₃ E−G− IPGYKTKNAISLRLW 0 — 0 — 89₂₂₃ E−G− AEDFNLFQFNDGQYE 0 — 0 — 89₂₆₁ E−G− EGKLLRLKQQFFLCS 0 — 0 — 89₂₆₇ E−G− LKQQFFLCSASLQDI 0 — 0 — 89₃₁₃ E−G− PTLAIPELMRLLMDE 0 — 0 — 89₃₆₀ E−G− QSVMRKLLPRQMEII 0 — 0 — 89₃₇₅ E−G− EEIDKRFREMVISTR 0 — 0 — 89₄₀₆ E−G− PQKPVVRMANLCVVS 0 — 0 — 89₄₃₄ E−G− ILKEELFADYVSIWP 0 — 0 — 89₄₆₀ E−G− PRRWLRFCNPELSEI 1 240  1 153 89₅₀₁ E−G− EKLHAEWAAAKLASK 0 — 0 — 89₅₄₀ E−G− IKRIHEYKRQLMNIL 0 — 2  45 89₅₄₆ E−G− YKRQLMNILGAVYRY 2 187  1  43 89₅₅₄ E−G− LGAVYRYKKLKEMSA 3 54 1  43 89₅₈₃ E−G− GKAFATYTNAKRIVK 2 68 0 — 89₅₉₃ E−G− KRIVKLVNDVGAVVN 1 77 2 195 89₆₁₂ E−G− VNKYLKVVFIPNYNV 0 — 1 213 89₆₁₉ E−G− VFIPNYNVSVAEVLI 2 28 6 259 89₆₈₁ E−G− EDNFFLFGAKADQVA 2 35 2 202 89₇₂₃ E−G− TFGTYDYTPLLDSLE 0 — 0 — 89₇₄₈ E−G− FLVGYDFPSYIDAQA 0 — 0 — 89₇₇₂ E−G− KRWIKMSILNTAGSG 1 107  3 136 89₇₉₆ E−G− QYAKEIWGITANPVP 2 105  3  99 90 90₃₃ E−G− KTLAVALGGARPLAT 0 — 1  30 90₄₅ E−G− LATRGVATFTLPDLP 0 — 2  30 90₅₆ E−G− PDLPYDYGALEPAIS 2 37 1  67 90₈₂ E−G− HATYVANYNKALEQL 0 — 1  57 90₁₀₃ E−G− GDASAVVQLQGAIKF 0 — 0 — 90₁₉₈ E−G− DPLVTKGANLIPLLG 0 — 0  87 90₂₀₅ E−G− ANLIPLLGIDVWEHA 0 — 1 113 90₂₁₈ E−G− HAYYLQYKNVRPDYL 1 80 2  48 90₂₂₉ E−G− PDYLTNIWKVVNWKY 1 30 1  70 91 91₃₅ E−G− APSGRIVMELYADVV 3 246  2  82 91₄₁ E−G− VMELYADVVPKTAEN 0 — 2  70 91₇₄ E−G− HYKGSSFHRVIPGFM 3 208  1 207 91₁₀₄ E−G− SIYGAKFADENFIKK 0 — 1  60 91₁₃₅ E−G− NGSQFFLCTAKTAWL 1 530  2 130 92 92₁ E−G− SQVHIRRPGGAGRDG 0 — 1 113 92₇ E−G− RPGGAGRDGGQLRIP 0 — 1 130 92₁₃ E−G− RDGGQLRIPSLLHGG 0 — 1  97 92₂₇ E−G− GHGCAQPAMERRKHI 0 — 2 233 92₃₈ E−G− RKHIEWNCDVCRHGD 0 — 1  83 93 93₁ E−G− WTTVMRASCGHHRFR 0 — 1  87 93₁₃ E−G− RFRDCVISSLADFKL 0 — 2  47 93₁₉ E−G− ISSLADFKLFPVLQH 0 — 1  67 93₂₉ E−G− PVLQHIISIAVLAIF 0 — 1 140 93₃₅ E−G− ISIAVLAIFIGLLMI 0 — 2 123

TABLE 5 Antibody reactivity and IL-5 production of NTGAs and NTGA-derived peptides. Anti- Anti- Pep- Pep- % gens gens % tides tides posi- Total IgE IgG tested positive positive tested positive tive SFC − + 24 14 58.3 173 46 26.6 6,154 + − 13 9 69.2 118 33 28.0 1,796 + + 16 12 75.0 187 93 49.7 7,229 − − 30 17 56.7 256 68 26.6 7,628 n.d. n.d. 10 2 20.0 88 10 11.4 1,053 93 54 64.8 822 250 28.4 23,860

TABLE 6 Epitopes tested positive for T Cell Recognition Total Total Antibody response response reactvity IL-5 IFNg Antigen Peptide IgE/IgG Sequence Events SFC Events SFC 1 1₁₆₁ E+G+ GNKQLVLPVPAFNVI 0 — 1 190 1₃₀₄ E+G+ VYKSFVSEYPIVSIE 1 40 0 — 1₃₄₂ E+G+ IVGDDLLVTNPTRVA 0 0 1 193 1₃₆₅ E+G+ NALLLKVNQIGSVTE 1 40 1 170 1₄₄₄ E+G+ LGAAAVYAGLKFRAP 0 — 1 153 2 2₁ E+G+ AEFEGVFLDFARQQA 2 58 0 — 2₂₀ E+G+ VDKLFKLAEAAKLKE 2 88 2 247 2₄₉ E+G+ ENRSVLHVALRAPRD 2 63 1 27 2₁₁₆ E+G+ FLGPLFVHTALQTDP 1 63 0 — 2₁₃₉ E+G+ RQLRFLANVDPVDVA 1 20 1 20 2₁₆₈ E+G+ VVSKTFTTAETMLNA 0 — 1 97 2₁₉₈ E+G+ VSKHMIAVSTNLKLV 2 80 1 20 2₂₃₂ E+G+ RYSVCSAVGVLPLSL 3 83 3 238 2₂₃₈ E+G+ AVGVLPLSLQYGFPI 3 71 4 121 2₂₄₄ E+G+ LSLQYGFPIVQRFLE 1 127 1 50 2₂₅₀ E+G+ FPIVQRFLEGASSID 2 92 1 90 2₂₆₆ E+G+ HFRTASFEKNIPVLL 1 33 0 — 2₂₇₈ E+G+ VLLGLLSVWNVSFLG 2 50 0 — 2₂₈₄ E+G+ SVWNVSFLGYPARAI 1 100 1 53 2₂₉₅ E+G+ ARAILPYSQALEKLA 1 120 1 27 2₃₄₆ E+G+ NGQHSFYQLIHQGRV 1 27 2 95 2₃₆₃ E+G+ CDFIGVIKSQQPVYL 2 98 2 238 2₃₈₇ E+G+ ELMSNFFAQPDALAY 2 102 3 99 2₄₂₁ E+G+ KTFKGNRPSLSFLLS 2 42 5 363 2₄₂₈ E+G+ PSLSFLLSSLSAYEI 1 67 1 53 2₄₃₉ E+G+ AYEIGQLLAIYEHRI 1 40 0 — 2₄₄₅ E+G+ LLAIYEHRIAVQGFI 1 77 2 42 2₄₅₆ E+G+ QGFIWGINSFDQWGV 1 113 0 — 2₄₉₃ E+G+ PVEGFNPSSASLLAR 1 143 1 47 2₄₉₉ E+G+ PSSASLLARYLAVEP 1 127 0 — 3 3₅₀ E+G+ LKDGSTYSFRFSFIV 1 20 0 — 4 4₆ E+G+ MKTIFDFESIKKLLA 0 — 1 43 4₁₂ E+G+ FESIKKLLASPKFSF 1 47 2 245 4₄₁ E+G+ RMFVDELGASESSLL 1 47 1 30 4₇₀ E+G+ PNLTYAKELVERMGL 0 — 1 33 4₁₀₆ E+G+ RNMVLGKRFFVTPSD 1 33 1 27 4₁₂₉ E+G+ AVQSIPYFASGLKGV 0 — 1 37 4₂₀₃ E+G+ GIWAVLAWLSIIAYK 0 — 1 107 4₂₆₀ E+G+ KELMANLVKMQSALS 1 327 1 97 4₂₆₆ E+G+ LVKMQSALSDVNKLI 2 35 0 — 5 5₂₇ E+G+ TVSDEYLAAVAKARR 0 — 1 73 6 6₁ E+G+ TLLFPHTQISLPSVR 2 32 0 — 6₄₄ E+G+ DNEKSGFISLVSRYL 2 38 0 — 6₉₂ E+G+ EATKALLNKLAVLKL 1 33 0 — 6₁₂₃ E+G+ IEVRNGFTFLDLIVL 1 27 0 — 6₁₃₁ E+G+ FLDLIVLQIESLNKK 1 33 0 — 6₁₄₂ E+G+ LNKKYGSNVPLLLMN 1 353 0 — 6₁₄₉ E+G+ NVPLLLMNSFNTHED 1 153 0 — 6₁₆₅ E+G+ LKIVEKYANSSIDIH 3 196 3 654 6₁₇₅ E+G+ SIDIHTFNQSQYPRV 2 113 1 243 6₂₂₄ E+G+ GKLDLLLSQGKEYVF 1 87 2 65 6₂₃₃ E+G+ GKEYVFIANSDNLGA 2 115 0 — 6₂₄₂ E+G+ SDNLGAIVDMKILNH 2 28 1 30 6₂₄₈ E+G+ IVDMKILNHLIHKQN 3 101 2 160 6₂₈₈ E+G+ VQLLEIAQVPDAHVD 1 73 0 — 6₃₀₄ E+G+ FKSIEKFKIFNTNNL 1 30 1 357 6₃₁₀ E+G+ FKIFNTNNLWVNLKA 2 60 0 — 6₃₁₆ E+G+ NNLWVNLKAIKRLVE 3 517 2 823 6₃₂₅ E+G+ IKRLVEADALKMEII 2 103 1 397 6₃₄₈ E+G+ VKVLQLETAAGAAIR 3 60 1 50 6₃₅₉ E+G+ AAIRFFDHAIGINVP 4 105 4 344 6₃₆₉ E+G+ GINVPRSRFLPVKAT 1 23 0 — 6₃₇₆ E+G+ RFLPVKATSDLQLVQ 2 60 1 83 6₃₈₃ E+G+ TSDLQLVQSDLYTLV 1 40 1 87 6₃₈₉ E+G+ VQSDLYTLVDGFVTR 2 82 1 60 6₄₁₈ E+G+ GPEFKKVGSFLGRFK 2 182 2 147 6₄₂₉ E+G+ GRFKSIPSIVELDSL 3 247 0 — 7 7₃₁ E+G+ GTIRNIINGTVFREP 3 109 2 523 7₁₀₁ E+G+ VFNFTGAGGVALAMY 3 118 3 968 7₁₂₁ E+G+ IQGFAEASMAIAYEK 2 33 1 50 7₁₂₇ E+G+ ASMAIAYEKKWPLYL 2 52 1 80 7₁₃₄ E+G+ EKKWPLYLSTKNTIL 1 63 1 117 7₁₅₃ E+G+ GRFKDIFQAVYEADW 1 57 2 63 7₁₇₇ E+G+ WYEHRLIDDMVAYAL 1 43 0 — 7₂₀₈ E+G+ VQSDFLAQGFGSLGL 2 35 1 80 7₂₆₀ E+G+ NSIASIFAWTRGLAH 0 — 1 63 7₂₈₀ E+G+ DNARLLDFTQKLEDA 2 37 0 — 7₃₀₄ E+G+ MTKDLALLVHGSSKV 1 40 2 128 7₃₂₄ E+G+ LNTEEFIDAVAAELQ 3 60 3 92 8 8₃ E+G+ TIVASGIENMKIFTR 0 — 1 293 9 9₅₆ E+G+ TDTIVYCAGRTFFFR 0 — 1 180 9₆₄ E+G+ GRTFFFRRLDAPLDA 0 — 1 383 9₁₅₂ E+G+ KSLVRAFMWDSGSTV 0 — 0 — 9₁₇₅ E+G+ RVLSCDFKPTRPFRI 0 — 1 97 9₃₅₅ E+G+ VSSLTYFPQSNPRTM 1 23 0 — 9₃₉₇ E+G+ TQIKCFVAAEEELIT 1 20 0 — 9₄₄₁ E+G+ NALNIAVQQPEFALI 1 60 0 — 9₄₅₀ E+G+ PEFALITTDSAIVLL 1 33 0 — 9₄₉₉ E+G+ KLRIYSISGDTLTEE 0 — 1 53 9₅₂₆ E+G+ IHYSPDVSMFASADA 1 30 0 — 9₅₅₄ E+G+ IKLKNMLFHTARINC 1 33 1 20 10 10₁₀ E+G+ GRYFSKDAVQIITKM 1 43 1 170 10₁₆ E+G+ DAVQIITKMAAANGV 1 160 1 83 10₂₉ E+G+ GVRRVWVGQDSLLST 0 — 2 30 10₃₉ E+G+ SLLSTPAVSAIIRER 1 37 2 30 10₄₅ E+G+ AVSAIIRERIAADGS 1 60 1 47 11 11₅₈ E+G+ SVGFVETLENDLAQL 1 30 1 47 11₁₁₁ E+G+ LGEAPYKFKSALEAV 1 53 2 488 11₁₁₇ E+G+ KFKSALEAVKTLRAE 1 43 1 73 11₁₃₇ E+G+ QYLPAFVIVDESGKS 1 23 0 — 11₁₆₁ E+G+ VVTFNFRADRMVMLA 2 50 0 — 11₁₆₈ E+G+ ADRMVMLAKALEFAD 1 40 0 — 11₂₀₆ E+G+ LKLPNKFLVSPPLIE 1 30 0 — 12 12₅ E+G+ YKLLCSSFPVITYHQ 2 60 0 — 12₁₂ E+G+ FPVITYHQGRNGNLS 1 103 0 — 12₂₁ E+G+ RNGNLSALACPLNQK 1 20 0 — 14 14₁ E+G+ LLGYLLWVVAIRRPR 1 110 0 — 16 16₃ E−G− DEKLLSVFREGVVYG 0 — 1 113 16₂₁ E−G− GPGVYDIHSPRIPSK 0 — 2 80 16₃₆ E−G− EEIADDFALFRGTRP 0 — 2 107 16₄₂ E−G− FALFRGTRPPRRPKK 0 — 1 97 16₆₈ E−G− LCPGFCLADVTPETY 0 — 2 45 17 17₂ E+G+ VCTRLSPFCCLYCIL 2 52 0 — 17₁₃ E+G+ YCILCCWYSMRLVTV 1 63 0 — 20 20₂₉₄ E+G− DKPVVAFIAGLTAPP 1 23 0 — 20₃₂₉ E+G− KIKALREAGVTVVES 1 23 0 — 22 22₁₃₁ E+G− QCAIIMFDVTSRLTY 1 27 0 — 22₂₀₆ E+G− KPFLYLARKLAGDAN 2 88 1 603 22₂₁₉ E+G− ANIHFVEAVALKPPE 0 — 1 63 22₂₄₅ E+G− EAELAAAAAQPLPDD 1 20 0 — 23 23₁ E+G− RTSSWGSGASLKIDR 1 27 0 — 23₁₀ E+G− SLKIDRRELVTTRIY 2 35 0 — 24 24₂₁ E+G− RFLHAAVAMATKRSV 0 — 1 150 24₄₄ E+G− KGKKVFLRADLNVPL 1 30 3 234 24₇₆ E+G− TIKFLLEKGAKVILA 2 47 0 — 24₈₂ E+G− EKGAKVILASHLGRP 1 63 0 — 24₁₀₉ E+G− VPRLSELLGVEVVMA 2 70 2 118 24₁₄₁ E+G− GGVLLLENVRFYKEE 2 45 1 23 24₁₆₀ E+G− PEFAKKLASVADLYV 2 45 0 — 24₁₉₃ E+G− KFLRPSVAGFLMQKE 3 38 1 177 24₁₉₉ E+G− VAGFLMQKELDYLVG 1 90 0 — 24₂₀₆ E+G− KELDYLVGAVANPKK 1 37 1 143 24₂₃₄ E+G− KIGVIESLLAKVDIL 1 57 0 — 24₂₅₃ E+G− GMIFTFYKAQGKAVG 0 — 2 397 24₂₇₂ E+G− EEDKLELATSLIETA 2 52 1 23 24₂₉₀ E+G− GVSLLLPTDVVVADK 1 90 0 — 25 25₂ E+G− SAPALRILRSFPSHS 1 97 1 143 26 26₁₃₈ E+G− KVINDRFGIVEGLMT 0 — 1 37 27 27₇₆ E+G− LQHISGVILFEETLY 1 53 0 — 27₁₄₄ E+G− YEAGARFAKWRAVLK 1 33 0 — 27₁₇₅ E+G− GLARYAIICQENGLV 2 33 1 140 27₂₀₆ E+G− RCAYVTEVVLAACYK 1 27 0 — 27₂₂₃ E+G− NDQHVLLEGSLLKPN 1 27 0 — 27₃₀₀ E+G− WFLSFSFGRALQQST 1 23 0 — 28 28₂ E+G− IPPAPHLKRWNRVVD 1 127 0 — 28₂₉ E+G− GAPFTGSGYRIAPYS 1 107 0 — 28₃₆ E+G− GYRIAPYSSILLKAT 0 — 2 477 29 29₂ E+G− SFRFFLAHSSIHPST 2 83 0 — 29₁₀₆ E+G− TEKGIELILSTEIVK 1 50 1 247 29₁₂₄ E+G− ASKTLTSAAGATFTY 1 30 0 — 29₁₉₉ E+G− LELSAALKLNNFDVT 1 133 0 — 30 30₂₈₅ E+G− VFNDDIQGTASVVLA 1 67 0 — 32 32₄₁ E−G+ IEIDSLFEGIDFYST 0 — 1 27 32₅₀ E−G+ IDFYSTITRARFEEL 1 20 0 — 32₁₂₆ E−G+ EAVAYGAAVQAAILS 0 — 1 30 32₁₄₇ E−G+ VQDLLLLDVTPLSLG 0 — 1 47 34 34₁₄₀ E−G+ KPIFHFVGTSTFSEY 1 40 0 — 34₃₄₉ E−G+ KFITHSVTFSEINKA 1 50 1 103 34₃₅₅ E−G+ VTFSEINKAFDLMAK 0 — 1 103 35 35₁ E−G+ ALRWNLQMGHSVLPK 1 47 0 — 35₂₅ E−G+ NLDVYDWSIPDDLLA 1 90 1 67 35₃₅ E−G+ DDLLAKFSEIKQTRL 1 30 0 — 39 39₁₁₁ E−G+ GESSEFVGDKVAYAL 0 — 1 30 39₁₁₈ E−G+ GDKVAYALAQGLKVI 1 67 1 73 40 40₂ E−G+ VWQHDRVEIIANDQG 1 40 0 — 40₈ E−G+ VEIIANDQGNRTTPS 1 27 0 — 41 41₁ E−G+ SSTRGWCSRRRAGRG 0 — 0 — 42 42₆₉ E−G+ GVIAGLNVLRIINEP 0 — 1 33 43 43₁₂₀ E−G+ YVVPWGFYKAVMHVK 1 20 0 — 43₁₉₁ E−G+ FAWSLLDNFEWRMGF 1 27 0 — 46 46₃ E−G+ RGLLRRARGGPHHRR 1 40 0 — 46₁₉ E−G+ RGAHRRVPLRPLRHR 0 — 1 60 46₄₀ E−G+ EGRRAKLRSAGEVEI 1 177 0 — 46₅₀ E−G+ GEVEIQFRRVKCKYP 4 60 0 — 46₆₇ E−G+ TKVTFHVVGVGPLLH 1 70 1 160 47 47₄₁ E−G+ GKFAAERGAFTVVLS 1 30 0 — 47₄₉ E−G+ AFTVVLSGGTLIDTL 1 43 0 — 47₉₆ E−G+ DSNYKLAVDGLLSKV 1 53 0 — 47₁₃₅ E−G+ TVLKQLVKSGVLAMS 2 22 0 — 47₁₄₂ E−G+ KSGVLAMSTATGFPR 1 40 0 — 48 48₂₆₉ E−G+ YAVGQKIKAYLEAES 0 — 1 297 49 49₁ E−G+ ELRKTYNLLDAVSRH 4 847 1 100 49₁₈ E−G+ QVYPRSWSAVMLTFD 2 602 0 — 49₂₆ E−G+ AVMLTFDNAGMWNVR 3 899 1 503 49₄₂ E−G+ NVWERHYLAGEMTLM 1 130 0 — 49₅₀ E−G+ GEQLYISVISPARSL 0 — 1 80 50 50₄₄ E−G+ IGNLRLDNTTLIDKD 1 40 0 — 50₈₈ E−G+ EIPMIQNILSRSQIF 0 — 2 158 50₉₂ E−G+ SRSQIFDGIPNLMSL 0 — 1 87 50₁₀₃ E−G+ DGIPNLMSLDNVVKI 0 — 2 158 50₁₅₀ E−G+ EFPVTWVSSPEVALL 0 — 1 97 50₁₅₈ E−G+ SPEVALLKSLAGKLR 1 27 1 87 50₁₇₄ E−G+ STKLIFRFLREDLVE 1 30 0 — 50₁₉₆ E−G+ GELLKDLKSIKAFAS 0 — 1 43 51 51₂₁ E−G+ LLETHLVPSSTAPES 0 — 1 47 51₃₃ E−G+ PESKVFYLKMKGDYH 1 27 1 53 51₆₇ E−G+ MNSYKAAQDIALADL 0 — 1 43 52 52₁ E−G+ LLGLLAPLASAQLSR 0 — 1 33 52₂₃ E−G+ PDAEKIVAAVIEKKL 1 20 0 — 52₄₅ E−G+ AGLLRLLFHDCFANG 1 113 1 37 52₆₀ E−G+ CDASILIDPLSNQSA 3 91 5 151 52₂₂₉ E−G+ IDSSYFANVLAKKMP 1 50 1 50 52₂₆₆ E−G+ KPNDFMPTFAKAMEK 0 — 1 33 52₂₇₂ E−G+ PTFAKAMEKLSVLKV 2 53 2 62 52₃₀₉ E−G+ GGSVIRISSANPEDL 1 70 2 72 53 53₁ E−G+ WSEIQTLKPNLIGPF 0 — 1 103 53₅₇ E−G+ AAYLATRGLDVVDAV 1 880 1 1030 53₆₄ E−G+ GLDVVDAVSNALIKS 1 23 0 — 53₈₄ E−G+ TKQQVFIQSEDPPVL 3 42 0 — 53₉₆ E−G+ PVLSAFKKFPKFNRV 1 53 0 — 53₁₀₃ E−G+ KFPKFNRVFEIEFDI 1 30 3 499 53₁₂₆ E−G+ VEIKEFANAVKLRRS 1 87 1 797 53₁₃₅ E−G+ VKLRRSSAAQVDGFY 3 104 0 — 53₁₇₀ E−G+ GVLKNEFMSLAFDYW 1 83 0 — 53₂₀₂ E−G+ GLVTEFPSTAAAYFR 1 63 1 153 54 54₃₉ E−G+ NIVVNVFNQLDQPLL 1 43 0 — 54₉₃ E−G+ IGSFFYFPSIGMQRT 5 447 4 183 54₁₁₆ E−G+ VVSRLLIPVPFDPPA 1 307 1 133 55 55₄₀ E−G− IGEIKGFADAVMVSR 0 — 1 167 55₆₀ E−G− VNGFFLTGFNDLVTE 0 — 1 903 56 56₂₁ E−G− KIASFLDPDGWKVVL 0 — 1 343 59 59₇₅ E−G− FLQQAKALLRPDFAV 0 — 1 33 59₈₁ E−G− ALLRPDFAVAAQNCW 0 — 1 23 59₁₀₆ E−G− ISAEMLVNLQVPWVI 0 — 1 37 59₁₃₈ E−G− ADKVAYALAQGLKVI 1 47 2 45 59₁₆₆ E−G− TTMEVVAAQTKAIAE 0 — 1 23 59₁₈₅ E−G− WTNVVLAYEPVWAIG 1 20 0 — 59₂₁₆ E−G− LRKWLHANVGPAVAE 0 — 2 138 59₂₆₆ E−G− PEFVDIIKSATVKSS 0 — 1 137 61 61₁₉ E−G− KVSKVLNTYIFLLYL 1 27 0 — 62 62₁₁ E−G− YQPAAMRRLSLILLA 1 63 0 — 62₁₄₀ E−G− CADILAIASRVLVTM 1 43 0 — 62₁₈₅ E−G− NFTVGRIIELFTAKG 4 200 6 223 62₁₉₁ E−G− IIELFTAKGFTVQEM 2 298 4 179 62₂₀₀ E−G− FTVQEMVALSGAHTL 0 — 1 537 62₂₇₆ E−G− FDNIYSVNIERGLGL 0 — 1 73 63 63₁₁ E−G− ILLLLHGANAALDEP 0 — 1 47 63₁₁₄ E−G− IHGWFAVDFTAAELV 1 120 2 227 64 64₁₁₁ E−G− KNPLKFDNTYFTELL 1 100 1 47 65 65₂₂ E−G− FSCDSAYQVTYIVRG 1 23 1 47 65₂₈ E−G− YQVTYIVRGSGRVQV 1 87 1 367 65₅₅ E−G− IEGGSLFIVPRFHVV 1 130 1 113 72 72₂₉₁ n.d. DAYICAIRRAKSFIY 1 40 1 77 72₄₃₃ n.d. DYLKAQQNRRFMIYV 1 190 1 33 73 73₃₂₆ n.d. DVLREPHLYTFSFRN 1 77 0 — 73₃₄₃ n.d. LEVTEVFNFSQDDLL 1 63 0 — 73₃₄₀ n.d. FNFSQDDLLTEDVMI 1 90 0 — 73₆₆₀ n.d. SRSFLKHSLLRTQRL 1 73 0 — 73₆₆₆ n.d. HSLLRTQRLHKFLVC 1 87 0 — 73₆₇₄ n.d. LHKFLVCSSMIGVMA 0 — 0 — 73₆₉₄ n.d. SGNLVMFQMQDHQLI 1 157 0 — 73₇₀₆ n.d. QLIYPLISPSFLVYS 1 200 0 — 73₇₁₂ n.d. ISPSFLVYSFFVHDL 1 77 0 — 76 76₁₁ E−G− NIWADDLAASLSTLE 0 — 1 390 76₁₇ E−G− IAIAFLSVSNNYEYI 1 47 0 — 76₄₀ E−G− TSCSLMHTAVDLVNE 1 160 0 — 76₅₅ E−G− TKLDSEIKSWLAFAA 1 200 1 323 76₈₅ E−G− LKDEAYFAANAAAQA 1 203 1 153 76₂₅₀ E−G− NPMTVFWSKMAQSMT 2 138 0 — 77 77₁₈₈ E−G− SPPVVSFRETVLDKS 1 107 0 — 77₂₁₂ E−G− NKHNRLYMEARPLEE 1 107 0 — 77₄₀₃ E−G− LPVIESFGFSATLRA 0 — 1 333 78 78₈₅ E−G− ELAEMEVSAAFHLFS 0 — 2 217 78₁₄₃ E−G− KISLSKVRSFLTEAK 0 — 1 783 79 79₁₃₂ E−G− QQYTAALSPILFECL 1 183 0 — 79₁₃₈ E−G− LSPILFECLIHPMLG 1 83 0 — 79₁₆₀ E−G− VEDNLVKLKNVLNVY 1 100 0 — 79₁₁ E−G− EVYEARLTKFKYLAG 0 — 1 47 79₁₈ E−G− TKFKYLAGDYLSLAD 1 37 0 — 79₅₇ E−G− VKAWWTDLLAKPSVQ 1 100 1 23 80 80₁ E−G− KLRFTCLSSTGSSCL 1 133 0 — 80₇ E−G− LSSTGSSCLFVLILF 1 147 1 63 81 81₁ E−G− EKLKKVLEVYEARLS 2 100 0 — 81₁₈ E−G− SYLAGDFVSFADLNH 1 40 0 — 82 82₁₀₉ E−G− GDLYIFESRAICKYA 1 290 0 — 83 83₅ E−G− ACSLFLNYAVSFNYF 1 57 0 — 83₁₂ E−G− YAVSFNYFVCNLLQE 1 70 1 37 83₂₂ E−G− NLLQERLKKLKSEHG 1 83 1 47 83₅₄ E−G− GMTGMLWETSLLDPE 1 107 0 — 83₉₆ E−G− PEGLLWLLLTGKVPT 1 93 1 33 83₁₈₆ E−G− IARLPQVASYVYRRI 1 187 1 33 83₂₀₉ E−G− ADNSLDYAANFSHML 1 130 1 53 83₂₂₇ E−G− DPKMLELMRLYITIH 1 63 1 40 83₂₆₀ E−G− ALSDPYLSFAAALNG 1 130 1 70 83₂₆₆ E−G− LSFAAALNGLAGPLH 1 103 0 — 83₃₀₆ E−G− QLKEYVWKTLKSGKV 1 90 1 40 83₃₄₉ E−G− EDPLFQLVSKLYEVV 1 160 0 — 83₃₅₅ E−G− LVSKLYEVVPGILTE 1 207 0 — 83₃₈₄ E−G− SGVLLNHFGLVEARY 1 140 0 — 83₄₀₀ E−G− TVLFGVSRSMGIGSQ 1 123 0 — 83₄₁₂ E−G− GSQLIWDRALGLPLE 1 37 1 57 84 84₁₀ E−G− GPVTILNWSFVRNDQ 1 47 0 — 84₆₉ E−G− EHAFYLDWAVHSFRI 1 53 1 303 84₁₀₃ E−G− FNDIIHSIINMDADV 1 50 0 — 84₁₆₅ E−G− VNKMLAVLDTNILWV 1 47 0 — 86 86₂₃₁ E−G− IMQLLRDNLTLWTSD 0 — 1 73 89 89₂₁ E−G− EPAYFATAESVRDHL 1 37 0 — 89₅₃ E−G− QTYYLSMEYLQGRAL 1 37 0 — 89₈₁ E−G− AEAVKKFGYELEALA 1 33 0 — 89₁₃₁ E−G− LRYRYGLFKQRIAKE 0 — 1 663 89₁₉₁ E−G− GEVLNALAYDVPIPG 2 288 1 1247 89₄₆₀ E−G− PRRWLRFCNPELSEI 1 240 1 153 89₅₄₀ E−G− IKRIHEYKRQLMNIL 0 — 2 45 89₅₄₆ E−G− YKRQLMNILGAVYRY 2 78 1 43 89₅₅₄ E−G− LGAVYRYKKLKEMSA 3 54 1 43 89₅₈₃ E−G− GKAFATYTNAKRIVK 2 68 0 — 89₅₉₃ E−G− KRIVKLVNDVGAVVN 1 77 2 195 89₆₁₂ E−G− VNKYLKVVFIPNYNV 0 — 1 213 89₆₁₉ E−G− VFIPNYNVSVAEVLI 2 28 6 259 89₆₈₁ E−G− EDNFFLFGAKADQVA 2 35 2 202 89₇₇₂ E−G− KRWIKMSILNTAGSG 1 107 3 136 89₇₉₆ E−G− QYAKEIWGITANPVP 2 105 3 99 90 90₃₃ E−G− KTLAVALGGARPLAT 0 — 1 30 90₄₅ E−G− LATRGVATFTLPDLP 0 — 2 30 90₅₆ E−G− PDLPYDYGALEPAIS 2 37 1 67 90₈₂ E−G− HATYVANYNKALEQL 0 — 1 57 90₁₉₈ E−G− DPLVTKGANLIPLLG 0 — 0 87 90₂₀₅ E−G− ANLIPLLGIDVWEHA 0 — 1 113 90₂₁₈ E−G− HAYYLQYKNVRPDYL 1 80 2 48 90₂₂₉ E−G− PDYLTNIWKVVNWKY 1 30 1 70 91 91₃₅ E−G− APSGRIVMELYADVV 3 246 2 82 91₄₁ E−G− VMELYADVVPKTAEN 0 — 2 70 91₇₄ E−G− HYKGSSFHRVIPGFM 3 208 1 207 91₁₀₄ E−G− SIYGAKFADENFIKK 0 — 1 60 91₁₃₅ E−G− NGSQFFLCTAKTAWL 1 530 2 130 92 92₁ E−G− SQVHIRRPGGAGRDG 0 — 1 113 92₇ E−G− RPGGAGRDGGQLRIP 0 — 1 130 92₁₃ E−G− RDGGQLRIPSLLHGG 0 — 1 97 92₂₇ E−G− GHGCAQPAMERRKHI 0 — 2 233 92₃₈ E−G− RKHIEWNCDVCRHGD 0 — 1 83 93 93₁ E−G− WTTVMRASCGHHRFR 0 — 1 87 93₁₃ E−G− RFRDCVISSLADFKL 0 — 2 47 93₁₉ E−G− ISSLADFKLFPVLQH 0 — 1 67 93₂₉ E−G− PVLQHIISIAVLAIF 0 — 1 140 93₃₅ E−G− ISIAVLAIFIGLLMI 0 — 2 123

REFERENCES

-   1. Brozek J L, et al. (2010) Allergic Rhinitis and its Impact on     Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol     126(3):466-476. -   2. Nathan R A (2007) The burden of allergic rhinitis. Allergy Asthma     Proc 28(1):3-9. -   3. Bauchau V & Durham SR (2004) Prevalence and rate of diagnosis of     allergic rhinitis in Europe. Eur Respir J 24(5):758-764. -   4. Rolland J M, Douglass J, & O'Hehir R E (2000) Allergen     immunotherapy: current and new therapeutic strategies. Expert Opin     Investig Drugs 9(3):515-527. -   5. Laprise C & Boulet L P (1996) Airway responsiveness and atopy in     families of patients with asthma. Clin Invest Med 19(6):461-469. -   6. Romagnani S (2000) The role of lymphocytes in allergic disease. J     Allergy Clin Immunol 105(3):399-408. -   7. Andersson K & Lidholm J (2003) Characteristics and immunobiology     of grass pollen allergens. Int Arch Allergy Immunol 130(2):87-107. -   8. Basketter D A & Kimber I (2011) Assessing the potency of     respiratory allergens: uncertainties and challenges. Regul Toxicol     Pharmacol 61(3):365-372. -   9. Gieras A, et al. (2007) Molecular determinants of     allergen-induced effector cell degranulation. J Allergy Clin Immunol     119(2):384-390. -   10. Vijayanand P, et al. (2012) Interleukin-4 production by     follicular helper T cells requires the conserved 114 enhancer     hypersensitivity site V. Immunity 36(2):175-187. -   11. Mehlhop P D, et al. (1997) Allergen-induced bronchial     hyperreactivity and eosinophilic inflammation occur in the absence     of IgE in a mouse model of asthma. Proc Natl Acad Sci USA     94(4):1344-1349. -   12. Oseroff C, et al. (2010) Molecular determinants of T cell     epitope recognition to the common Timothy grass allergen. J Immunol     185(2):943-955. -   13. Benitez D, et al. (2001) Specific immune response to Phleum     pratense plant profilin in atopic patients and control subjects.     Allergol Immunopathol (Madr) 29(1):9-15. -   14. Wurtzen P A, van Neerven R J, Arnved J, Ipsen H, & Sparholt S     H (1998) Dissection of the grass allergen-specific immune response     in patients with allergies and control subjects: T-cell     proliferation in patients does not correlate with specific serum IgE     and skin reactivity. J Allergy Clin Immunol 101(2 Pt 1):241-249. -   15. Oseroff C, et al. (2012) T Cell Responses to Known Allergen     Proteins Are Differently Polarized and Account for a Variable     Fraction of Total Response to Allergen Extracts. J Immunol. -   16. Oseroff C, et al. (2012) Analysis of T Cell Responses to the     Major Allergens from German Cockroach: Epitope Specificity and     Relationship to IgE Production. J Immunol 189(2):679-688. -   17. Sette A, et al. (2008) Selective CD4+ T cell help for antibody     responses to a large viral pathogen: deterministic linkage of     specificities. Immunity 28(6):847-858. -   18. Lanzavecchia A (1985) Antigen-specific interaction between T and     B cells. Nature 314(6011):537-539. -   19. Chen C, et al. (2011) Identification of CD4+ T cell epitopes     in C. burnetii antigens targeted by antibody responses. PLoS One     6(3):e17712. -   20. Chain B M, Mitchison N A, Mitchison T J, Davies D H, &     Marcinkiewicz J (1989) Antigen processing: current issues,     exceptional cases (Thy 1 alloantigen, MHC class-II-restricted     cytolytic T cells), and implications for vaccine development. J     Autoimmun 2 Suppl:45-53. -   21. Wang P, et al. (2008) A systematic assessment of MHC class II     peptide binding predictions and evaluation of a consensus approach.     PLoS Comput Biol 4(4):e1000048. -   22. Wang P, et al. (2010) Peptide binding predictions for HLA DR, DP     and DQ molecules. BMC Bioinformatics 11:568. -   23. Lowenstein H (1978) Quantitative immunoelectrophoretic methods     as a tool for the analysis and isolation of allergens. Prog Allergy     25:1-62. -   24. Chapman M D (2008) Allergen nomenclature. Clin Allergy Immunol     21:47-58. -   25. Petersen A, Schramm G, Schlaak M, & Becker W M (1998)     Post-translational modifications influence IgE reactivity to the     major allergen Phl p 1 of timothy grass pollen. Clin Exp Allergy     28(3):315-321. -   26. Schuhbauer D M, Mitchison N A, & Mueller B (2000) Interaction     within clusters of dendritic cells and helper T cells during initial     Th1/Th2 commitment. Eur J Immunol 30(5):1255-1262. -   27. Wachholz P A & Durham S R (2004) Mechanisms of immunotherapy:     IgG revisited. Curr Opin Allergy Clin Immunol 4(4):313-318. -   28. Skripak J M, et al. (2008) A randomized, double-blind,     placebo-controlled study of milk oral immunotherapy for cow's milk     allergy. J Allergy Clin Immunol 122(6):1154-1160. -   29. Cady C T, et al. (2010) IgG antibodies produced during     subcutaneous allergen immunotherapy mediate inhibition of basophil     activation via a mechanism involving both FcgammaRIIA and     FcgammaRIIB. Immunol Lett 130(1-2):57-65. -   30. Terada T, Zhang K, Belperio J, Londhe V, & Saxon A (2006) A     chimeric human-cat Fcgamma-Fel d1 fusion protein inhibits systemic,     pulmonary, and cutaneous allergic reactivity to intratracheal     challenge in mice sensitized to Fel d1, the major cat allergen. Clin     Immunol 120(1):45-56. -   31. Wallner M, et al. (2009) Immunologic characterization of     isoforms of Car b 1 and Que a 1, the major hornbeam and oak pollen     allergens. Allergy 64(3):452-460. -   32. Zerbino D R & Birney E (2008) Velvet: algorithms for de novo     short read assembly using de Bruijn graphs. Genome Res     18(5):821-829. -   33. Hannon G J (2010) FASTX-Toolkit     http://hannonlab.cshl.edu/fastx_toolkit/%3E. -   34. Surget-Groba Y & Montoya-Burgos J I (2010) Optimization of de     novo transcriptome assembly from next-generation sequencing data.     Genome Res 20(10):1432-1440.1. 

1-84. (canceled)
 85. A method for increasing immunological tolerance in a subject, the method comprising administering at least once an effective amount of a protein or peptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NOS: 67, 68, 69, 70, 71, 72, 73, 1-66 and 75-620 or b) an amino acid sequence having a sequence identity of at least 80% with an amino acid sequence selected from the group of SEQ ID NOs listed in a), or c) a T cell epitope-containing subsequence of an amino acid sequence selected from the group consisting of SEQ ID NOS: 67, 68, 69, 70, 71, 72, 73, 74, 1-66 and 75-620 or d) an amino acid sequence having a sequence identity of at least 80% with the subsequence of c).
 86. A method for treating a subject of allergy, the method comprising administering at least once an effective amount of a protein or peptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NOS: 67, 68, 69, 70, 71, 72, 73, 1-66 and 75-620, or b) an amino acid sequence having a sequence identity of at least 80% with an amino acid sequence selected from the group of SEQ ID NOs listed in a), or c) a T cell epitope-containing subsequence of an amino acid sequence selected from the group consisting of SEQ ID NOS: 67, 68, 69, 70, 71, 72, 73, 74, 1-66 and 75-620 or d) an amino acid sequence having a sequence identity of at least 80% with the subsequence of c).
 87. The method according to claim 85, wherein the protein or peptide elicits, stimulates, promotes, induces or enhances a T cell response.
 88. The method according to claim 85, wherein the protein or peptide induces IL-5 responses in PBMCs from patients allergic to timothy grass.
 89. The method according to claim 85, wherein the protein or peptide is reactive with IgE in patients allergic to timothy grass.
 90. The method according to claim 85, wherein the subsequence has a length of 10 to 30 amino acids.
 91. The method according to claim 85, wherein the subsequence is selected from the group consisting of SEQ ID NOS: 1521-1549, 1443-1520 and 1550-2264.
 92. The method according to claim 85, wherein the subsequence is selected from the group consisting of SEQ ID NOS: 1521, 1523, 1525-1535, 1537-1549, 1454, 1458, 1459, 1460, 1463-1469, 1471-1489, 1492, 1495-1499, 1502, 1504, 1507, 1508, 1513, 1550-1561, 1563, 1576-1579, 1582, 1584-1586, 1589-1602, 1605-1608, 1624, 1628-1634, 1655, 1656, 1668, 1671-1677, 1679-1691, 1696, 1703-1709, 1712-1714, 1716, 1717, 1720, 1739, 1758-1762, 1776, 1782-1786, 1817, 1818, 1823, 1824, 1828, 1832, 1837, 1840, 1847-1857, 1868, 1877-1881, 1883-1886, 1888, 1889, 1891, 1892, 1895-1897, 1899-1903, 1905, 1906, 1908, 1911-1917, 1919-1921, 1923, 1925, 1928, 1931, 1935, 1953, 1954, 1956, 1958-1962, 1971, 1972, 1977-1982, 1985, 1988, 1992, 1994-1996, 2038, 2044, 2062-2064, 2075, 2076, 2078-2080, 2087, 2088, 2091, 2092, 2095, 2100, 2107, 2108, 2113, 2126, 2129-2132, 2134, 2135, 2137-2141, 2149, 2151-2155, 2159-2163, 2166-2172, 2175, 2176, 2178, 2202, 2209, 2210, 2212, 2214, 2217, 2227, 2229-2236, 2239-2244 and 2246-2264.
 93. A solid pharmaceutical formulation of a protein or peptide, said protein or peptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NOS: 67, 68, 69, 70, 71, 72, 73, 1-66 and 75-620, or b) an amino acid sequence having a sequence identity of at least 80% with an amino acid sequence selected from the group of SEQ ID NOs listed in a), or c) a T cell epitope-containing subsequence of an amino acid sequence selected from the group consisting of SEQ ID NOS: 67, 68, 69, 70, 71, 72, 73, 74, 1-66 and 75-620 or d) an amino acid sequence having a sequence identity of at least 80% with the subsequence of c).
 94. The solid pharmaceutical formulation according to claim 93, wherein the protein or peptide elicits, stimulates, promotes, induces or enhances a T cell response.
 95. The solid pharmaceutical formulation according to claim 93, which is a powder or a tablet.
 96. The solid pharmaceutical formulation according to claim 93, which is in a freeze-dried state.
 97. The solid pharmaceutical formulation according to claim 93, which is contained in an ampule or vial.
 98. A composition comprising a combination of two or more non-identical peptides selected from the group consisting of a T cell epitope-containing subsequence of any one of SEQ ID NOs: 67, 68, 69, 70, 71, 72, 73, 74, 1-66 and 75-620 or an amino acid sequence having a sequence identity of at least 80% with the subsequence.
 99. The composition according to claim 98, wherein said peptides elicit, stimulate, promote, induce or enhance a T cell response.
 100. The composition according to claim 98, wherein the subsequence has a length of 10 to 30 amino acids.
 101. The composition according to claim 98, wherein the subsequence is selected from the group consisting of SEQ ID NOS: 1521-1549, 1443-1520 and 1550-2264.
 102. The composition according to claim 98, wherein the subsequence is selected from the group consisting of SEQ ID NOS: 1521, 1523, 1525-1535, 1537-1549, 1454, 1458, 1459, 1460, 1463-1469, 1471-1489, 1492, 1495-1499, 1502, 1504, 1507, 1508, 1513, 1550-1561, 1563, 1576-1579, 1582, 1584-1586, 1589-1602, 1605-1608, 1624, 1628-1634, 1655, 1656, 1668, 1671-1677, 1679-1691, 1696, 1703-1709, 1712-1714, 1716, 1717, 1720, 1739, 1758-1762, 1776, 1782-1786, 1817, 1818, 1823, 1824, 1828, 1832, 1837, 1840, 1847-1857, 1868, 1877-1881, 1883-1886, 1888, 1889, 1891, 1892, 1895-1897, 1899-1903, 1905, 1906, 1908, 1911-1917, 1919-1921, 1923, 1925, 1928, 1931, 1935, 1953, 1954, 1956, 1958-1962, 1971, 1972, 1977-1982, 1985, 1988, 1992, 1994-1996, 2038, 2044, 2062-2064, 2075, 2076, 2078-2080, 2087, 2088, 2091, 2092, 2095, 2100, 2107, 2108, 2113, 2126, 2129-2132, 2134, 2135, 2137-2141, 2149, 2151-2155, 2159-2163, 2166-2172, 2175, 2176, 2178, 2202, 2209, 2210, 2212, 2214, 2217, 2227, 2229-2236, 2239-2244, 2246-2264.
 103. The composition according to claim 98, wherein the peptides are isolated or purified.
 104. A protein or peptide comprising a) an amino acid sequence selected from the group consisting of SEQ ID NOS: 67, 68, 69, 70, 71, 72, 73, 1-66 and 75-620, or b) an amino acid sequence having a sequence identity of at least 80% with an amino acid sequence selected from the group of SEQ ID NOs listed in a), or c) a T cell epitope-containing subsequence of an amino acid sequence selected from the group consisting of SEQ ID NOS: 67, 68, 69, 70, 71, 72, 73, 74, 1-66 and 75-620 or d) an amino acid sequence having a sequence identity of at least 80% with the subsequence of c).
 105. The protein or peptide according to claim 104, wherein said protein or peptide elicits, stimulates, promotes, induces or enhances a T cell response.
 106. The protein or peptide according to claim 104, wherein the subsequence has a length of 10 to 30 amino acids.
 107. The protein or peptide according to claim 104, wherein the subsequence is selected from the group consisting of SEQ ID NOS: 1521-1549, 1443-1520 and 1550-2264.
 108. The protein or peptide according to claim 104, wherein the subsequence is selected from the group consisting of SEQ ID NOS: 1521, 1523, 1525-1535, 1537-1549, 1454, 1458, 1459, 1460, 1463-1469, 1471-1489, 1492, 1495-1499, 1502, 1504, 1507, 1508, 1513, 1550-1561, 1563, 1576-1579, 1582, 1584-1586, 1589-1602, 1605-1608, 1624, 1628-1634, 1655, 1656, 1668, 1671-1677, 1679-1691, 1696, 1703-1709, 1712-1714, 1716, 1717, 1720, 1739, 1758-1762, 1776, 1782-1786, 1817, 1818, 1823, 1824, 1828, 1832, 1837, 1840, 1847-1857, 1868, 1877-1881, 1883-1886, 1888, 1889, 1891, 1892, 1895-1897, 1899-1903, 1905, 1906, 1908, 1911-1917, 1919-1921, 1923, 1925, 1928, 1931, 1935, 1953, 1954, 1956, 1958-1962, 1971, 1972, 1977-1982, 1985, 1988, 1992, 1994-1996, 2038, 2044, 2062-2064, 2075, 2076, 2078-2080, 2087, 2088, 2091, 2092, 2095, 2100, 2107, 2108, 2113, 2126, 2129-2132, 2134, 2135, 2137-2141, 2149, 2151-2155, 2159-2163, 2166-2172, 2175, 2176, 2178, 2202, 2209, 2210, 2212, 2214, 2217, 2227, 2229-2236, 2239-2244, 2246-2264. 